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Abstract	  	  
Burkholderia	   pseudomallei	   is	   a	   Class	   III	   bacterial	   pathogen	   of	   humans	   and	   the	  causative	   agent	   of	   melioidosis,	   a	   disease	   endemic	   to	   South	   East	   Asia	   and	  Australia.	  This	  work	  describes	  X-­‐ray	  crystallographic	  and	  biochemical	  studies	  of	  the	   BPSL1204	   protein	   from	   B.	   pseudomallei.	   The	   amino	   acid	   sequence	   of	  BPSL1204	   possesses	   an	   N-­‐terminal	   glyceryl-­‐cysteine	   lipid-­‐anchoring	   motif	   for	  covalent	  association	  with	  a	  membrane.	  After	  genetic	  truncation	  of	  the	  anchoring	  sequence,	  the	  BPSL1204	  truncate	  was	  cloned,	  over-­‐expressed	  and	  purified	  from	  
E.	  coli	  before	  being	  subjected	  to	  crystallisation	  trials.	  	  The	   1.05	   Å	   resolution	   crystal	   structure	   of	   BPSL1204	   was	   solved	   by	  Selenomethionine	   MAD	   and	   revealed	   a	   two-­‐domain	   fold	   similar	   to	   that	   of	   β–Lactamase	   Inhibitory	   Protein	   I	   (BLIP-­‐I).	   Like	   BLIP-­‐I,	   the	   BPSL1204	   structure	  consists	   of	   two	   similar	   domains.	   However	   TEM1	   β–lactamase	   assays	   showed	  BPSL1204	  to	  lack	  the	  general	  inhibitory	  activity	  of	  BLIP-­‐I.	  	  Pull-­‐down	   assays	   to	   uncover	   biological	   binding	   partners	   of	   the	   BPSL1204	  homologue	   BCAL2351	   from	   the	   paraphyletic	   Class	   II	   B.	   cenocepacia	   were	  undertaken.	   Although	   a	   methionyl-­‐tRNA	   synthetase	   was	   isolated,	   no	   complex	  was	   seen	   to	   form	   between	   pure	   samples	   of	   the	   proteins.	   Antibodies	   raised	  against	   pure	   BPSL1204	   were	   used	   to	   locate	   the	   BCAL2351	   homologue	   in	  fractionated	   B.	   cenocepacia.	   BCAL2351	   was	   found	   exclusively	   in	   the	   purified	  outer	  membrane	  by	  immunoblot	  analysis.	  	  Some	   evidence	   of	   binding	   of	   antibodies	   to	   whole	   B.	   cenocepacia	   cells	   was	  observed	   by	   fluorescence	   microscopy,	   indicative	   of	   external	   BCAL2351	   and	  BPSL1204.	   However,	   other	   slides	   containing	   samples	   from	   the	   same	   culture	  showed	   no	   such	   binding,	   suggestive	   of	   internal	   or	   absent	   protein.	   Surface	  presence	  may	  be	  cell-­‐cycle	  dependant.	  However,	  no	  immune	  response	  was	  found	  when	  BPSL1204	  was	  challenged	  with	  anti-­‐B.	  mallei	  human	  sera.	  	  Thus	  by	  a	  cross-­‐disciplinary	  approach	  to	  investigating	  the	  structure	  and	  function	  of	   a	   protein	   of	   unknown	   function	   from	   the	   pathogenic	  B.	   pseudomallei,	   it	   was	  concluded	  that	  BPSL1204	  is	  a	  protein	  with	  a	  BLIP-­‐like	  fold	  potentially	  located	  on	  either	   the	   periplasmic	   or	   possibly	   outer	   face	   of	   the	   outer	   membrane	   of	   the	  bacterium.	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  micrometre	  (1x10-­‐6	  m)	  nm	  –	  nanometre	  (1x10-­‐9	  m)	  Å	  –	  Angström	  (1x10-­‐10	  m)	  	  
Time	  and	  Speed	  yr	  –	  year	  hr	  –	  hour	  min	  –	  minute	  s	  –	  second	  rpm	  –	  revolutions	  per	  minute	  krpm	  –	  kilo	  revolutions	  per	  minute	  	  
Concentration	  M	  –	  molar	  (1)	  mM	  –	  millimolar	  (1x10-­‐3	  M)	  µM	  –	  micromolar	  (1x10-­‐6	  M)	  nM	  –	  nanomolar	  (1x10-­‐9	  M)	  [x]	  –	  concentration	  of	  x	  	  
Temperature	  °C	  –	  degrees	  Celsius	  K	  –	  Kelvin	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Chapter	  1:	  Introduction	  	  This	  thesis	  describes	  structural	  studies	  on	  a	  lipoprotein	  from	  the	  pathogen	  
Burkholderia	  pseudomallei.	  In	  the	  first	  part	  of	  this	  chapter	  I	  describe	  the	  background	  to	  this	  bacterium.	  In	  the	  second	  part	  aspects	  of	  the	  structure	  and	  function	  of	  lipoproteins	  are	  discussed.	  	  
1.1	  Burkholderia	  pseudomallei	  	  	  1.1.1	  An	  Introduction	  to	  Melioidosis	  	  Meliodosis,	  from	  the	  Greek	  ‘melis’	  (distemper	  of	  asses)	  and	  ‘eidos’	  (resemblance),	  is	  an	  infectious	  disease	  caused	  by	  Burkholderia	  pseudomallei,	  a	  Gram-­‐negative,	  bipolar	  aerobe	  that	  is	  pathogenic	  to	  humans	  and	  animals	  (Aldhous,	  2005).	  B.	  pseudomallei	  was	  first	  identified	  as	  the	  causative	  agent	  of	  the	  disease	  by	  the	  English	  pathologist	  Major	  Alfred	  Whitmore	  in	  opium	  addicts	  in	  Rangoon	  (Burma/Myanmar)(Cheng	  &	  Currie,	  2005).	  It	  has	  since	  been	  realised	  that	  this	  motile,	  2-­‐5µm-­‐long,	  rod-­‐shaped	  bacterium	  exists	  in	  up	  to	  7	  ‘morphotypes’	  (Stone,	  2007)	  (Figure	  1.1)	  and	  is	  endemic	  most	  notably	  to	  South-­‐East	  Asia	  and	  Northern	  Australia	  (Figure	  1.2)	  (Dance,	  2000).	  Dubbed	  ‘The	  Great	  Mimicker’	  by	  some	  (Wiersinga	  et	  al,	  2006)	  ,	  this	  bacterium	  can	  reside	  within	  its	  host	  before	  exhibiting	  symptoms	  anywhere	  between	  2	  days	  to	  62	  years	  (Ngauy	  et	  al,	  2005;	  Stone,	  2007),	  and	  even	  when	  symptoms	  occur	  the	  disease	  is	  often	  misdiagnosed	  as	  TB	  (Vidyalakshmi	  et	  al,	  2008)	  or	  even	  cancer	  (Reechaipichitkul,	  2004).	  This	  is	  often	  due	  to	  the	  formation	  of	  abscesses	  in	  the	  spleen	  and	  lymph	  nodes	  that	  to	  an	  unaware	  eye	  may	  appear	  cancerous,	  but	  are	  in	  fact	  infectious	  cultures	  of	  B.	  pseudomallei	  (Saravu	  et	  al,	  2012).	  The	  disease	  can	  also	  manifest	  itself	  as	  a	  septicaemic	  infection	  of	  the	  blood	  (Puthucheary	  et	  al,	  1992),	  to	  many	  the	  most	  life-­‐threatening	  and	  fast-­‐acting	  incarnation	  of	  the	  disease	  of	  which	  9	  out	  of	  10	  Thai	  patients	  die	  with	  septic	  shock	  (Currie	  et	  al,	  2000;	  Stone,	  2007),	  as	  well	  as	  a	  pneumonic	  infection	  often	  associated	  with	  exposure	  to	  extreme-­‐weather	  events	  or	  victims	  of	  near-­‐drowning	  (Chaowagul	  et	  al,	  1989).	  It	  has	  also	  been	  noted	  that	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Figure 1.1: The 7 recorded morphotypes of B. pseudomallei of which Type I is the 
most prevalent. A wide range of morphologies further obscures identification of 
melioidosis upon culturing from infected patients. Adapted from Stone (Stone, 2007). 
Figure 1.2: Global distribution of the occurrence of melioidosis, linked to regions 
of B. pseudomallei endemicity. Map supplied by the CDC, adapted from Cheng 
(Cheng & Currie, 2005). 
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patients	  that	  suffer	  from	  an	  onset	  of	  melioidosis	  have	  often	  a	  chronic	  co-­‐illness	  such	  as	  diabetes	  (Wiersinga	  et	  al,	  2006),	  kidney	  disease	  (Stone,	  2007)	  and	  thalassemia	  (Cheng	  &	  Currie,	  2005),	  the	  significance	  of	  which	  is	  still	  under	  investigation.	  Added	  to	  this,	  the	  organism	  has	  been	  seen	  to	  infect	  both	  phagocytic	  and	  non-­‐phagocytic	  cells,	  whilst	  avoiding	  the	  immune-­‐response,	  leading	  to	  the	  formation	  of	  multi-­‐nucleated	  giant	  cells	  (Suparak	  et	  al,	  2005)	  created	  using	  an	  actin-­‐based	  membrane	  protrusion	  system	  (Kespichayawattana	  et	  al,	  2000).	  	  It	  is	  widely	  suspected	  (Ashdown,	  1979)	  that	  infection	  is	  initiated	  by	  entering	  the	  body/blood-­‐stream	  via	  cuts	  and	  abrasions	  in	  the	  feet	  and	  hands	  (such	  as	  with	  Thai	  paddy	  farmers)	  (Stone,	  2007),	  via	  ingestion	  through	  contaminated	  foodstuffs	  (Galyov	  et	  al,	  2010)	  or	  inhalation	  (such	  as	  US	  Vietnam-­‐veterans	  breathing	  in	  helicopter	  up-­‐draft)	  (Aldhous,	  2005;	  Cheng	  &	  Currie,	  2005)	  (Figure	  1.3).	  Due	  to	  these	  characteristics,	  B.	  pseudomallei	  is	  considered	  a	  potential	  bio-­‐terror	  threat,	  with	  its	  high	  infectivity	  based	  upon	  inhalation,	  and	  thus	  it	  carries	  potential	  as	  an	  aerosolized	  bio-­‐weapon	  (Holden	  et	  al,	  2004;	  Stone,	  2007).	  	  1.1.2	  Burkholderia	  pseudomallei	  is	  the	  Causative	  Agent	  of	  Melioidosis	  	  
Burkholderia	  pseudomallei	  (also	  known	  as	  Pseudomonas	  pseudomallei)	  (Dance	  et	  al,	  1989;	  Yabuuchi	  et	  al,	  1992)	  is	  a	  bacterium	  pathogenic	  to	  humans,	  and	  causes	  the	  multi-­‐symptom	  disease	  known	  as	  melioidosis	  (White,	  2003).	  With	  low	  peptidoglycan	  content	  in	  its	  cell	  wall,	  B.	  pseudomallei	  is	  a	  gram-­‐negative,	  soil-­‐dwelling	  saprophyte	  that	  respires	  aerobically,	  and	  is	  commonly	  found	  to	  inhabit	  rice-­‐paddy	  fields	  (Vongphayloth	  et	  al,	  2012).	  B.	  pseudomallei	  can	  be	  differentiated	  from	  its	  paraphyletic	  cousin	  Burkholderia	  mallei	  (the	  causative	  agent	  of	  the	  cattle	  disease	  Glanders)	  (Lever	  et	  al,	  2003;	  Tomaso	  et	  al,	  2005)	  cytologically	  by	  B.	  pseudomallei’s	  motility	  on	  hanging-­‐drop	  microscopy	  as	  B.	  
mallei	  is	  a	  non-­‐motile	  bacillus	  (Neubauer	  et	  al,	  2005),	  by	  24-­‐48	  hours	  visual	  growth	  on	  Ashdown’s	  medium	  (B.	  mallei	  grows	  slower,	  taking	  about	  72	  hours)	  (Peacock	  et	  al,	  2005)	  or	  physiologically	  by	  occurrence	  of	  the	  Strauss	  reaction	  in	  inoculated	  Guinea	  pigs,	  in	  which	  only	  B.	  mallei	  causes	  swelling	  of	  	  




Figure 1.3: Manifestations of B. pseudomallei infections, highlighting physical 
presentation of melioidosis symptoms and proposed modes of infection. Image taken 
from Nature Reviews: Microbiology (Wiersinga et al, 2006). 
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the	  Guinea	  pig	  scrotum	  (Cheng	  &	  Currie,	  2005;	  Scholz	  et	  al,	  2006).	  	  	  The	  7.25	  mega-­‐base	  (Mb)	  genome	  of	  B.	  pseudomallei	  is	  composed	  of	  2	  chromosomes	  (Holden	  et	  al,	  2004),	  of	  which	  BPSL	  (Burkholderia	  
pseudomallei	  Large)	  is	  4.07	  Mb	  and	  BPSS	  (Burkholderia	  pseudomallei	  Small)	  is	  3.17	  Mb.	  In	  comparison,	  B.	  pseudomallei’s	  closest	  cousin	  B.	  mallei	  has	  a	  large	  chromosome	  of	  3.5	  Mb	  and	  a	  small	  chromosome	  of	  2.3	  Mb	  (Nierman	  et	  al,	  2004).	  These	  two	  significantly	  larger	  chromosomes	  in	  B.	  pseudomallei	  also	  show	  some	  degree	  of	  partitioning	  in	  terms	  of	  the	  functional	  genes	  they	  contain,	  with	  the	  larger	  BPSL	  controlling	  metabolism	  and	  growth	  in	  majority	  and	  BPSS	  genes	  functioning	  more	  towards	  roles	  of	  adaptation	  and	  survival	  (Holden	  et	  al,	  2004).	  A	  further	  point	  of	  interest	  in	  the	  genomic	  structuring	  of	  
B.	  pseudomallei	  is	  the	  presence	  of	  16	  ‘genomic	  islands’	  that	  contribute	  up	  to	  6.1%	  of	  the	  genome,	  yet	  are	  totally	  absent	  in	  the	  paraphyletic	  B.	  mallei	  (Holden	  et	  al,	  2004).	  It	  has	  been	  seen	  that	  these	  GIs	  are	  highly	  variable	  between	  strains	  of	  B.	  pseudomallei,	  and	  thus	  actively	  transmissible,	  which	  may	  play	  a	  key	  role	  in	  the	  varying	  pathogenicity	  of	  strains	  to	  humans	  and	  animals	  as	  well	  as	  perhaps	  defining	  specificity	  for	  hosts	  compared	  to	  the	  relatively	  non	  human-­‐pathogenic	  B.	  mallei	  and	  B.	  thailandensis	  or	  the	  plant	  pathogen	  B.	  cenocepacia	  (Holden	  et	  al,	  2004).	  	  Consistent	  with	  the	  locations	  of	  reported	  cases	  of	  melioidosis	  (Cheng	  &	  Currie,	  2005),	  B.	  pseudomallei	  is	  endemic	  to	  quite	  specific	  areas	  of	  South-­‐East	  Asia	  and	  the	  Northern	  Territories	  of	  Australia	  (Dance,	  2000)(see	  Figure	  1.2).	  A	  ‘hotspot’	  for	  B.	  pseudomallei	  is	  Thailand	  (Aldhous,	  2005),	  where	  the	  first	  case	  of	  melioidosis	  wasn’t	  reported	  until	  1955,	  but	  since	  1986	  the	  MORU	  lab	  (Mahidol-­‐Oxford	  Tropical	  Medicine	  Research	  Unit)	  in	  Bangkok	  has	  documented	  more	  than	  3000	  cases	  (Stone,	  2007)	  and	  Sappasitprasong	  Hospital	  in	  Ubon	  Ratchathani	  in	  north-­‐east	  Thailand	  admits	  around	  200	  patients	  annually	  that	  are	  positive	  for	  B.	  pseudomallei	  infection,	  of	  which	  nearly	  half	  die	  (Aldhous,	  2005).	  These	  figures	  may	  however	  be	  a	  mere	  shadow	  of	  a	  much	  larger	  number	  of	  fatalities,	  due	  to	  lower	  accessibility	  to	  appropriate	  healthcare	  in	  more	  peripheral	  areas	  where	  B.	  pseudomallei	  is	  still	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endemic	  (Dance,	  1991).	  Many	  cases	  admitted	  correlate	  with	  the	  suspected	  modes	  of	  acquisition,	  as	  rice	  farmers	  work	  in	  paddy	  fields	  bare-­‐foot	  and	  become	  infected	  through	  cuts	  to	  the	  feet	  thus	  inoculating	  patients	  in	  an	  environment	  teeming	  with	  B.	  pseudomallei.	  This	  thinking	  is	  supported	  by	  the	  fact	  that	  when	  boots	  were	  made	  available	  to	  farmers	  in	  2004	  to	  reduce	  water-­‐borne	  leptospirosis,	  the	  incidence	  rate	  of	  melioidosis	  dropped	  in	  areas	  such	  as	  Ubon	  Ratchathani	  where	  boots	  were	  supplied,	  but	  when	  farmers	  began	  to	  discard	  footwear	  in	  favour	  of	  traditional	  methods,	  the	  cases	  of	  melioidosis	  began	  to	  appear	  more	  rapidly	  (Stone,	  2007).	  	  	  Outside	  of	  areas	  of	  high	  endemicity	  in	  South-­‐East	  Asia	  (Malaysia,	  Singapore	  and	  Thailand)	  and	  Northern	  Australia,	  there	  are	  relatively	  few	  reported	  cases	  of	  melioidosis	  (Cheng	  &	  Currie,	  2005),	  although	  over	  time	  there	  appears	  to	  be	  a	  gradually	  emerging	  spread	  of	  the	  disease’s	  occurrence	  in	  humans	  (Dance,	  2000).	  	  Methods	  of	  measuring	  the	  extent	  of	  the	  disease	  are	  limited	  to	  published	  case-­‐reports	  and	  sero-­‐positivity	  sampling	  for	  antibodies	  against	  B.	  
pseudomallei	  (Dance,	  2000),	  even	  though	  the	  bacterium	  appears	  to	  be	  able	  to	  evade	  the	  immune	  response	  in	  most	  cases	  (Cheng	  &	  Currie,	  2005).	  	  Sero-­‐positivity	  studies	  have	  shown	  that	  in	  Vellore,	  India,	  10.7%	  of	  villagers	  were	  sero-­‐positive	  (Kang	  et	  al,	  1996),	  whilst	  the	  southern	  Chinese	  provinces	  of	  Guangdong	  and	  Guangxi	  have	  exhibited	  sero-­‐positivity	  of	  3.8-­‐15.2%	  (Li	  et	  al,	  1994).	  Both	  these	  areas	  of	  India	  and	  China	  share	  sub-­‐tropical	  status	  with	  the	  regions	  of	  established	  endemicity	  in	  areas	  such	  as	  north-­‐east	  Thailand,	  but	  fall	  considerably	  short	  of	  the	  ~70%	  sero-­‐positivity	  there	  (Stone,	  2007).	  	  Any	  cases	  of	  B.	  pseudomallei	  infection	  reported	  farther	  afield	  exist	  as	  individual	  reports	  and	  appear	  to	  have	  originated	  from	  areas	  of	  higher	  occurrence	  such	  as	  the	  Indian	  or	  South-­‐East	  Asian	  sub-­‐continents.	  For	  example,	  of	  15	  UK	  cases	  since	  1988	  5	  originated	  in	  Bangladesh	  and	  2	  from	  India	  and	  Pakistan	  (Dance	  et	  al,	  1999),	  suggestive	  of	  ‘imported’	  melioidosis	  rather	  than	  any	  claim	  to	  an	  endemic	  spread	  of	  environmental	  B.	  pseudomallei	  (Dance,	  2000).	  	  Other	  examples	  of	  imported	  melioidosis	  include	  ‘L’affaire	  du	  Jardin	  des	  Plantes’	  in	  the	  mid-­‐1970s,	  in	  which	  an	  outbreak	  of	  B.	  pseudomallei	  infections	  occurred	  in	  a	  zoo	  in	  Paris	  killing	  many	  mammals,	  including	  several	  zoo	  keepers,	  which	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was	  suspected	  to	  have	  occurred	  when	  a	  panda	  infected	  with	  the	  bacteria	  was	  donated	  from	  China	  (White,	  2003).	  	  While	  the	  threat	  of	  sustainable	  endemic	  spread	  of	  B.	  pseudomallei	  seems	  to	  be	  limited	  by	  specific	  environments	  (even	  within	  the	  Thai	  ‘hot-­‐spot’	  B.	  
pseudomallei	  isn’t	  prevalent	  in	  central	  Thailand	  where	  its	  relatively	  harmless	  cousin	  B.	  thailandensis	  presides,	  presumably	  due	  to	  soil	  conditions)	  (Aldhous,	  2005),	  and	  in	  areas	  where	  the	  bacterium	  can	  be	  found	  to	  flourish	  it	  does	  so	  with	  great	  effect,	  and	  thrives	  in	  many	  conditions	  otherwise	  intolerable	  to	  other	  species.	  An	  example	  of	  exactly	  how	  hardy	  it	  is	  lies	  in	  its	  ability	  to	  live	  in	  double-­‐distilled	  water,	  devoid	  of	  any	  sustenance,	  for	  18	  years	  and	  still	  form	  viable	  plate	  cultures	  (Moore	  et	  al,	  1999).	  This	  has	  been	  compared	  to	  the	  survival	  rate	  of	  various	  other	  microbial	  species	  in	  nothing	  but	  distilled	  water	  (some	  closely	  related	  to	  B.	  pseudomallei,	  some	  not),	  of	  which	  only	  B.	  
pseudomallei	  and	  P.	  aeruginosa	  survived	  beyond	  30	  days	  (Moore	  et	  al,	  1999).	  This	  of	  course	  may	  lead	  to	  horrifying	  consequences	  when	  water	  supplies	  become	  contaminated,	  a	  mode	  of	  delivery	  through	  which	  several	  Australian	  cases	  of	  melioidosis	  have	  already	  been	  connected	  (Inglis	  et	  al,	  2000).	  In	  the	  other	  extreme,	  B.	  pseudomallei	  can	  also	  ‘hide-­‐out’	  in	  its	  host	  for	  a	  great	  length	  of	  time	  before	  some	  form	  of	  trigger	  causes	  melioidosis	  eruption,	  with	  records	  of	  US	  Vietnamese	  war	  veterans	  being	  diagnosed	  26	  years	  after	  serving,	  and	  the	  farthest	  case	  is	  of	  an	  82-­‐year-­‐old	  American	  diagnosed	  62	  years	  after	  being	  a	  Japanese	  POW	  (Ngauy	  et	  al,	  2005).	  In	  one	  unlucky	  case,	  a	  61-­‐year-­‐old	  Englishman	  died	  of	  melioidosis	  over	  2	  weeks	  after	  visiting	  Thailand,	  not	  through	  infection	  whilst	  there	  but	  instead	  when	  gardening	  wearing	  his	  holiday	  shoes	  and	  a	  thorn	  punctured	  his	  B.	  pseudomallei-­‐contaminated	  shoe’s	  sole	  and	  inoculated	  him	  (Torrens	  et	  al,	  1999).	  	  	  This	  hardiness	  is	  not	  just	  limited	  to	  environment,	  but	  also	  is	  reflected	  in	  the	  application	  of	  antibiotics.	  The	  aminoglycoside	  gentamicin	  and	  the	  polymyxin	  colistin	  are	  usually	  very	  effective	  against	  Gram-­‐negative	  species,	  by	  interrupting	  the	  bacterial	  30S	  ribosome	  subunit	  (in	  the	  case	  of	  gentamicin)	  (Yoshizawa	  et	  al,	  1998)	  or	  by	  permeating	  the	  bacterial	  cytoplasmic	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membrane	  (as	  is	  the	  mode	  of	  action	  for	  colistin)	  (Falagas	  &	  Kasiakou,	  2005).	  However,	  these	  antibiotics	  have	  no	  discernable	  effect	  on	  B.	  pseudomallei	  due	  to	  an	  efficient	  multi-­‐drug	  efflux	  system	  known	  as	  AmrOB-­‐OprA	  (Moore	  et	  al,	  1999).	  Until	  recently,	  a	  ‘cocktail’	  of	  4	  more	  conventional	  antibiotics	  was	  the	  most	  effective	  treatment	  for	  melioidosis	  (deoxycycline,	  chloramphenicol,	  cotrimoxazole	  and	  kanamycin)	  (Leelarasamee,	  1998),	  but	  even	  with	  these	  the	  mortality	  rate	  of	  patients	  with	  septacemic	  melioidosis	  was	  82-­‐87%	  (Leelarasamee,	  1998).	  In	  more	  recent	  times	  a	  newer,	  more	  effective	  treatment	  has	  emerged	  and	  using	  the	  cephalosporin	  ceftazidime	  the	  mortality	  rate	  has	  been	  halved	  to	  35-­‐40%	  (White,	  2003).	  Ceftazidime	  functions	  by	  binding	  and	  inhibiting	  penicillin-­‐binding	  proteins	  (PBPs)	  such	  as	  PBP-­‐3	  (Hayes	  &	  Orr,	  1983),	  thus	  increasing	  susceptibility	  to	  lysis	  by	  incorrect	  peptidoglycan	  synthesis	  (Horii	  et	  al,	  1998).	  However	  due	  to	  the	  highest	  rates	  of	  melioidosis	  occurring	  in	  relatively	  poor,	  in	  some	  cases	  ‘3rd	  world’	  countries,	  due	  to	  the	  endemicity	  of	  B.	  pseudomallei,	  the	  expensive	  treatments	  can	  often	  deny	  patients	  a	  fair	  chance	  of	  survival	  (Aldhous,	  2005).	  A	  class	  of	  antibiotics	  thought	  to	  be	  emerging	  as	  more	  effective	  is	  the	  carbapenems	  that	  bind	  a	  different	  class	  of	  PBPs	  (PBP-­‐1/-­‐2)	  (Horii	  et	  al,	  1998)	  but	  due	  to	  the	  high	  cost	  of	  $100	  per	  patient,	  per	  day	  the	  currently	  inconclusive	  trials	  are	  difficult	  to	  pursue	  further	  due	  to	  the	  large	  overhead	  (Aldhous,	  2005).	  	  Given	  its	  effectiveness	  at	  manifesting	  into	  such	  a	  life-­‐threatening	  disease-­‐state	  as	  melioidosis,	  B.	  pseudomallei	  is	  gaining	  increasingly	  more	  potential	  as	  a	  prospective	  bio-­‐weapon,	  with	  most	  concern	  focused	  on	  the	  threat	  posed	  should	  such	  a	  weapon	  fall	  into	  the	  hands	  of	  bioterrorists	  (Aldhous,	  2005).	  The	  Center	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  categorises	  B.	  pseudomallei	  as	  a	  Category	  B	  biothreat,	  alongside	  Typhus	  fever	  and	  the	  Ricin	  toxin	  (DeShazer,	  2004).	  This	  is	  especially	  of	  importance	  as	  its	  cousin	  B.	  mallei	  is	  one	  of	  the	  few	  bacteria	  to	  have	  ever	  been	  deployed	  in	  biological	  warfare,	  used	  by	  German	  agents	  to	  cause	  Glanders	  in	  Allied	  horses	  during	  World	  War	  I	  (Stone,	  2007).	  Indeed	  it	  is	  regrettably	  not	  too	  hard	  to	  imagine	  the	  deadliness	  of	  an	  aerosolized	  weapon	  that	  when	  inhaled	  can	  kill	  within	  42	  hours	  and	  is	  resistant	  to	  the	  most	  readily	  available,	  large-­‐scale	  produced	  anti-­‐biotics.	  Even	  those	  who	  escape	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immediate	  acute	  septicaemia	  may	  also	  relapse	  or	  form	  life-­‐threatening	  abscesses	  later	  in	  life	  (Cheng	  &	  Currie,	  2005).	  	  	  
1.2	  Membrane-­Anchored	  Proteins	  	  1.2.1	  Characteristics	  of	  Lipoproteins	  and	  Membrane	  Association	  	  In	  order	  to	  maintain	  the	  smooth	  operation	  of	  such	  a	  complex	  biochemical	  environment	  as	  a	  cell,	  a	  wide	  variety	  of	  molecular	  machinery	  is	  required	  to	  fulfill	  all	  the	  required	  processes	  that	  ensure	  cellular	  survival.	  In	  the	  vast	  majority	  of	  cases	  these	  processes	  are	  mediated	  by	  the	  functional	  abilities	  endowed	  upon	  proteins	  in	  their	  own	  very	  exact	  niches.	  The	  amino-­‐acid	  compositions	  of	  a	  protein	  and	  the	  resulting	  tertiary	  structures	  they	  form	  upon	  folding	  strictly	  define	  their	  role	  in	  a	  cell	  or	  organism.	  	  	  Lipoproteins	  are	  a	  subset	  of	  the	  proteins	  that	  are	  associated	  with	  the	  inner	  or	  outer	  membrane	  of	  bacteria.	  Proteins	  with	  a	  long	  stretch	  of	  hydrophobic	  residues	  at	  their	  carboxyl	  or	  amino	  terminus	  can	  potentially	  insert	  into	  the	  hydrophobic	  interior	  of	  a	  cell	  membrane	  and	  act	  as	  membrane-­‐anchored	  proteins	  (Eisenberg	  et	  al,	  1984),	  assuming	  that	  the	  hydrophobic	  ‘tail’	  or	  loop	  is	  not	  in	  fact	  an	  integral	  component	  of	  a	  protein’s	  hydrophobic	  core	  (Munoz	  et	  al,	  1995).	  This	  form	  of	  membrane	  anchor	  is	  not	  the	  sole	  type	  of	  membrane-­‐anchored	  protein.	  Aside	  from	  the	  hydrophobic	  sequence-­‐insertion,	  proteins	  can	  also	  become	  membrane-­‐anchored	  via	  covalent	  bonding	  to	  a	  hydrophobic,	  membrane-­‐affiliated	  compound	  such	  as	  glycosylphosphatidylinositol	  (GPI)	  (Fujita	  &	  Kinoshita,	  2012),	  by	  electrostatic	  binding	  to	  phospholipid	  head-­‐groups	  (Mukhopadhyay	  &	  Cho,	  1996)	  and	  also	  by	  membrane-­‐insertion	  of	  amphipathic	  helices	  into	  the	  plane	  of	  the	  phospholipid	  bilayer,	  known	  as	  IPM	  anchors	  (in-­‐plane	  membrane	  anchors)	  (Sapay	  et	  al,	  2006).	  In	  addition,	  a	  hydrophobic	  N-­‐terminal	  sequence	  may	  act	  as	  a	  signal	  for	  export	  (Lee	  &	  Hannink,	  2001)	  or	  for	  lipid	  anchoring	  (Zimmermann	  et	  al,	  2010)	  (Figure	  1.4).	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Figure 1.4: Diagram to illustrate the variety of methods through which proteins 
can interact with a cell membrane. The forms of protein membrane-associations 
that were potentially under investigation in this project were the GPI-glycolipid, 
phospholipid and IPM protein-lipid interactions. Figure adapted from online 
material made publically available by the University of Toronto. 
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1.2.2	  Glycerylcysteine	  Lipid	  Anchoring	  	  Another	  method	  of	  lipoprotein	  membrane	  anchoring	  is	  the	  focus	  of	  the	  main	  target	  in	  this	  body	  of	  work,	  namely	  membrane-­‐association	  via	  a	  covalent	  glycerylcysteine	  moiety	  (Nielsen	  &	  Lampen,	  1982).	  Following	  a	  highly	  hydrophobic	  amino-­‐terminal	  signaling	  sequence	  a	  lipoprotein	  cleavage	  (/)	  motif	  of	  LLAG⁄CX	  can	  be	  found,	  where	  X	  acts	  as	  a	  determinant	  of	  membrane	  localization	  (Hayashi	  &	  Wu,	  1990).	  In	  E.	  coli,	  an	  Asp	  residues	  at	  this	  +2	  position	  localises	  a	  lipoprotein	  to	  the	  periplasmic	  face	  of	  the	  inner	  cell	  membrane,	  whereas	  a	  greater	  variety	  of	  residues,	  most	  commonly	  Ser+2,	  leads	  to	  localisation	  to	  the	  periplasmic	  face	  of	  the	  outer	  cell	  membrane	  or	  less	  commonly	  the	  outer	  face	  of	  the	  outer	  cell	  membrane	  (Yamaguchi	  et	  al,	  1988)	  (Figure	  1.5).	  	  	  In	  this	  mode	  of	  membrane-­‐association,	  upon	  translocation	  across	  the	  cytoplasmic	  membrane	  into	  the	  periplasmic	  space,	  a	  prolipopotein	  +1	  Cys	  residue	  is	  acted	  upon	  by	  a	  glyceryl	  transferase	  recognizing	  the	  LLAG/C	  motif,	  to	  create	  a	  glycerylcysteine	  moiety	  from	  a	  donating	  phosphatidylglycerol	  (Hayashi	  &	  Wu,	  1990).	  This	  glyceryl-­‐prolipoprotein	  is	  then	  recognised	  by	  a	  glyceryl-­‐prolipoprotein	  transacylase	  to	  form	  a	  +1	  Cys	  diglyceride	  via	  an	  ester-­‐linkage	  between	  the	  glyceryls	  (Hayashi	  &	  Wu,	  1990).	  Diglyceride-­‐proplipoprotein	  is	  then	  cleaved	  at	  the	  LAG/C-­‐diglyceride	  site	  by	  a	  prolipoprotein	  signal-­‐peptidase	  to	  release	  the	  hydrophobic	  signal	  peptide	  (to	  be	  degraded	  to	  composite	  amino	  acids	  by	  peptidases)	  (von	  Heijne	  &	  Abrahmsen,	  1989)	  from	  the	  lipoprotein,	  with	  the	  exposed	  N-­‐terminal	  –NH	  group	  of	  the	  lipoprotein	  becoming	  further	  modified	  by	  acetylation	  by	  the	  action	  of	  a	  transacylase	  (Hayashi	  &	  Wu,	  1990).	  This	  leaves	  the	  N-­‐acyl-­‐S-­‐diacylglyceryl-­‐cysteine	  lipoprotein	  associated	  to	  a	  membrane	  by	  covalently	  attached	  diglyceride	  and	  acyl-­‐moieties	  (Figure	  1.6a	  and	  b).	  	  Once	  tethered	  to	  a	  membrane	  by	  this	  or	  any	  type	  of	  anchor,	  a	  membrane-­‐anchored	  protein	  is	  now	  localised	  to	  fulfill	  its	  specialised	  role,	  such	  as	  acting	  as	  effectors	  (Liscum	  &	  Faust,	  1987)	  or	  adaptors	  linking	  extra-­‐cellular	  signals	  to	  internal	  down-­‐stream	  signalling	  cascades	  (Kovacs-­‐Simon	  et	  al)	  or	  aiding	  the	  delivery	  of	  bio-­‐molecules	  via	  membrane	  trafficking	  (Gandhi	  et	  al,	  2010).	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Construct	  Sequence	  Lipoprotein-­‐28	   MKLTTHHLRTGAALLLAGILLAG	  CDQSSSDAKHIKVGVI-­‐-­‐-­‐-­‐	  Major	  lipoprotein	   	  	  	  	  	  	  	  	  	  MKATKLVLGAVILGSTLLAG	  CSSNAKIDQLSS-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐	  pJG	  311	   	  	  	  	  	  	  	  	  	  MKATKLVLGAVILGSTLLAG	  CSSNAKIDQGEDQ-­‐β-­‐lactamase	  pKY	  201	   MKLTTHHLRTGAALLLAGILLAG	  CDQSSSDAKHIKDLRIPG-­‐β-­‐lactamase	  pKY	  316	   	  	  	  	  	  	  	  	  	  MNRTKLVLGAVILGSTLLAG	  CDQSSSDAKHIKDLRIPG-­‐β-­‐lactamase	  pKY	  313	  	   	  	  	  	  	  	  	  	  	  MNRTKLVLGAVILGSTLLAG	  CDQSSSDAKHIKVGVIN-­‐-­‐	  pKY	  623	  	   MKLTTHHLRTGAALLLAGILLAG	  CSSNAKIDQLSS-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐	  pKY	  702	  	   	  	  	  	  	  	  	  	  	  MKATKLVLGAVILGSTLLAG	  CDSNAKIDQGEDQ-­‐β-­‐lactamase	  pKY	  841	   MKLTTHHLRTGAALLLAGILLAG	  CSQSSSDAKHIKDLRIPG-­‐β-­‐lactamase	  pKY	  831	   	  	  	  	  	  	  	  	  	  MNRTKLVLGAVILGSTLLAG	  CSQSSSDAKHIKDLRIPG-­‐β-­‐lactamase	  
Figure 1.5: Investigation of the +2 lipoprotein-sorting rule in E. coli. Lipoprotein-28 
(+2D) is located to the inner membrane, whilst the major lipoprotein (+2S) is an 
outer membrane protein.        represents the site of LLAG/C cleavage. The pJG and 
pKY constructs represent variations in exchange of N-terminal signal sequence and 
replacments of +2D with +2S and vice-versa. β–lactamase constructs provided an 
identification tool for location of the protein when membranes were purified. 
 
In all cases, when lipoprotein-28 +2 was changed to serine, it was detected in the 
outer membrane instead of the inner membrane, regardless of alterations to the N-
terminal sequence. Conversely, the alteration to +2D in the major lipoprotein sent it 
to the inner membrane. This experiment illustrated that localisation of lipoproteins 
in E. coli is directed by the residue found in the +2 position after LLAG/C cleavage. 
Figure adapted from the findings of Yamaguchi (Yamaguchi et al, 1988). 
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    Diglyceride 
 
  Acyl--NH-C-X----SD 
-20                +1+2 
M-------------------L-A-G-C-X----soluble domains (SD) 
    Diglyceride 
 
M-------------------L-A-G    +    NH2-C-X----SD 
   Diglyceride 
 
M-------------------L-A-G-C-X----SD 
   Glyceryl    
        
M-------------------L-A-G-C-X----SD Transacylase	  (O-­‐acyl	  transferase)	  
Prolipoprotein	  Signal	  Peptidase	  
Diglyceride-­‐Lipoprotein	  Transacylase	  (N-­‐acylase)	  
Signal	  Peptide	  Peptidase	  
Prolipoprotein	  Glyceryl	  Transferase	  
Figure 1.6b: A schematic of the enzymatic processing of prolipoprotein to fully 
glyceryl-cysteine lipid-anchored lipoprotein. The final acyl-diglyceryl-lipoprotein 
is anchored to the membrane interior by its newly acquired covalently attached 
fatty acids. 
Figure 1.6a: The chemical structure of an N-acyl-S-diacylglyceryl-cysteine 
lipoprotein anchor from the E. coli murein protein (Bishop, 2000). 
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1.2.4	  General	  Functions	  Associated	  With	  Bacterial	  Lipoproteins	  	  Bacterial	  lipoproteins	  play	  a	  fundamental	  role	  in	  many	  of	  the	  key	  processes	  that	  ensure	  the	  survival	  of	  all	  the	  members	  of	  the	  bacterial	  phylogenetic	  domain.	  They	  can	  perform	  extracellular	  roles	  such	  as	  mediating	  cell	  adhesion	  (Otto	  &	  Silhavy,	  2002)	  and	  reproduction	  through	  conjugation	  (Seubert	  et	  al,	  2003),	  to	  carrying	  out	  survival	  functions	  such	  as	  aiding	  in	  the	  process	  of	  transporting	  proteins,	  nutrients	  and	  toxins	  across	  cell	  membranes,	  either	  as	  a	  mode	  of	  uptake	  or	  release	  (Hayashi	  &	  Wu,	  1990).	  Bacterial	  lipoproteins	  are	  commonly	  involved	  in	  sensing	  the	  environment	  and	  transmitting	  signals	  across	  membranes	  and	  through	  the	  cell	  to	  affect	  core	  regulatory	  processes	  such	  as	  gene	  transcription	  and	  protein	  synthesis,	  often	  acting	  as	  adaptors	  of	  the	  primary	  detection-­‐and-­‐signalling	  systems	  found	  associated	  with	  the	  outer	  and	  inner	  membranes	  of	  a	  bacterial	  cell	  (Leverrier	  et	  al,	  2011).	  In	  spore-­‐forming	  bacteria,	  lipoproteins	  can	  act	  as	  a	  trigger	  for	  switching	  between	  a	  spore-­‐forming	  or	  germination	  event	  (Banse	  et	  al,	  2011).	  All	  of	  these	  processes	  link	  to	  the	  manipulation	  of	  cell	  growth	  and	  division	  that	  exists	  as	  a	  fine	  balance	  to	  ensure	  the	  viability	  of	  each	  bacterium	  of	  all	  bacterial	  species.	  	  1.2.5	  Examples	  of	  Lipoproteins	  in	  B.	  pseudomallei	  	  Several	  lipoproteins	  with	  putative	  or	  assigned	  function	  have	  been	  identified	  in	  B.	  
pseudomallei,	  although	  due	  to	  the	  high	  variation	  in	  biological	  functions	  from	  a	  small	  number	  of	  lipoproteins	  discovered	  it	  was	  proposed	  that	  many	  more	  functions	  for	  many	  more	  different	  lipoproteins	  are	  yet	  to	  be	  discovered	  in	  the	  organism.	  In	  regards	  to	  glyceryl-­‐cysteine	  lipid-­‐anchored	  lipoproteins,	  the	  discovery	  of	  a	  putative	  Lipoprotein	  Signal	  Peptidase	  II	  (LSPII)	  responsible	  for	  the	  cleavage	  of	  a	  diacylglyceryl-­‐prolipoprotein	  prior	  to	  membrane	  insertion	  illustrates	  the	  cyclical	  nature	  of	  biology,	  as	  a	  lipoprotein	  that	  potentially	  acts	  upon	  a	  different	  lipoprotein	  of	  unrelated	  function	  (Holden	  et	  al,	  2004).	  An	  example	  of	  such	  a	  B.	  pseudomallei	  protein	  that	  may	  be	  processed	  by	  lipoproteins	  such	  as	  LSPII	  is	  the	  LAGC-­‐motif-­‐containing	  OprM-­‐homolog,	  homologous	  to	  a	  protein	  thought	  responsible	  for	  multi-­‐drug	  resistance	  in	  Pseudomonas	  
aeriguinosa	  (Bianco	  et	  al,	  1997).	  This	  resistance-­‐nodulation-­‐division	  (RND)	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protein	  forms	  part	  of	  an	  outer	  membrane	  drug-­‐efflux	  system,	  which	  expels	  toxins	  from	  the	  bacterial	  cell,	  such	  as	  antibiotics	  (Bianco	  et	  al,	  1997).	  	  Exhibiting	  a	  different	  biological	  role,	  OppA	  is	  a	  periplasmic	  lipoprotein	  anchored	  to	  the	  inner	  membrane	  and	  acts	  as	  an	  oligopeptide	  binding	  protein	  of	  the	  Opp	  system,	  which	  is	  responsible	  for	  bacterial	  nutrient	  uptake	  and	  signalling.	  It	  has	  also	  been	  shown	  to	  perform	  a	  role	  in	  virulence	  of	  species	  such	  as	  Staphylococcus	  
aureus	  as	  well	  as	  B.	  pseudomallei	  (Harland	  et	  al,	  2007).	  Amongst	  other	  examples,	  a	  protein	  such	  as	  the	  small,	  45	  residue,	  4.3	  kDa	  Entericidin	  B	  is	  a	  lipoprotein	  putatively	  assigned	  to	  be	  part	  of	  the	  B.	  pseudomallei	  response	  to	  externally	  sensed	  toxins	  from	  the	  growth	  environment,	  representing	  a	  cell-­‐signalling	  role	  for	  lipoproteins	  within	  the	  organism	  (DeShazer	  et	  al,	  2006).	  The	  lipoproteins	  briefly	  described	  in	  this	  section	  illustrate	  the	  essential	  and	  varied	  roles	  such	  membrane-­‐associated	  proteins	  play	  in	  the	  growth,	  survival	  and	  virulence	  of	  the	  
B.	  pseudomallei	  bacterium.	  	  
1.3	  Aims	  of	  the	  Research	  	  1.3.1	  Bioinformatical	  Discovery	  of	  a	  Novel,	  Membrane-­‐associated	  Target	  	  It	  was	  proposed	  that	  by	  studying	  the	  Kyte-­‐Doolittle	  hydropathy	  plots	  (Kyte	  &	  Doolittle,	  1982)(Figure	  1.7)	  created	  for	  the	  entire	  catalogue	  of	  hypothetical	  proteins	  translated	  from	  all	  the	  genes	  of	  B.	  pseudomallei,	  it	  may	  be	  possible	  to	  identify	  membrane-­‐associated	  proteins	  by	  the	  presence	  of	  potentially	  membrane-­‐interacting	  hydrophobic	  termini.	  Once	  a	  short-­‐list	  of	  targets	  was	  created,	  database	  analysis	  would	  be	  employed	  to	  identify	  a	  target	  to	  which	  no	  known	  function	  was	  assigned,	  and	  after	  the	  selection	  of	  several	  targets	  sequence	  analysis	  would	  be	  undertaken	  to	  identify	  the	  final	  selection	  that	  would	  be	  likely	  to	  be	  most	  suitable	  for	  crystallographic	  experiments.	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Figure 1.7: Hydropathy plots of B. pseudomallei proteins using the Kyte-Doolittle scale 
of hydrophobicity (Kyte & Doolittle, 1982), created using the Molecular Toolkit server 
from Colorado State University (www.vivo.colostate.edu/molkit/). 
 
Top: The hydropathy plot of BPSL1204, a lipoprotein of unknown function. As can be 
seen, a highly hydrophobic (>1.0) N-terminal region is seen, which forms a signalling 
peptide for insertion though a cell membrane. 
 
Bottom: The hydropathy plot of BPSL1549, a known secreted toxin (Cruz-Migoni et al, 
2011). No N- or C-terminal hydrophobic sequences are seen, as this protein is secreted 
and does not associate with a membrane. 
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1.3.2	  Prediction	  of	  Unknown	  Function	  From	  Structure	  	  The	  most	  common	  application	  of	  structural	  biology	  is	  to	  take	  a	  protein	  of	  known	  function,	  and	  through	  structural	  analysis	  discover	  the	  biomechanics	  and	  chemistry	  of	  the	  molecules’	  biological	  functions	  at	  the	  atomic	  level.	  In	  recent	  years,	  as	  the	  Protein	  Database	  (PDB)	  (www.pdb.org)(Berman	  et	  al,	  2000)	  has	  compiled	  an	  increasing	  amount	  of	  structural	  coordinates	  (Figure	  1.8),	  the	  process	  of	  discovering	  structures	  of	  known	  function	  has	  often	  become	  experimentally	  simpler	  due	  to	  the	  international	  accessibility	  to	  a	  database	  of	  homologous	  structures	  that	  facilitate	  a	  more	  pipeline-­‐based	  method	  of	  solving	  structures	  by	  Molecular	  Replacement	  (Blow	  and	  Rossmann,	  1962)	  (McCoy	  et	  al,	  2007).	  Therefore,	  the	  structural	  solution	  of	  a	  protein	  of	  totally	  unknown	  function	  with	  no	  known	  homologous	  structures	  provides	  both	  a	  more	  experimentally	  challenging	  aim	  to	  a	  project,	  but	  also	  holds	  within	  the	  potential	  to	  discover	  a	  novel	  biological	  process	  in	  the	  organism	  under	  investigation.	  	  With	  an	  X-­‐ray	  crystal	  structure	  solved,	  structural	  coordinates	  of	  the	  protein	  of	  unknown	  function	  can	  be	  compared	  to	  databases	  of	  known	  structural	  coordinates	  to	  search	  for	  structural	  similarity,	  even	  if	  sequence	  homology	  does	  not	  exist.	  Many	  proteins	  carry	  out	  similar	  processes	  to	  each	  other,	  but	  totally	  lack	  any	  sequence	  homology.	  For	  example,	  the	  FtsZ	  bacterial	  septum	  protein	  (Bramhill	  &	  Thompson,	  1994)	  has	  no	  sequence	  homology	  to	  any	  eukaryotic	  tubulin	  proteins	  (Howard	  &	  Hyman,	  2003),	  yet	  structurally	  they	  are	  very	  similar	  and	  play	  analogous	  roles	  in	  contraction	  and	  cell	  division	  (Carballido-­‐Lopez	  &	  Errington,	  2003).	  Therefore	  a	  protein	  that	  has	  no	  function	  assigned	  to	  its	  sequence	  may	  be	  investigated	  structurally	  to	  discover	  a	  possible	  function	  in	  a	  biological	  process	  using	  comparative	  bioinformatics	  techniques.	  	  1.3.3	  Support	  of	  Structural	  Findings	  with	  Experimental	  Data	  	  Upon	  structural	  assessment	  and	  the	  assignment	  of	  a	  putative	  biological	  role	  to	  the	  protein	  under	  investigation,	  a	  series	  of	  experiments	  are	  required	  to	  give	  biological	  proof	  of	  the	  proposed	  function.	  These	  take	  the	  form	  of	  activity	  assays,	  
	   18	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  
Figure 1.8: A bar chart plotting the growth of the PDB (Total and Yearly 
depositions) (www.pdb.org) (Berman et al, 2000). Since its conception in 1971 
with a total of 7 structures, the PDB has slowly grown over time, and began to 
develop rapidly in the late 1990’s with the dawn of modern structural biology 
techniques and the World Wide Web.  
 
As of 1st September 2012, there were 84,381 structures deposited, of which 74131 
were X-ray crystallographic. Of these, nearly 70% were solved by Molecular 
Replacement methods. 
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interaction	  assays,	  structural	  investigation	  of	  complexes	  and	  potentially	  microbiological	  investigation	  in	  the	  form	  of	  knockout	  and	  localisation	  studies.	  With	  results	  that	  corroborate	  with	  the	  structural	  assignment	  of	  function,	  it	  can	  be	  declared	  that	  the	  function	  of	  a	  previously	  undiscovered	  protein	  has	  been	  deduced	  through	  the	  application	  of	  structural	  biology.	  This	  process	  will	  also	  indicate	  the	  likely	  function	  of	  proteins	  with	  high	  sequence	  homology.	  	  1.3.4	  Potential	  Medical	  Applications	  	  Very	  little	  is	  known	  regarding	  the	  biochemical	  background	  to	  melioidosis,	  and	  even	  less	  is	  known	  about	  the	  role	  of	  membrane-­‐associated	  proteins	  in	  B.	  
pseudomallei.	  Therefore	  the	  investigation	  of	  proteins	  of	  unknown	  function	  and	  the	  discovery	  of	  their	  cellular	  roles	  holds	  the	  potential	  to	  unlock	  new	  understanding	  about	  the	  pathogenic	  nature	  of	  B.	  pseudomallei,	  the	  disease	  state	  of	  melioidosis	  and	  hopefully	  give	  insight	  into	  the	  treatment	  of	  such	  a	  dangerous	  disease.	  	  	  As	  discussed	  previously,	  membrane-­‐associated	  proteins	  are	  often	  involved	  with	  processes	  such	  as	  defence	  against	  antibiotic	  attack,	  survival	  by	  nutrient	  uptake	  and	  toxin	  expulsion	  and	  are	  often	  instrumental	  in	  the	  processes	  that	  allow	  a	  bacterial	  cell	  to	  adhere	  to,	  culture	  inside	  of	  and	  attack	  a	  host	  organism	  (Hayashi	  &	  Wu,	  1990).	  As	  such,	  especially	  in	  the	  latter	  example,	  membrane-­‐associated	  proteins	  such	  as	  lipoproteins	  may	  also	  act	  as	  surface	  antigenic	  agents	  that	  can	  be	  exploited	  as	  a	  means	  of	  detecting	  an	  infection	  with	  increased	  rapidity.	  By	  understanding	  the	  biological	  defence,	  survival	  and	  attack	  roles	  that	  an	  unknown	  membrane-­‐protein	  may	  play	  in	  B.	  pseudomallei	  infections,	  therapeutic	  applications	  could	  be	  developed	  to	  aid	  in	  the	  treatment	  of	  melioidosis	  and	  thus	  decrease	  the	  mortality	  rate	  of	  a	  life-­‐threatening	  disease	  that	  affects	  so	  many	  people	  in	  regions	  of	  endemicity.	  
	   20	  
Chapter	  2:	  X-­ray	  Crystallographic	  Theory	  	  
2.1	  Introduction	  	  The	  science	  of	  determining	  the	  3D	  structure	  of	  a	  biomacromolecule	  using	  the	  diffraction	  of	  X-­‐rays	  from	  a	  crystalline	  protein	  sample	  has	  been	  evolved	  over	  a	  long	  period	  of	  time.	  Wilhelm	  Conrad	  Röntgen	  discovered	  X-­‐rays	  in	  Würzberg	  in	  1895	  with	  the	  first	  crystallographic	  diffraction	  experiments	  carried	  out	  in	  Cambridge	  by	  William	  and	  Henry	  Bragg	  in	  1912.	  Max	  Perutz	  and	  John	  Kendrew	  eventually	  adapted	  these	  to	  provide	  the	  first	  protein	  crystal	  structure	  of	  myoglobin	  in	  1958	  (Kendrew	  &	  Perutz,	  1957).	  The	  introduction	  of	  multiple-­‐wavelength	  synchrotron	  radiation	  for	  phasing	  experiments	  around	  1994	  has	  led	  to	  the	  modern	  age	  of	  protein	  structure	  determination,	  in	  which	  the	  variation	  and	  number	  of	  known	  protein	  structures	  has	  rapidly	  increased,	  reflected	  by	  the	  contents	  of	  the	  PDB	  (Berman	  et	  al,	  2000)	  (Figure	  1.8	  in	  Section	  1.3.2).	  	  This	  section	  aims	  to	  briefly	  describe	  the	  basic	  practices	  and	  principles	  that	  allow	  for	  the	  determination	  of	  a	  novel	  protein	  structure	  using	  X-­‐ray	  methods	  upon	  crystalline	  protein.	  For	  more	  in	  depth	  historical	  accounts	  and	  greater	  details	  on	  experimentally	  and	  theoretically	  derived	  evidence,	  the	  author	  directs	  you	  to	  the	  texts	  of	  Rhodes,	  G	  (2000),	  Blow,	  D	  (2002)	  and	  Rupp,	  B	  (2009).	  	  
2.2	  Protein	  Crystallisation	  	  2.2.1	  Introduction	  	  In	  order	  to	  immobilise	  protein	  in	  a	  form	  that	  can	  be	  manipulated,	  and	  to	  amplify	  the	  signal	  generated	  from	  the	  weak	  X-­‐ray	  diffraction	  from	  a	  protein’s	  electrons,	  the	  crystallisation	  of	  a	  protein	  is	  an	  essential	  first	  step	  in	  structure	  determination	  by	  X-­‐ray	  methods.	  The	  ultimate	  aim	  of	  a	  crystallisation	  experiment	  is	  to	  increase	  the	  saturation	  of	  a	  protein	  in	  solution	  as	  to	  favour	  the	  organised	  removal	  of	  protein	  from	  solution	  into	  a	  solid	  state	  consisting	  of	  a	  regularly	  arranged	  crystal	  lattice,	  with	  the	  lattice	  held	  together	  by	  weak	  intermolecular	  forces.	  As	  such,	  protein	  crystals	  are	  very	  fragile	  and	  easily	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damaged	  or	  destroyed.	  Crystallisation	  is	  done	  in	  the	  presence	  of	  various	  precipitants,	  buffers	  and	  additives	  that	  create	  an	  environment	  with	  the	  correct	  pH	  for	  appropriate	  surface-­‐charge	  distributions,	  conformational	  homogeneity	  and	  availability	  of	  intermolecular	  contacts	  to	  allow	  a	  periodic	  array	  of	  macromolecules	  to	  form.	  The	  phase	  diagram	  in	  Figure	  2.1	  represents	  the	  overall	  aim	  of	  a	  protein	  crystallisation	  experiment	  (Rupp,	  2009).	  	  2.2.2	  Vapour	  Diffusion	  	  	  The	  most	  commonly	  employed	  method	  for	  crystallisation	  involves	  the	  process	  of	  water	  vapour	  diffusion	  from	  a	  protein-­‐containing	  solution	  leading	  to	  an	  increase	  in	  protein	  concentration	  that	  eventually	  leads	  to	  super-­‐saturation,	  resulting	  in	  crystallisation	  success	  or	  material	  precipitation	  (Benvenuti	  &	  Mangani,	  2007).	  The	  following	  sub-­‐sections	  describe	  the	  key	  steps	  and	  aims	  in	  variations	  of	  vapour-­‐diffusion	  experiments:	  	  
2.2.2a:	  Hanging-­drop	  Vapour	  Diffusion:	  a	  small	  drop	  (commonly	  2	  µl)	  of	  protein	  solution	  is	  placed	  in	  the	  centre	  of	  a	  sterile,	  siliconised	  cover	  slip,	  into	  which	  is	  mixed	  an	  equal	  volume	  of	  the	  crystallisation	  solution.	  This	  leads	  to	  the	  two-­‐fold	  dilution	  of	  the	  crystallisation	  solution	  in	  the	  drop.	  The	  cover	  slip	  is	  then	  inverted	  over	  a	  reservoir-­‐well	  containing	  the	  original	  crystallisation	  solution	  in	  much	  greater	  volume	  (500-­‐1000	  µl),	  with	  the	  well-­‐lip	  greased	  to	  allow	  the	  sealing	  of	  a	  enclosed	  system	  by	  the	  inverted	  cover-­‐slip.	  	  	  Over	  time,	  water	  vapour	  diffuses	  from	  the	  drop	  into	  the	  reservoir	  in	  order	  to	  equilibrate	  the	  concentration	  of	  chemicals	  in	  the	  reservoir	  with	  those	  in	  the	  drop,	  and	  in	  doing	  so	  slowly	  raises	  the	  concentration	  of	  protein	  and	  precipitant	  chemicals	  in	  the	  drop	  (Mikol	  et	  al,	  1990).	  At	  some	  point,	  protein	  becomes	  saturated	  and	  slowly	  begins	  to	  drop	  out	  of	  solution.	  If	  the	  conditions	  this	  occurs	  in	  are	  appropriate,	  then	  periodic	  protein	  nucleation	  begins,	  leading	  to	  crystal	  growth	  (Chayen,	  1998).	  The	  set-­‐up	  for	  a	  hanging-­‐drop	  experiment	  is	  illustrated	  in	  Figure	  2.2.	  This	  method	  has	  the	  advantage	  of	  often	  producing	  larger	  crystals,	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Figure 2.1: Crystallisation phase diagram. The starting drop (SD) consists of 1:1 
protein solution (P): precipitant reservoir (R). As vapour diffusion into the reservoir 
occurs, the concentration of protein and precipitant in the drop increases, until: 
 
1) Solution becomes saturated enough for spontaneous nucleation 
2) Crystals may start to grow 
3) While the crystals grow, the [protein] depletes in the solution, and a few 
initial crystals grower larger in the growth region 
4) Once the larger crystals are in equilibrium with the saturated protein 
solution, growth slows and stops. Crystals have reached final size. 
 
If the protein solution supersaturates too quickly, or the precipitant reservoir does 
not stabilise protein folding, spontaneous precipitation occurs. Figure adapted from 
Rupp, 2009 
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Figure 2.2: Illustrations of the set-up of crystallisation 
experiments. Top: Hanging-drop vapour diffusion. 
Bottom: Sitting-drop vapour diffusion.  
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with	  the	  volume	  of	  drops	  and	  reservoirs	  used	  easily	  varied.	  In	  addition,	  the	  manipulation	  of	  crystals	  from	  the	  flat-­‐bottomed	  (when	  cover	  slips	  are	  re-­‐inverted)	  larger	  drops	  is	  a	  relatively	  easier	  process	  than	  in	  other	  methods,	  as	  crystals	  rarely	  grow	  in	  contact	  with	  the	  cover	  slip	  and	  are	  accessible	  from	  multiple	  angles.	  A	  major	  disadvantage	  of	  this	  technique	  is	  that	  it	  cannot	  be	  automated,	  and	  thus	  the	  setting-­‐up	  of	  experiments	  can	  be	  laborious,	  time-­‐consuming	  and	  expensive.	  	  
2.2.2b:	  Sitting	  Drop	  Vapour	  Diffusion:	  The	  principles	  involved	  in	  this	  technique	  are	  similar	  to	  those	  of	  hanging-­‐drop	  experiments.	  The	  main	  difference	  is	  the	  set-­‐up	  of	  the	  experiment.	  The	  crystallisation	  drop	  is	  mixed	  on	  a	  raised,	  indented	  pedestal	  in	  the	  reservoir	  well,	  with	  the	  system	  often	  sealed	  with	  clear	  tape	  (Chayen,	  1998).	  This	  set-­‐up	  is	  illustrated	  in	  Figure	  2.2.	  This	  allows	  for	  the	  creation	  of	  small-­‐scale	  crystallisation	  plates,	  often	  with	  96	  wells,	  which	  can	  be	  readily	  automated	  for	  speed	  and	  consistency.	  	  	  The	  smaller-­‐scale	  (often	  200-­‐400	  nl	  drops	  and	  50-­‐100	  µl	  reservoirs)	  and	  automated	  speed	  allows	  for	  more	  screens	  to	  be	  performed	  per	  volume	  of	  pure	  protein	  solution	  available.	  This	  can	  led	  to	  more	  efficient	  investigation	  on	  the	  effects	  of	  temperature	  or	  protein	  concentration	  on	  crystal	  growth,	  with	  repeats	  of	  the	  same	  screen	  left	  to	  incubate	  in	  a	  variety	  of	  temperatures	  and	  protein	  concentrations.	  As	  such,	  modern	  crystallography	  laboratories	  regularly	  use	  automated	  sitting-­‐drop	  plates	  as	  a	  first	  screening	  step	  in	  the	  crystallisation	  process.	  This	  technique	  does	  have	  disadvantages	  though,	  as	  frequently	  only	  small	  crystals	  grow	  in	  the	  smaller	  drops	  and	  they	  have	  the	  potential	  to	  settle	  on	  and	  stick	  to	  the	  bottom	  of	  the	  raised	  well.	  The	  fragile	  protein	  crystals	  are	  also	  much	  harder	  to	  manipulate	  for	  diffraction	  studies	  due	  to	  fewer	  angles	  of	  accessibility.	  In	  addition	  the	  dispensing	  of	  96	  or	  more	  conditions	  before	  the	  sealing	  of	  plates	  can	  lead	  to	  conditions	  that	  differ	  slightly	  from	  those	  intended,	  making	  re-­‐growth	  more	  challenging,	  especially	  if	  solutions	  contain	  high	  concentrations	  of	  volatile	  chemicals	  are	  exposed	  to	  the	  environment	  for	  too	  long.	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2.2.3	  Batch	  Diffusion	  	  In	  this	  method,	  high-­‐concentration	  drops	  of	  protein	  solution	  and	  crystallisation	  condition	  are	  mixed	  and	  sealed	  under	  oil,	  or	  are	  applied	  to	  an	  oil	  covered	  micro-­‐titer	  plate	  and	  allowed	  to	  sink	  through	  the	  oil	  to	  mix.	  This	  keeps	  the	  supersaturated	  drop	  sealed	  away	  from	  the	  environment.	  Water-­‐permeable	  oil	  can	  be	  used	  to	  allow	  for	  the	  very	  slow	  diffusion	  of	  water	  vapour	  from	  the	  drop	  into	  the	  environment	  to	  further	  increase	  concentrations	  in	  the	  drop	  over	  time	  (Chayen,	  1998).	  This	  method	  lends	  itself	  to	  automation	  due	  to	  sealing	  by	  the	  application	  of	  small	  volumes	  of	  oil,	  and	  has	  a	  main	  advantage	  in	  that	  conditions	  are	  sealed	  immediately	  and	  not	  exposed	  to	  the	  environment	  during	  set-­‐up,	  reducing	  variation	  from	  intended	  conditions.	  However,	  this	  process	  is	  the	  most	  difficult	  to	  manipulate	  crystals	  from,	  with	  access	  to	  crystals	  blocked	  by	  the	  depth	  of	  the	  vessel	  used	  for	  the	  experiment	  and	  the	  need	  to	  loop	  a	  weak	  protein	  crystal	  through	  a	  layer	  of	  immiscible	  oil.	  	  2.2.4	  Dialysis	  	  The	  well-­‐established	  principle	  of	  dialysis	  has	  been	  adapted	  to	  the	  growth	  of	  protein	  crystals.	  Dialysis	  ‘buttons’	  made	  of	  acrylic	  with	  a	  dialysis-­‐membrane-­‐sealable	  opening	  allow	  the	  free	  transfer	  of	  small	  molecules	  such	  as	  buffers	  and	  precipitants	  across	  the	  membrane,	  but	  retain	  the	  larger	  protein	  molecules	  and	  high	  molecular	  weight	  precipitants	  such	  as	  poly-­‐ethylene	  glycols	  (PEGs).	  This	  facilitates	  the	  transfer	  of	  the	  crystallisation	  drop	  from	  one	  crystallisation	  solution	  to	  another,	  often	  carried	  out	  in	  a	  screen-­‐designed	  sequence	  (Thomas	  et	  al,	  1989).	  This	  can	  allow	  for	  the	  supersaturation	  of	  the	  solution,	  and	  thus	  protein	  crystallisation,	  by	  increasing	  the	  concentration	  and/or	  type	  of	  precipitant	  in	  the	  drop.	  This	  method	  is	  particularly	  useful	  for	  the	  growth	  or	  larger	  crystals,	  and	  allows	  for	  screening	  of	  many	  conditions	  using	  just	  one	  dialysis	  button.	  However,	  this	  process	  cannot	  be	  miniaturised	  and	  cannot	  be	  automated.	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2.2.5	  Optimisation	  of	  Crystallisation	  	  After	  the	  establishing	  of	  a	  solution	  that	  generates	  at	  least	  poor	  quality	  crystals,	  a	  screen	  is	  set	  up	  to	  optimise	  this	  condition	  to	  produce	  the	  best	  quality	  crystals	  possible	  for	  diffraction	  studies.	  Often	  this	  is	  achieved	  by	  a	  screen	  set	  up	  to	  vary	  all	  applicable	  parameters	  (pH,	  [precipitant],	  [salt],	  [protein],	  temperature	  and	  drop	  volume	  and	  ratio)	  around	  the	  original	  hit	  to	  probe	  for	  the	  best	  condition	  possible.	  However,	  this	  may	  also	  involve	  the	  use	  of	  a	  different	  technique	  than	  the	  one	  originally	  employed,	  for	  example	  slowing	  down	  the	  rate	  of	  rapidly	  nucleating	  hanging-­‐drop	  conditions	  by	  batch-­‐diffusion	  methods	  or	  by	  replicating	  sitting-­‐drop	  conditions	  as	  hanging	  drops	  to	  improve	  crystal	  size,	  number	  of	  crystal	  per	  drop	  or	  accessibility	  to	  particularly	  weak	  crystals.	  In	  addition	  to	  method	  variation,	  occasionally	  crystals	  can	  be	  encouraged	  to	  grow	  larger	  by	  seeding	  drops	  with	  nucleation-­‐points	  derived	  from	  the	  fragmentation	  of	  smaller	  pre-­‐formed	  crystals.	  This	  induces	  crystal	  growth	  by	  reducing	  the	  saturation	  required	  before	  crystal	  can	  grow,	  as	  a	  nucleation	  origin	  is	  already	  supplied.	  	  If	  screening	  by	  the	  methods	  described	  above	  yields	  no	  crystals,	  which	  is	  possible	  as	  no	  protein	  can	  be	  guaranteed	  to	  crystallise,	  then	  modification	  of	  the	  protein	  sample	  may	  be	  required	  (Dale	  et	  al,	  2003).	  Common	  methods	  included	  removal	  of	  purification	  tags,	  directed	  or	  random	  proteolysis,	  cloning	  of	  individual	  domains,	  co-­‐crystallisation	  with	  a	  binding-­‐partner	  or	  substrate	  and	  modifications	  such	  as	  glycosylation	  or	  deglycosylation	  (Dale	  et	  al,	  2003).	  Modified	  protein	  samples	  are	  then	  re-­‐screened	  and	  optimised.	  Once	  high	  quality	  crystals	  are	  achieved,	  then	  X-­‐ray	  diffraction	  studies	  can	  begin.	  	  
2.3	  Generation	  of	  X-­rays	  	  2.3.1	  Rotating	  Anodes	  	  X-­‐rays	  are	  required	  to	  be	  used	  for	  diffraction	  experiments,	  as	  they	  exist	  in	  the	  electromagnetic	  spectrum	  as	  photons	  with	  wavelengths	  that	  closely	  match	  the	  lengths	  of	  chemical	  bonds	  and	  therefore	  allow	  atomic	  structures	  to	  be	  resolved.	  Moderately	  hard	  X-­‐rays	  are	  used,	  due	  to	  their	  ability	  to	  penetrate	  matter.	  Most	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in-­‐house	  X-­‐ray	  production	  is	  carried	  out	  using	  a	  copper	  anode	  to	  emit	  X-­‐rays	  as	  CuKα-­‐wavelength	  photons.	  This	  results	  in	  monochromatic	  X-­‐rays	  of	  1.54	  Å	  wavelength	  at	  an	  energy	  of	  8040	  eV.	  X-­‐rays	  are	  produced	  when	  high-­‐energy	  electrons	  decelerate	  rapidly	  in	  an	  electron-­‐dense	  target	  material;	  therefore	  a	  high-­‐energy	  electron	  beam	  is	  required.	  This	  is	  produced	  by	  a	  metal	  filament	  cathode	  (commonly	  tungsten)	  opposite	  a	  copper	  anode	  in	  a	  vacuum-­‐sealed	  tube.	  When	  high	  voltage	  is	  applied	  to	  the	  cathode	  high-­‐energy	  electrons	  leave	  the	  cathode	  and	  travel	  to	  the	  anode.	  Upon	  impacting	  the	  anode,	  occasionally	  an	  electron	  is	  removed	  from	  the	  inner-­‐shell	  of	  a	  copper	  atom,	  leaving	  a	  ‘hole’	  that	  is	  filled	  by	  an	  outer-­‐shell	  electron	  dropping	  down	  energy	  levels	  to	  complete	  the	  inner-­‐shell	  and	  relax	  the	  high-­‐energy	  state.	  	  	  The	  energy	  released	  by	  the	  transfer	  of	  the	  electron	  down	  the	  electronic	  energy	  shells	  is	  released	  as	  heat	  and	  photons	  in	  the	  X-­‐ray	  range.	  It	  is	  important	  to	  note	  that	  approximately	  99%	  of	  energy	  released	  transfers	  into	  heat.	  In	  order	  to	  prevent	  the	  melting	  of	  the	  anode	  during	  high-­‐energy	  X-­‐ray	  generation	  (which	  historically	  occurred	  in	  sealed	  cathode	  ray	  tubes)	  the	  target	  anode	  is	  made	  to	  rotate	  at	  high	  speed	  (~10	  krpm)	  through	  a	  water-­‐cooled	  housing.	  This	  allows	  the	  dissipation	  of	  heat	  energy	  and	  spreads	  the	  impingement	  of	  the	  electron	  beam	  over	  the	  entire	  surface	  of	  the	  anode	  instead	  of	  on	  one	  fixed	  point,	  allowing	  for	  greater	  energies	  used	  in	  X-­‐ray	  production	  and	  increasing	  the	  longevity	  of	  the	  anode	  material.	  	  Emitted	  X-­‐rays	  are	  then	  directed	  and	  collimated	  by	  allowing	  a	  small	  fraction	  through	  an	  entrance	  slit,	  which	  is	  made	  from	  a	  material	  that	  absorbs	  X-­‐rays	  above	  the	  CuKα	  range,	  such	  as	  nickel,	  or	  by	  use	  of	  a	  graphite	  or	  germanium	  crystal	  as	  a	  monochromator.	  This	  is	  then	  collimated	  into	  a	  less	  divergent	  beam	  by	  a	  secondary	  slit,	  before	  the	  X-­‐rays	  pass	  through	  the	  small	  holes	  of	  a	  collimator	  to	  leave	  a	  near	  parallel	  beam	  for	  focussing	  onto	  a	  crystal.	  This	  beam,	  though	  dramatically	  reduced	  in	  divergence,	  can	  still	  have	  a	  relatively	  large	  minimum	  area	  of	  exposure	  of	  500	  µm.	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2.3.2	  Synchrotron	  Radiation	  	  In	  order	  to	  achieve	  energies	  that	  allow	  for	  high-­‐resolution	  diffraction	  from	  a	  protein	  crystal	  to	  contain	  information	  bordering	  on	  a	  sub-­‐atomic	  level,	  and	  to	  utilise	  the	  unique	  absorptive	  properties	  of	  heavy	  atoms	  in	  calculating	  phase	  solutions	  (see	  Section	  2.6.2),	  tuneable,	  high-­‐energy	  particle	  accelerators	  called	  synchrotrons	  are	  used	  in	  modern	  crystallography	  (Hendrickson,	  2000).	  When	  a	  beam	  of	  electrons	  is	  forced	  by	  application	  of	  electrical	  and	  magnetic	  fields	  to	  move	  in	  a	  circular	  orbit,	  acceleration	  occurs	  due	  to	  centripetal	  force	  and	  radiation	  is	  emitted.	  When	  supplied	  with	  sufficient	  energy,	  electrons	  can	  maintain	  a	  stable	  circular	  orbit.	  Radiation	  is	  emitted	  tangentially	  from	  and	  restricted	  to	  the	  plane	  of	  the	  electron	  orbit.	  	  	  Synchrotrons	  (so	  named	  as	  they	  keep	  electrons	  in	  a	  synchronous	  path)	  are	  initiated	  by	  a	  electron	  gun	  fired	  into	  a	  linear	  injector	  for	  pre-­‐acceleration,	  from	  which	  high-­‐energy	  electrons	  are	  fed	  into	  a	  main	  storage	  ring	  in	  bunches	  after	  passing	  through	  a	  smaller	  booster	  ring.	  When	  injected	  into	  the	  storage	  ring,	  in	  order	  to	  maintain	  a	  stable	  orbit,	  energy	  lost	  by	  radiation	  is	  replaced	  on	  each	  pass	  of	  the	  ring	  using	  radio-­‐frequency	  generators.	  Electrons	  are	  then	  accelerated	  to	  near	  the	  speed	  of	  light	  by	  deflection	  into	  a	  ring	  by	  bending	  magnets,	  and	  more	  powerful	  insertion	  devices	  such	  as	  undulators	  and	  wigglers	  that	  ‘wiggle’	  the	  electrons	  through	  a	  high,	  alternating	  magnetic	  field.	  As	  the	  magnetic	  contribution	  to	  an	  electromagnetic	  wave	  contributes	  significantly	  less	  than	  the	  electronic	  component,	  the	  considerable	  size	  of	  these	  magnets	  required	  to	  generate	  a	  strong	  enough	  magnetic	  field	  is	  one	  of	  the	  reasons	  synchrotrons	  are	  so	  large	  (Rupp,	  2009).	  	  Beamlines	  are	  built	  from	  the	  main	  ring	  at	  a	  tangent	  to	  the	  forward	  direction	  of	  the	  electron	  orbit	  to	  collect	  the	  tangentially	  emitted	  radiation	  that	  includes	  photons	  in	  the	  X-­‐ray	  range.	  X-­‐rays	  are	  then	  selected	  from	  the	  radiation	  beam	  by	  an	  array	  of	  optics	  many	  metres	  long,	  such	  as	  collimating	  mirrors	  that	  fine-­‐focus	  a	  large	  fraction	  of	  polychromatic	  light	  onto	  double-­‐crystal	  monochromators.	  The	  relative	  positions	  of	  these	  devices	  allow	  for	  the	  selection	  of	  specific	  wavelengths	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of	  radiated	  light	  with	  high-­‐intensity	  and	  low-­‐divergence,	  resulting	  in	  brilliant,	  focussed	  beams	  (down	  to	  micro-­‐beams	  of	  10	  µm2)	  of	  a	  tuneable	  energy.	  	  2.3.3	  Detection	  of	  X-­‐rays	  	  
2.3.3a:	  Image	  Plate	  Detectors:	  This	  method	  of	  X-­‐ray	  detection	  utilises	  the	  photoluminescence	  induced	  in	  BaFBr	  crystals,	  treated	  with	  lanthanide	  ions	  such	  as	  Eu2+,	  when	  exposed	  to	  X-­‐ray	  radiation	  (Miyahari	  et	  al,	  1986).	  The	  non-­‐diffracted	  beam	  is	  blocked	  by	  the	  diffractometer	  backstop,	  as	  the	  sample	  protein	  crystal	  does	  not	  diffract	  the	  majority	  of	  the	  X-­‐ray	  beam.	  The	  BaFBr-­‐lanthanide	  crystals	  in	  the	  detector	  phosphoresce	  at	  the	  points	  of	  exposure	  to	  diffracted	  beams,	  and	  are	  scanned	  by	  He-­‐Ne	  lasers	  to	  induce	  energy	  release	  from	  the	  plate-­‐crystals	  as	  photons,	  which	  are	  read	  by	  a	  photomultiplier	  and	  saved	  as	  a	  digital	  image.	  High	  intensity	  white	  light	  is	  used	  to	  erase	  the	  plate	  for	  use	  with	  the	  next	  image	  collection.	  The	  slow	  readout	  time	  generally	  makes	  these	  detectors	  only	  compatible	  with	  in-­‐house	  sources	  (such	  as	  CuKα	  rotating	  anode	  sources).	  	  
2.3.3b:	  Charged-­Coupled	  Device	  (CCD)	  detectors:	  CCD	  detectors	  deliver	  a	  digital	  image	  of	  diffraction	  via	  high-­‐pixel	  CCD	  semi-­‐conductor	  chips.	  These	  are	  connected	  to	  a	  thin	  fluorescent	  screen	  (commonly	  made	  of	  Gd2O2S	  treated	  with	  Tb)	  via	  optical	  glass-­‐fibre	  tapers	  (Pflugrath,	  1999).	  Photons	  emitted	  from	  X-­‐rays	  absorbed	  by	  the	  fluorescent	  screen	  pass	  via	  the	  optical	  glass-­‐fibre,	  and	  upon	  contact	  with	  the	  semi-­‐conductor	  chips	  in	  the	  CCD	  core	  generate	  free	  electrons	  proportional	  to	  the	  number	  of	  photons	  emitted	  from	  the	  screen	  to	  create	  a	  raw	  electronic	  image	  (Kraft	  et	  al,	  2009).	  Due	  to	  limitations	  of	  how	  many	  chips	  and	  optical	  tapers	  can	  be	  associated	  with	  one	  screen,	  an	  array	  of	  detectors	  (3	  x	  3	  for	  example)	  are	  usually	  combined	  to	  record	  each	  image	  to	  the	  highest	  resolution.	  Due	  to	  very	  high	  sensitivity	  and	  near-­‐instantaneous	  image	  collection,	  with	  no	  resetting	  of	  the	  detector	  required,	  exposure	  time	  to	  high-­‐intensity	  synchrotron	  radiation	  sources	  is	  kept	  low.	  Entire	  datasets	  can	  be	  collected	  in	  a	  matter	  of	  minutes	  using	  CCD	  detectors	  and	  synchrotron	  radiation	  (Hammersley	  et	  al,	  1997),	  compared	  to	  the	  long	  exposures	  required	  (5	  minutes	  per	  image	  and	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several	  minutes	  to	  record	  each	  =	  21	  hours	  for	  a	  standard	  180°	  dataset	  in	  space-­‐group	  C2)	  using	  image-­‐plates	  and	  CuKα	  radiation	  sources.	  	  
2.4	  Basics	  of	  X-­ray	  Diffraction	  	  2.4.1	  Braggs	  Law	  	  One	  of	  the	  most	  important	  concepts	  in	  X-­‐ray	  crystallography,	  which	  is	  crucial	  to	  the	  interpretation	  of	  diffraction	  experiments,	  is	  the	  satisfaction	  of	  the	  Bragg	  condition	  for	  coherent,	  constructive	  scattering	  (Ilari	  &	  Savino,	  2008).	  For	  the	  derivation	  of	  this	  law,	  groups	  of	  atoms	  are	  considered	  as	  being	  arranged	  in	  sets	  of	  adjacent	  planes.	  In	  order	  for	  the	  scattering	  of	  X-­‐rays	  from	  the	  electrons	  of	  an	  atom	  to	  be	  constructive	  (that	  is	  to	  add	  together)	  as	  opposed	  to	  destructive	  (cancel	  each	  other	  out)	  the	  distance	  between	  sets	  of	  adjacent	  atomic	  planes	  must	  keep	  the	  beam	  of	  incidence	  and	  the	  beam	  of	  reflection	  in	  phase.	  The	  Bragg	  equation	  is:	  	   nλ	  =	  2dhklsinθ	  	  where	  θ	  is	  the	  scattering	  angle	  and	  dhkl	  is	  the	  interplanar	  distance	  between	  sets	  of	  reflecting	  planes	  hkl	  (in	  Miller	  indices)	  and	  n	  is	  an	  integer	  (Perkins,	  1988).	  In	  order	  for	  constructive	  diffraction	  to	  occur,	  n	  is	  required	  to	  be	  an	  integer.	  	  If	  the	  diffracted	  beams	  from	  two	  planes	  emerge	  out	  of	  phase,	  then	  they	  cancel	  each	  other	  out.	  However	  if	  they	  emerge	  in-­‐phase,	  then	  they	  become	  additive	  and	  generate	  a	  stronger,	  cumulative	  reflection.	  Figure	  2.3	  illustrates	  the	  conditions	  required	  in	  order	  to	  satisfy	  the	  Bragg	  condition	  for	  constructive	  diffraction.	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Figure 2.3: Illustration to explain the Bragg Equation. The difference in 
path of the two partial waves between atoms in parallel planes is equal to 
2dsinθ. In order to achieve constructive interference, in which both waves 
emerge in phase, the path difference must equal an integer multiple of nλ.  
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The	  application	  of	  Bragg’s	  law,	  whereby	  X-­‐ray	  diffraction	  is	  treated	  as	  reflection	  from	  discrete	  planes	  of	  atoms,	  allows	  for	  the	  interpretation	  of	  diffraction	  patterns,	  as	  the	  angle	  of	  diffraction	  becomes	  linked	  to	  the	  spacing	  within	  the	  lattice.	  This	  can	  allow	  the	  rearrangement	  of	  the	  commonly	  quoted	  Bragg	  equation	  to	  give:	  	   nλ	  =	  2dhklsinθ	  	   becoming	  	  	  	  	  	  	  	  	  	  1/dhkl	  =	  2sinθ/nλ	  
	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  where	  1/dhkl	  is	  the	  distance	  in	  the	  reciprocal	  lattice,	  or	  in	  other	  words	  the	  distance	  between	  reflections	  measured	  in	  the	  crystal	  diffraction	  pattern.	  	  A	  change	  in	  oscillation	  angle	  during	  data	  collection	  is	  employed	  to	  ensure	  that	  all	  planes	  meet	  the	  Braggs	  condition.	  The	  positioning	  of	  a	  Bragg-­‐plane	  within	  a	  crystal	  into	  a	  geometric	  construction	  known	  as	  the	  Ewald	  Sphere	  allows	  for	  the	  prediction	  of	  2-­‐D	  reciprocal	  lattice	  points	  that	  can	  be	  potentially	  measured	  from	  3-­‐D	  diffraction	  over	  planes	  of	  distance	  1/dhkl	  (Figure	  2.4)	  (Ewald,	  1969).	  The	  sphere	  (shown	  as	  a	  2-­‐D	  circle	  in	  Figure	  2.4)	  with	  1/λ	  radius	  is	  combined	  with	  a	  representation	  of	  all	  the	  reciprocal	  lattice	  diffraction	  possibilities	  of	  the	  given	  crystal	  lattice	  placed	  over	  the	  point	  of	  origin	  on	  the	  Ewald	  Sphere.	  The	  reflections	  that	  carry	  the	  potential	  to	  be	  detected	  upon	  constructive	  diffraction	  of	  X-­‐rays	  from	  the	  Bragg-­‐planes	  in	  the	  crystal	  lie	  on	  the	  sphere’s	  circumference.	  	  When	  rotation	  of	  the	  crystal	  occurs,	  the	  correlating	  rotation	  of	  the	  reciprocal	  lattice	  on	  the	  sphere’s	  circumference	  allows	  the	  calculation	  of	  positions	  of	  reciprocal	  lattice	  reflections	  that	  fulfil	  the	  Bragg-­‐diffraction	  condition	  upon	  the	  change	  of	  diffraction	  angle	  (Leslie,	  2006).	  	  2.4.2	  Structure	  Factors	  and	  B-­‐Factors.	  	  Structure	  factors	  are	  expressions	  of	  the	  amplitude	  and	  phase-­‐angle	  of	  a	  wave	  after	  diffracting	  from	  a	  plane	  in	  a	  crystal	  lattice	  described	  by	  hkl	  (or	  h)	  Miller	  indices.	  Structure	  factors	  (Fhkl)	  are	  summations	  (Σ)	  of	  the	  scattering	  of	  X-­‐rays	  of	  every	  atom	  on	  a	  unit	  cell,	  and	  are	  calculated	  by:	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Figure 2.4: The Ewald Construction for a 2-D reciprocal lattice with Miller 
indices h0l. Reciprocal lattice points that fall upon the Ewald Sphere fulfil the 
Bragg-condition for diffraction, as the distance from the 000 origin (reflections 
-101 and -10-1 above) equals 1/dhkl = 2sinθ/1λ. 
 
Rotation of the crystal above rotates the reciprocal lattice by the same 
increment, bringing other lattice points such a -201 into the Ewald Sphere, 
creating a newly positioned diffraction spot that fulfils the Bragg condition from 
a different crystal plane. 
 
The construction above demonstrates the relationship between reciprocal lattice 
reflections and real lattice diffraction in 2-D for ease of illustration. In actuality 
these processes occur in 3-D, on the surface of a sphere and with a reciprocal 
lattice of variable hkl.  
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  atom	  
Fhkl	  =	  Σ	  	  ƒs0j	  ·exp[-­‐Bj(sinθ/λ)2]exp(2πihxj)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  j	  =	  1	  where	  h	  is	  the	  direction	  of	  atomic	  scattering	  (ƒs),	  whilst	  xj	  is	  the	  position	  of	  the	  jth	  atom	  measured	  in	  fractional	  coordinates.	  	  	  
Bj	  represents	  an	  isotropic	  displacement	  parameter,	  or	  in	  other	  words	  a	  B-­factor	  to	  account	  for	  the	  motion	  of	  atoms	  within	  a	  molecule	  where	  Biso	  =	  8π2<u2iso>	  (where	  <u2iso>	  is	  the	  mean	  square	  isotropic	  displacement	  of	  an	  atom	  from	  its	  mean	  position)	  (Einstein,	  1926).	  Also	  known	  as	  a	  Debye-­‐Waller	  factor	  (Debye,	  1913;	  Waller,	  1923),	  B-­‐factors	  describe	  displacement	  of	  an	  atom	  from	  a	  mean	  position,	  as	  a	  product	  of	  thermal	  or	  vibration	  movement,	  and	  disorder	  within	  a	  lattice.	  These	  effects	  attenuate	  atomic	  scattering,	  and	  as	  such	  have	  a	  negative	  effect	  on	  diffraction	  intensity	  and	  thus	  amplitude.	  The	  B-­‐factor	  of	  each	  atom	  scattering	  is	  related	  to	  the	  scattering	  vector	  calculated	  using	  the	  diffraction	  angle,	  represented	  by	  the	  (sinθ/λ)2	  term.	  As	  the	  summed	  amplitudes	  of	  diffraction	  are	  subject	  to	  atomic	  scattering	  positions	  in	  a	  defined	  direction,	  attenuated	  by	  B-­‐factors	  (Rupp,	  2009),	  these	  terms	  can	  be	  condensed	  and	  structure	  factors	  can	  be	  re-­‐written	  as:	  	  
Fh	  =	  |Fh|	  exp	  [2πi	  φ(h)]	  	  Where	  φ(h)	  represents	  the	  interpretation	  of	  hxj	  as	  a	  summed	  phase-­‐angle	  applied	  to	  summed	  amplitudes	  |Fhkl|.	  In	  a	  Bragg’s	  diffraction	  such	  as	  in	  Figure	  2.3,	  the	  addition	  of	  an	  atom	  in	  a	  new,	  parallel	  plane	  that	  still	  fulfils	  the	  same	  Bragg	  condition	  creates	  a	  phase	  difference	  between	  the	  scattering	  from	  the	  atoms	  in	  the	  original	  and	  new	  planes.	  Upon	  the	  addition	  of	  all	  atoms	  in	  all	  planes	  that	  satisfy	  the	  Bragg	  condition	  in	  a	  given	  crystalline	  molecule,	  a	  net	  phase-­‐difference	  is	  created.	  These	  summations	  can	  be	  shown	  in	  an	  Argand	  diagram	  (Figure	  2.5)	  in	  which	  cumulative	  plotting	  of	  atomic	  scattering	  factors	  (proportional	  to	  amplitudes)	  of	  all	  atoms	  with	  individual	  phase	  differences	  leads	  to	  the	  final	  structure	  factor	  with	  a	  net-­‐phase	  angle	  (Taylor,	  2010).	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Figure 2.5: Argand diagram to illustrate the calculation of structure factors as a 
summation of individual scattering vectors. Plotted are the vectors of Zn(NO3)2, 
containing 8 light atoms and one heavy atom, for one reflection.  
 
The lengths determined by scattering power (proportional to the number of 
scattering electrons) and related by differences in phase shows the creation of a 
structure factor (Fh) with overall phase angle (φ). 
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However,	  in	  a	  diffraction	  experiment	  only	  the	  intensities	  (the	  square	  of	  structure	  factor	  amplitudes)	  of	  scattering	  at	  1/dhkl	  are	  measured	  and	  the	  phase	  information	  is	  lost.	  Therefore	  experiments	  (Section	  2.6)	  are	  required	  to	  calculate	  a	  protein	  crystal’s	  phases.	  Once	  phases	  have	  been	  determined,	  electron	  density	  can	  be	  calculated	  and	  a	  model	  built	  into	  it,	  and	  structure	  factors	  and	  electron	  density	  can	  be	  interconverted	  without	  loss	  of	  information	  using	  Fourier	  transforms,	  therefore	  allowing	  the	  assessment	  of	  the	  refined	  model	  built	  into	  the	  density	  (Section	  2.8).	  	  
2.5	  Data	  Processing	  	  2.5.1	  Indexing	  	  Indexing	  is	  a	  process	  in	  which	  the	  diffraction	  spots	  (as	  representatives	  of	  the	  reciprocal	  lattice)	  are	  assigned	  a	  consistent	  set	  of	  three	  reciprocal	  lattice	  vectors	  designated	  h,	  k	  and	  l	  (a*,	  b*	  and	  c*).	  These	  relate	  to	  a,	  b	  and	  c	  real	  lattice	  vectors	  (separated	  by	  angles	  α,	  β	  and	  γ)	  that	  define	  the	  unit	  cell	  parameters.	  Factors	  such	  as	  minimum	  and	  maximum	  spot	  size	  and	  background	  pixel	  density	  are	  defined	  to	  discern	  individual	  reflections.	  Two	  or	  more	  diffraction	  images	  are	  taken	  in	  order	  to	  account	  for	  any	  anisotropy	  present	  and	  to	  retrieve	  enough	  strong	  reflections	  from	  more	  than	  one	  angle	  to	  assign	  a	  unit	  cell	  without	  ambiguity.	  Transformed	  lattice	  vectors	  are	  then	  created,	  to	  which	  maximum	  symmetry	  criteria	  can	  be	  applied	  for	  the	  unit	  cell	  calculated.	  	  	  There	  are	  7	  crystal	  systems,	  from	  which	  a	  total	  of	  230	  space	  groups	  originate.	  Of	  these,	  only	  65	  allow	  for	  the	  chirality	  seen	  in	  proteins	  (Rupp,	  2009)	  (Wukovitz	  &	  Yeates,	  1995)	  and	  therefore	  impose	  limitations	  on	  the	  symmetry	  operations	  possible	  in	  biomolecular	  crystallography.	  Indexing	  algorithms	  in	  programmes	  such	  as	  iMOSFLM	  (Battye	  et	  al,	  2011)	  then	  present	  the	  possible	  space-­‐groups	  and	  unit	  cells	  from	  the	  measured	  reciprocal	  vectors	  with	  a	  penalty	  function.	  The	  lowest	  penalty	  (excluding	  triclinic	  P1,	  which	  can	  always	  be	  fitted	  with	  no	  penalties)	  represents	  the	  most	  likely	  space-­‐group	  unit-­‐cell	  parameters	  for	  the	  reflections	  supplied.	  This	  is	  not	  always	  totally	  accurate,	  as	  internal	  symmetry	  within	  the	  unit	  cell	  may	  override	  cell	  symmetry,	  but	  if	  this	  appears	  to	  be	  the	  case	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a	  lower	  symmetry	  lattice	  for	  strategy	  determination	  is	  selected.	  This	  allows	  for	  the	  collection	  of	  redundant	  data	  that	  can	  be	  incorporated	  later,	  as	  opposed	  to	  collecting	  data	  for	  an	  incorrect,	  complicated	  symmetry	  group	  that	  leads	  to	  uncollected	  data	  post-­‐strategy	  determination.	  	  	  In	  general,	  data-­‐collection	  strategies	  focus	  on	  the	  collection	  of	  datasets	  with	  the	  minimum	  exposure	  to	  radiation	  that	  allow	  for	  the	  optimal	  recording	  of	  the	  maximum	  number	  of	  reflections	  from	  the	  minimum	  number	  of	  angles	  for	  the	  cell-­‐symmetry	  (Laue	  symmetry)	  calculated.	  	  2.5.2	  Integration	  	  Once	  images	  are	  collected	  and	  indexed,	  multiple	  images	  are	  used	  to	  refine	  cell	  parameters	  and	  measure	  the	  mosaicity	  of	  the	  crystal.	  Indexed,	  raw	  pixel	  intensities	  of	  reflection	  spots	  then	  require	  correction	  against	  several	  factors,	  such	  as	  detector-­‐specific	  spatial	  calibrations,	  beam	  geometry,	  crystal	  orientation	  and	  beam	  strength	  over	  time	  are	  corrected	  for,	  alongside	  the	  potential	  monochromatic	  polarisation	  of	  light	  by	  the	  crystal	  and	  the	  time	  each	  Bragg	  plane	  has	  spent	  in	  a	  diffracting	  position	  (the	  Lorentz-­‐polarisation	  correction)	  (Phillips	  et	  al,	  1976).	  Once	  corrected,	  the	  raw	  pixel	  intensities	  over	  all	  images	  are	  integrated,	  with	  any	  partial	  reflections	  caught	  in	  a	  Bragg	  reflection	  plane	  spread	  over	  several	  images	  combined	  into	  single	  reflections.	  Spots	  are	  identified	  by	  2-­‐D	  box-­‐profiles	  of	  pixel	  intensity,	  with	  locations	  predicted	  based	  upon	  unit-­‐cell	  and	  symmetry	  projections.	  Pixel	  counts	  outside	  of	  the	  photon-­‐counting	  profile	  provide	  background.	  This	  allows	  the	  calculation	  and	  listing	  of	  intensity	  and	  error	  values	  for	  each	  reflection	  (Leslie,	  2006).	  	  2.5.3	  Scaling	  and	  Data	  Reduction	  	  The	  unmerged,	  integrated	  reflections	  are	  then	  scaled	  against	  each	  other	  to	  reduce	  the	  data	  to	  a	  list	  of	  a	  single,	  merged	  intensity	  values	  for	  each	  unique	  reflection	  measured	  over	  several	  images	  by	  a	  process	  of	  intensity	  averaging.	  A	  high	  redundancy,	  or	  multiplicity,	  of	  the	  collected	  data	  improves	  the	  reliability	  of	  this	  averaging.	  On	  the	  occasion	  that	  scaling	  weak	  intensities	  gives	  negative	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values,	  skewing	  factors	  are	  applied	  to	  the	  averaging	  of	  weak	  intensities	  to	  generate	  positive	  values	  (Evans,	  2006).	  Data	  is	  further	  improved	  by	  reduction	  by	  applying	  of	  resolution	  limits	  to	  measured	  reflections,	  performed	  as	  re-­‐scaling	  with	  imposed	  limits	  on	  the	  resolution	  of	  data	  used.	  	  	  High-­‐resolution	  data	  is	  weaker	  than	  the	  more	  reliably	  and	  regularly	  measured	  low-­‐resolution	  reflections,	  therefore	  in	  order	  to	  achieve	  the	  best	  signal:noise	  ratio	  (I/σI)	  with	  the	  highest	  resolution,	  scaled	  data	  is	  analysed	  for	  several	  factors.	  Completeness	  of	  the	  dataset	  is	  assessed,	  as	  randomly	  missing	  data	  will	  create	  noise	  in	  electron	  density	  maps,	  whilst	  regularly	  missing	  reflections	  such	  as	  those	  that	  do	  not	  enter	  the	  Ewald	  Sphere	  discussed	  in	  Section	  2.4.3	  may	  lead	  to	  total	  phasing	  failure.	  Redundancy	  of	  data	  is	  calculated	  and	  represented	  in	  the	  terms	  Rmerge	  and	  Rpim.	  Rmerge	  represents	  how	  well	  unique	  reflections	  merge	  together	  over	  multiple	  images	  in	  the	  dataset,	  and	  as	  such	  normally	  is	  higher	  at	  high-­‐resolution	  as	  fewer	  well-­‐measured	  reflections	  may	  vary	  (due	  to	  physical	  equipment/crystal	  slippage	  or	  radiation	  damage	  of	  the	  unit	  cell)	  and	  are	  thus	  poorly	  merged	  over	  the	  dataset.	  Rpim	  is	  a	  more	  precise	  indication	  of	  merging,	  by	  incorporation	  of	  variance	  of	  distribution	  into	  the	  Rmerge	  statistic,	  therefore	  representing	  well-­‐related	  intensities	  as	  it	  decreases	  with	  increasing	  redundancy	  (Evans,	  2006).	  	  	  Once	  an	  acceptable	  resolution	  limit	  is	  found	  that	  gives	  high-­‐redundancy,	  reliable	  data	  with	  a	  good	  signal:noise	  ratio,	  data	  are	  re-­‐scaled	  and	  can	  also	  be	  used	  to	  recalculate	  cell	  symmetry	  for	  confirmation	  that	  processed	  data	  has	  been	  prepared	  with	  the	  correct	  unit	  cell	  parameters	  applied.	  Scaled	  and	  merged	  intensities	  (accompanied	  by	  a	  list	  of	  Miller	  indices)	  can	  then	  be	  used	  to	  determine	  their	  associated	  amplitudes	  by	  calculation	  of	  the	  square	  root	  of	  each	  intensity.	  This	  gives	  a	  final	  scaled	  and	  reduced	  dataset	  listing	  Miller	  indices	  with	  associated	  amplitudes	  and	  their	  associated	  error	  estimations	  (Evans,	  2006).	  	  
	   39	  
2.6	  Determination	  of	  Phases	  	  2.6.1	  The	  Patterson	  Function	  	  A	  key	  utility	  in	  crystallographic	  structure	  solution	  is	  the	  Patterson	  function.	  In	  essence	  it	  is	  a	  Fourier	  transform	  of	  the	  intensities	  (or	  the	  square	  of	  structure	  factor	  amplitudes)	  of	  measured	  reflections,	  with	  phases	  set	  to	  zero	  (Grosse-­‐Kunstleve	  &	  Adams,	  2003).	  This	  is	  important,	  as	  it	  does	  not	  require	  phase	  information	  (yet	  to	  be	  discovered),	  and	  can	  be	  used	  despite	  the	  ‘phase	  problem’	  (see	  Section	  2.6.6).	  The	  Patterson	  function	  allows	  the	  calculation	  of	  a	  vector	  map	  by	  effectively	  placing	  every	  atom	  at	  the	  origin	  in	  turn,	  and	  plotting	  the	  protein’s	  transformed	  intensities	  as	  interatomic	  vectors.	  When	  this	  is	  repeated	  for	  each	  atom	  of	  the	  protein,	  with	  all	  positions	  of	  the	  peaks	  recorded,	  it	  theoretically	  allows	  for	  the	  location	  of	  all	  the	  atoms	  in	  the	  substructure,	  with	  the	  Fourier	  transform	  of	  intensities	  proportional	  to	  the	  electron	  density	  of	  the	  scattering	  atoms	  (Grosse-­‐Kunstleve	  &	  Adams,	  2003).	  	  	  	  However,	  due	  to	  the	  very	  large	  number	  of	  light	  atoms	  with	  weak	  scattering	  power	  that	  make	  up	  proteins	  it	  is	  impossible	  to	  solve	  a	  protein	  structure	  using	  this	  method	  alone.	  If	  the	  structure	  has	  N	  atoms,	  then	  a	  plotted	  Patterson	  map	  has	  
NxN	  peaks,	  of	  which	  N	  are	  superimposed	  upon	  the	  origin,	  therefore	  giving	  N2-­N	  of	  non-­‐origin	  Patterson	  peaks.	  This	  creates	  a	  noisy	  Patterson	  map	  filled	  with	  many	  indistinguishable	  peaks.	  Using	  direct	  methods	  (Section	  2.6.2),	  small	  molecules	  have	  the	  potential	  to	  be	  solved	  this	  way	  (Sheldrick,	  2008).	  In	  addition,	  the	  rotation	  and	  translation	  of	  Patterson	  maps	  of	  target	  protein	  and	  phased-­‐density	  homologues	  used	  in	  Molecular	  Replacement	  (not	  discussed	  in	  this	  thesis)	  allow	  for	  the	  correct	  alignment	  of	  target	  and	  model	  data	  for	  phase-­‐imposition	  (DeLano	  &	  Brunger,	  1995).	  However,	  Patterson	  maps	  can	  be	  used	  in	  experimental-­‐phasing	  in	  protein	  crystallography	  to	  locate	  and	  position	  a	  small	  number	  of	  heavy	  atoms	  used	  in	  solving	  the	  phase	  problem	  (Section	  2.6.5).	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2.6.2	  SHELX	  and	  Direct	  Methods	  	  Direct	  methods	  utilise	  the	  implicit	  relations	  between	  structure	  factor	  amplitudes	  to	  solve	  the	  phases	  of	  a	  structure,	  or	  of	  a	  heavy	  atom	  substructure	  in	  proteins.	  This	  method	  originates	  from	  the	  structure	  solution	  methods	  used	  for	  small	  molecules	  but	  due	  to	  the	  complexity	  and	  size	  of	  proteins,	  often	  with	  relatively	  low	  resolution	  data,	  direct	  methods	  are	  usually	  only	  applicable	  to	  solving	  the	  phases	  of	  heavy	  atom	  substructures	  as	  a	  first	  step	  to	  solving	  protein	  phases	  (Sheldrick	  et	  al,	  1993).	  Successful	  phase	  solution	  requires	  the	  fulfilment	  of	  Sheldrick’s	  Rule,	  in	  which	  data	  giving	  atomic	  separation	  >1.2	  Å	  are	  required	  (Morris	  &	  Bricogne,	  2003).	  Due	  to	  stereochemical	  and	  repulsion	  limitations,	  anomalously	  scattering	  atoms	  in	  a	  protein	  heavy	  atom	  substructure	  are	  rarely	  <3.5	  Å	  apart.	  	  Heavy	  atom	  data,	  with	  anomalous	  intensities	  and	  thus	  amplitudes	  identified	  and	  related	  to	  scattering	  factors	  (Section	  2.4.2),	  are	  prepared	  by	  the	  solution	  of	  phasing	  equations	  described	  in	  Section	  2.6.6.	  Computation	  of	  information	  about	  the	  phase-­‐shift	  between	  heavy	  atom	  phase	  and	  protein	  phase	  can	  now	  occur,	  but	  this	  is	  not	  yet	  representative	  of	  the	  protein’s	  phase	  (Rupp,	  2009).	  Reflections	  representing	  heavy	  atoms	  in	  the	  lattice	  planes	  can	  now	  have	  starting-­‐phase	  relationships	  derived.	  Multiple	  trial	  phase	  sets	  are	  produced	  for	  the	  strongest	  structure	  factors,	  however	  remaining	  weaker	  phases	  are	  also	  required.	  A	  process	  of	  tangent	  refinement	  follows,	  in	  which	  squared	  density	  peaks	  are	  recycled	  through	  the	  Hauptman-­‐Karle	  equation	  to	  determine	  potential	  phase	  values	  (Sheldrick	  et	  al,	  1993).	  	  The	  macromolecular	  phasing	  program	  SHELXD	  employs	  dual-­‐space	  direct	  methods	  (Schneider	  &	  Sheldrick,	  2002).	  Observed	  heavy	  atom	  structure	  factor	  vectors	  are	  selected	  from	  a	  Patterson	  analysis,	  and	  used	  to	  identify	  the	  strongest	  translational	  superimpositions	  by	  assigning	  a	  score,	  with	  the	  best	  solutions	  extended	  to	  include	  the	  expected	  number	  of	  heavy	  atoms	  by	  further	  superimpositions.	  In	  the	  case	  of	  Seleno-­‐met	  MAD	  phasing,	  the	  number	  of	  atoms	  is	  determined	  by	  the	  number	  of	  methionines	  per	  copy	  of	  protein	  in	  each	  unit	  cell.	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The	  best	  correlation	  score	  of	  each	  set	  of	  heavy	  atoms	  between	  the	  observed	  values	  and	  those	  calculated	  by	  superimposition	  are	  kept	  to	  generate	  a	  trial	  structure.	  This	  ‘seeding’	  by	  Patterson	  allows	  for	  the	  rapid,	  automated	  computation	  of	  in-­‐phase	  peaks	  that	  are	  then	  cycled	  through	  the	  Hauptman-­‐Karle	  tangent	  formula	  to	  refine	  test-­‐phases	  against	  structure	  factors.	  The	  more	  sharp	  peaks	  generated	  in	  the	  trial	  electron	  density	  maps,	  the	  greater	  the	  success	  of	  the	  refinement	  (Schneider	  &	  Sheldrick,	  2002).	  	  	  SHELXD	  also	  calculates	  the	  occupancy	  of	  each	  heavy	  atom	  in	  the	  structure,	  allowing	  for	  identification	  of	  partial	  sites	  (Schneider	  &	  Sheldrick,	  2002).	  This	  allows	  for	  analysis	  of	  substructure	  solution,	  as	  a	  sharp	  drop	  in	  occupancy	  indicates	  a	  correct	  solution.	  	  2.6.3	  MAD	  and	  Anomalous	  Scattering	  	  Multi-­‐wavelength	  Anomalous	  Dispersion	  (MAD)	  is	  a	  technique	  that	  utilises	  unique	  X-­‐ray	  scattering	  properties	  of	  electron-­‐dense	  atoms	  to	  provide	  information	  for	  calculating	  phases	  and	  thus	  the	  solution	  of	  de	  novo	  protein	  structures	  (Ealick,	  2000).	  All	  materials	  absorb	  X-­‐rays,	  with	  the	  heavier	  the	  atom	  the	  greater	  the	  amount	  of	  absorbance.	  In	  experimental	  terms,	  this	  can	  be	  a	  major	  source	  of	  radiation	  damage	  when	  heavy	  atoms	  are	  incorporated	  (even	  in	  low	  abundance)	  into	  a	  protein	  crystal	  (Murray	  et	  al,	  2005).	  However,	  X-­‐rays	  absorbed	  by	  heavy	  atoms	  causes	  useful	  properties	  in	  the	  atom.	  	  	  As	  electrons	  in	  the	  electric	  field	  of	  the	  atom	  oscillate,	  certain	  electromagnetic	  frequencies	  induce	  energy	  transfer	  in	  the	  electron	  levels	  in	  the	  core	  shells,	  not	  just	  the	  valence	  shells	  seen	  in	  optical	  transitions,	  leading	  to	  energy	  release	  by	  emission	  of	  X-­‐ray	  radiation	  equal	  to	  the	  energy	  of	  the	  original.	  The	  higher	  the	  X-­‐ray	  energy	  used,	  the	  greater	  the	  energy	  of	  the	  electron	  that	  can	  be	  dislodged.	  The	  terms	  K-­‐,	  L-­‐	  and	  M-­‐edge	  describe	  the	  energies	  required	  for	  heavy-­‐atom	  emission	  from	  electrons	  shells	  of	  decreasing	  energy,	  with	  the	  K-­‐edge	  being	  the	  highest	  energy	  needed	  to	  resonate	  a	  high-­‐energy	  inner-­‐shell	  electron	  (Hendrickson,	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1991).	  Figure	  2.6	  describes	  the	  X-­‐ray	  absorption	  spectrum	  of	  the	  heavy	  atoms	  Selenium	  and	  Gold	  compared	  to	  that	  of	  the	  light	  atom	  Oxygen.	  	  	  The	  absorption	  and	  emission	  of	  photons	  from	  heavy	  atoms	  induces	  anomalous	  dispersion	  components	  into	  atomic	  scattering	  factors,	  represented	  as:	  	   ƒs	  =	  ƒ0s	  +	  ƒ´+	  i·ƒ´´	  	  The	  real	  and	  imaginary	  anomalous	  scattering	  contributors,	  ƒ´	  and	  i·ƒ´´	  respectively,	  are	  scattering	  angle-­‐independent	  and	  are	  additive	  to	  the	  normal	  scattering-­‐angle-­‐dependant	  atomic	  scattering	  ƒ0s	  seen	  in	  the	  non-­‐anomalous	  Structure	  Factor	  calculation	  in	  Section	  2.4.2.	  The	  Kramers-­‐Kronig	  equation	  allows	  precise	  calculation	  of	  ƒ´	  from	  the	  measured	  i·ƒ´´	  measured	  at	  the	  absorption	  edge	  peak,	  where	  i·ƒ´´	  is	  proportional	  to	  an	  atomic	  absorption	  coefficient	  at	  the	  wavelength	  used.	  The	  negative	  ƒ´	  peak	  coincides	  with	  the	  steepest	  slope	  of	  the	  i·ƒ´´	  inflection	  (Hodeau	  et	  al,	  2001).	  In	  practice,	  data	  collected	  nearest	  to	  the	  peak	  wavelength	  gives	  the	  best	  estimation	  of	  the	  imaginary	  component	  i·ƒ´´,	  with	  data	  collected	  at	  the	  wavelength	  of	  the	  inflection	  point	  approximating	  the	  real	  ƒ´	  scattering	  component.	  	  At	  an	  absorption	  edge,	  dispersive	  differences	  arise	  that	  result	  in	  greater	  intensity	  of	  measured	  intensity	  of	  the	  same	  reflection	  at	  the	  peak	  absorption	  wavelength	  than	  a	  less	  absorptive	  wavelength,	  giving	  a	  measurable	  change	  in	  scattering	  due	  to	  absorption.	  This	  property	  is	  taken	  advantage	  of	  in	  MAD,	  as	  the	  same	  reflection	  can	  be	  measured	  from	  the	  same	  crystal	  at	  different	  X-­‐ray	  energies	  (peak/	  imaginary	  i·ƒ´´	  component,	  inflection/	  real	  ƒ´	  component	  and	  a	  non-­‐anomalous	  remote	  energy)	  to	  create	  a	  comparable	  difference	  in	  diffraction	  intensity	  (and	  thus	  amplitude	  by	  square	  root).	  Compared	  to	  non-­‐absorptive	  scattering	  of	  light	  atoms,	  absorption	  of	  X-­‐ray	  energy	  by	  heavy	  atoms	  also	  creates	  a	  retardant	  effect	  that	  affects	  ƒ´´	  by	  inducing	  a	  phase	  change	  (90°).	  This	  anomalous	  difference	  is	  utilised	  by	  techniques	  such	  as	  MAD	  to	  allow	  for	  the	  calculation	  of	  phases	  by	  the	  breaking	  of	  internal	  centrosymmetry	  within	  diffraction	  patterns,	  described	  in	  the	  next	  sections	  (Hendrickson,	  1991).
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Figure 2.6: X-ray absorption plot (f ´and f˝) for the light element oxygen, the 
‘medium’ electron-density selenium and the very electron-dense gold in an 
energy range achievable by synchrotron light sources (5-18.5 KeV). A key is 
shown top right. 
 
The standard in-house copper-anode energy (CuKα) is marked, to illustrate the 
lack of anomalous signal peaks achievable and thus to highlight the importance 
of synchrotron radiation use.  
 
From left to right, the L-III, L-II and L-I edges are achievable for Au, with the 
greatest anomalous difference seen at L-III. Only the K-I edge is available for 
use in Se experiments. Oxygen (the heaviest of the most common, light protein 
atoms, H, C, N and O) gives no anomalous signal. 
 
This plot was produced using Ethan Merritt’s online anomalous scattering 
tutorial (http://skuld.bmsc.washington.edu/scatter/). 
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2.6.4	  Friedel’s	  Law	  	  	  Centric	  reflections	  are	  phase-­‐reflected	  reflections	  caused	  by	  diffraction	  from	  centrosymmetrically	  related	  atoms,	  defined	  by	  the	  symmetry	  of	  the	  crystal	  structure	  itself.	  They	  are	  found	  in	  centric	  positions	  in	  the	  diffraction	  pattern	  (reciprocal	  space)	  and	  structure	  factors	  for	  these	  reflections	  have	  exactly	  the	  same	  magnitude	  with	  conjugate	  phase-­‐angles.	  These	  are	  known	  as	  Friedel	  Pairs,	  and	  follow	  Friedel’s	  Law:	  	   Fh	  =	  F-­‐h	   	  	  	   with	   	   φh	  =	  -­‐(φ-­‐h)	  	  As	  structure	  factors	  are	  summations	  of	  amplitudes,	  and	  amplitudes	  are	  proportional	  to	  the	  square	  root	  of	  measured	  diffraction	  intensities,	  this	  leads	  to	  a	  connection	  between	  phases	  and	  intensity.	  Anomalous	  scattering	  (measured	  as	  intensity	  changes)	  allows	  for	  the	  breakdown	  of	  Friedel’s	  Law,	  and	  as	  such	  provides	  a	  means	  to	  calculate	  the	  phase	  angle	  associated	  with	  an	  anomalously	  dispersive	  heavy	  atom	  (Zwart,	  2005).	  	  	  Figure	  2.7	  shows	  an	  Argand	  diagram	  visualisation	  of	  how	  anomalous	  dispersion	  breaks	  Friedel’s	  Law.	  When	  the	  sum	  of	  normally	  scattering	  atoms	  (FP)	  is	  plotted	  against	  an	  anomalously	  dispersive	  atom	  (FA)	  in	  an	  inappropriate	  energy	  for	  anomalous	  absorption,	  structure	  factor	  amplitudes	  (FPA)	  remain	  mirrored	  about	  the	  real	  axis	  as	  Friedel’s	  law	  remains	  true.	  However,	  upon	  anomalous	  diffraction	  conditions,	  the	  real	  (ƒ´)	  component	  of	  anomalous	  scattering	  (with	  the	  same	  phase	  as	  the	  FP	  as	  the	  scattering	  atom	  has	  not	  changed	  position	  in	  the	  two	  scenarios)	  also	  mirrors	  about	  the	  real	  axis,	  with	  Friedel’s	  Law	  holding.	  However,	  the	  ƒ´´-­‐phase-­‐lagging-­‐component	  induces	  a	  +90°	  (or	  -­‐270°)	  phase	  shift,	  resulting	  in	  |FPA|	  ≠	  |F-­‐PA|	  and	  thus	  breaking	  Friedel’s	  Law	  (Taylor,	  2003).	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Figure 2.7: Breaking Friedel’s Law. In a non-anomalously scattering crystal, the 
vector FP represents the partial sum of non-anomalous atomic contributions, with FA 
representing the contribution of the anomalously scattering atoms at an inappropriate 
wavelength for anomalous absorption. Friedel’s Law holds and FPA = F-PA, mirrored 
about the real axis.  
 
Upon generation of anomalous signal, the real (ƒ0 and ƒ´) and (ƒ0 and ƒ´)- contribution 
to FA and F-A remain symmetrical about the real axis, but the imaginary anomalous 
component ƒ˝ (with the greatest anomalous difference between Bijvoet pairs) induces 
a 90° phase-retardation. This alters the FA vector orientation with respect to F-A, 
leading to FPA ≠ F-PA and the breakdown of Friedel’s Law. 
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  The	  difference	  in	  measured	  amplitude	  between	  broken	  Friedel	  mates	  is	  called	  the	  Bijvoet	  Difference:	  	   ΔF	  =	  |F+|	  -­‐	  |F-­‐|	  	  Bijvoet	  pairs	  are	  true	  symmetry	  equivalents	  of	  Friedel	  pairs,	  which	  do	  not	  have	  identical	  amplitudes	  in	  the	  presence	  of	  anomalous	  scattering	  (Blow,	  2003).	  Friedel	  pairs	  exist	  as	  F(hkl)	  and	  F(-­‐h-­‐k-­‐l),	  whilst	  Bijvoet	  pairs	  are	  other	  pairs	  that	  that	  can	  take	  the	  form	  F(hkl)	  and	  F(-­‐hkl),	  dependant	  on	  space	  group.	  Therefore	  one	  Friedel	  mate	  forms	  a	  set	  of	  true	  symmetry	  equivalents	  with	  the	  same	  amplitude	  (|F+|),	  while	  the	  other	  Friedel	  mate	  forms	  a	  set	  of	  equivalents	  that	  share	  a	  different	  amplitude	  (|F-­‐|)	  (Hendrickson,	  1991).	  This	  aids	  the	  location	  of	  anomalously	  scattering	  heavy-­‐atoms	  for	  MAD	  phase-­‐calculation,	  as	  a	  Patterson	  map	  of	  ΔF2	  shows	  only	  the	  interatomic	  distance	  vectors	  of	  anomalous-­‐scattering	  heavy-­‐atoms.	  	  2.6.5	  Calculation	  of	  Heavy	  Atom	  Substructure	  Phases	  	  The	  Difference	  Patterson	  described	  at	  the	  end	  of	  Section	  2.6.3	  shows	  N(N-­1)	  strong	  interatomic	  distances,	  where	  N	  is	  the	  number	  of	  peaks	  of	  anomalously	  scattering	  atoms.	  As	  in	  Section	  2.6.1,	  this	  plot	  depends	  on	  the	  intensities	  (squared	  amplitudes)	  and	  is	  phase-­‐independent.	  The	  location	  of	  heavy	  atoms	  is	  manually	  facilitated	  by	  the	  application	  of	  general	  position	  generators	  (tabulated	  in	  the	  International	  Tables	  of	  Crystallography)	  of	  the	  proposed	  space	  group	  of	  the	  substructure.	  Harker	  sections,	  that	  represent	  space-­‐group	  dependant	  slices	  of	  the	  Patterson	  map,	  are	  used	  to	  assign	  atomic	  coordinates	  to	  the	  locations	  of	  heavy	  atoms	  in	  the	  substructure	  (Terwilliger	  &	  Berendzen,	  1999).	  	  	  In	  automated	  methods,	  the	  SHELX	  suite	  of	  programs	  is	  designed	  to	  facilitate	  the	  calculation	  of	  heavy	  atom	  substructure	  solution	  by	  direct	  methods,	  as	  described	  in	  Section	  2.6.2.	  Through	  a	  process	  of	  locating	  heavy	  atom	  density	  peaks,	  calculated	  from	  reflection-­‐originated	  structure	  factors	  that	  share	  phases	  from	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similar	  Bragg	  lattices,	  phases	  are	  refined	  for	  the	  solution	  of	  a	  heavy	  atom	  substructure.	  This	  is	  similar	  to	  the	  solution	  of	  entire	  small	  molecule	  structures.	  Once	  phases	  for	  the	  heavy-­‐atom	  substructure	  are	  known,	  their	  contribution	  to	  the	  overall	  phases	  of	  the	  heavy	  atom	  protein	  derivative	  can	  be	  used	  to	  calculate	  phase-­‐angles	  for	  the	  protein	  structure	  factors	  (Sheldrick,	  2008).	  	  	  2.6.6	  Phasing	  the	  Protein	  Structure.	  	  As	  a	  useful	  aid	  to	  visualise	  phase-­‐ambiguity,	  Harker	  diagrams	  can	  be	  drawn,	  utilising	  the	  structure	  factor	  vector	  relationship	  FPA	  =	  FP	  +	  FA	  (Figure	  2.8a).	  A	  structure	  factor	  (FP)	  of	  known	  magnitude	  but	  unknown	  phase	  can	  lie	  anywhere	  on	  a	  circle	  of	  radius	  FP	  centred	  on	  the	  origin	  of	  FP.	  A	  second	  circle	  can	  be	  drawn	  with	  radius	  FPA	  centred	  on	  a	  point	  determined	  by	  –FA	  and	  the	  phase-­‐angle	  (φA)	  determined	  by	  the	  solution	  of	  the	  marker	  atom	  substructure	  (Figure	  2.8b).	  The	  potential	  phases	  of	  both	  of	  these	  circles	  lies	  anywhere	  upon	  their	  circumference.	  Where	  these	  two	  circles	  cross	  creates	  two	  potential	  phase-­‐angle	  solutions	  (φP1	  or	  φP2)	  when	  the	  amplitude	  vectors	  for	  FP	  are	  compared	  to	  the	  real	  axis	  (or	  X-­‐axis	  =	  0°).	  This	  creates	  a	  2-­‐fold	  phase-­‐ambiguity	  (Taylor,	  2003).	  	  With	  the	  MAD	  data,	  peak	  ƒ´´	  data	  contain	  anomalous	  phases	  of	  centric	  reflections	  offset	  from	  other	  data	  such	  as	  ƒ´	  inflection	  by	  90°	  as	  a	  product	  of	  heavy	  atom	  absorption	  (the	  source	  of	  breaking	  Friedel’s	  Law).	  Therefore	  circles	  of	  radii	  FPA+	  and	  FPA-­	  respectively	  are	  centred	  at	  origins	  of	  the	  F˝A+	  and	  (F˝A-­‐)-­‐	  vectors,	  90°	  from	  the	  origin	  of	  the	  –FA	  vector.	  When	  applied	  to	  the	  Harker	  construct	  in	  Figure	  2.8b,	  the	  diagram	  in	  Figure	  2.8c	  reveals	  the	  true	  protein	  phase	  value,	  thus	  solving	  the	  phase	  ambiguity	  (Taylor,	  2003).	  Such	  phasing	  calculations	  were	  made	  into	  equations	  by	  Karle	  and	  Hendrickson	  (Hendrickson	  et	  al,	  1985)	  to	  allow	  for	  more	  linearised,	  and	  more	  importantly,	  computationally	  processed	  solutions.	  	  	  A	  process	  of	  probability	  distribution	  analysis	  then	  allows	  for	  the	  refinement	  of	  original	  phases,	  accounting	  for	  factors	  such	  as	  circle-­‐closure	  errors	  in	  Harker-­‐construct-­‐based	  calculations,	  positional	  errors	  in	  the	  heavy-­‐atom	  substructure	  and	  the	  agreement	  of	  calculated	  phases	  from	  all	  datasets.	  The	  calculation	  of	  the	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Figure 2.8: Phase solution using anomalous scattering and Harker plots.  
a) Relationship between protein (FP), heavy atom (FA) and heavy-atom derivative  
(FPA) structure factor vectors for a generic reflection hkl. b) Circles of radius of |FP| 
and |FPA| magnitudes with unknown phase (φ) offset by –FA with known φA. Two 
possible φP are presented by intersecting circles. c) Anomalous scattering induces a 
90° Δφ due to the ƒ˝ absorptive contribution. Circles with radii of magnitude |FPA+| 
and |FPA-|, with anomalous scattering origins at F˝A+ and (F˝A-)- respectively, 
intersect at one correct phase angle φP°. Adapted from Rupp, 2009. 
a)	   b)	  
c)	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best	  phase	  (φBEST)	  from	  soaked-­‐in/co-­‐crystallised	  heavy	  atoms	  is	  also	  subject	  to	  enantiomorphic	  variation,	  or	  ‘handedness’,	  resulting	  from	  the	  centrosymmetrical	  nature	  of	  the	  Pattersons	  used	  to	  calculate	  the	  heavy-­‐atom	  substructure.	  In	  the	  case	  of	  MAD	  using	  selenomethionine	  (which	  is	  relevant	  to	  the	  experimental	  phasing	  used	  later	  in	  this	  thesis),	  the	  heavy	  atom	  substructure	  is	  non-­‐centrosymmetrical,	  due	  to	  being	  subject	  to	  the	  chirality	  of	  the	  protein	  structure,	  and	  as	  such	  there	  is	  a	  50%	  chance	  of	  obtaining	  the	  right	  ‘handedness’	  (Sheldrick,	  2008).	  An	  electron	  density	  map	  calculated	  on	  the	  incorrect	  enantiomorph	  will	  give	  uninterpretable	  noise.	  	  
2.7	  Calculations	  and	  Modification	  of	  Electron	  Density	  	  2.7.1	  Calculation	  of	  Electron	  Density	  	  Electron	  density,	  annotated	  as	  ρ(r)	  or	  ρ(x,	  y,	  z),	  can	  be	  calculated	  by	  the	  Fourier	  transform	  of	  phased	  structure	  factor	  amplitudes.	  For	  a	  more	  in-­‐depth	  discussion	  of	  Fourier	  transformation	  the	  author	  refers	  the	  reader	  to	  the	  paper	  by	  Lynn	  Ten	  Eyck	  (Ten	  Eyck,	  1985).	  Once	  the	  phases	  of	  the	  complex	  structure	  factors	  have	  been	  solved	  (also	  considered	  as	  resolving	  the	  ‘phase-­‐problem’),	  they	  can	  be	  combined	  with	  the	  structure	  factor	  amplitudes	  and	  used	  in	  the	  following	  calculation:	  	  	   Σ	  F(h)	  •	  exp[-­‐2πi(h•r)	  +	  iφ(h)]	  =	  ρ(r)	  	  where	  F(h)	  =	  amplitude	  of	  each	  measured	  reflection	  and	  φ(h)	  =	  the	  phase	  for	  each	  available	  reflection.	  Calculated	  electron	  density	  can	  now	  be	  back-­‐Fourier	  transformed	  (FT-­‐1)	  to	  structure	  factors	  (Cowtan	  &	  Main,	  1996)	  without	  any	  loss	  of	  information,	  via:	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  a,	  b,	  c	  FT-­‐1	  	  =	  F(hkl)	  =	  V	  Σ	  Σ	  Σ	  ρ(x,	  y,	  z)	  •	  exp	  [2πi	  (hx	  +	  ky	  +	  lz)]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  x,	  y,	  z	  =	  0	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and	  back	  to	  electron	  density	  by:	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  +∞	  FT	  =	  ρ(x,	  y,	  z)	  =	  1	  Σ	  Σ	  Σ	  F(hkl)	  •	  exp	  [-­‐2πi	  (hx	  +	  ky	  +	  lz)]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  V	  	  	  	  hkl	  =	  -­‐∞	  	  Once	  an	  electron	  density	  map	  has	  been	  calculated,	  the	  quality	  of	  it	  can	  be	  assessed.	  Visual	  investigation	  allows	  confirmation	  of	  correct	  enantiomorphs	  if	  the	  maps	  are	  clearly	  interpretable	  and	  combined	  with	  the	  identification	  of	  secondary	  structure	  elements	  such	  as	  α–helices	  and	  β–sheets	  allows	  for	  the	  judgement	  of	  ‘handedness’	  (i.e.	  a	  right-­‐handed	  helix	  is	  correct)	  and	  the	  assessment	  of	  quality	  due	  to	  phasing	  or	  source	  data.	  Once	  an	  initial	  electron	  density	  map	  has	  been	  calculated,	  several	  methods	  can	  be	  employed	  to	  improve	  it	  prior	  to	  model	  building,	  and	  a	  couple	  (not	  an	  exhaustive	  list)	  are	  discussed	  in	  the	  next	  sections.	  	  2.7.2	  Solvent	  Flattening	  	  This	  method	  of	  density	  modification	  relies	  on	  the	  different	  physical	  properties	  between	  the	  immobilised	  protein	  molecules	  in	  a	  crystal	  and	  the	  disordered	  solvent	  that	  surrounds	  them	  (Wang,	  1985).	  On	  average,	  50%	  of	  a	  protein	  crystal	  consists	  of	  solvent	  channels	  (Heras	  &	  Martin,	  2005).	  This	  technique	  exploits	  the	  fact	  that	  solvent	  regions	  of	  electron	  density	  should	  be	  essentially	  ‘flat’	  (that	  is	  to	  say	  mainly	  water,	  with	  maybe	  slight	  variation	  due	  to	  the	  components	  of	  the	  crystallisation	  condition).	  Pure	  water	  has	  electron	  density	  of	  approximately	  0.33	  e-­‐/Å3	  (a	  concentrated	  salt	  solution	  will	  be	  higher	  than	  this)	  and	  protein	  has	  an	  averaged	  approximate	  electron	  density	  of	  0.44	  e-­‐/Å3.	  These	  values	  are	  calculable	  via	  the	  application	  of	  Avogadro’s	  number	  to	  each	  molecule	  (or	  average	  protein)	  mol/cm3	  with	  correction	  to	  Å	  values,	  to	  give	  number	  of	  molecules	  per	  Å,	  which	  can	  then	  be	  used	  to	  divide	  the	  number	  of	  e-­‐	  per	  molecule	  to	  give	  e-­‐/Å3.	  	  	  An	  initial	  electron	  density	  map	  that	  has	  distinguishable,	  contiguous	  solvent	  regions	  compared	  to	  the	  molecular	  envelope	  is	  the	  minimum	  requirement	  for	  solvent	  flattening.	  With	  a	  3-­‐D	  grid	  placed	  over	  the	  density,	  spheres	  of	  defined	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radius	  (~10	  Å)	  are	  plotted	  at	  grid	  points	  and	  the	  density	  within	  the	  sphere	  assessed	  against	  a	  predefined	  cut-­‐off	  value.	  If	  this	  value	  is	  not	  reached,	  then	  the	  contents	  of	  the	  sphere	  are	  deemed	  part	  of	  the	  solvent	  region.	  Assuming	  the	  map	  is	  of	  a	  useful	  quality,	  definition	  between	  solvent	  and	  protein	  should	  be	  found	  (Wang,	  1985).	  Maps	  that	  fail	  this	  process	  are	  likely	  to	  be	  of	  no	  use	  anyway,	  with	  re-­‐processing	  data,	  re-­‐calculating	  phases	  or	  even	  re-­‐collecting	  better	  data	  likely	  to	  be	  the	  source	  of	  improvement.	  	  	  The	  solvent	  region	  is	  then	  set	  to	  the	  solvent	  average	  (0.33	  e-­‐/Å3	  if	  the	  crystal	  were	  grown	  from	  pure	  water,	  more	  if	  from	  salt	  solution)	  and	  new	  structure	  factors	  are	  calculated	  by	  inverse	  Fourier	  transform	  (FT-­‐1).	  The	  new	  structure	  factor	  phases	  are	  then	  combined	  with	  the	  original	  phases	  for	  FT	  back	  to	  electron	  density.	  Because	  the	  solvent	  regions	  really	  should	  be	  flat	  and	  not	  noisy,	  this	  leads	  to	  a	  map	  with	  improved	  phases	  therefore	  better	  defining	  the	  regions	  of	  protein.	  This	  process	  can	  then	  be	  repeated	  until	  a	  more	  interpretable	  map	  is	  achieved.	  Parameters	  involved	  may	  need	  adjusting,	  such	  as	  the	  radius	  of	  solvent-­‐masking	  spheres,	  in	  order	  to	  explicitly	  flatten	  solvent	  and	  not	  regions	  of	  protein.	  The	  calculation	  of	  a	  Matthews	  probability	  (in	  which	  the	  solvent	  content	  of	  a	  given	  unit	  cell	  is	  estimated	  based	  upon	  the	  mass	  and	  number	  of	  copies	  of	  the	  protein	  present)	  may	  aid	  in	  the	  judgement	  of	  excessive	  or	  conservative	  solvent-­‐masking	  (Kantardjieff	  &	  Rupp,	  2003).	  Often	  the	  resulting	  electron	  density	  map	  post-­‐solvent	  flattening	  is	  a	  viable	  map	  for	  manual	  or	  even	  automated	  model	  building.	  	  2.7.3	  NCS	  Averaging	  	  Many	  unit	  cells	  contain	  asymmetric	  units	  (ASUs)	  that	  contain	  multiple	  copies	  of	  the	  protein,	  sometimes	  in	  the	  form	  of	  oligomers.	  This	  Non-­‐Crystallographic	  Symmetry	  (NCS)	  means	  that	  the	  diffraction	  patterns	  collected	  contain	  redundant	  information	  due	  to	  this	  local	  symmetry,	  and	  the	  electron	  density	  maps	  show	  two	  or	  more	  approximately	  identical	  copies	  of	  the	  same	  molecule.	  If	  averages	  of	  these	  copies	  are	  taken	  and	  combined,	  then	  the	  electron	  density	  may	  be	  improved.	  The	  alignment	  of	  such	  NCS	  averaged	  molecules	  requires	  the	  application	  of	  transformation	  functions,	  in	  the	  case	  of	  MAD	  or	  other	  heavy-­‐atom	  substructure-­‐
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phased	  density	  maps,	  this	  can	  often	  be	  facilitated	  by	  the	  rotation	  and	  translation	  of	  the	  heavy-­‐atom	  substructure.	  In	  other	  cases,	  alignment	  of	  Patterson	  map	  peaks	  can	  calculate	  the	  required	  transformations.	  In	  this	  short	  introduction	  to	  the	  basics	  of	  crystallographic	  theory,	  the	  statistics	  of	  NCS	  averaging	  transformations	  are	  not	  discussed,	  but	  the	  author	  directs	  the	  reader	  to	  the	  text	  of	  Bernhard	  Rupp	  (Rupp,	  2009)	  for	  a	  detailed	  description.	  	  As	  with	  solvent-­‐flattening	  (Section	  2.7.2)	  a	  Matthews	  solvent-­‐probability	  calculation	  helps	  determine	  the	  number	  of	  molecules	  present,	  and	  thus	  a	  target	  for	  the	  number	  of	  molecules	  to	  be	  averaged.	  In	  modern	  times,	  with	  an	  ever-­‐expanding	  PDB	  (Berman	  et	  al,	  2000),	  the	  calculated	  solvent	  content	  can	  be	  compared	  to	  thousands	  of	  other	  structures	  at	  the	  same	  resolution	  to	  more	  accurately	  estimate	  the	  number	  of	  molecules	  present	  with	  such	  a	  calculated	  Matthews	  coefficient	  (Kantardjieff	  &	  Rupp,	  2003).	  	  With	  the	  number	  N	  of	  identical	  molecular	  envelopes	  aligned	  (in	  real	  space),	  the	  improvement	  in	  signal:noise	  ratio	  is	  proportional	  to	  N½.	  With	  this	  improvement	  in	  signal:noise	  increasing	  with	  each	  copy	  in	  the	  ASU,	  it	  can	  be	  seen	  how	  powerful	  this	  method	  can	  be	  for	  highly	  repetitive	  oligomers,	  especially	  with	  crystallised,	  highly	  symmetrical	  virus	  particles	  (Stehle	  et	  al,	  1996).	  	  	  
2.8	  Structure	  Refinement	  	  Upon	  the	  calculation	  of	  a	  phased	  electron	  density	  map	  that	  has	  been	  subjected	  to	  density	  modification,	  a	  chemically	  viable	  protein	  structure	  can	  be	  modelled	  into	  the	  lumen	  of	  regions	  of	  connected	  electron	  density.	  This	  section	  describes	  some	  of	  the	  methods	  used	  to	  refine	  and	  validate	  an	  accurate	  model	  that	  remains	  true	  to	  the	  experimentally	  observed	  data.	  The	  techniques	  described	  are	  not	  an	  exclusive	  list	  of	  methods	  and	  are	  applied	  after	  the	  building	  of	  an	  initial	  model,	  either	  by	  manual	  or	  automated	  methods	  not	  described	  here.	  For	  model-­‐building	  methods	  and	  processes,	  the	  author	  directs	  the	  reader	  to	  the	  program	  literature	  of	  CCP4i	  for	  the	  running	  of	  refinement	  programs	  (Potterton	  et	  al,	  2003),	  ARP/wARP	  for	  automated	  model	  fitting	  to	  electron	  density	  (Morris	  et	  al,	  2003)	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and	  Coot	  for	  the	  manual	  building	  of	  protein	  models	  into	  experimentally	  determined	  electron	  density	  (Emsley	  &	  Cowtan,	  2004).	  	  2.8.1	  The	  Maximum-­‐Likelihood	  Function	  	  Maximum-­‐likelihood	  (ML)	  works	  on	  the	  basic	  principle	  that	  the	  best	  model	  built	  is	  the	  one	  that	  is	  most	  consistent	  with	  the	  experimentally	  derived	  observations	  (Terwilliger,	  2000).	  The	  model	  built	  into	  the	  observed	  density	  can	  be	  changed	  to	  match	  the	  experimental	  data	  (practically	  done	  within	  a	  3-­‐D	  model-­‐building	  computer	  program),	  and	  thus	  its	  likelihood	  for	  correctness	  increases	  and	  the	  model	  is	  considered	  better.	  This	  in	  effect	  ‘sharpens’	  the	  probability	  of	  correctness.	  The	  refinement	  process	  can	  also	  be	  restrained	  by	  the	  application	  of	  set	  bond-­‐lengths,	  bond-­‐angles,	  isotropic	  or	  anisotropic	  B-­‐factors/temperature-­‐factors	  and	  occupancies,	  with	  weights	  applied	  to	  prevent	  the	  building	  of	  models	  that	  fall	  out	  of	  chemically	  acceptable	  parameters	  (Vagin	  et	  al,	  2004).	  Translation/Libration/Screw	  (TLS)	  restraint-­‐parameterisation	  is	  a	  more	  advanced	  interpretation	  of	  B-­‐factor	  restraints	  in	  which	  molecular	  motion	  (in	  terms	  of	  horizontal	  and	  vertical	  movement	  combined	  with	  potential	  rocking-­‐and-­‐twisting	  motion)	  between	  a	  defined	  region	  of	  atoms	  is	  weighted	  (Winn	  et	  al,	  2003).	  Constraints	  on	  the	  number	  of	  parameters	  are	  also	  applied,	  perhaps	  only	  allowing	  for	  variation	  in	  a	  certain	  number	  of	  restraints,	  such	  as	  allowing	  only	  torsion	  angle-­‐changes	  instead	  of	  all	  x,	  y,	  z	  coordinates.	  	  	  The	  repositioning	  of	  atoms	  within	  the	  electron	  density	  alters	  the	  calculated	  phases,	  as	  the	  position	  of	  atoms	  within	  Bragg	  planes	  gives	  the	  origin	  of	  phase	  differences	  from	  the	  experimental	  data.	  This	  can	  in	  turn	  improve	  the	  structure	  if	  an	  atom	  is	  moved	  in	  one	  direction,	  and	  perturb	  accurate	  phases	  if	  the	  atom	  is	  modelled	  further	  away	  from	  a	  correct	  Bragg	  plane.	  As	  such,	  Fobs	  are	  assigned	  a	  figure	  of	  merit	  statistic	  (m	  where	  m	  =	  <cos(Δφ)>)	  that	  represents	  the	  probability	  of	  a	  phase	  angle	  to	  be	  correct	  in	  relation	  to	  the	  probability-­‐averaged,	  best	  Fcalc(Rupp,	  2009).	  In	  addition,	  to	  account	  for	  positional	  errors	  a	  term	  of	  variance	  (σA)	  is	  applied	  to	  the	  structure	  factor	  probability	  distribution.	  σA	  is	  determined	  by	  cross-­‐validating	  structure	  factor	  amplitudes	  calculated	  from	  a	  partially	  built	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model	  with	  the	  complete	  set	  of	  amplitudes	  from	  the	  experimentally	  observed	  structure	  factors	  (Read,	  1997).	  The	  better	  the	  model	  being	  built	  into	  the	  electron	  density	  is,	  the	  lower	  the	  σA	  variance	  that	  is	  calculated.	  	  When	  a	  model	  in	  which	  all	  parameters	  are	  variable	  is	  built	  into	  the	  initial	  density	  (calculated	  from	  observed	  structure	  factor	  amplitudes,	  Fobs,	  with	  experimental	  phases),	  it	  allows	  for	  the	  calculation	  of	  structure	  factors	  from	  the	  model	  placed	  into	  the	  density	  (Fcalc).	  The	  best	  fit	  between	  these	  two	  sets	  of	  values	  can	  then	  be	  determined	  by	  a	  mathematical	  process	  of	  likelihood	  functions	  that	  asses	  whether	  the	  probability	  of	  the	  Fcalcs	  is	  proportional	  to	  the	  experimentally	  calculated	  Fobs.	  These	  functions	  also	  attribute	  a	  scaling	  factor	  (D)	  to	  Fcalcs	  in	  relation	  to	  Fobs.	  Another	  way	  of	  looking	  at	  this	  is	  to	  ask	  whether	  the	  Fcalcs	  could	  be	  back	  calculated	  to	  give	  the	  amplitudes	  measured	  from	  the	  square-­‐roots	  of	  the	  original	  diffraction	  pattern	  intensities.	  	  	  ML	  is	  carried	  out	  over	  many	  cycles	  with	  variations	  in	  restraints	  and	  constraints,	  with	  new	  electron	  density	  maps	  via	  FT.	  However,	  these	  new	  maps	  are	  subject	  to	  newly	  calculated	  differences	  between	  Fobs	  and	  Fcalcs,	  and	  are	  thus	  termed	  difference	  maps	  with:	  	   (m|Fobs|	  -­‐	  D|Fcalc|)	  exp(2πiφcalc)	  	  where	  m	  is	  the	  figure	  of	  merit	  for	  Fobs	  phases,	  D	  is	  a	  scaling	  factor	  and	  Fcalc	  and	  φcalc	  are	  structure	  factor	  amplitudes	  and	  phases	  calculated	  from	  the	  model.	  ML	  values	  are	  derived	  from	  the	  gradient	  of	  the	  likelihood	  function	  between	  the	  observed	  structure	  factors	  and	  the	  ones	  from	  the	  current	  model.	  	  In	  practice,	  model-­‐building	  programs	  represent	  positive	  (likely	  region	  of	  unaccounted	  density)	  and	  negative	  density	  (should	  be	  no	  density)	  calculated	  by	  these	  differences	  to	  facilitate	  further	  model-­‐refinement.	  However,	  it	  is	  worth	  considering	  the	  quality	  of	  data	  before	  any	  confident	  refinement	  by	  ML	  can	  occur.	  Poor	  data	  means	  poor	  structure	  factors	  (Fobs),	  which	  also	  means	  poor	  phases.	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Therefore	  poor	  data	  also	  means	  poor	  refinement,	  and	  as	  such	  refinement	  procedures	  require	  validation.	  	  	  2.8.2	  Validation	  of	  Refinement	  by	  Rwork	  and	  Rfree	  	  The	  R-­‐factor	  measurements	  are	  an	  assessment	  of	  how	  well	  the	  crystallographic	  model	  agrees	  with	  the	  experimentally	  observed	  data,	  that	  is	  they	  measure	  how	  well	  a	  refined	  structure	  predicts	  observed	  diffraction.	  In	  order	  for	  this	  to	  function,	  a	  FreeR	  set	  of	  experimental	  data	  (usually	  5%)	  is	  excluded	  from	  any	  model	  refinement	  and	  used	  for	  cross-­‐validation	  of	  the	  model	  with	  unrefined	  experimental	  data	  (Brunger,	  1993).	  The	  working,	  refined	  data	  set	  (giving	  the	  Rwork	  value)	  and	  the	  unrefined	  FreeR	  dataset	  (giving	  the	  Rfree	  value)	  are	  then	  calculated	  for	  agreement	  against	  the	  entire	  model-­‐fitted	  data	  using	  the	  calculations:	  	   Rfree	  =	  Σ	  	  	  |Fobs	  -­‐	  kFcalc|	  	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  hfree	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  Σ	  	  	  Fobs	  	  	  	  	  	  	  	  hfree	  	  and	  	   Rwork	  =	  Σ	  	  	  |Fobs	  -­‐	  kFcalc|	  	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  hfree	  	   	  	  	  	  	  	  	  	  	  	  Σ	  	  	  Fobs	  hfree	  	  Both	  the	  Rwork	  and	  Rfree	  should	  improve	  (decrease)	  as	  refinement	  progresses	  and	  the	  model	  becomes	  more	  complete,	  however	  the	  Rfree	  value	  will	  always	  be	  greater	  than	  Rwork.	  A	  change	  to	  the	  model	  that	  improves	  the	  way	  it	  interprets	  physical	  reality	  (i.e.	  the	  actual	  data)	  will	  be	  reflected	  in	  the	  way	  the	  model	  fits	  to	  the	  data	  contained	  in	  Rfree,	  which	  was	  not	  used	  in	  the	  refinement	  process	  (Brunger,	  1993).	  This	  can	  also	  be	  used	  as	  an	  assessment	  of	  restraint	  requirements,	  as	  if	  a	  certain	  number	  of	  enforced	  parameters	  give	  no	  change	  in	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Rfree	  compared	  to	  a	  less	  or	  unrestrained	  model	  then	  a	  model	  is	  being	  over-­‐parameterised,	  maybe	  even	  to	  the	  point	  of	  bias.	  A	  decreasing	  Rwork	  with	  a	  stable	  or	  increasing	  Rfree	  is	  also	  an	  indication	  of	  bias,	  perhaps	  symptomatic	  of	  changes	  being	  made	  that	  the	  experimental	  data	  does	  not	  agree	  with.	  A	  judgement	  of	  Rfree	  may	  also	  be	  useful	  in	  determining	  the	  optimum	  modelling	  of	  a	  protein	  structure	  too	  as	  a	  rapid	  loss	  of	  improvement	  in	  Rfree,	  regardless	  of	  restraint	  or	  constraint	  variations,	  may	  mean	  that	  the	  model	  now	  fits	  the	  experimental	  data	  to	  the	  best	  ML.	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Chapter	  3:	  Materials	  and	  Methods	  	  
3.1	  Materials	  	  Throughout	  the	  experiments	  carried	  out	  in	  the	  construction	  of	  this	  thesis	  all	  equipment	  and	  reagents	  used	  were	  common	  to	  most	  laboratories	  and	  available	  for	  purchase	  from	  a	  range	  of	  suppliers.	  The	  grades	  of	  chemicals	  used	  were	  matched	  to	  the	  specific	  requirements	  of	  individual	  experiments,	  and	  as	  such	  any	  deviation	  from	  standard	  usages	  will	  be	  mentioned	  later	  on	  in	  this	  work	  on	  a	  case-­‐by-­‐case	  basis.	  As	  it	  was	  generally	  considered	  that	  the	  source	  of	  chemicals	  would	  have	  a	  negligible	  effect	  on	  the	  outcome	  of	  the	  experiments	  undertaken,	  an	  extensive	  description	  of	  all	  reagents	  does	  not	  appear	  in	  this	  work.	  	  
3.2	  General	  Methods	  	  This	  section	  documents	  the	  standard	  methods	  used	  during	  the	  experimental	  processes	  of	  this	  thesis.	  Any	  variations	  from	  the	  typical	  details	  of	  each	  method	  are	  described	  here.	  	  3.2.1	  PCR	  	  PCR	  (Bartlett	  &	  Stirling,	  2003)	  was	  used	  for	  2	  different	  applications:	  (I)	  amplification	  of	  inserts	  for	  cloning,	  and	  (II)	  colony	  PCR	  to	  confirm	  the	  insert	  presence	  in	  the	  purified	  plasmid	  post-­‐cloning.	  In	  both	  cases	  the	  following	  reaction	  conditions	  or	  multiples	  thereof	  were	  used,	  and	  were	  occasionally	  varied	  by	  the	  addition	  of	  10%	  DMSO	  to	  reduce	  primer	  secondary	  structure	  formation:	  	  	   0.5	  µl	  sense	  primer	  (5µM)	  	   0.5	  µl	  antisense	  primer	  (5µM)	  	   0.5	  µl	  genomic	  template	  (approx	  2µM)	  	   6.25	  µl	  2xBioMix	  	   4.74ul	  sterile,	  deionised	  water	  	   12.5	  µl	  reaction	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BioMix	  is	  a	  premixed	  PCR	  cocktail	  containing	  Taq	  DNA	  polymerase,	  reaction	  buffer	  and	  free	  dNTPs	  available	  from	  Bioline.	  This	  reaction	  mix	  was	  subjected	  to	  the	  following	  conditions	  using	  a	  Techne	  TC-­‐312	  Thermocycler.	  A	  variation	  of	  the	  annealing	  temperature	  by	  no	  more	  than	  5°C	  was	  occasionally	  employed	  to	  optimise	  specific	  binding	  of	  some	  primers:	  	   94	  °C	  Initial	  Denaturation	  94	  °C	  Denaturation	  55	  °C	  Annealing	  72	  °C	  Extension	  72	  °C	  Final	  Extension	  	  In	  the	  case	  of	  colony	  PCR	  the	  genomic	  template	  was	  replaced	  by	  boiled	  cell-­‐lysate	  from	  colonies	  picked	  from	  an	  agar	  plate	  and	  resuspended	  in	  30	  µl	  sterile	  water.	  	  3.2.2	  Agarose	  Gel	  Electrophoresis	  	  Separation	  of	  DNA	  vectors	  or	  fragments	  for	  analysis	  or	  purification	  was	  carried	  out	  by	  running	  samples	  on	  a	  1%	  agarose	  gel	  and	  visualising	  their	  migration	  through	  the	  gel	  matrix.	  Gel	  production	  was	  commonly	  achieved	  by	  melting	  0.5g	  agarose	  into	  50ml	  of	  TAE	  buffer	  (40mM	  Tris	  pH	  8.0,	  20mM	  glacial	  acetic	  acid,	  1mM	  EDTA)	  into	  a	  200	  ml	  Duran	  using	  a	  microwave,	  and	  adding	  5	  µl	  of	  x10,000	  GelRed	  or	  ethidium	  bromide	  once	  the	  vessel	  had	  cooled	  down	  enough	  to	  comfortably	  touch	  with	  un-­‐gloved	  hands.	  	  	  Ethidium	  bromide	  was	  added	  to	  intercalate	  with	  the	  base-­‐pairs	  of	  the	  DNA	  under	  investigation	  to	  allow	  fluorescent	  visualisation	  of	  migration	  under	  UV	  light.	  The	  melted	  agarose	  was	  allowed	  to	  cool	  slightly	  to	  prevent	  the	  inhalation	  of	  vapours,	  as	  ethidium	  bromide	  is	  a	  carcinogenic	  agent.	  GelRed	  is	  available	  from	  Biotium	  and	  is	  a	  safer	  alternative	  to	  ethidium	  bromide	  that	  cannot	  cross	  cell	  membranes	  and	  leaches-­‐out	  less	  from	  gels	  to	  give	  improved	  resolution	  of	  results.	  	  
30	  Cycles	  
	   59	  
The	  gels	  were	  poured	  into	  BioRad	  Mini-­‐Sub	  Cell	  gel-­‐beds	  with	  a	  comb	  inserted	  to	  form	  wells,	  and	  were	  allowed	  to	  set	  for	  approximately	  20	  minutes.	  Once	  set,	  the	  gels	  were	  submerged	  in	  TAE	  buffer	  so	  that	  a	  thin	  layer	  of	  buffer	  covered	  the	  gel’s	  surface.	  Appropriately	  diluted	  samples	  were	  combined	  with	  loading	  buffer	  (0.25%	  Bromophenol	  Blue,	  30%	  Glycerol)	  from	  a	  x6	  stock	  and	  carefully	  loaded	  into	  the	  designated	  well.	  Gels	  also	  had	  a	  molecular	  weight	  marker	  lane	  included	  such	  as	  Hyperladder	  I	  from	  Bioline	  or	  1KB-­‐Geneladder	  from	  NEB	  in	  order	  to	  identify	  DNA	  fragments	  by	  their	  migration	  compared	  to	  fragments	  of	  known	  molecular	  weight.	  Gel-­‐tank	  lids	  were	  connected	  to	  their	  correctly	  orientated	  electrodes	  and	  were	  run	  at	  100V.	  Time	  was	  varied	  to	  account	  for	  the	  separation	  of	  differently	  sized	  samples.	  Smaller	  PCR	  products	  were	  run	  for	  40	  minutes	  whilst	  larger	  samples	  such	  as	  digested	  plasmids	  were	  run	  for	  60-­‐70	  minutes.	  After	  the	  electrophoresis	  had	  concluded,	  the	  gels	  were	  visualised	  using	  a	  UV	  lamp	  and	  a	  photographic	  record	  was	  made	  using	  a	  digital	  camera,	  a	  Polaroid	  camera,	  or	  a	  photomultiplier	  set-­‐up	  when	  available.	  	  3.2.3	  SDS-­‐PAGE	  	  This	  method	  was	  used	  to	  analyse	  the	  presence	  and	  purity	  of	  proteins	  by	  separating	  proteins	  based	  upon	  their	  individual	  molecular	  weights.	  The	  protocol	  used	  was	  adapted	  from	  the	  protocol	  established	  by	  Laemmli	  (Laemmli,	  1970).	  All	  SDS-­‐PAGE	  gels	  in	  this	  thesis	  were	  made	  to	  have	  a	  13.5%	  resolve	  with	  5%	  stack	  for	  well	  formation,	  following	  the	  recipe:	  	  
Reagent	   Vol	  used	  for	  13.5%	  Resolve	   Vol	  used	  for	  5%	  Stack	  30%	  Acrylamide	  soln	   2.81ml	   0.63ml	  1M	  Tris	  pH	  8.8	   2.35ml	   	  1M	  Tris	  pH	  6.8	   	   0.47ml	  Deionised	  water	   0.97ml	   2.6ml	  10%	  SDS	   62.5µl	   37.5µl	  TEMED	   6.25µl	   3.75µl	  10%	  APS	   62.5µl	   37.5µl	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Samples	  were	  created	  to	  contain	  10-­‐15	  µg	  of	  protein,	  mixed	  to	  dilute	  x4	  LDS	  Loading	  Buffer	  (40%	  glycerol,	  4%	  lithium	  dodecyl	  sulfate,	  0.025%	  phenol	  red,	  0.025%	  Coomassie	  G250,	  2mM	  EDTA,	  0.8M	  triethanolamine-­‐Cl	  pH	  7.6	  –	  available	  from	  Invitrogen)	  and	  x10	  reducing	  agent	  (1M	  DTT)	  and	  made	  up	  to	  30	  µl	  using	  deionised	  water.	  The	  samples	  were	  then	  boiled	  for	  2	  minutes.	  After	  centrifuging	  at	  13kpm	  for	  20	  seconds	  in	  an	  MSE	  Micro-­‐Centaur	  rotor	  the	  samples	  were	  loaded	  into	  the	  wells	  of	  the	  stacking	  gel	  alongside	  the	  Mark	  12	  molecular	  weight	  ladder	  from	  Invitrogen.	  	  SDS-­‐PAGE	  gels	  were	  ran	  at	  60V	  for	  10	  minutes	  to	  ensure	  samples	  entered	  the	  resolves	  at	  the	  same	  time,	  before	  being	  run	  at	  200V	  for	  approximately	  45	  minutes	  or	  until	  the	  running-­‐front	  marker	  Coomassie	  G250	  began	  to	  run	  off	  the	  bottom	  of	  the	  gel.	  Gels	  were	  stained	  overnight	  in	  1:1:1	  methanol:acetic	  acid:water	  with	  0.1%	  Coomassie	  Blue	  and	  washed	  then	  soaked	  in	  destain	  (10%	  methanol,	  10%	  acetic	  acid)	  overnight,	  changing	  into	  fresh	  destain	  several	  times.	  Gels	  were	  then	  dried	  by	  soaking	  2	  squares	  of	  DryEase	  cellophane	  from	  Invitrogen	  in	  drying	  solution	  (4:2:2:1	  methanol:ethanol:isopropanol:glycerol)	  and	  using	  these	  to	  sandwich	  the	  drying	  solution-­‐rinsed	  gel,	  which	  was	  then	  clip-­‐sealed	  into	  a	  drying-­‐cassette	  and	  left	  to	  dry	  naturally.	  SDS-­‐PAGE	  gels	  were	  then	  scanned	  to	  be	  included	  in	  this	  thesis.	  	  	  3.2.4	  Determination	  of	  Protein	  Concentration	  	  Protein	  concentrations	  were	  determined	  by	  the	  Bradford	  Assay	  (Bradford,	  1976),	  in	  which	  the	  Bradford	  reagent	  binds	  to	  the	  hydrophobic	  regions	  of	  proteins	  causing	  an	  increase	  in	  absorption	  at	  595nm	  proportional	  to	  protein	  concentration.	  Samples	  were	  analysed	  in	  a	  spectrophotometer	  using	  the	  following	  composition:	  	  	   200	  µl	  Bradford	  Reagent	  	   800	  µl	  deionised	  water	  	   1-­‐10	  µl	  protein	  sample	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The	  following	  equation	  was	  used	  to	  establish	  the	  concentration	  of	  the	  protein	  samples	  from	  the	  absorption	  read	  from	  the	  spectrophotometer:	  	  	   OD	  595nm	  x	  15	   =	   mg/ml	  	   µl	  protein	  	  	  where	  15	  L	  mol-­‐1	  cm-­‐1	  is	  the	  absorption	  coefficient	  for	  the	  Bradford	  reagent.	  	  
3.3	  Bioinformatical	  Methods	  	  Throughout	  this	  work,	  nucleotide	  and	  protein	  sequences	  were	  extracted	  from	  the	  databases	  of	  the	  NCBI	  or	  GeneDB.org.	  Gene	  and	  protein	  sequences	  were	  analysed	  for	  comparison	  of	  homologues	  and	  the	  detection	  of	  their	  presence	  in	  specific	  bacterial	  species	  using	  the	  NCBI	  BLAST	  server	  (Altschul	  et	  al,	  1990).	  Gene	  sequences	  were	  analysed	  for	  potential	  restriction	  sites	  using	  the	  NEBcutter	  server	  (Vincze	  et	  al,	  2003),	  whilst	  protein	  sequences	  were	  analysed	  for	  predicted	  regions	  of	  disorder	  using	  the	  RONN	  server	  (Yang	  et	  al,	  2005)	  and	  were	  input	  to	  the	  ExPASy	  ProtParam	  server	  for	  calculation	  of	  mass,	  theoretical	  pI	  and	  atomic	  composition	  (Gasteiger	  et	  al,	  2003).	  Prof.	  Pete	  Artymiuk	  generated	  genome-­‐wide,	  individual	  Kyte-­‐Doolittle	  Scale	  hydrophobicity	  plots	  	  (Kyte	  &	  Doolittle,	  1982)	  using	  a	  program	  he	  wrote	  that	  extracted	  protein	  sequences	  from	  the	  translated	  Burkholderia	  pseudomallei	  genome	  data	  from	  the	  NCBI	  database.	  He	  then	  wrote	  a	  script	  to	  automatically	  create	  hydrophobicity	  plots	  using	  the	  Staden	  HYDROPLOT	  program	  (Staden,	  1994).	  Fold-­‐recognition	  investigations	  were	  carried-­‐out	  using	  the	  GenThREADer	  server	  from	  Psipred	  (Jones,	  1999a).	  	  
3.4	  Cloning	  of	  Constructs	  	  3.4.1	  Oligonucleotide	  Primers	  	  All	  the	  primers	  designed	  for	  this	  thesis	  were	  designed	  using	  the	  program	  AmplifX	  1.5.4	  (http://ifrjr.nord.univ-­‐mrs.fr/AmplifX),	  which	  also	  ran	  a	  mock	  PCR	  reaction	  based	  upon	  calculations	  of	  Tm,	  potential	  secondary	  structure	  predictions	  and	  self-­‐dimerisation	  likelihoods	  against	  the	  target	  gene	  sequence.	  
	   62	  
	  The	  following	  primers	  were	  designed	  for	  the	  production	  of	  PCR	  fragments,	  and	  were	  synthesised	  by	  Sigma-­‐Aldrich:	  	  
Name	   Sequence	  (+Restriction	  Site)	   Gene	   Vector	  BPSL1204-­‐F	   ATGCAGCCGTGGCAGCAATTTC	   BPSL1204-­‐MA	   pETBlue-­‐1	  BPSL1204-­‐R	   GCGTGTCAAATGACTTCGGGCG	   BPSL1204-­‐MA	   pETBlue-­‐1	  wtBCAL2351F	   	   TTAAATTTCCATGGGACGCATTCGCATTCCCGCG	  (NcoI)	   wtBCAL2351	   pBAD/hisB	  wtBCAL2351R	   TAGTAGGTTTCGAATCAGAACAGAACAGGGTGCGGCGAT	  (HindIII)	   wtBCAL2351	   pBAD/hisB	  nH2351-­‐F	   AATTACATATGCAGCAATACCAGGCCGGCCA	  (NdeI)	   His-­‐tagged	  BCAL2351-­‐	   pET28a	  nH2351-­‐R	   ATTAACCTAGGTCAGAACAGGGTGCGGCGAT	  (BamHI)	   His-­‐tagged	  BCAL2351-­‐	   pET28a	  wt0998F_	   CATTTAGACCATGGGATCCGCATCCGACCTCACTTC	  (NcoI)	   BPSL0998	   pBAD/hisB	  wt0998R	   ATTAAAGCTTCGAATCACTTCACGCGCATGCCGG	  (HindIII)	   BPSL0998	   pBAD/hisB	  	  	  3.4.2	  Sub-­‐cloning	  of	  PCR	  products	  	  	  PCR	  products	  were	  purified	  from	  the	  PCR	  reaction	  mix	  using	  either	  the	  Qiagen	  PCR	  Purification	  Kit,	  or	  were	  agarose	  gel-­‐extracted	  using	  the	  Qiagen	  Gel	  Extraction	  Kit	  if	  the	  PCR	  produced	  contaminating	  bands.	  Both	  the	  PCR	  insert	  and	  the	  corresponding	  purified	  vector	  of	  choice	  were	  treated	  with	  the	  same	  two	  enzymes	  in	  a	  double-­‐digest	  reaction	  at	  37°C	  for	  1-­‐6	  hrs.	  Pure	  plasmid-­‐vectors	  were	  obtained	  using	  the	  Qiagen	  Miniprep	  Kit	  from	  maintained	  cell-­‐line	  stocks.	  Digested	  plasmids	  were	  purified	  by	  Qiagen	  Gel-­‐Extraction	  and	  inserts	  were	  purified	  by	  Qiagen	  PCR	  Purification.	  Some	  problematic	  digestions	  were	  further	  treated	  with	  Antartic	  Phosphatase	  from	  NEB	  to	  remove	  5´	  phosphate	  groups	  to	  prevent	  plasmid	  re-­‐circularisation.	  Overnight	  ligations	  were	  carried	  out	  using	  T4	  Ligase	  from	  NEB	  by	  incubation	  overnight	  at	  either	  4°C,	  16°C	  or	  a	  using	  a	  gradient	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of	  0-­‐20°C.	  All	  kit-­‐based	  methods	  were	  carried	  out	  as	  directed	  by	  the	  manufacturers	  manual.	  	  In	  cases	  where	  blunt-­‐end-­‐ligation	  into	  the	  pETBlue	  vector	  was	  used	  PCR	  products	  were	  amplified	  and	  then	  gel	  extracted	  if	  not	  already	  pure,	  then	  ligated	  into	  the	  supplied,	  pre-­‐linearised	  vector	  using	  T4	  ligase	  overnight	  at	  4°C.	  After	  transforming	  into	  the	  sub-­‐cloning	  strain,	  colonies	  with	  correctly	  orientated	  inserts	  were	  identified	  using	  the	  3´PCR	  primer	  and	  the	  upstream-­‐of-­‐insert	  pETBlue-­‐1	  specific	  5´T7F	  primer	  (Studier	  &	  Moffatt,	  1986).	  	  3.4.3	  E.	  coli	  Strains	  Used	  For	  Sub-­‐cloning	  and	  Over-­‐expression	  	  The	  following	  bacterial	  strains	  were	  used	  in	  the	  cloning	  and	  over-­‐expression	  of	  target	  genes:	  	  Sub-­‐cloning	  strains	  and	  genotypes:	  
NovaBlue	  –	  endA1	  hsdR17	  (rK12-­‐mK12+)	  supE44	  thi-­‐1	  recA1	  gyrA96	  lac	  F'[proA+B+	  laclqZΔM15::Tn10]	  (TetR)	  (from	  Merck	  Biosciences)	  
DH5α	  -­‐	  fhuA2Δ(argF-­‐lacZ)U169	  phoA	  glnV44	  Φ80	  Δ(lacZ)M15	  gyrA96	  recA1	  relA1	  endA1	  thi-­‐1	  hsdR17	  (from	  NEB)	  
XLBlue	  –	  recA1	  endA1	  gyrA96	  thi-­‐1	  hsdR17	  supE44	  relA1	  lac	  [F	  ́	  proAB	  lacIqZ∆M15	  Tn10	  (Tetr)]	  (from	  Stratagene)	  	  Over-­‐expression	  strains	  and	  genotypes:	  
Tuner	  –	  F-­‐ompT	  hsdSB	  (rB-­‐mB-­‐)	  gal	  dcm	  lacY1	  (from	  Merck	  Biosciences)	  
BL21(DE3)	  -­‐	  F-­‐	  ompT	  hsdSB(rB-­‐mB-­‐)	  gal	  dcm	  (DE3)	  (from	  Invitrogen)	  
Top10	  -­‐	  F-­‐	  mcrA	  (mrr-­‐hsdRMS-­‐mcrBC)	  80lacZM15	  lacX74	  recA1	  ara139	  (ara-­‐leu)7697	  galU	  galK	  rpsL	  (StrR)	  endA1	  nupG	  (from	  Invitrogen)	  	  All	  strains	  were	  transformed	  with	  ligated	  plasmids	  as	  suggested	  in	  the	  manufacturers	  literature.	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3.5	  Protein	  Expression	  	  3.5.1	  Media	  and	  Agar	  	  For	  all	  standard	  bacterial	  growths	  on	  all	  scales	  liquid	  LB	  media	  was	  used	  (Bertani,	  2004),	  using	  the	  following	  contents	  per	  litre	  of	  media:	  	  10	  g	  Tryptone	  5	  g	  Yeast	  Extract	  10	  g	  NaCl	  made	  to	  1	  L	  with	  deionised	  water	  	  For	  the	  creation	  of	  solid	  LB	  agar	  media,	  the	  above	  list	  was	  supplemented	  with	  15	  g	  Bactoagar	  per	  litre.	  All	  standard	  LB	  media	  were	  autoclaved	  to	  sterilise	  before	  use.	  This	  also	  promoted	  the	  solubilisation	  of	  agar	  into	  the	  media	  to	  allow	  proper	  mixing.	  Stocks	  of	  liquid	  and	  solid	  media	  were	  stored	  at	  room	  temperature	  in	  an	  aseptic	  room	  with	  a	  UV	  bulb	  used	  when	  unoccupied.	  All	  media	  were	  handled	  using	  proper	  aseptic	  technique	  to	  avoid	  contamination	  wherever	  possible.	  	  	  3.5.2	  Minimal	  Media	  for	  Seleno-­‐methione	  Incorporation	  	  For	  growth	  experiments	  attempting	  to	  incorporate	  seleno-­‐methionine	  into	  over-­‐expressed	  protein,	  minimal	  media	  was	  created	  to	  cause	  the	  inhibition	  of	  methionine	  synthesis	  by	  the	  induced	  E.	  coli	  and	  also	  to	  promote	  the	  forced	  inclusion	  of	  seleno-­‐methionine	  into	  protein	  synthesis	  in	  the	  place	  of	  naturally	  occurring	  methionine.	  The	  following	  chemicals	  were	  used	  to	  create	  the	  minimal	  media	  per	  litre:	  	  10.5	  g	  Dipotassium	  phosphate	  1	  g	  Ammonium	  sulphate	  4.5	  g	  Potassium	  dihydrogen	  phosphate	  0.5	  g	  Tri-­‐sodium	  citrate	  5	  ml	  100%	  Glycerol	  0.5	  g	  Adenine	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0.5	  g	  Guanosine	  0.5	  g	  Thymine	  0.5	  g	  Uracil	  made	  to	  1	  litre	  with	  deionised	  water	  	  The	  above	  mixture	  was	  split	  into	  two	  2-­‐litre	  baffled-­‐flasks	  containing	  490	  ml	  each,	  or	  multiples	  thereof	  for	  larger	  growths,	  and	  was	  then	  autoclaved	  to	  sterilise.	  Baffled-­‐flasks	  were	  used	  to	  promote	  better	  aeration	  as	  a	  combatant	  against	  the	  negative	  effects	  on	  growth	  of	  using	  lower	  nutrient	  media.	  To	  the	  above	  autoclaved	  bulk	  of	  the	  media,	  the	  following	  non-­‐autoclavable	  components	  were	  added	  to	  each	  490	  ml:	  	  1	  ml	  50	  mg/ml	  L-­‐Lysine	  2.5	  ml	  20	  mg/ml	  L-­‐Phenylalanine	  1	  ml	  50	  mg/ml	  L-­‐Threonine	  1	  ml	  25	  mg/ml	  L-­‐Isoleucine	  2	  ml	  12.5	  mg/ml	  L-­‐Leucine	  1	  ml	  25	  mg/ml	  L-­‐Valine	  1	  ml	  0.5	  mg/ml	  Magnesium	  Sulphate	  1	  ml	  2	  mg/ml	  Thiamine	  
1	  ml	  20	  mg/ml	  Seleno-­methionine	  	  All	  stock	  solutions	  were	  stored	  at	  -­‐20°C	  with	  the	  exception	  of	  seleno-­‐methionine	  which	  was	  made	  fresh	  every	  time.	  	  	  When	  used	  for	  growth	  of	  bacterial	  culture,	  all	  media	  were	  supplemented	  with	  the	  appropriate	  antibiotic	  at	  the	  established	  effective	  concentration	  for	  the	  specific	  strain	  used.	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3.5.3	  E.	  coli	  Over-­‐expression	  –	  General	  Overview	  	  As	  a	  standard	  all	  initial	  expressions	  were	  carried	  out	  in	  a	  similar	  fashion.	  Specific	  details	  of	  individual	  over-­‐expressions	  are	  given	  in	  the	  appropriate	  Results	  chapter.	  250	  µl	  of	  a	  50	  ml	  overnight	  culture	  was	  used	  to	  5%-­‐inoculate	  4.75	  ml	  fresh	  LB	  media,	  which	  was	  allowed	  to	  grow	  to	  an	  OD600nm	  of	  0.6-­‐0.7	  at	  37°C	  on	  a	  250	  rpm	  shaking	  platform.	  OD	  was	  measured	  against	  a	  blank	  of	  sterile	  LB	  media	  in	  a	  spectrophotometer.	  The	  culture	  was	  then	  induced	  for	  3	  hours	  with	  either	  1	  mM	  IPTG	  for	  genes	  under	  the	  control	  of	  the	  lac	  operon	  or	  0.01%	  arabinose	  for	  genes	  under	  the	  control	  of	  the	  ara	  operon.	  A	  non-­‐induced	  control	  culture	  was	  carried	  out	  alongside	  induction	  samples.	  Cells	  were	  pelleted	  by	  centrifugation	  at	  5000	  rpm	  at	  10°C	  then	  the	  supernatant	  was	  decanted	  and	  pipetted	  off.	  Pellets	  were	  subjected	  to	  Novagen	  BugBuster	  fractionation	  as	  directed	  by	  the	  manufacturer’s	  manual	  to	  generate	  soluble	  and	  insoluble	  fractions	  that	  were	  analysed	  for	  protein	  over-­‐expression	  by	  SDS-­‐PAGE	  gel.	  Based	  upon	  the	  results	  of	  the	  gel,	  over-­‐expressions	  were	  optimised	  by	  varying	  one	  or	  more	  of:	  induction	  OD,	  concentration	  of	  inducing	  agent,	  time-­‐period	  of	  induction	  and	  temperature	  of	  induced	  samples.	  The	  specific	  conditions	  for	  each	  protein	  target	  are	  described	  individually	  later	  on	  in	  this	  thesis.	  	  After	  optimum	  over-­‐expression	  conditions	  were	  discovered	  for	  achieving	  sufficient	  soluble	  protein,	  the	  growth	  was	  then	  scaled	  up	  and	  repeated	  in	  bulk	  volumes	  of	  multiples	  of	  500	  ml.	  After	  large-­‐scale	  growth,	  cells	  were	  pelleted	  in	  500	  ml	  centrifugation	  canisters	  by	  centrifugation	  at	  5000	  rpm	  at	  8°C	  using	  a	  Beckman	  Avanti	  and	  a	  J10.500	  rotor.	  Then	  the	  pellet	  was	  transferred	  to	  a	  50	  ml	  Falcon	  tube	  by	  scooping	  out	  most	  of	  the	  pellet	  and	  re-­‐suspending	  the	  rest	  in	  the	  lowest	  volume	  of	  media	  possible	  and	  pipetting	  into	  the	  Falcon.	  Several	  canisters’	  pellets	  were	  combined	  into	  one	  Falcon,	  which	  was	  then	  spun	  for	  20	  minutes	  at	  5000	  rpm	  at	  8°C	  in	  a	  Sigma	  11133	  rotor	  to	  re-­‐pellet	  into	  the	  stock	  cell-­‐paste.	  Supernatant	  was	  removed	  and	  the	  cell-­‐paste	  stored	  at	  -­‐80°C	  until	  used	  for	  protein	  purification.	  Before	  initial	  use	  in	  purification,	  a	  Bugbuster	  fractionation	  and	  an	  SDS-­‐PAGE	  analysis	  were	  carried	  out	  on	  a	  sample	  of	  the	  paste	  to	  ensure	  the	  scale-­‐up	  did	  not	  change	  the	  desired	  over-­‐expression	  profile.	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Large-­‐scale	  over-­‐expression	  of	  seleno-­‐methionine-­‐incorporated	  protein	  began	  with	  the	  growth	  of	  cells	  to	  an	  OD600nm	  of	  0.6	  in	  LB	  as	  with	  the	  standard	  protocol.	  However	  at	  this	  point,	  cells	  were	  pelleted	  by	  centrifugation	  for	  20	  minutes	  at	  5000	  rpm	  using	  a	  J10.500	  rotor	  at	  8°C	  and	  the	  LB	  supernatant	  was	  decanted	  off	  and	  the	  pellet	  washed	  gently	  in	  minimal	  media	  so	  as	  to	  not	  re-­‐suspend	  cells,	  which	  was	  then	  gently	  removed	  by	  decanting	  and	  pipetting.	  Each	  pellet	  was	  then	  re-­‐suspended	  in	  50	  ml	  fresh	  minimal	  media	  taken	  from	  500	  ml	  in	  a	  2	  L	  flask,	  now	  containing	  450	  ml.	  The	  50	  ml	  re-­‐suspension	  was	  then	  added	  back	  to	  the	  flask	  of	  origin,	  and	  the	  cells	  allowed	  to	  equilibrate	  and	  begin	  growth	  again	  for	  30	  minutes	  at	  the	  optimum	  over-­‐expression	  temperature.	  Cells	  were	  then	  induced	  and	  left	  for	  21	  hrs	  to	  over-­‐express.	  This	  extended	  expression	  period	  was	  required	  for	  sufficient	  yield	  of	  both	  cell	  count	  and	  maximum	  protein	  produced	  per	  cell,	  due	  to	  the	  growth-­‐lagging	  effect	  of	  minimal	  media	  and	  the	  cytotoxic	  effect	  of	  seleno-­‐methionine	  presence	  (Strub	  et	  al,	  2003).	  	  	  3.5.4	  Glycerol	  Stocks	  	  In	  order	  to	  maintain	  cell-­‐lines	  proven	  to	  be	  over-­‐expressing	  target	  proteins,	  and	  to	  facilitate	  future	  culturing,	  stocks	  of	  the	  original	  overnight	  cultures	  were	  combined	  with	  glycerol	  to	  a	  final	  concentration	  of	  30%	  (700	  µl	  culture	  vortexed	  with	  300	  µl	  100%	  glycerol).	  These	  stocks	  were	  then	  stored	  at	  -­‐80°C	  for	  up	  to	  18	  months	  and	  used	  to	  create	  50	  ml	  overnight	  cultures	  for	  future	  large-­‐scale	  over-­‐expressions.	  Fresh	  30%	  glycerol	  stocks	  were	  created	  after	  every	  culture	  to	  replace	  older	  stocks.	  	  
3.6	  Protein	  Purification	  	  The	  following	  procedures	  are	  a	  generalisation	  on	  the	  techniques	  used	  in	  the	  experimental	  protein	  purifications	  carried	  out	  during	  the	  research	  on	  which	  this	  thesis	  is	  based.	  The	  specifics	  of	  individual	  purifications	  are	  given	  later	  on	  in	  this	  body	  of	  work.	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3.6.1	  Preparing	  Cell-­‐free	  Extract	  	  In	  order	  to	  achieve	  accessible	  soluble	  protein,	  cell	  membranes,	  insoluble	  proteins	  and	  other	  cell-­‐debris	  needed	  to	  be	  separated	  from	  the	  soluble	  cytoplasm	  of	  the	  cell-­‐paste	  used.	  The	  weight	  of	  cells	  to	  be	  used	  was	  re-­‐suspended	  from	  the	  pellet	  kept	  at	  -­‐80°C	  in	  1:10	  g:ml	  of	  a	  suitable	  buffer	  such	  as	  50	  mM	  Tris	  ph8.0.	  For	  example	  this	  meant	  that	  3	  g	  of	  cell-­‐paste	  was	  re-­‐suspended	  in	  25-­‐30	  ml	  of	  buffer.	  This	  re-­‐suspension	  was	  split	  between	  3x20	  ml	  pots,	  and	  on	  a	  bath	  of	  ice	  each	  pot	  was	  subjected	  to	  3x20	  seconds	  sonication	  at	  16	  microns	  using	  an	  MSE	  Soniprep	  150	  machine	  and	  a	  blunt-­‐ended	  sonication	  probe.	  Each	  pot	  was	  returned	  to	  ice	  after	  each	  20-­‐second	  sonication	  to	  prevent	  overheating,	  thus	  avoiding	  denaturation	  of	  the	  protein	  sample.	  Pots	  were	  combined	  into	  a	  centrifuge	  tube	  and	  disintegrated	  cell-­‐debris	  was	  pelleted	  by	  centrifugation	  at	  24000	  rpm	  for	  15	  minutes	  at	  8°C	  using	  a	  Beckman	  Avanti	  and	  a	  JA25.50	  rotor.	  The	  soluble	  protein	  supernatant	  was	  decanted	  away	  from	  the	  pellet	  and	  used	  immediately	  for	  the	  next	  step	  of	  purification.	  	  3.6.2	  Ion-­‐Exchange	  Chromatography	  	  Ion-­‐exchange	  chromatography	  utilises	  surface	  net	  charge	  differences	  present	  between	  different	  proteins.	  As	  such	  it	  separates	  proteins	  based	  upon	  their	  ability	  to	  resist	  ionic-­‐perturbation	  from	  a	  charged	  resin	  when	  a	  salt-­‐gradient	  is	  introduced	  to	  the	  column	  used.	  Cell-­‐free	  extract	  was	  applied	  to	  a	  DEAE	  anion-­‐exchange	  column	  pre-­‐equilibrated	  with	  a	  salt-­‐free	  buffer	  such	  as	  50mM	  Tris	  pH8.0	  by	  gentle	  injection	  from	  a	  50	  ml	  Superloop	  connected	  to	  a	  ÄKTAprime	  purification	  system.	  The	  rate	  of	  sample	  application	  was	  determined	  by	  the	  pressure-­‐capacity	  limits	  of	  the	  specific	  column	  used.	  After	  samples	  were	  applied	  and	  the	  flow-­‐through	  collected	  for	  analysis	  later	  on,	  the	  column	  was	  washed	  with	  3	  column	  volumes	  of	  salt-­‐free	  buffer	  until	  no	  more	  protein	  was	  eluted,	  detectable	  by	  a	  UV	  trace.	  All	  proteins	  left	  were	  bound	  to	  the	  positively	  charged	  column	  via	  their	  anionic	  surface	  charges.	  A	  300ml	  salt	  gradient	  of	  0-­‐0.5	  M	  NaCl	  in	  the	  same	  buffer	  as	  that	  used	  to	  wash	  was	  then	  applied	  to	  gradually	  increase	  the	  Cl-­‐	  concentration	  in	  the	  column	  to	  perturb	  protein:column	  interactions.	  The	  more	  negatively	  charged	  the	  protein,	  the	  more	  salt	  required	  to	  prevent	  interaction	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with	  the	  column,	  thus	  allowing	  separation	  based	  upon	  charge.	  4	  ml	  fractions	  were	  collected,	  and	  those	  that	  fell	  under	  the	  peaks	  on	  the	  UV-­‐trace	  were	  analysed	  by	  SDS-­‐PAGE	  for	  the	  presence	  of	  the	  target	  protein.	  The	  fractions	  that	  contained	  the	  correct	  peak	  were	  combined	  for	  the	  next	  stage	  of	  purification.	  	  3.6.3	  Ammonium	  Sulphate	  Precipitation	  	  By	  adding	  high	  concentrations	  of	  (NH4)2SO4	  it	  was	  possible	  to	  alter	  the	  solubility	  of	  a	  target	  protein	  to	  purify	  it	  away	  from	  contaminants	  by	  precipitation.	  Combined	  fractions	  from	  a	  purification	  step	  such	  as	  DEAE	  ion	  exchange	  were	  diluted	  with	  4	  M	  (NH4)2SO4	  to	  a	  final	  concentration	  of	  1.6	  M.	  Precipitated	  proteins	  were	  spun	  into	  a	  pellet	  by	  centrifugation	  in	  a	  Beckman	  Avanti	  JA25.50	  rotor	  at	  24000	  rpm	  at	  8°C	  for	  15	  minutes.	  The	  supernatant	  was	  kept	  for	  analysis,	  and	  the	  pellet	  re-­‐suspended	  in	  the	  minimal	  possible	  volume	  of	  stabilising	  buffer.	  The	  re-­‐suspension	  was	  spun	  at	  13000	  rpm	  in	  a	  desktop	  micro-­‐centrifuge	  for	  5	  minutes	  to	  re-­‐pellet	  any	  permanently	  insoluble	  material,	  and	  then	  the	  soluble	  supernatant	  was	  taken	  for	  SDS-­‐PAGE	  analysis	  of	  purity	  and	  further	  purification	  if	  required.	  	  3.6.4	  Gel-­‐Filtration	  	  	  Gel	  filtration	  or	  size-­‐exclusion	  chromatography	  was	  used	  to	  separate	  proteins	  based	  upon	  their	  molecular	  weight	  and	  stoichiometric	  ratios.	  By	  passing	  a	  mixed	  protein	  solution	  though	  a	  gel-­‐matrix	  of	  porous	  beads,	  a	  larger	  protein	  would	  access	  fewer	  of	  the	  pores	  of	  the	  gel,	  therefore	  the	  protein	  eluted	  from	  the	  column	  faster	  via	  a	  shorter	  elution	  route.	  	  If	  a	  protein	  naturally	  formed	  a	  polymeric	  complex,	  this	  would	  be	  reflected	  in	  the	  elution	  profile,	  with	  estimated	  molecular	  weights	  calculable	  against	  a	  standard	  curve.	  A	  Superdex200	  GF	  column	  from	  GE	  Healthcare	  was	  pre-­‐equilibrated	  with	  the	  stabilising	  buffer	  of	  choice	  (50	  mM	  Tris	  pH8.0,	  0.5	  M	  NaCl	  as	  a	  standard)	  and	  the	  sample	  was	  applied	  in	  a	  volume	  of	  1-­‐2	  ml	  at	  a	  rate	  of	  1	  ml/min.	  At	  the	  same	  rate,	  the	  column	  was	  run	  for	  its	  entire	  inclusion	  volume,	  with	  2	  ml	  fractions	  collected	  and	  monitored	  by	  a	  UV	  trace	  for	  protein	  peaks.	  Peaks	  were	  assessed	  by	  SDS-­‐PAGE	  for	  presence	  of	  target	  protein,	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and	  fractions	  under	  the	  peak	  combined	  for	  the	  next	  stage	  of	  purification	  or	  for	  experimental	  use	  as	  a	  pure	  protein	  sample.	  	  3.6.5	  Viva-­‐Spin	  Concentration	  	  In	  order	  to	  achieve	  highly	  concentrated	  protein	  solutions	  for	  crystallographic	  experiments	  and	  to	  perform	  buffer-­‐exchanges,	  Vivaspin	  centrifuge	  columns	  from	  Sartorious	  Biotech	  were	  used.	  The	  cut-­‐off	  molecular	  weight	  of	  the	  columns	  filter	  was	  varied	  according	  to	  the	  molecular	  weight	  of	  the	  target	  protein	  in	  order	  to	  maximise	  sample-­‐retention	  and	  purity.	  Samples	  were	  concentrated	  by	  centrifugation	  through	  the	  filter	  at	  4500	  rpm	  in	  a	  Sigma	  11133	  rotor	  at	  5°C.	  The	  period	  of	  time	  concentration	  occurred	  for	  varied	  between	  experiments,	  and	  was	  determined	  by	  the	  desired	  final	  concentration	  as	  measured	  by	  the	  Bradford	  Assay.	  This	  method	  was	  also	  used	  to	  exchange	  the	  buffers	  of	  protein	  samples	  when	  required,	  as	  the	  much	  lower	  molecular	  weight	  buffers	  easily	  passed	  through	  even	  the	  lowest	  molecular-­‐weight	  filter.	  Replacing	  the	  old	  buffer	  in	  the	  concentrated	  protein	  sample	  with	  many-­‐fold	  more	  volumes	  of	  new	  buffer	  and	  re-­‐concentrating	  could	  change	  the	  buffers.	  This	  was	  repeated	  several	  times	  to	  complete	  the	  exchange.	  	  	  
3.7	  Crystallographic	  methods	  
	  3.7.1	  Initial	  Screening	  	  Using	  the	  HydraII	  crystallisation	  robot	  from	  Matrix	  Technologies,	  96-­‐well	  sitting-­‐drop	  vapour-­‐diffusion	  experiments	  were	  used	  to	  perform	  initial	  crystallisation	  experiments	  using	  a	  selection	  of	  pre-­‐mixed	  screens	  bought	  from	  Qiagen	  (JCSG+,	  Classics,	  PACT,	  PEG,	  Ammonium	  Sulphate,	  MPD	  and	  pHClear	  screens).	  The	  robot	  pipetted	  100	  µl	  of	  each	  screen	  condition	  into	  a	  micro-­‐plate’s	  reservoir-­‐well,	  and	  then	  ~200	  nl	  was	  transferred	  into	  the	  sitting-­‐drop	  indented-­‐ledge	  of	  each	  well.	  The	  nano-­‐needle	  then	  dispensed	  ~200	  nl	  of	  the	  supplied	  pure	  protein	  solution	  into	  each	  sitting-­‐drop	  ledge	  and	  the	  completed	  microplates	  were	  sealed	  with	  a	  transparent	  film	  and	  spun	  at	  2000	  rpm	  for	  1	  minute	  to	  ensure	  sitting-­‐drops	  were	  mixed	  at	  the	  bottom	  of	  each	  ledge.	  Trials	  were	  left	  at	  either	  7°C	  or	  17°C	  for	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water-­‐vapour	  equilibration	  and	  with	  the	  aim	  of	  crystallising	  the	  target	  protein.	  The	  micro-­‐plates	  were	  gently	  checked	  under	  a	  light-­‐microscope	  once	  every	  2	  days	  for	  the	  first	  fortnight,	  then	  weekly	  after	  that.	  	  	  3.7.2	  Siliconisation	  of	  Coverslips	  	  100-­‐200	  glass	  cover	  slips	  from	  Menzel-­‐Gläser	  were	  placed	  into	  a	  glass-­‐dish	  and	  the	  dish	  was	  rested	  on	  top	  of	  a	  glass	  beaker	  containing	  10	  ml	  of	  dimethyldichlorosilane	  siliconising	  solution.	  This	  was	  placed	  into	  a	  glass-­‐vacuum	  chamber,	  and	  the	  entire	  procedure	  was	  carried	  out	  in	  a	  fume	  cupboard	  with	  the	  extraction-­‐fan	  on	  and	  the	  shield	  down	  as	  far	  as	  practically	  possible.	  Gloves	  were	  worn	  due	  to	  the	  toxic	  nature	  of	  the	  siliconising	  solution.	  With	  the	  chamber	  lid	  in	  place,	  a	  tube	  was	  connected	  from	  the	  chamber	  to	  a	  Buchner	  flask,	  from	  which	  a	  tube	  ran	  intersected	  by	  a	  water	  pipe.	  As	  water	  was	  run,	  air	  was	  removed	  and	  the	  chamber	  interior	  became	  a	  vacuum.	  The	  chamber	  exhaust	  was	  sealed,	  and	  the	  cover	  slips	  left	  in	  the	  siliconising	  vacuum	  for	  20	  minutes,	  after	  which	  the	  chamber	  was	  depressurised	  by	  releasing	  the	  exhaust	  and	  the	  cover	  slips	  removed	  for	  storage	  in	  a	  sterile	  Petri	  dish.	  Each	  cover	  slip	  was	  polished	  using	  lens-­‐tissue	  in	  an	  air-­‐stream	  before	  use	  in	  crystallisation	  experiments.	  	  3.7.3	  Condition	  Optimisation	  	  Following	  the	  identification	  of	  successful	  crystal	  growth	  in	  the	  initial	  screens,	  conditions	  were	  optimised	  to	  focus	  in	  on	  the	  best	  crystallisation	  condition	  by	  varying	  the	  reservoir	  components	  and	  volume,	  drop	  size	  and	  drop	  ratio,	  protein	  concentration	  used	  and	  incubation	  temperature	  in	  24-­‐well	  hanging-­‐drop	  trays.	  Drops	  of	  protein	  and	  reservoir	  solution	  were	  mixed	  together	  on	  a	  siliconised	  coverslip,	  gently	  inverted	  to	  suspend	  the	  drop	  over	  the	  reservoir	  and	  then	  sealed	  as	  a	  lid	  to	  the	  well	  by	  using	  vacuum-­‐grease	  to	  line	  the	  lip	  of	  the	  well.	  Initial	  optimisations	  were	  typically	  done	  in	  duplicate	  to	  allow	  investigation	  of	  the	  effect	  of	  temperature	  on	  crystallisation,	  with	  one	  duplicate	  left	  at	  17°C	  and	  one	  left	  at	  7°C	  during	  the	  length	  of	  the	  experiment.	  Sometimes	  several	  rounds	  of	  condition	  variation	  and	  optimisation	  were	  required	  to	  focus	  in	  on	  the	  best	  possible	  crystal	  growth.	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3.7.4	  Mounting	  of	  Crystals	  onto	  an	  X-­‐ray	  Source	  	  Once	  growth	  of	  sufficiently	  large,	  individual	  crystals	  had	  been	  achieved	  they	  required	  looping	  from	  the	  mother-­‐liquor	  that	  they	  had	  grown	  in	  so	  they	  could	  be	  put	  onto	  the	  in-­‐house	  X-­‐ray	  source	  for	  testing.	  Pre-­‐mounted	  polyimide	  litholoops	  from	  Molecular	  Dimensions	  of	  widths	  appropriate	  for	  the	  crystal	  to	  be	  looped	  were	  immobilised	  on	  a	  magnetic	  base	  using	  superglue.	  In	  order	  to	  be	  compatible	  with	  future,	  automated	  experiments	  at	  the	  Diamond	  Synchrotron	  Light	  Source	  (DSLS)	  the	  base	  used	  was	  bar-­‐coded	  and	  of	  a	  specific	  Crystal	  Cap	  HT	  design,	  from	  Hampton	  Research,	  for	  the	  sample-­‐loading	  robot	  used	  at	  Diamond.	  	  	  Under	  a	  microscope,	  crystals	  were	  gently	  manipulated	  into	  a	  loop	  from	  their	  growth-­‐drop	  and	  smoothly	  transferred	  to	  a	  2	  µl	  drop	  of	  cryo-­‐buffer,	  described	  in	  Section	  3.7.5,	  and	  left	  to	  soak	  for	  1-­‐2	  minutes.	  The	  angle	  and	  direction	  of	  the	  looping	  motion	  was	  dependant	  on	  the	  crystal	  form	  to	  be	  looped,	  as	  thinner,	  longer	  crystals	  with	  potential	  shatter-­‐points	  needed	  different	  angles	  of	  leverage	  than	  fatter,	  evenly	  dimensioned	  crystals.	  Using	  the	  same	  loop,	  or	  a	  sterile	  loop	  of	  the	  same	  size	  if	  multiple	  crystals	  or	  crystal	  debris	  were	  originally	  transferred,	  the	  individual	  crystal	  was	  then	  transferred	  to	  the	  head	  of	  the	  goniometer	  quickly	  to	  avoid	  evaporation	  of	  water	  from	  the	  loop	  to	  the	  air,	  but	  also	  as	  carefully	  as	  possible	  as	  to	  avoid	  physical	  damage	  to	  the	  sample	  via	  collisions	  or	  vibrations.	  For	  this	  reason	  also,	  the	  goniometer	  magnet	  was	  not	  engaged	  until	  the	  loop	  was	  in	  position	  on	  the	  head	  as	  to	  avoid	  the	  sudden	  pull	  of	  magnetism	  as	  the	  base	  entered	  the	  goniometers	  proximity.	  	  This	  now	  placed	  the	  isolated	  crystal	  in	  the	  nitrogen	  stream	  and	  attached	  to	  a	  goniometer	  that	  allowed	  for	  orientation	  changes	  to	  the	  crystal	  while	  it	  was	  aligned	  in	  the	  X-­‐ray	  beam.	  For	  long-­‐term	  saving	  after	  in-­‐house	  testing,	  the	  crystal	  could	  be	  carefully	  removed	  from	  the	  X-­‐ray	  machine	  surrounded	  by	  a	  cryo-­‐tube	  full	  of	  liquid	  nitrogen	  and	  stored	  in	  a	  nitrogen-­‐filled	  Dewar.	  From	  this	  storage	  it	  was	  then	  possible	  to	  unload	  the	  crystal	  in	  the	  loop	  and	  base	  into	  a	  crystal	  transport	  ‘puck’	  using	  a	  magnet-­‐tipped	  rod	  under	  a	  pool	  of	  nitrogen.	  This	  could	  now	  safely	  be	  transported	  to	  the	  synchrotron	  in	  a	  liquid	  nitrogen-­‐filled	  Dewar	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for	  automated	  loading	  onto	  a	  beam-­‐line	  using	  a	  robotic	  arm	  for	  more	  advanced	  data	  collection.	  	  3.7.5	  Cryo-­‐protection	  of	  Crystals	  	  To	  reduce	  radiation	  damage	  to	  crystals	  due	  to	  exposure	  to	  prolonged	  high-­‐intensity	  radiation,	  crystals	  were	  cooled	  in	  a	  nitrogen	  stream	  during	  data-­‐collection.	  In	  order	  to	  prevent	  crystallisation	  of	  water	  ice	  when	  data	  are	  collected	  at	  temperatures	  below	  the	  freezing	  point	  of	  water,	  typically	  100	  Kelvin,	  the	  solution	  in	  which	  the	  crystals	  were	  looped	  onto	  the	  X-­‐ray	  machine	  needed	  to	  be	  supplemented	  with	  a	  cryo-­‐protectant	  (Garman,	  2003).	  Compounds	  such	  as	  glycerol,	  ethylene	  glycol	  and	  MPD	  were	  added	  to	  the	  mother-­‐liquor	  in	  gradients	  of	  5%	  from	  0-­‐25%.	  The	  ability	  of	  the	  solution	  to	  act	  as	  a	  cryo-­‐buffer	  was	  assessed	  by	  the	  looping	  of	  cryo-­‐buffer	  followed	  by	  exposure	  to	  high-­‐intensity	  X-­‐rays	  whilst	  under	  a	  nitrogen	  stream.	  The	  cryo-­‐buffer	  used	  was	  the	  lowest	  %	  cryo-­‐agent	  that	  prevented	  formation	  of	  ice	  crystals	  (detected	  by	  diffraction)	  without	  compromising	  the	  physical	  integrity	  of	  the	  crystal.	  	  	  3.7.6	  Metal-­‐Soaking	  of	  Crystals	  	  In	  order	  to	  experimentally	  calculate	  phases	  to	  break	  the	  phase	  ambiguity,	  measurements	  of	  anomalous	  scattering	  from	  the	  crystal	  were	  required.	  Where	  it	  was	  not	  possible	  to	  use	  selenomethionine	  (Section	  3.5.3),	  in	  some	  cases	  attempts	  to	  generate	  this	  anomalous	  signal	  were	  carried	  out	  by	  the	  soaking	  in	  of	  heavy-­‐atom	  containing	  compounds.	  In	  general,	  preformed	  crystals	  were	  gently	  looped	  from	  the	  mother-­‐drop	  and	  transferred	  to	  a	  drop	  containing	  cryo-­‐buffer	  +	  10	  mM	  metal-­‐compound	  where	  they	  were	  left	  to	  soak	  for	  30-­‐40	  minutes.	  Crystals	  were	  then	  looped	  onto	  an	  X-­‐ray	  machine	  for	  testing,	  and	  anomalous	  data	  were	  collected	  at	  a	  synchrotron	  light-­‐source.	  The	  individual	  soaks	  and	  resulting	  diffraction	  experiments	  are	  described	  later	  on	  in	  this	  work.	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3.7.7	  Data	  Collection	  	  Crystals	  were	  tested	  for	  protein	  diffraction,	  resolution	  limits	  and	  if	  possible	  the	  calculation	  of	  cell-­‐parameters	  using	  an	  in-­‐house	  Mar345dtb	  goniometer	  and	  detector	  set-­‐up	  linked	  to	  a	  computer	  running	  the	  Mar345dtb	  6.1.0	  program	  and	  iMOSFLM	  (Battye	  et	  al,	  2011).	  When	  suitable	  crystals	  were	  identified	  for	  each	  specific	  dataset	  desired,	  they	  were	  transported	  in	  liquid	  nitrogen	  to	  the	  DSLS	  in	  Oxford.	  At	  the	  synchrotron,	  X-­‐rays	  of	  much	  higher	  intensity	  were	  used	  to	  collect	  the	  most	  complete,	  highest	  resolution	  datasets	  possible	  for	  native	  data,	  and	  beam	  lines	  were	  attenuated	  to	  vary	  the	  wavelength	  of	  the	  radiation	  used	  for	  the	  collection	  of	  anomalous	  data	  for	  MAD	  phasing.	  Diffraction	  images	  were	  collected	  on	  an	  ADSC	  Q315r	  CCD	  detector	  and	  saved	  to	  a	  portable	  hard-­‐drive	  for	  future	  processing	  and	  analysis.	  	  3.7.8	  Data	  Processing	  	  Data	  images	  were	  indexed	  and	  integrated	  as	  complete	  datasets	  in	  the	  program	  iMOSFLM	  (Battye	  et	  al,	  2011)	  and	  output	  as	  .mtz	  files.	  This	  program	  was	  also	  used	  for	  the	  calculation	  of	  unit	  cell	  parameters	  and	  symmetry	  space-­‐group	  from	  test	  images	  and	  the	  design	  of	  a	  strategy	  to	  optimise	  data-­‐collection	  in	  advance	  of	  dataset-­‐length	  exposure	  to	  radiation.	  	  	  Datasets	  were	  then	  transferred	  to	  the	  CCP4	  suite	  of	  programs	  (Winn	  et	  al,	  2011).	  Datasets	  of	  experimental	  intensities	  were	  scaled	  using	  SCALA	  (Evans,	  2006)	  and	  converted	  to	  amplitudes	  by	  running	  Ctruncate	  (Padilla	  &	  Yeates,	  2003),	  and	  were	  output	  in	  Scalepack	  format	  as	  unmerged,	  scaled	  .sca	  files.	  For	  MAD	  phase	  solution,	  these	  data	  were	  then	  input	  into	  ShelX	  C,	  D	  and	  E	  (Sheldrick,	  2010),	  run	  through	  HKL2MAP	  (Pape	  and	  Schneider,	  2004),	  for	  the	  preparation	  of	  data	  from	  .sca	  to	  .hkl	  files	  for	  phasing,	  heavy	  atom	  location	  and	  then	  phasing	  and	  electron	  density	  modification	  respectively.	  	  	  Using	  the	  CCP4i	  F2mtz	  import	  program,	  each	  of	  the	  two	  output	  ShelXE	  enantiomorph	  .phs	  files	  of	  phased	  electron	  density	  were	  converted	  back	  to	  .mtz	  files.	  They	  were	  then	  subjected	  to	  automatic	  model-­‐building	  using	  ARP/wARP	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(Langer	  et	  al,	  2008),	  which	  when	  supplemented	  with	  the	  expected	  amino	  acid	  sequence	  as	  a	  .pir	  file	  attempted	  to	  fit	  as	  many	  residues	  into	  the	  calculated	  electron	  density	  as	  possible	  and	  output	  the	  result	  as	  a	  .mtz	  file	  of	  density	  alongside	  a	  .pdb	  file	  representing	  the	  model	  built.	  The	  resulting	  density	  map	  and	  output	  model	  were	  viewed	  in	  the	  molecular	  graphics	  program	  Coot	  (Emsley	  &	  Cowtan,	  2004).	  The	  enantiomorph	  chosen	  was	  the	  solution	  that	  calculated	  an	  electron	  map	  in	  which	  protein	  features	  could	  be	  most	  reasonably	  deduced,	  such	  as	  α–helices,	  β-­‐sheets	  and	  solvent	  boundaries.	  	  	  After	  the	  auto-­‐fitted	  model	  was	  viewed	  in	  the	  electron	  density	  in	  Coot,	  any	  residues	  left	  un-­‐built	  were	  fitted	  in	  the	  electron	  density	  according	  to	  the	  predicted	  sequence	  to	  complete	  as	  much	  of	  the	  model	  as	  the	  calculated	  electron	  density	  allowed.	  In	  addition,	  each	  residue	  either	  built	  by	  ARP/wARP	  or	  manually	  was	  further	  analysed	  to	  correct	  residue	  orientation	  utilising	  chemical	  knowledge	  of	  charged	  residues	  and	  bond	  lengths	  for	  correct	  hydrogen	  bonding	  or	  ionic	  interactions.	  Water	  molecules	  were	  also	  built	  into	  ‘blobs’	  of	  density	  where	  chemically	  possible.	  For	  every	  significant	  batch	  of	  changes	  made	  to	  the	  model,	  a	  cycle	  of	  refinement	  in	  the	  Refmac	  program	  (Murshudov	  et	  al,	  1997)	  was	  used	  to	  refine	  the	  density	  to	  the	  model,	  using	  a	  FreeR	  dataset	  of	  5%	  of	  the	  data	  to	  reduce	  data-­‐bias,	  producing	  new	  density	  .mtz	  and	  model	  .pdb	  files.	  	  	  Once	  the	  most	  complete	  model	  was	  built	  in	  Coot,	  the	  structure	  coordinates	  in	  the	  .pdb	  file	  were	  structurally	  analysed	  using	  the	  MolProbity	  server	  (Davis	  et	  al,	  2007)	  and	  ProCheck	  (Laskowski	  et	  al,	  1993)	  in	  CCP4i.	  The	  outputs	  from	  these	  analytical	  programs	  were	  used	  to	  assess	  the	  Ramachandran	  distribution	  (Ramachandran	  et	  al,	  1963)	  of	  residues	  and	  any	  potential	  errors	  in	  the	  structure	  such	  as	  non-­‐biological	  conformations	  of	  residues	  and	  impossible	  chemistry	  such	  as	  irregular	  B-­‐factors.	  Any	  flagged	  residues	  were	  then	  fixed	  in	  Coot	  and	  then	  the	  model	  was	  re-­‐analysed	  until	  deemed	  as	  correct.	  With	  a	  complete	  model	  built	  into	  the	  calculated	  electron	  density,	  the	  final	  .pdb	  file	  was	  loaded	  into	  the	  molecular	  graphics	  program	  PyMol	  (Schrödinger,	  LLC)	  for	  the	  graphical	  representation	  of	  the	  completed	  protein	  molecule	  in	  the	  form	  of	  a	  cartoon	  for	  illustrative	  purposes	  of	  key	  features	  and	  the	  overall	  3D	  structure.	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  3.8	  Assays	  	  3.8.1	  β–lactamase	  Inhibition	  Assays	  	  Assays	  were	  carried	  out	  for	  this	  thesis	  to	  identify	  the	  effect	  of	  one	  of	  the	  proteins	  of	  interest	  on	  the	  hydrolysis	  of	  β–lactam-­‐containing	  antibiotics	  such	  as	  penicillin	  by	  the	  general	  β–lactamase	  TEM-­‐1	  (available	  from	  Invitrogen).	  Inhibition	  analysis	  was	  carried	  out	  by	  spectrophotometrically	  measuring	  the	  absorption	  change	  of	  390nm	  to	  486nm	  of	  the	  penicillin	  analogue	  Nitrocefin,	  product	  and	  protocol	  both	  available	  from	  Calbiochem,	  upon	  β–lactam	  ring	  hydrolysis	  by	  TEM-­‐1.	  Measurements	  were	  carried	  out	  using	  an	  Agilent	  Cary	  Eclipse	  spectrophotometer	  linked	  to	  a	  PC	  for	  recording	  of	  results	  as	  a	  Microsoft	  Excel	  file.	  	  100	  µl	  of	  a	  0.5	  mg/ml	  Nitrocefin,	  5%	  DMSO,	  100	  mM	  PBS	  pH7.0	  stock	  was	  added	  to	  900	  µl	  of	  50	  mM	  Tris	  pH	  7.0	  in	  a	  sterile,	  1	  ml	  glass	  cuvette	  to	  create	  the	  substrate	  solution	  for	  the	  reaction.	  The	  entire	  preparation	  procedure	  and	  assay	  was	  carried	  out	  with	  as	  little	  exposure	  to	  light	  as	  possible	  to	  minimise	  any	  effects	  caused	  by	  the	  photoreactive	  nature	  of	  Nitrocefin.	  With	  the	  Cary	  machine’s	  darkened	  measurement	  chamber	  ready	  for	  recording,	  the	  substrate-­‐solution	  was	  supplemented	  with	  a	  1	  µl	  premix	  of	  1:1,	  1:2,	  1:10	  or	  1:4000	  mix	  of	  5	  ng	  TEM-­‐1:	  χ	  ng	  potential	  inhibitor	  in	  50	  mM	  Tris	  pH	  7.0.	  Control	  experiments	  were	  carried	  out	  with	  just	  5	  ng	  TEM-­‐1	  and	  without	  TEM-­‐1.	  Immediately	  upon	  the	  addition	  of	  the	  protein	  premix	  and	  a	  quick,	  vigorous	  inversion	  to	  mix,	  measurements	  were	  taken	  every	  30	  seconds	  over	  a	  period	  of	  90	  minutes	  and	  recorded	  as	  an	  Excel	  file,	  for	  statistical	  interpretation	  and	  representation	  as	  line	  graphs.	  	  3.8.2	  Affi-­‐Gel15	  Pull-­‐Down	  Assays	  	  Affi-­‐Gel15	  beads,	  available	  from	  BioRad,	  were	  used	  to	  covalently	  bind	  free	  primary	  amine-­‐groups	  of	  acidic	  bait	  proteins.	  The	  following	  method	  was	  applied	  to	  both	  the	  bait	  protein	  under	  investigation	  and	  an	  unrelated	  control	  protein.	  50	  µl	  of	  the	  cross-­‐linked	  agarose	  beads	  were	  transferred	  to	  a	  1.5	  ml	  Eppendorf	  by	  using	  a	  1000	  µl	  pipette	  tip	  with	  the	  end	  1	  mm	  cut	  off	  to	  reduce	  beads	  sticking	  to	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the	  tip.	  The	  beads	  were	  washed	  from	  their	  isopropanol	  storage-­‐solution	  by	  allowing	  beads	  to	  settle	  then	  gently	  removing	  isopropanol	  by	  pipetting	  until	  the	  surface	  of	  the	  beads	  was	  nearly	  exposed.	  The	  tube	  was	  then	  topped	  up	  with	  1.5	  ml	  of	  sterile,	  deionised	  water,	  inverted	  to	  mix	  and	  then	  the	  beads	  were	  allowed	  to	  settle	  again.	  Beads	  were	  gently	  pelleted	  at	  the	  bottom	  of	  tubes	  if	  stuck	  on	  the	  sides	  by	  centrifugation	  at	  500	  rpm	  for	  30	  seconds.	  This	  was	  repeated	  two	  further	  times,	  and	  then	  an	  equilibrating	  wash-­‐step	  was	  carried	  out	  for	  the	  final	  time	  using	  50	  mM	  HEPES	  pH7.5.	  It	  was	  important	  to	  not	  use	  Tris	  as	  the	  reaction	  buffer,	  even	  if	  the	  bait	  proteins	  were	  usually	  purified	  into	  this	  buffer,	  as	  the	  primary	  amine	  in	  the	  Tris	  molecule	  would	  otherwise	  swamp	  the	  now	  active	  N-­‐hydroxysuccinimide	  esters	  coating	  the	  beads.	  	  3	  mg	  of	  bait	  protein	  in	  the	  highest	  concentration	  possible	  was	  prepared	  in	  50	  mM	  HEPES	  pH8.0	  and	  added	  to	  the	  equilibrated	  beads.	  Over	  a	  period	  of	  2	  hours	  the	  beads	  and	  protein	  were	  left	  to	  covalently	  bind	  in	  a	  4°C	  cabinet	  on	  a	  mixing	  wheel.	  The	  beads	  were	  then	  gently	  pelleted	  and	  the	  solution	  removed	  and	  assayed	  for	  protein	  concentration	  using	  the	  Bradford	  method.	  The	  beads	  were	  then	  washed	  with	  50	  mM	  HEPES	  pH7.5,	  0.1	  M	  NaCl,	  and	  then	  allowed	  to	  settle	  before	  the	  solution	  above	  was	  removed.	  Then	  1	  ml	  50	  mM	  HEPES	  pH7.5,	  2	  M	  NaCl	  was	  applied,	  followed	  by	  3x1	  ml	  50	  mM	  HEPES	  pH7.5	  washes	  until	  the	  removed	  solution	  no	  longer	  contained	  protein.	  At	  this	  point	  the	  mass	  of	  protein	  removed	  was	  subtracted	  from	  the	  mass	  originally	  added	  to	  the	  beads	  to	  calculate	  the	  mass	  of	  protein	  bound	  by	  the	  beads.	  100	  µl	  of	  1	  M	  ethanolamine	  was	  added	  to	  block	  any	  remaining	  binding	  sites	  and	  left	  to	  incubate	  for	  1	  hour	  at	  4°C	  on	  a	  wheel.	  Finally,	  the	  ethanolamine	  was	  removed	  and	  the	  beads	  were	  left	  in	  50	  mM	  HEPES	  pH7.5	  and	  stored	  at	  4°C	  until	  further	  use.	  2	  g	  of	  cell-­‐paste	  to	  be	  used	  for	  the	  pull-­‐down	  was	  re-­‐suspended	  in	  3	  volumes	  of	  50	  mM	  HEPES	  pH7.5	  and	  split	  into	  2x3	  ml	  aliquots	  and	  each	  was	  sonicated	  5x7	  seconds	  on	  ice	  at	  16	  microns,	  and	  cell-­‐debris	  was	  pelleted	  by	  centrifugation	  at	  70000xg	  for	  10	  minutes	  at	  8°C.	  The	  50	  µl	  of	  beads	  with	  bound	  bait	  protein	  were	  split	  into	  3	  by	  re-­‐suspending	  into	  850	  µl	  and	  with	  a	  1000	  µl	  pipette	  tip	  cut	  off	  by	  1	  mm,	  300	  µl	  of	  the	  bead	  suspension	  was	  put	  into	  3	  fresh	  1.5	  ml	  Eppendorfs	  and	  allowed	  to	  settle.	  The	  excess	  solution	  above	  was	  removed	  and	  the	  beads	  re-­‐
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suspended	  in	  1.5	  ml	  of	  the	  concentrated	  cell-­‐free	  extract,	  with	  the	  addition	  of	  final	  concentrations	  of	  0,	  0.1	  or	  0.2	  M	  NaCl	  to	  investigate	  affinity–strength	  of	  the	  pull-­‐down.	  The	  pull-­‐down	  interactions	  were	  allowed	  to	  happen	  for	  2	  hours	  at	  4°C	  on	  a	  wheel	  before	  being	  washed	  5x1.5	  ml	  in	  the	  corresponding	  concentration	  of	  NaCl	  and	  50	  mM	  HEPES	  pH7.5.	  	  	  Each	  set	  of	  beads	  were	  re-­‐suspended	  in	  1	  ml	  of	  buffer	  and	  split	  further	  into	  2x0.5	  ml,	  spun	  for	  500	  rpm	  for	  30	  seconds	  to	  gather	  at	  the	  bottom	  of	  the	  tube	  and	  had	  the	  buffer	  removed	  to	  the	  surface	  of	  the	  beads.	  One	  set	  of	  beads	  were	  eluted	  once	  with	  the	  addition	  of	  20	  µl	  2	  M	  NaCL	  to	  approximately	  1.5	  M	  NaCl	  when	  diluted	  by	  the	  beads,	  with	  gentle	  mixing	  for	  1	  minute,	  and	  then	  after	  the	  removal	  of	  the	  first	  eluate	  this	  was	  repeated	  to	  elute	  at	  2	  M	  NaCl.	  SDS-­‐PAGE	  samples	  were	  made	  by	  addition	  of	  2	  µl	  1	  M	  DTT	  and	  5	  µl	  4xLDS	  loading	  buffer	  to	  10	  µl	  of	  each	  eluate.	  The	  other	  portion	  was	  boiled	  in	  10	  µl	  water,	  2	  µl	  1M	  DTT	  and	  5	  µl	  4xLDS	  loading	  buffer	  to	  elute	  based	  upon	  LDS	  denaturation.	  Samples	  of	  each	  different	  NaCl	  molarity	  pull-­‐down,	  eluted	  by	  both	  1.5	  M	  NaCl	  or	  2	  M	  NaCl	  or	  LDS,	  were	  ran	  on	  a	  13.5%	  SDS-­‐PAGE	  gel	  against	  the	  corresponding	  experiments	  with	  the	  control	  protein	  and	  the	  beginning	  bait,	  control	  and	  cell-­‐extract	  protein	  samples	  used.	  After	  staining	  the	  gel	  with	  colloidal	  Coomassie	  and	  then	  de-­‐staining	  the	  gel,	  the	  lanes	  were	  compared	  to	  discover	  any	  bands	  that	  appeared	  only	  in	  the	  bait	  protein	  experiments,	  which	  were	  then	  identified	  using	  mass	  spectrometry	  of	  trypsin-­‐digested	  fragments.	  	  
3.9	  Localisation	  and	  Antigenic	  Studies	  	  3.9.1	  Fractionation	  of	  Burkholderia	  cenocepacia	  	  A	  500	  ml	  overnight	  culture	  of	  B.	  cenocepacia	  was	  grown	  following	  the	  protocol	  for	  E.	  coli	  culturing	  described	  in	  Section	  3.5.3.	  LB	  media	  was	  supplemented	  with	  a	  final	  concentration	  of	  100	  µg/ml	  ampicillin.	  Cells	  were	  harvested	  by	  centrifugation	  as	  described	  in	  Section	  3.5.3.	  The	  sub-­‐sections	  that	  follow	  document	  the	  chronological	  process	  of	  acquiring	  cell	  fractions	  from	  a	  cell	  pellet.	  The	  methods	  described	  were	  adapted	  from	  a	  periplasmic	  and	  outer	  membrane	  preparation	  protocol	  for	  the	  Gram-­‐negative	  bacterium	  Campylobacter	  jejuni,	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provided	  by	  Professor	  David	  Kelly	  (University	  of	  Sheffield,	  Dept.	  of	  MBB).	  All	  work	  was	  carried	  out	  in	  a	  BioMat2	  Class	  II	  Microbiology	  Safety	  Cabinet	  with	  laminar	  airflow,	  sealable	  protective	  screen	  and	  UV	  sterilisation.	  	  
3.9.1a	  Secreted	  Fraction:	  The	  media	  supernatant	  left	  after	  centrifugal	  pelleting	  of	  cells	  contained	  secreted	  proteins.	  100	  ml	  of	  the	  media	  was	  taken	  from	  the	  top	  of	  the	  supernatant	  prior	  to	  decantation	  from	  the	  pellet	  to	  avoid	  a	  contaminating	  re-­‐suspension	  of	  cells.	  50	  ml	  of	  this	  was	  treated	  with	  a	  final	  concentration	  of	  ~3.5	  M	  ammonium	  sulphate	  by	  the	  gradual	  addition	  of	  23	  g	  of	  solid	  ammonium	  sulphate,	  to	  precipitate	  proteins	  into	  a	  concentrated	  pellet.	  BPSL1204,	  and	  thus	  by	  inference	  BCAL2351,	  precipitated	  in	  ≥	  1.6	  M	  ammonium	  sulphate	  (see	  Section	  3.6.3).	  The	  remaining	  50	  ml	  was	  used	  as	  a	  ‘native’	  secreted	  fraction,	  to	  be	  loaded	  on	  analytical	  SDS-­‐PAGEs	  post-­‐boiling	  in	  LDS	  to	  concentrate.	  Samples	  were	  stored	  at	  -­‐20°C.	  	  
3.9.1b	  Periplasmic	  Fraction:	  The	  cell	  pellet	  was	  gently	  re-­‐suspended	  in	  20	  ml	  STE	  buffer	  (20%	  sucrose,	  30	  mM	  Tris	  pH8.0,	  1	  mM	  EDTA)	  and	  shaken	  at	  room	  temperature	  for	  30	  minutes,	  following	  which	  cells	  were	  harvested	  by	  centrifugation	  in	  a	  Sigma	  11133	  rotor	  at	  5000	  rpm	  for	  10	  minutes	  at	  room	  temperature.	  The	  supernatant	  was	  discarded	  and	  osmotic	  shock	  was	  applied	  by	  re-­‐suspension	  in	  10	  ml	  of	  ice-­‐cold	  10	  mM	  Tris	  pH	  8.0,	  followed	  by	  incubation	  with	  gentle	  shaking	  at	  4°C	  for	  2	  hours.	  The	  suspension	  was	  then	  centrifuged	  at	  11000	  rpm	  in	  a	  JA	  25.50	  rotor	  for	  25	  minutes	  at	  4°C,	  and	  the	  periplasm-­‐containing	  supernatant	  was	  collected	  and	  stored	  as	  0.5	  ml	  aliquots	  at	  -­‐20°C.	  	  
3.9.1c	  Cytoplasmic	  Fraction:	  The	  post-­‐osmotic-­‐shock	  pellet	  was	  re-­‐suspended	  in	  20	  ml	  of	  10	  mM	  HEPES	  pH	  7.4,	  and	  sonicated	  on	  ice	  for	  6	  x	  15	  seconds	  at	  16	  microns,	  using	  a	  MSE	  SoniPrep	  150	  with	  a	  sealable	  screen,	  to	  destroy	  intact	  cell	  membranes.	  The	  sonicate	  was	  then	  centrifuged	  in	  a	  JA25.50	  rotor	  for	  20	  minutes	  at	  15000	  rpm	  at	  4°C	  to	  pellet	  unbroken	  cells	  and	  debris.	  The	  supernatant	  was	  carefully	  removed	  and	  transferred	  to	  a	  pre-­‐chilled,	  polyallomer	  Beckman	  ultra-­‐centrifuge	  tube	  on	  ice,	  and	  the	  pellet	  was	  discarded.	  Against	  a	  same-­‐tube	  water-­‐balance	  (to	  within	  0.05g),	  the	  supernatant	  was	  ultra-­‐centrifuged	  in	  a	  pre-­‐chilled	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Beckman	  70.1	  Ti	  angle-­‐rotor	  at	  100,000xg	  for	  1	  hr	  at	  4°C.	  The	  supernatant	  was	  removed	  as	  the	  purified	  cytoplasmic	  fraction	  and	  stored	  as	  0.5	  ml	  aliquots	  at	  -­‐20°C.	  	  
3.9.1d	  Inner	  Membrane	  Fraction:	  The	  ultra-­‐centrifuged	  pellet	  had	  its	  surface	  washed	  by	  the	  gentle	  addition	  of	  a	  full	  tube	  of	  10	  mM	  HEPES	  pH7.4	  that	  was	  gently	  poured	  off.	  This	  was	  repeated	  twice.	  2	  ml	  of	  10	  mM	  HEPES	  pH7.4	  was	  then	  added,	  and	  the	  membrane	  was	  fully	  suspended	  by	  gentle	  agitation	  with	  a	  glass	  rod.	  To	  selectively	  solubilise	  the	  inner	  membrane	  (Buchanan,	  1999),	  2	  ml	  of	  2%	  sodium	  N-­‐lauroyl	  sarcosinate	  (Sarkosyl)	  dissolved	  in	  10	  mM	  HEPES	  pH	  7.4	  was	  mixed	  with	  the	  membrane-­‐solution	  thoroughly	  (but	  not	  so	  that	  foam	  formed),	  and	  was	  then	  incubated	  at	  37°C	  for	  30	  minutes.	  After	  centrifugation	  in	  a	  JA25.50	  rotor	  for	  30	  minutes	  at	  20,000	  rpm	  at	  15C,	  the	  supernatant	  was	  carefully	  removed	  as	  the	  soluble	  inner	  membrane	  fraction	  and	  was	  stored	  as	  0.5	  ml	  aliquots	  at	  -­‐20°C.	  	  
3.9.1e	  Outer	  Membrane	  Fraction:	  The	  outer	  membrane	  pellet	  was	  washed	  twice	  by	  the	  gentle	  addition	  and	  removal	  of	  a	  full	  tube	  of	  10	  mM	  HEPES	  pH	  7.4.	  The	  outer	  membrane	  pellet	  was	  then	  suspended	  in	  0.5	  ml	  of	  10	  mM	  HEPES	  pH7.4	  and	  stored	  at	  -­‐20°C.	  	  3.9.2	  Buffers	  used	  in	  Immuno-­‐blotting	  	  For	  the	  Western	  blotting	  (Burnette,	  1981)	  and	  immuno-­‐blotting	  methods	  several	  buffers	  were	  required	  to	  be	  prepared,	  which	  are	  summarised	  in	  this	  section:	  	  
Western	  Transfer	  buffer:	  25mM	  Tris	  (do	  not	  alter	  pH),	  192	  mM	  glycine	  and	  10%	  methanol.	  Stored	  at	  4°C.	  	  
X10	  Phosphate-­buffered	  Saline	  (PBS)	  pH	  7.4:	  80	  g	  NaCl,	  2.0	  g	  KCl,	  14.4	  g	  Na2HPO4	  and	  2.4	  g	  KH2PO4	  dissolved	  in	  850	  ml	  deionised	  water,	  pH	  adjusted	  to	  pH	  7.4	  and	  then	  water	  added	  to	  1	  L.	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M-­T-­PBS:	  5%	  non-­‐fat	  milk	  powder,	  0.1%	  Tween-­‐20	  in	  1xPBS	  pH	  7.4.	  Stored	  at	  4°C.	  	  
T-­PBS:	  0.1%	  Tween-­‐20	  in	  1xPBS	  pH	  7.4.	  	  
PBS:	  1xPBS	  pH	  7.4.	  	  3.9.3	  Western	  Blotting	  	  A	  13.5%	  SDS-­‐PAGE	  gel	  was	  created	  and	  samples	  were	  run	  through	  it	  as	  described	  in	  Section	  3.2.3.	  A	  pre-­‐stained	  protein	  marker	  was	  used,	  as	  this	  would	  transfer	  to	  the	  blotted	  nitrocellulose	  membrane	  to	  aid	  in	  molecular	  weight	  determination	  of	  any	  bands	  seen.	  An	  Invitrogen	  XCell	  Surelock	  tank	  with	  an	  XCell	  II	  Blot	  Module	  was	  used	  for	  all	  Western	  blots,	  kept	  cold	  by	  surrounding	  with	  ice	  in	  a	  polystyrene	  icebox.	  Prior	  to	  assembly	  of	  the	  blot,	  seven	  10.5x9.5	  cm	  sponge	  pads	  were	  soaked	  and	  left	  submerged	  in	  cold	  Transfer	  buffer,	  ensuring	  that	  all	  air	  bubbles	  were	  pressed	  out.	  A	  9x9	  cm	  nitrocellulose	  membrane,	  available	  from	  Invitrogen,	  and	  two	  9x9	  cm	  sheets	  of	  filter	  paper	  were	  also	  soaked	  in	  cold	  Transfer	  buffer.	  The	  negative-­‐electrode	  compartment	  of	  the	  XCell	  II	  module	  was	  laid	  down	  first,	  and	  then	  stacked	  horizontally	  with	  3	  buffer-­‐soaked	  sponge	  pads.	  Using	  gloved	  hands	  only,	  a	  piece	  of	  filter	  paper	  was	  then	  placed	  on	  the	  sponges,	  on	  top	  of	  which	  the	  SDS-­‐PAGE	  gel	  was	  gently	  lain,	  ensuring	  no	  tearing	  or	  creasing	  occurred.	  The	  nitrocellulose	  membrane	  was	  then	  placed	  on	  top	  of	  the	  gel,	  followed	  by	  the	  second	  piece	  of	  filter	  paper	  and	  4	  buffer-­‐soaked	  sponge	  pads.	  The	  stack	  was	  created	  ensuring	  that	  no	  bubbles	  were	  caught	  within	  any	  layer,	  and	  ordered	  so	  that	  the	  current	  ran	  through	  the	  stack	  to	  the	  positive-­‐electrode,	  transferring	  the	  SDS-­‐coated	  negatively	  charged	  proteins	  from	  the	  gel	  to	  the	  nitrocellulose	  membrane.	  	  The	  positive-­‐electrode	  lid	  of	  the	  module	  was	  then	  used	  to	  gently	  compress	  the	  Western	  stack	  between	  the	  two	  electrode	  panels,	  sealing	  against	  the	  rubber	  gasket.	  The	  whole	  module	  was	  then	  placed	  into	  the	  XCell	  Surelock	  tank	  and	  locked	  into	  place	  by	  the	  plastic	  lever-­‐arch	  mechanism.	  Cold	  transfer	  buffer	  was	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used	  to	  fill	  the	  module	  to	  approximately	  1	  cm	  above	  the	  stack,	  to	  prevent	  drying	  out	  whilst	  creating	  the	  minimum	  electrical	  conductivity,	  and	  thus	  the	  lowest	  heat	  possible.	  The	  buffer-­‐compartment	  was	  filled	  with	  cold	  Transfer	  buffer	  in	  order	  to	  further	  dissipate	  heat,	  and	  account	  for	  any	  module-­‐leakage.	  Blots	  were	  run	  using	  cold	  equipment	  and	  buffers,	  as	  excessive	  heat	  may	  have	  damaged	  the	  module	  electrodes	  and	  melted	  or	  distorted	  the	  gel	  and	  nitrocellulose.	  The	  wired-­‐lid	  was	  attached	  to	  the	  tank	  so	  that	  electrodes	  were	  correctly	  orientated,	  and	  then	  the	  blot	  was	  run	  at	  65	  V	  for	  120	  minutes.	  	  3.9.4	  Immuno-­‐blotting	  	  	  Using	  gloved	  hands,	  the	  Western-­‐blotted	  nitrocellulose	  membrane	  was	  transferred	  to	  a	  clean,	  plastic	  gel-­‐box	  containing	  100	  ml	  of	  M-­‐T-­‐PBS,	  and	  was	  left	  sealed	  on	  a	  gently	  rocking	  platform	  overnight	  at	  4°C,	  to	  block	  the	  regions	  of	  the	  membrane	  not	  occupied	  with	  electro-­‐blotted	  proteins.	  After	  the	  blocking	  incubation,	  the	  membrane	  was	  rinsed	  in	  T-­‐PBS,	  and	  then	  was	  transferred	  into	  50	  ml	  of	  M-­‐T-­‐PBS	  containing	  an	  experimentally	  determined	  dilution	  of	  primary	  antibody.	  This	  primary	  binding	  reaction	  was	  allowed	  to	  incubate	  for	  60	  minutes	  at	  room	  temperature	  on	  a	  gently	  rocking	  platform.	  No	  primary	  antibody	  was	  added	  to	  control	  membranes.	  	  After	  incubation	  with	  the	  primary	  antibody,	  the	  membrane	  was	  washed	  with	  3x50	  ml	  of	  T-­‐PBS,	  each	  for	  5	  minutes,	  to	  remove	  any	  residual	  unbound	  primary	  antibody.	  Next,	  the	  membrane	  was	  incubated	  with	  50	  ml	  M-­‐T-­‐PBS	  containing	  an	  experimentally	  determined	  dilution	  of	  secondary	  reporter	  antibody,	  on	  a	  gently	  rocking	  platform	  at	  room	  temperature	  for	  30	  minutes	  to	  allow	  for	  high-­‐affinity	  secondary	  binding	  to	  the	  primary	  antibody.	  The	  membrane	  was	  then	  again	  washed	  with	  3x50	  ml	  of	  T-­‐PBS	  to	  remove	  any	  unbound	  secondary	  reporter	  antibody,	  before	  being	  rinsed	  in	  PBS	  to	  remove	  residual	  Tween-­‐20	  detergent.	  	  3.9.5	  Chemiluminesence	  Assays	  	  To	  facilitate	  safe	  and	  measurable	  exposure	  of	  the	  membrane	  to	  photoreactive	  chemicals	  and	  X-­‐ray	  film,	  the	  chemiluminescent	  reaction	  was	  carried	  out	  
	   83	  
contained	  within	  plastic	  wrap.	  With	  gloved	  hands,	  a	  piece	  of	  plastic	  wrap	  several	  times	  larger	  than	  the	  membrane	  was	  laid	  totally	  flat	  onto	  a	  flat,	  clean	  lab	  surface.	  A	  solution	  of	  Enhanced	  Chemiluminescence	  (ECL)	  reagent,	  from	  Pierce	  ThermoScientific,	  was	  pipetted	  onto	  the	  centre	  of	  the	  plastic	  wrap,	  forming	  a	  dome	  of	  solution.	  The	  horseradish	  peroxidase	  (HRP,	  the	  reporter	  used	  on	  the	  secondary	  antibody)	  ECL	  substrate	  was	  made	  by	  mixing	  a	  1:1	  solution	  of	  the	  2	  components	  of	  the	  reagent,	  with	  care	  taken	  due	  to	  the	  highly	  toxic	  nature	  of	  the	  solution	  in	  the	  concentrations	  used.	  For	  a	  9x9	  cm	  membrane,	  a	  500	  µl	  final	  volume	  was	  ample	  for	  total	  coverage.	  The	  membrane	  was	  smoothly	  laid	  down	  on	  top	  of	  the	  ECL	  solution,	  blotted-­‐side	  down	  as	  indicated	  by	  the	  presence	  of	  the	  pre-­‐stained	  protein	  markers,	  and	  using	  a	  glass	  rod	  to	  gently	  roll	  back-­‐and-­‐forth	  the	  membrane	  was	  coated	  bubble-­‐free	  in	  ECL	  reagent.	  The	  plastic	  wrap	  border	  was	  carefully	  folded	  over	  the	  back	  of	  the	  membrane	  and	  sealed	  with	  tape.	  A	  marker	  was	  drawn	  on	  the	  tape	  to	  indicate	  the	  orientation	  of	  the	  membrane	  in	  the	  plastic	  wrap.	  	  The	  ECL	  reagent	  was	  highly	  reactive	  within	  the	  first	  30	  minutes	  of	  mixing;	  therefore	  the	  sealed	  membrane	  was	  immediately	  taken	  to	  a	  photographic	  dark	  room.	  When	  in	  the	  dark	  room	  and	  when	  not	  in	  use	  for	  exposure,	  the	  membrane	  was	  kept	  in	  a	  clean,	  opaque	  container	  to	  prevent	  bleaching	  of	  unprotected	  X-­‐ray	  film.	  When	  lit	  by	  only	  red-­‐filtered	  safety	  lights,	  a	  piece	  of	  CL-­‐XPosure	  X-­‐ray	  film	  from	  Pierce	  ThermoScientific	  was	  removed	  from	  it	  protective	  sleeve	  and	  placed	  onto	  a	  black-­‐foam	  positioning	  tablet.	  The	  membrane	  was	  then	  placed	  upon	  the	  film	  and	  its	  edges	  were	  marked	  for	  later	  reference.	  Exposure	  was	  allowed	  to	  occur	  for	  a	  range	  of	  time	  periods	  from	  10	  seconds	  to	  5	  minutes	  in	  order	  to	  achieve	  the	  optimal	  exposure	  time	  for	  the	  best	  signal:noise.	  Film	  was	  then	  developed	  using	  a	  Konica	  SRX-­‐101a	  Automatic	  X-­‐ray	  film-­‐processing	  unit.	  Film	  could	  then	  be	  aligned	  with	  the	  membrane	  edges	  to	  compare	  the	  molecular	  weights	  of	  the	  bands	  recorded	  on	  the	  developed	  film	  against	  the	  pre-­‐stained	  protein	  markers	  on	  the	  membrane.	  	  	  The	  immuno-­‐blotting	  and	  chemiluminescent	  assay	  were	  then	  optimised	  by	  the	  alteration	  of	  primary	  antibody	  and	  secondary	  antibody	  dilutions	  used	  and	  then	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further	  improved	  by	  variation	  in	  the	  length	  of	  X-­‐ray	  film	  exposure	  time,	  until	  the	  most	  interpretable	  signal:noise	  was	  achieved	  (Kricka,	  1991).	  	  3.9.6	  Preparation	  of	  Slides	  for	  Fluorescence	  Microscopy	  	  A	  10	  ml	  overnight	  culture	  of	  cells	  was	  grown	  in	  LB	  media,	  and	  then	  the	  following	  morning	  100	  µl	  was	  used	  to	  2%	  inoculate	  a	  fresh	  4.9	  ml	  of	  LB	  that	  was	  allow	  to	  culture	  at	  37°C	  and	  200	  rpm	  until	  an	  OD600nm	  of	  0.6	  was	  reached.	  This	  was	  with	  the	  aim	  of	  collecting	  a	  sample	  of	  cells	  within	  which	  existed	  cells	  in	  various	  stages	  of	  the	  cell	  cycle.	  1	  ml	  of	  this	  culture	  was	  taken	  into	  a	  sterile	  1.5	  ml	  microfuge	  tube	  and	  pelleted	  by	  centrifugation	  in	  an	  MSE	  Micro-­‐Centaur	  rotor	  for	  5	  minutes	  at	  13000	  rpm	  at	  room	  temperature.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  re-­‐suspended	  in	  0.5	  ml	  of	  PBS,	  and	  then	  mixed	  with	  0.5	  ml	  of	  fresh	  fixation	  solution	  (Hopwood,	  1972).	  Fixation	  solution	  was	  made	  by	  the	  addition	  of	  420	  µl	  of	  15%	  formaldehyde	  and	  500	  µl	  of	  25%	  glutaraldehyde	  to	  2.08	  ml	  PBS.	  The	  cell	  fixation	  reaction	  was	  allowed	  to	  continue	  for	  30	  minutes	  at	  room	  temperature	  on	  a	  rotary	  wheel.	  	  Once	  fixed,	  the	  cells	  were	  collected	  by	  centrifugation	  at	  13000	  rpm	  at	  room	  temperature	  in	  an	  MSE	  Micro-­‐Centaur	  rotor,	  and	  the	  pellet	  was	  gently	  washed	  twice	  with	  1.5	  ml	  of	  PBS.	  At	  this	  stage,	  fixed	  cells	  could	  be	  stored	  at	  -­‐20°C	  if	  required.	  The	  fixed-­‐cell	  pellet	  was	  re-­‐suspended	  in	  0.5	  ml	  of	  PBS	  and	  10	  µl	  of	  the	  re-­‐suspension	  was	  pipetted	  onto	  the	  centre	  of	  a	  poly-­‐L-­‐lysine-­‐coated	  slide	  (Huang	  et	  al,	  1983),	  fixed-­‐cells	  were	  allowed	  to	  bind	  to	  the	  slide	  and	  then	  were	  air	  dried	  whilst	  protected	  by	  a	  cover	  to	  prevent	  environmental	  contamination.	  Once	  dry	  the	  slide	  was	  rehydrated	  with	  50	  µl	  PBS	  and	  unbound	  poly-­‐L-­‐lysine	  was	  blocked	  with	  2%	  bovine	  serum	  albumin	  (BSA)	  in	  PBS	  for	  15	  minutes	  at	  room	  temperature.	  The	  fixed-­‐	  and	  slide-­‐immobilised	  cells	  were	  then	  incubated	  for	  2	  hours	  with	  an	  experimentally	  determined	  dilution	  of	  primary	  antibody	  in	  2%	  BSA	  in	  PBS.	  No	  primary	  antibody	  was	  added	  to	  control	  slides.	  	  	  Cells	  were	  washed	  8	  times	  by	  the	  addition	  of	  0.5ml	  PBS	  followed	  by	  air	  aspiration.	  Then	  cells	  were	  incubated	  with	  an	  experimentally	  determined	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dilution	  of	  secondary	  antibody	  FITC-­‐conjugate	  in	  2%	  w/v	  BSA	  in	  PBS	  for	  30	  minutes.	  From	  this	  stage	  onwards,	  slides	  were	  manipulated	  in	  the	  dark	  to	  prevent	  bleaching	  of	  the	  FITC	  fluorophore	  (Lichtman	  &	  Conchello,	  2005).	  Cells	  were	  again	  washed	  8	  times	  with	  0.5	  ml	  PBS	  followed	  by	  air	  aspiration.	  The	  slide	  was	  then	  treated	  with	  5	  µl	  of	  Slow	  Fade	  Gold	  AntiFade	  reagent,	  to	  suppress	  photobleaching	  and	  improve	  fluorescent	  signal.	  Finally,	  slides	  were	  sealed	  with	  DPX	  mountant	  media.	  	  3.9.7	  Fluorescence	  Microscopy	  Image	  Collection	  and	  Processing	  	  Slides	  were	  viewed	  using	  a	  DeltaVision	  deconvolution	  fluorescence	  microscope	  and	  confocal	  Z-­‐stack	  images	  were	  acquired	  and	  analysed	  using	  SoftWoRx	  3.5.0	  software,	  from	  Applied	  Precision	  Solutions.	  Fluorescence	  of	  FITC	  was	  achieved	  by	  setting	  a	  laser	  excitation	  wavelength	  of	  490nm.	  Quick	  Projection	  image	  processing,	  in	  which	  images	  are	  stacked	  upon	  one	  another	  to	  create	  a	  single	  focussed	  image,	  was	  applied	  when	  only	  an	  overview	  of	  the	  data	  collected	  was	  required	  due	  to	  limited	  or	  lack	  of	  fluorescence	  in	  the	  experiment.	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Chapter	  4:	  Target-­Selection,	  Over-­expression	  and	  Purification	  of	  BPSL1204	  	  
4.1	  Bioinformatical	  Selection	  of	  BPSL1204	  	  4.1.1	  Analysis	  of	  Hydropathy	  Plots	  	  All	  the	  5521	  potential	  translated	  protein	  sequences	  from	  the	  proteome	  of	  B.	  
pseudomallei	  were	  plotted	  as	  hydropathy	  plots	  by	  Prof.	  Peter	  Artymiuk	  as	  described	  in	  section	  3.3	  and	  then	  each	  was	  individually	  examined	  by	  eye.	  Each	  plot	  and	  related	  sequence	  were	  then	  categorised	  as	  either	  having	  a	  significant	  N-­‐terminal	  or	  C-­‐terminal	  peak	  of	  hydrophobicity	  perhaps	  representative	  of	  a	  membrane-­‐anchoring	  sequence,	  or	  as	  either	  having	  no	  significant	  hydrophobicity	  or	  multiple	  hydrophobic	  peaks	  representative	  of	  a	  multi-­‐pass	  membrane	  protein.	  This	  left	  525	  proteins	  from	  the	  5521	  proteins	  of	  both	  chromosomes	  that	  appeared	  to	  potentially	  have	  hydrophobic	  N-­‐	  or	  C-­‐terminal	  tails.	  	  	  The	  list	  of	  proteins	  with	  hydrophobic	  termini	  was	  further	  reduced	  by	  only	  accepting	  proteins	  with	  a	  terminal	  peak	  greater	  than	  2.0	  on	  the	  Kyte-­‐Doolittle	  scale	  (Kyte	  &	  Doolittle,	  1982),	  leaving	  a	  list	  of	  205	  for	  further	  analysis	  and	  target	  selection	  (Figure	  4.1).	  	  4.1.2	  Selection	  of	  Potentially	  Novel	  Folds	  	  The	  amino	  acid	  sequences	  of	  the	  205	  proteins	  were	  batch-­‐input	  in	  groups	  of	  around	  30	  sequences	  into	  the	  BLAST	  server	  from	  NCBI	  (Altschul	  et	  al,	  1990),	  and	  aligned	  against	  the	  PDB	  sequence	  database	  to	  discover	  if	  any	  homologs	  with	  known	  structure	  and	  function	  were	  already	  known.	  As	  the	  aim	  was	  to	  discover	  the	  structures	  of	  novel,	  membrane-­‐anchored	  proteins	  any	  significantly	  positive	  hits	  found	  during	  this	  search	  were	  rejected.	  This	  process	  of	  positive	  discrimination	  led	  to	  a	  shortening	  of	  the	  list	  to	  102	  proteins	  with	  a	  profile	  of	  an	  E-­‐value>0.1	  and	  less	  than	  50%	  ID	  when	  compared	  to	  the	  PDB	  sequences.	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Figure 4.1: Analysis of hydropathy plots of proteins from B. pseudomallei, in order to 
identify targets with potential hydrophobic membrane-insertion sequences. Hydropathy 
was plotted using the Kyte-Doolittle scale (Kyte & Doolittle, 1982) and a window size 
of 9. Top left: BPSS1839, rejected as a soluble protein. Top right: BPSL1509, rejected 
as multi-pass membrane protein. Bottom left: BPSS0580, rejected as N-terminally 
hydrophobic <2.0. Bottom right: BPSL1204, selected as N-terminally hydrophobic 
>2.0. Plots created using the Molecular Toolkit from the University of Colorado 
(www.vivo.colostate.edu/molkit). 
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This	  still	  extensive	  list	  was	  therefore	  shortened	  further	  by	  demanding	  potential	  targets	  had	  a	  lowest	  E-­‐value	  of	  >1.0	  Therefore	  any	  hits	  generated	  by	  the	  BLAST	  search	  could	  be	  considered	  as	  random	  and	  we	  could	  be	  confident	  that	  no	  structure	  with	  homologous	  sequence	  existed.	  This	  left	  a	  short-­‐list	  of	  43	  targets	  to	  pass	  onto	  the	  next	  stage	  of	  selection.	  	  4.1.3	  Further	  Exclusion	  of	  Targets	  from	  the	  Short-­‐List	  	  Excluding	  targets	  based	  upon	  the	  following	  criteria	  further	  reduced	  the	  list	  of	  proteins	  that	  had	  no	  positive	  PDB	  result	  and	  a	  highly	  hydrophobic	  N-­‐	  or	  C-­‐terminus:	  	  -­‐	  Discard	  proteins	  with	  any	  region	  of	  potential	  disorder	  >0.5	  probability,	  other	  than	  perhaps	  the	  potential	  hydrophobic	  membrane-­‐anchor	  region,	  as	  predicted	  by	  the	  RONN	  server	  (Yang	  et	  al,	  2005)	  (www.strubi.ox.ac.uk/RONN).	  This	  was	  done	  to	  increase	  chances	  of	  ordered	  crystal	  formation	  in	  the	  future.	  	  -­‐	  Compare	  the	  short-­‐list	  to	  the	  Target	  Database	  (Chen	  et	  al,	  2004)	  (http://targetdb-­‐dev.rutgers.edu/)	  of	  targets	  currently	  under	  investigation	  by	  structural	  genomics	  consortia,	  and	  discard	  any	  that	  are	  already	  being	  investigated.	  	  	  -­‐	  Utilise	  the	  Psipred	  GenThreader	  tool	  (http://bioinf.cs.ucl.ac.uk/psipred)	  (Jones,	  1999a)	  to	  probe	  for	  structural	  predictions	  based	  upon	  common	  sequence	  motifs	  for	  a	  specific	  domain	  fold.	  Reject	  any	  targets	  that	  produce	  a	  fold-­‐recognition	  with	  any	  degree	  of	  certainty	  to	  further	  increase	  the	  chances	  of	  working	  with	  a	  novel	  protein	  fold.	  	  	  -­‐	  Use	  the	  BLAST	  server	  (http://blast.ncbi.nlm.nih.gov/Blast.cgi)	  (Altschul	  et	  al,	  1990)	  to	  search	  for	  homologs	  of	  the	  B.	  pseudomallei	  short-­‐listed	  targets	  in	  the	  paraphyletic,	  non-­‐virulent	  B.	  thailandensis,	  and	  only	  select	  those	  with	  an	  E-­‐value	  <1e-­‐15.	  This	  increased	  the	  likeliness	  of	  selecting	  a	  target	  protein	  that	  was	  safe	  to	  work	  with	  in	  the	  standard	  Class	  I	  lab	  environment.	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-­‐	  Reject	  any	  protein	  that	  does	  not	  contain	  3	  or	  more	  methionine	  residues	  (not	  including	  the	  N-­‐terminal	  residue,	  which	  is	  often	  disordered	  or	  post-­‐translationally	  removed).	  As	  the	  desired	  target	  was	  to	  be	  of	  a	  potentially	  new	  fold	  with	  no	  known	  homologous	  structure,	  the	  preferred	  method	  of	  solving	  the	  phase-­‐problem	  would	  be	  to	  use	  MAD	  data	  collected	  from	  a	  crystal	  of	  a	  seleno-­‐methionine	  derivative	  of	  the	  target.	  In	  order	  for	  incorporation	  of	  seleno-­‐methionine	  and	  the	  generation	  of	  significant	  anomalous	  signal	  for	  phasing,	  multiple	  methionines	  were	  required	  to	  be	  in	  the	  chosen	  amino	  acid	  sequence.	  	  	  4.1.4	  Final	  Selection	  of	  BPSL1204	  and	  Truncation	  	  The	  following	  table	  describes	  the	  short-­‐list	  of	  potential	  targets,	  narrowed	  down	  from	  a	  predicted	  proteome	  of	  5521	  proteins	  to	  3	  potentially	  novel	  membrane-­‐anchored	  targets:	  	  Gene	  ID	   MW	  (kDa)	   Membrane-­‐anchor	  truncation	  MW	  (kDa)	   E-­‐value	  against	  	  B.	  thailandensis	   No	  of	  Methionines	  BPSL1204	   19189	   17197	   2e-­‐86	   4	  BPSL1927	   26379	   24420	   2e-­‐126	   4	  BPSL2756	   19466	   15904	   1e-­‐74	   4	  	  	  Attempts	  to	  clone	  and	  over-­‐express	  soluble	  protein	  of	  all	  three	  truncated	  proteins	  led	  to	  success	  only	  with	  BPSL1204-­‐MA	  (i.e.	  BPSL1204	  with	  its	  Membrane	  Anchor	  removed).	  The	  cloning	  and	  over-­‐expression	  processes	  applied	  to	  BPSL1204	  (described	  in	  Sections	  4.2.1-­‐4.3.2)	  were	  applied	  to	  BPSL1927	  and	  BPSL2756	  but	  did	  not	  result	  in	  soluble	  protein.	  	  
4.2	  Cloning	  of	  BPSL1204-­MA	  	  4.2.1	  Primer	  Design	  and	  PCR	  of	  Truncated	  BPSL1204	  	  Primers	  BPSL1204-­‐F	  (forward)	  and	  BPSL1204-­‐R	  (reverse)	  were	  designed	  against	  the	  BPSL1204	  gene	  sequence	  for	  amplification	  directly	  from	  purified	  B.	  
pseudomallei	  K9263	  genomic	  DNA.	  The	  primers	  have	  been	  described	  in	  Section	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3.4.1.	  These	  primers	  omitted	  from	  the	  amplified	  fragment	  the	  initial	  60	  5´	  base	  pairs,	  resulting	  in	  a	  translated	  protein	  product	  truncated	  by	  the	  first	  20	  N-­‐terminal	  amino	  acid	  residues.	  The	  decision	  to	  truncate	  by	  60	  nucleotides	  was	  based	  upon	  the	  comparison	  of	  the	  gene-­‐product’s	  hydropathy	  plot	  aligned	  with	  its	  sequence.	  At	  the	  point	  where	  the	  hydrophobicity	  of	  the	  amino	  acid	  sequence	  approached	  0	  on	  the	  Kyte-­‐Doolittle	  scale	  was	  the	  point	  of	  truncation	  (Figure	  4.2).	  The	  primers	  incorporated	  only	  the	  fragment	  of	  BPSL1204-­‐MA	  to	  be	  over-­‐expressed	  with	  no	  overhanging	  bases.	  	  Primers	  were	  synthesised	  by	  Dr	  Arthur	  Moir	  of	  the	  University	  of	  Sheffield,	  and	  kept	  at	  -­‐20°C	  as	  a	  100	  µM	  master	  stock	  from	  which	  5	  µl	  were	  diluted	  with	  95	  µl	  of	  sterile,	  deionised	  water	  to	  make	  a	  5	  µM	  working	  stock.	  The	  PCR	  method	  as	  described	  in	  section	  3.4.1	  was	  applied,	  with	  the	  only	  variation	  being	  the	  use	  of	  55°C	  as	  an	  annealing	  temperature	  which	  was	  required	  for	  optimum	  BPSL1204-­‐MA	  amplification.	  The	  purity	  of	  the	  PCR	  product	  was	  analysed	  by	  1%	  agarose	  gel	  electrophoresis	  (Figure	  4.3)	  and	  was	  discovered	  to	  be	  pure,	  and	  in	  order	  for	  efficient	  ligation	  into	  the	  pETBlue-­‐1	  vector	  the	  insert	  sample	  amplified	  by	  the	  PCR	  reaction	  was	  purified	  from	  the	  PCR	  buffer	  into	  40	  µl	  sterile,	  deionised	  water	  using	  the	  Qiagen	  PCR	  Purification	  kit.	  	  	  4.2.2	  Blunt-­‐End	  Ligation	  into	  pETBlue-­‐1	  	  Following	  the	  AccepTor	  Vector	  kit	  protocol,	  the	  following	  blunt-­‐end	  ligation	  reaction	  was	  set	  up:	  	  3	  µl	  50	  ng/µl	  BPSL1204-­‐MA	  PCR	  product	  1	  µl	  50	  ng/µl	  linearised	  pETBlue-­‐1	  vector	  	  5	  µl	  Clonables	  mix	  (contains	  ligase	  and	  ligase-­‐buffer)	  1	  µl	  sterile,	  deionised	  water	  10	  µl	  reaction	  	  The	  pETBlue-­‐1	  vector	  was	  supplied	  from	  Novagen	  as	  a	  pre-­‐linearised	  vector.	  











Figure 4.2: Amino acid sequence of BPSL1204 (bottom). When the amino acid 
sequence was compared to the hydropathy plot of the 30 N-terminal residues of 
BPSL1204 (top), it was seen that hydropathy drops off after approximately 20 
residues. Plots were created using the Kyte-Doolittle scale (Kyte & Doolittle, 1982) 
and a window size of 9, using the Molecular Toolkit from the University  
of Colorado (www.vivo.colostate.edu/molkit). 
 
Investigation of the N-terminal 20 residues revealed a high occurrence of 
hydrophobic residues (Phe/F, Val/V, Cys/C and Leu/L). Therefore BPSL1204-MA 
was a truncate formed by the deletion of 20 N-terminal residues/60 5´ base pairs 
during cloning. 
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Figure 4.3: 1% agarose gel of pure BPSL1204-MA PCR product.  
Lane 1: Hyperladder I (Bioline). Lane 2: BPSL1204-MA PCR	  (444bp)	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The	  ligation	  reaction	  was	  allowed	  to	  proceed	  overnight	  at	  4°C.	  	  4.2.3	  Sub-­‐cloning	  into	  NovaBlue	  	  The	  ligation	  of	  pETBlue-­‐1:BPSL1204-­‐MA	  was	  used	  to	  transform	  the	  sub-­‐cloning	  
E.	  coli	  NovaBlue,	  tetracycline-­‐resistant	  cell-­‐line.	  A	  pre-­‐aliquoted	  50	  µl	  tube	  of	  cells	  was	  removed	  from	  storage	  at	  -­‐80°C	  and	  allowed	  to	  gently	  thaw	  on	  ice	  for	  5	  minutes.	  1	  µl	  of	  the	  ligation	  was	  gently	  mixed	  into	  the	  thawed	  cells	  and	  left	  on	  ice	  for	  a	  further	  10-­‐15	  minutes.	  The	  cells	  were	  then	  heat-­‐shocked	  at	  42°C	  for	  30	  seconds	  and	  then	  placed	  back	  on	  ice	  for	  2	  minutes.	  250	  µl	  of	  room	  temperature	  LB	  media	  was	  then	  added	  to	  a	  final	  volume	  of	  300	  µl	  and	  a	  60	  minute	  period	  of	  out-­‐growth	  was	  carried	  out	  at	  37°C	  and	  200	  rpm.	  Three	  LB	  agar	  plates	  containing	  30	  µg/ml	  tetracycline	  and	  100	  µg/ml	  carbenicillin	  were	  pre-­‐soaked	  with	  35	  µl	  50	  mg/ml	  Xgal	  and	  20	  µl	  100	  mM	  IPTG	  and	  then	  were	  spread	  with	  the	  transformed	  culture	  using	  200	  µl,	  100	  µl	  and	  the	  excess	  liquid	  from	  the	  spreader	  from	  the	  100	  µl	  plate.	  This	  was	  in	  order	  to	  establish	  at	  least	  one	  plate	  with	  a	  usable	  colony	  count.	  Double	  antibiotic-­‐resistance	  selection	  was	  used	  as	  pETBlue-­‐1	  carries	  the	  ampicillin/carbenicillin	  resistance	  gene.	  Plates	  were	  allowed	  to	  soak-­‐in	  and	  then	  inverted	  overnight	  at	  37°C	  for	  growth	  of	  colonies	  and	  further	  analysis.	  	  4.2.4	  Identification	  of	  Successful	  Clones	  	  The	  Novablue	  cell-­‐line	  was	  compatible	  with	  the	  pETBlue-­‐1	  vector	  to	  facilitate	  blue-­‐white	  screening	  of	  colonies.	  The	  linearised	  pETBlue-­‐1	  was	  constructed	  so	  that	  the	  incorporated	  lacZ	  gene	  was	  broken,	  and	  upon	  re-­‐circularisation	  a	  functional	  gene	  was	  restored	  to	  allow	  the	  expression	  of	  lacZ	  as	  induced	  by	  the	  1mM	  IPTG	  incorporated	  into	  the	  plates.	  This	  allowed	  for	  functional	  β–galactosidase	  production,	  established	  by	  the	  production	  of	  blue	  colonies	  as	  the	  enzyme	  cleaved	  the	  Xgal	  in	  the	  plate	  media.	  However,	  when	  the	  BPSL1204-­‐MA	  insert	  was	  blunt-­‐end	  ligated	  into	  pre-­‐linearised	  pETBlue-­‐1	  this	  prevented	  the	  production	  of	  active	  β–galactosidase,	  therefore	  any	  colonies	  containing	  vector	  with	  ligated-­‐insert	  were	  selected	  as	  they	  presented	  as	  white	  colonies.	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Due	  to	  the	  blunt-­‐ended	  nature	  of	  ligation,	  ligated	  vectors	  could	  exist	  in	  3	  different	  forms	  leading	  to	  white	  colonies;	  BPSL1204-­‐MA	  correctly	  orientated	  5´-­‐3´	  in	  the	  forwards	  reading-­‐frame,	  BPSL1204-­‐MA	  incorrectly	  orientated	  3´-­‐5´	  in	  the	  forwards	  reading-­‐frame	  or	  not	  incorporated	  at	  all	  and	  the	  white	  colony	  was	  an	  unexplained	  false-­‐positive	  actually	  containing	  only	  re-­‐circularised	  pETBlue-­‐1.	  Therefore	  each	  white	  colony	  was	  subjected	  to	  colony-­‐PCR	  using	  the	  method	  described	  in	  section	  3.4.1	  but	  changed	  so	  that	  alongside	  the	  insert-­‐specific	  3´	  reverse	  primer	  the	  5´	  primer	  used	  was	  0.5	  µl	  of	  5	  mM	  pETBlue-­‐1-­‐specific	  T7F	  primer.	  This	  primer	  would	  only	  bind	  the	  T7	  promoter-­‐region	  upstream	  of	  the	  insertion	  site	  so	  that	  only	  colonies	  with	  correctly	  orientated	  5´-­‐3´	  inserted	  pETBlue:BPSL1204-­‐MA	  would	  generate	  PCR	  products.	  Colonies	  that	  generated	  positive	  PCR	  products	  were	  identified	  by	  1%	  agarose	  gel	  electrophoresis	  (Figure	  4.4).	  	  Once	  a	  white,	  positive	  colony-­‐PCR	  colony	  was	  identified,	  it	  was	  grown	  up	  overnight	  in	  5	  ml	  LB	  media	  +	  30	  µg/ml	  tetracycline	  +	  100	  µg/ml	  carbenicillin	  at	  37°C	  and	  250	  rpm.	  The	  cloned-­‐vector	  was	  then	  purified	  by	  Qiagen	  Miniprep	  to	  be	  sequenced	  using	  the	  T7F	  primer	  by	  Geneservice,	  to	  confirm	  again	  the	  presence	  of	  the	  insert	  in	  the	  correct	  orientation	  and	  to	  double-­‐check	  that	  no	  mutations	  had	  occurred	  by	  comparison	  of	  the	  sequenced	  data	  to	  that	  of	  the	  original	  sequence	  taken	  from	  the	  BLAST	  server.	  	  	  4.2.5	  Cloning	  of	  Full-­‐length	  BPSL1204	  	  The	  restriction	  cloning	  protocol	  described	  in	  Section	  3.4.2	  was	  applied	  to	  full-­‐length	  BPSL1204,	  with	  NcoI	  and	  BamHI	  restriction	  enzymes,	  using	  the	  primers	  in	  Section	  3.4.1	  and	  using	  the	  standard	  PCR	  reaction	  described	  in	  Section	  3.2.1	  with	  an	  annealing	  temperature	  of	  55°C.	  The	  digested,	  full-­‐length	  BPSL1204	  gene	  was	  ligated	  into	  the	  arabinose-­‐inducible	  pBAD/hisB	  vector	  and	  sub-­‐cloned	  in	  DH5α,	  following	  the	  protocol	  in	  Section	  3.4.3.	  Successful	  clones	  were	  identified	  by	  colony	  PCR	  using	  the	  original	  primers.	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Figure 4.4: Colony-PCR agarose gel of white Novablue:pETBlue:BPSL1204 
colonies. 
 
Lane 1, 7 and 14: Hyperladder I (Bioline).  
Lane 6: 1 Kb ladder (Fermentas).  
Lane 2-5 and 8-13: white colonies 1-10. 
 
Colonies 2, 4 and 10 gave expected bands of ~444 bp.  
Colonies 1, 3 and 5-9 contained contaminating bands but no BPSL1204-MA.  
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4.3	  Over-­expression	  of	  BPSL1204-­MA	  	  4.3.1	  Transformation	  into	  Tuner	  Cells	  	  Correctly	  sequenced,	  cloned	  vector	  was	  transformed	  into	  competent,	  chloramphenicol-­‐resistant	  Tuner(DE3)LacI	  cells	  for	  investigation	  of	  the	  over-­‐expression	  of	  the	  cloned	  gene-­‐product.	  A	  20	  µl	  aliquot	  of	  competent	  cells	  in	  a	  1.5	  ml	  Eppendorf	  was	  removed	  from	  storage	  at	  -­‐80°C	  and	  was	  gently	  thawed	  on	  ice	  for	  5	  minutes	  and	  the	  cells	  were	  re-­‐suspended	  by	  gently	  flicking	  twice.	  1	  µl	  of	  a	  1:50	  dilution	  of	  a	  50	  ng/µl	  stock	  of	  pETBlue:BPSL1204-­‐MA	  was	  pipetted	  into	  the	  aliquot	  of	  cells	  and	  gently	  mixed	  on	  ice	  using	  the	  tip	  of	  the	  pipette.	  The	  Tuner	  cells	  and	  plasmid	  were	  allowed	  to	  incubate	  on	  ice	  for	  a	  further	  10	  minutes.	  	  	  The	  cells	  were	  then	  heat-­‐shocked	  for	  30	  seconds	  at	  42°C	  in	  a	  water-­‐bath	  to	  promote	  the	  uptake	  of	  DNA	  before	  being	  placed	  back	  in	  ice	  for	  another	  2	  minutes.	  80	  µl	  of	  sterile	  LB	  media	  at	  room	  temperature	  was	  then	  added	  and	  the	  cells	  were	  left	  for	  an	  outgrowth	  step	  at	  37°C	  and	  250	  rpm	  for	  60	  minutes.	  2	  plates	  of	  LB	  agar	  containing	  100	  µg/ml	  carbenicillin	  and	  34	  µg/ml	  chloramphenicol	  were	  prepared,	  onto	  one	  of	  which	  all	  100	  µl	  of	  the	  transformation	  were	  spread,	  after	  which	  the	  excess	  liquid	  left	  on	  the	  spreader	  used	  was	  spread	  onto	  the	  second	  plate	  in	  order	  to	  guarantee	  at	  least	  one	  plate	  would	  supply	  a	  suitably	  diluted,	  usable	  colony	  count.	  Plates	  were	  left	  to	  soak-­‐in,	  then	  inverted	  and	  left	  at	  37°C	  for	  15-­‐18	  hours	  to	  grow.	  	  4.3.2	  Over-­‐expression	  and	  Solubility	  Tests	  	  A	  colony	  from	  a	  successfully	  transformed	  Tuner:pETBlue:BPSL1204-­‐MA	  plate	  was	  picked	  and	  used	  to	  inoculate	  10	  ml	  LB	  media,	  supplemented	  with	  34	  µg/ml	  chloramphenicol	  and	  100	  µg/ml	  carbenicillin	  which	  was	  left	  to	  culture	  at	  37°C	  and	  200	  rpm	  overnight.	  Once	  uniformly	  re-­‐suspended	  by	  inversion,	  this	  starter-­‐culture	  was	  then	  used	  to	  5%	  inoculate	  7	  x	  4.75	  ml	  of	  fresh	  LB	  in	  sterile	  15	  ml	  Falcon	  tubes,	  supplemented	  with	  the	  same	  antibiotics,	  by	  the	  addition	  of	  250	  µl	  of	  starter-­‐culture	  to	  each	  to	  a	  final	  volume	  of	  5	  ml.	  This	  was	  then	  allowed	  to	  culture	  at	  37°C	  and	  250	  rpm	  until	  an	  OD600nm	  of	  0.6-­‐0.7	  was	  reached	  in	  the	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seventh	  tube.	  The	  other	  six	  tubes	  were	  left	  to	  culture	  untouched	  with	  the	  assumption	  of	  uniform	  growth	  throughout	  all	  seven	  tubes.	  Six	  1	  ml,	  30%	  glycerol	  stocks	  were	  created	  using	  a	  portion	  of	  the	  excess	  starter-­‐culture	  and	  were	  stored	  at	  -­‐80°C	  for	  future	  use	  in	  repeating	  the	  culture.	  	  When	  the	  correct	  optical	  density	  of	  cells	  was	  measured,	  three	  of	  the	  six	  tubes	  were	  induced	  by	  the	  addition	  of	  5	  µl	  1	  M	  IPTG	  to	  a	  final	  concentration	  of	  1	  mM,	  whereas	  the	  other	  three	  tubes	  served	  as	  non-­‐induced	  controls.	  Three	  pairs	  consisting	  of	  one	  induced	  and	  one	  non-­‐induced	  tube	  were	  created	  and	  each	  pair	  were	  left	  to	  over-­‐express	  protein	  at	  25°C,	  30°C	  or	  37°C	  for	  three	  hours	  at	  250	  rpm.	  Cells	  were	  then	  pelleted	  by	  centrifugation	  at	  4500	  rpm	  for	  20	  minutes	  at	  10°C	  in	  a	  Sigma	  3-­‐16K	  11133	  rotor	  and	  the	  supernatant	  discarded	  by	  decanting	  and	  then	  removing	  the	  liquid	  left	  on	  the	  surface	  of	  the	  pellet	  by	  pipetting.	  	  	  The	  pellets	  were	  subjected	  to	  Bugbuster	  and	  Benzonase	  (Nestle	  &	  Roberts,	  1969)	  fractionation	  using	  the	  method	  described	  by	  Novagen,	  with	  the	  insoluble	  pellets	  re-­‐suspended	  in	  4%	  SDS	  using	  half	  the	  original	  Bugbuster	  volume,	  to	  increase	  the	  concentration	  of	  the	  samples.	  The	  protein	  concentrations	  of	  each	  fraction	  were	  calculated	  using	  the	  Bradford	  method	  described	  in	  Section	  3.2.4	  and	  samples	  containing	  15	  µg	  of	  protein	  were	  boiled	  with	  LDS	  loading-­‐buffer	  and	  DTT,	  then	  loaded	  onto	  a	  13.5%	  resolving	  SDS-­‐PAGE	  gel	  and	  ran	  for	  45-­‐50	  minutes	  at	  200	  V,	  before	  staining	  for	  several	  hours	  and	  then	  de-­‐staining	  until	  bands	  were	  visible.	  The	  gel	  in	  Figure	  4.5	  shows	  that	  the	  optimum	  temperature	  for	  soluble	  over-­‐expression	  of	  BPSL1204-­‐MA	  over	  a	  three	  hour	  induction	  is	  37°C	  when	  compared	  to	  the	  uninduced	  control,	  the	  other	  soluble	  variations	  in	  temperature	  and	  the	  corresponding	  insoluble	  fractions.	  	  4.3.3	  Large-­‐scale	  Over-­‐expression	  	  Based	  upon	  the	  findings	  of	  the	  previous	  over-­‐expression	  tests,	  large-­‐scale	  over-­‐expression	  was	  undertaken	  with	  a	  few	  variations	  in	  order	  to	  provide	  sufficient	  material	  for	  purification	  of	  BPSL1204-­‐MA.	  A	  100	  ml	  starter-­‐culture	  was	  set	  off	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Figure 4.5: SDS-PAGE analysis of Tuner 
BPSL1204-MA over-expression.  
 
Lane 1: Mark 12 ladder (Invitrogen).  
Lane 2: Non-induced Insoluble 
Lane 3: 25°C Insoluble 
Lane 4: 30°C Insoluble 
Lane 5: 37°C Insoluble 
Lane 6: Non-induced Soluble 
Lane 7: 25°C Soluble 
Lane 8: 30°C Soluble 
Lane 9: 37°C Soluble 	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overnight	  at	  37°C	  and	  200	  rpm	  the	  night	  prior	  to	  the	  scaled-­‐up	  over-­‐expression.	  Six	  2	  L	  flasks	  containing	  490	  ml	  LB	  were	  autoclaved,	  supplemented	  with	  antibiotics	  and	  warmed	  to	  approximately	  37°C	  to	  reduce	  the	  lag-­‐phase	  of	  bacterial	  growth.	  Each	  was	  then	  2%	  inoculated	  with	  10	  ml	  of	  the	  starter-­‐culture	  to	  a	  final	  volume	  of	  500	  ml	  and	  left	  to	  culture	  at	  37°C	  and	  250	  rpm	  until	  an	  OD600nm	  of	  0.6	  was	  reached.	  They	  were	  then	  induced	  by	  the	  addition	  of	  0.5	  ml	  of	  1	  M	  IPTG	  to	  a	  final	  concentration	  of	  1	  mM	  and	  left	  to	  over-­‐express	  for	  four	  hours	  at	  37°C	  and	  250	  rpm,	  after	  which	  cells	  were	  collected	  by	  centrifugation	  as	  described	  in	  Section	  3.5.3	  and	  stored	  as	  cell-­‐paste	  in	  50	  ml	  Falcon	  tubes	  at	  -­‐80°C	  until	  further	  use	  in	  purification	  experiments.	  	  The	  lower	  inoculation	  percentage	  used	  was	  in	  the	  hope	  of	  generating	  more	  ‘fresh’	  cells	  than	  in	  the	  original	  tests	  that	  would	  grow	  within	  an	  experimentally	  practical	  time-­‐period.	  The	  use	  of	  a	  four-­‐hour	  instead	  of	  three-­‐hour	  induction	  was	  based	  upon	  the	  total	  lack	  of	  insoluble	  BPSL1204-­‐MA	  in	  the	  three-­‐hour	  tests,	  thus	  again	  aiming	  to	  achieve	  more	  soluble	  material	  per	  gram	  of	  cells	  within	  an	  experimentally	  practical	  time-­‐period.	  A	  scraping	  of	  cells	  was	  removed	  from	  the	  cell-­‐paste	  pellet	  and	  subjected	  to	  SDS-­‐PAGE	  analysis	  post-­‐Bugbuster	  fractionation,	  which	  showed	  that	  the	  scaling-­‐up	  of	  the	  over-­‐expression	  had	  no	  negative	  effect	  on	  the	  production	  of	  soluble	  BPSL1204-­‐MA.	  	  4.3.4	  Over-­‐expression	  of	  Full-­‐length	  BPSL1204	  	  After	  the	  transformation	  of	  purified	  pBAD/hisB:BPSL1204	  into	  the	  TOP10	  cell-­‐line,	  variations	  in	  temperature,	  induction-­‐time	  and	  the	  percentage	  of	  arabinose	  used	  for	  induction	  were	  applied	  to	  the	  over-­‐expression	  protocol	  described	  in	  Section	  3.5.3.	  As	  can	  be	  seen	  in	  Figure	  4.6,	  full-­‐length	  BPSL1204	  was	  found	  to	  be	  insoluble.	  However	  this	  was	  considered	  a	  positive	  result	  in	  comparison	  to	  colleagues’	  success	  at	  producing	  soluble	  protein	  via	  similar	  methods	  applied	  to	  a	  pBAD/hisB	  construct	  (Robert	  Salmon	  and	  Professor	  David	  Kelly,	  University	  of	  Sheffield,	  Dept	  of	  MBB,	  personal	  communication).	  As	  full	  length	  BPSL1204	  was	  predicted	  to	  consist	  of	  a	  targeting	  sequence	  followed	  by	  a	  glycerylcysteine	  lipoprotein	  moiety	  before	  the	  soluble	  BPSL1204-­‐MA	  domains,	  the	  presence	  of	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Figure 4.6: SDS-PAGE analysis of full-length BPSL1204 (19.2 kDa) 
over-expression at 37°C for 3 hours. 
 
Lane 1-3 = No induction, 0.1 and 0.01% arabinose soluble 
Lane 4-6 = No induction, 0.1 and 0.01% arabinose insoluble 
Lane 7 = Mark12 (kDa) 
 
Full-length BPSL1204 is insoluble when over-expressed in E. coli. 
This was assumed to be due to the presence of an N-terminal 
anchoring sequence usually cleaved in native B. pseudomallei. 
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insoluble	  BPSL1204	  suggests	  the	  presence	  of	  a	  non-­‐folded,	  non-­‐localised	  pre-­‐prolipoprotein.	  This	  led	  to	  strengthen	  the	  hypothesis	  that	  BPSL1204	  functions	  whilst	  anchored	  to	  a	  membrane.	  	  
4.4	  Purification	  of	  BPSL1204-­MA	  	  4.4.1	  Fractionation	  of	  Cell-­‐Paste	  	  A	  portion	  of	  the	  cell-­‐paste	  was	  re-­‐suspended	  in	  10	  ml	  Tris	  pH	  8.0	  per	  1	  g	  of	  cells.	  To	  achieve	  enough	  pure	  protein	  per	  round	  of	  purification	  in	  order	  to	  carry	  out	  efficient	  screening	  or	  optimisation	  it	  was	  established	  that	  3.5	  g	  of	  cells	  were	  to	  be	  used	  at	  the	  start	  of	  each	  purification,	  re-­‐suspended	  in	  35	  ml	  buffer.	  The	  suspension	  was	  then	  sonicated	  on	  ice	  for	  3	  x	  20	  seconds	  at	  16	  microns	  and	  the	  insoluble	  fraction	  was	  pelleted	  by	  centrifugation,	  as	  described	  in	  section	  3.6.1.	  The	  35	  ml	  of	  soluble	  supernatant	  was	  used	  immediately	  for	  DEAE	  ion-­‐exchange	  chromatography.	  	  	  4.4.2	  DEAE	  Ion-­‐Exchange	  Chromotography	  	  The	  35	  ml	  cell-­‐free	  extract	  was	  applied	  to	  a	  Superloop	  attached	  to	  the	  injection	  valve	  of	  an	  AKTAprime	  purification	  machine	  connected	  to	  a	  20	  ml	  HiPrep	  16/10	  DEAE-­‐FF	  column	  from	  Amersham	  Pharmacia	  that	  had	  all	  been	  pre-­‐equilibrated	  with	  50	  mM	  Tris	  pH	  8.0.	  The	  cell-­‐free	  extract	  was	  loaded	  onto	  the	  column	  from	  the	  Superloop	  by	  injecting	  at	  4	  ml/min,	  and	  the	  flow-­‐through	  was	  kept	  for	  analysis.	  Once	  loaded,	  the	  column	  was	  then	  washed	  with	  60	  ml	  of	  50	  mM	  Tris	  pH	  8.0	  to	  remove	  any	  unbound	  material	  and	  the	  eluate	  was	  collected	  for	  analysis.	  	  Once	  the	  UV-­‐trace	  continuously	  read	  at	  the	  pre-­‐equilibrated	  base	  line,	  a	  gradient	  of	  0-­‐0.5	  M	  NaCl	  (by	  increase	  of	  0-­‐50%	  of	  a	  50	  mM	  Tris	  pH	  8.0,	  1	  M	  NaCl	  buffer	  off-­‐set	  against	  50	  mM	  Tris	  pH	  8.0)	  was	  applied	  over	  300	  ml	  whilst	  4	  ml	  fractions	  were	  collected.	  The	  peaks	  that	  appeared	  on	  the	  UV-­‐trace	  were	  analysed	  by	  13.5%	  resolve	  SDS-­‐PAGE	  to	  identify	  the	  peak	  that	  contained	  BPSL1204-­‐MA.	  Figure	  4.7	  shows	  the	  analysis	  of	  the	  peaks	  post-­‐DEAE	  chromatography.	  	  
	   102	  
Figure 4.7: DEAE ion exchange of BPSL1204-MA. The UV trace of fractions 
collected from a DEAE column loaded with cell-free extract (top) showed 5 peaks 
eluted over a 0-0.5 M NaCl gradient. SDS-PAGE analysis of peak fractions 
(bottom) showed that BPSL1204-MA eluted in the first DEAE peak. 
 
Lane 1 = Mark 12 (kDa) 
Lane 2 = Crude cell-free extract 
Lane 3-7 = Fractions under peaks 1-5. 
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BPSL1204-­‐MA	  elutes	  at	  approximately	  80	  mM	  NaCl	  in	  50	  mM	  Tris	  pH	  8.0	  in	  the	  first	  peak	  of	  the	  experiment.	  The	  5	  fractions	  contained	  within	  the	  BPSL1204-­‐MA	  peak	  were	  combined	  for	  further	  purification	  by	  (NH4)2SO4	  precipitation.	  A	  standard	  combined	  concentration	  was	  0.9	  mg/ml,	  as	  determined	  by	  Bradford	  Assay,	  thus	  taking	  forwards	  18	  mg	  of	  protein	  in	  20	  ml.	  	  4.4.3	  Ammonium	  Sulphate	  Precipitation	  	  The	  combined	  20	  ml	  taken	  forwards	  from	  ion-­‐exchange	  chromatography	  was	  transferred	  to	  a	  sterile	  centrifuge	  tube	  and	  combined	  with	  8	  ml	  of	  4	  M	  (NH4)2SO4	  to	  create	  a	  final	  28	  ml	  mixture	  of	  protein	  in	  1.6	  M	  (NH4)2SO4.	  At	  this	  stage	  it	  was	  possible	  to	  see	  protein	  precipitating	  out	  of	  solution	  as	  the	  mixture	  became	  a	  cloudy,	  white	  suspension.	  Precipitation	  was	  allowed	  to	  occur	  for	  5-­‐10	  minutes	  on	  ice	  before	  the	  insoluble	  precipitate	  was	  pelleted	  by	  centrifugation	  at	  24,500	  rpm	  in	  a	  JA25.50	  rotor	  at	  8°C	  for	  15	  minutes.	  	  	  The	  soluble	  fraction	  was	  removed	  by	  decanting	  the	  bulk	  of	  the	  solution	  and	  carefully	  pipetting	  from	  the	  surface	  of	  the	  pellet	  and	  stored	  at	  4°C	  for	  future	  analysis.	  The	  pellet	  was	  resuspended	  in	  1.5	  ml	  of	  50	  mM	  Tris	  pH	  8.0	  by	  pipetting	  and	  then	  transferred	  to	  a	  1.5	  ml	  Eppendorf	  which	  was	  then	  spun	  at	  13000	  rpm	  in	  a	  Sigma	  3-­‐16K	  12154	  rotor	  for	  5	  mins	  at	  8°C	  to	  pellet	  permanently	  insoluble	  material.	  This	  second	  supernatant	  was	  then	  assessed	  for	  the	  presence	  of	  BPSL1204-­‐MA	  by	  SDS-­‐PAGE	  as	  shown	  in	  Figure	  4.8	  and	  then	  taken	  forward	  to	  the	  next	  stage	  of	  purification	  by	  gel	  filtration.	  A	  standard	  concentration	  after	  re-­‐suspension	  of	  the	  (NH4)2SO4	  pellet	  was	  6.5	  mg/ml,	  as	  determined	  by	  Bradford	  Assay,	  thus	  taking	  forwards	  9.75	  mg	  of	  protein	  in	  1.5	  ml	  of	  buffer.	  	  4.4.4	  Gel	  Filtration	  	  A	  120	  ml	  HiLoad	  16/60	  Superose	  6	  gel	  filtration	  column	  from	  Amersham	  Pharmacia	  was	  connected	  to	  an	  AKTAPrime	  purification	  machine	  and	  equilibrated	  with	  a	  buffer	  of	  50mM	  Tris	  pH	  8.0,	  0.5	  M	  NaCl	  at	  1	  ml/min	  for	  1.5	  column	  volumes.	  The	  1.5	  ml	  re-­‐suspension	  from	  the	  (NH4)2SO4	  precipitation	  was	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Figure 4.8: SDS-PAGE analysis of (NH4)2SO4-precipitation of BPSL1204-MA 
from combined DEAE fractions. 
 
Lane 1 = Mark12 (kDa)    
Lane 2 = Combined DEAE fractions   
Lane 3 = Supernatant post-2 M (NH4)2SO4 
Lane 4 = Re-suspended 2 M (NH4)2SO4 pellet 
Lane 5 = Insoluble material post-2 M (NH4)2SO4 pellet re-suspension 
Lane 6 = Supernatant post-1.5 M (NH4)2SO4 
Lane 7 = Re-suspended 1.5 M (NH4)2SO4 pellet 
Lane 8 = Insoluble material post-1.5 M (NH4)2SO4 pellet re-suspension 
 
It was considered that 1.5 M (NH4)2SO4 precipitation purified BPSL1204-MA 
from more contaminants than 2 M (NH4)2SO4. However, both concentrations led 
to the generation of some insoluble material (Lanes 5 and 8). This effective 
technique was used as a compromise between purification speed and yield.  
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loaded	  onto	  the	  top	  of	  the	  column	  and	  then	  the	  column	  was	  immediately	  re-­‐connected	  and	  the	  gel	  filtration	  program	  run	  on	  the	  AKTAPrime.	  At	  1	  ml/min	  a	  45	  ml	  void-­‐elution	  was	  allowed	  to	  run	  into	  waste-­‐disposal,	  and	  then	  the	  remaining	  75	  ml	  was	  collected	  in	  2	  ml	  fractions	  alongside	  the	  recording	  of	  a	  UV	  trace.	  The	  peak	  fraction	  on	  the	  trace	  was	  assessed	  for	  the	  presence	  of	  pure	  BPSL1204-­‐MA.	  The	  4	  fractions	  under	  the	  peak	  were	  combined	  for	  concentration	  and	  buffer-­‐exchange	  by	  Viva-­‐spin	  centrifugation.	  	  	  A	  standard	  concentration	  after	  gel	  filtration	  was	  0.5	  mg/ml,	  as	  determined	  by	  Bradford	  Assay,	  thus	  taking	  forwards	  4	  mg	  of	  protein.	  The	  gel	  filtration	  also	  acted	  as	  a	  method	  of	  buffer-­‐exchange	  away	  from	  residual	  (NH4)2SO4.	  Analysis	  of	  the	  gel-­‐filtration	  trace	  against	  a	  standard	  curve	  from	  the	  column	  used	  suggested	  the	  elution	  of	  pure,	  totally	  monomeric	  BPSL1204-­‐MA	  (Figure	  4.9)	  with	  the	  purity	  of	  the	  final	  protein	  sample	  and	  the	  effectiveness	  of	  the	  purification	  protocol	  assessed	  by	  SDS-­‐PAGE	  (Figure	  4.10).	  BPSL1204-­‐MA	  was	  purified	  to	  a	  high	  purity.	  	  4.4.5	  N-­‐terminal	  Sequencing	  	  The	  presence	  of	  BPSL1204-­‐MA	  in	  the	  final	  purified	  sample	  was	  confirmed	  by	  Edman-­‐degradation	  N-­‐terminal	  sequencing	  (Niall,	  1973).	  There	  was	  little	  to	  no	  background	  contamination	  detected	  by	  this	  procedure.	  Dr	  Arthur	  Moir	  of	  the	  University	  of	  Sheffield	  carried	  out	  the	  sequencing.	  	  
4.5	  Synthesis	  of	  a	  Selenomethionine	  Derivative	  	  4.5.1	  Large-­‐scale	  Over-­‐expression	  and	  Purification	  of	  SeMet	  BPSL1204-­‐MA	  	  Following	  the	  protocol	  described	  in	  section	  3.5.2,	  4	  x	  500	  ml	  cultures	  at	  0.7	  OD	  600nm,	  each	  in	  2	  L	  baffled-­‐flasks,	  were	  induced	  with	  1	  mM	  IPTG	  for	  24	  hrs	  at	  37°C	  and	  250	  rpm.	  7	  g	  of	  cell-­‐paste	  was	  harvested	  and	  stored	  as	  2	  x	  3.5	  g	  pellets	  at	  -­‐80°C	  until	  further	  use	  in	  purification.	  Soluble	  over-­‐expression	  was	  confirmed	  by	  SDS-­‐PAGE	  as	  shown	  in	  Figure	  4.11.	  The	  purification	  protocol	  employed	  for	  the	  native	  BPSL1204-­‐	  protein	  was	  applied	  to	  the	  seleno-­‐met	  derivative,	  and	  was	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UV	  –	  1	  V	  
Fraction	  
100	  ml	  
Figure 4.9: Gel filtration trace of BPSL1204-MA purification The UV 
sensitivity was set to 1 V and 2 ml fractions were collected. A single 
monomeric peak of BPSL1204-MA was witnessed in Fraction 27, after 
an elution volume of 100 ml. 
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Figure 4.10: SDS-PAGE analysis of the 
BPSL1204-MA purification protocol. 
 
Lane 1: Mark 12 (Invitrogen) 
Lane 2: Cell-free Extract 
Lane 3: Post DEAE 
Lane 4: Post (NH4)2SO4 
Lane 5: Post Gel Filtration	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Figure 4.11: SDS-PAGE analysis of Seleno-
methionine BPSL1204-MA over-expression. 
 
Lane 1: Mark 12 (Invitrogen) 
Lane 2: 4 hours 
Lane 3: 6 hours 
Lane 4: 12 hours 
Lane 5: 16 hours 
Lane 6: 20 hours 
Lane 7: 24 hours 
21.5	  kDa	  
14.4	  kDa	  
	  	  	  	  	  	  	  1	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   4	  	  	  	  	  	  	  	  	  	  	  	  	  5	   	  	  	  	  	  	  	  	  	  	  	  	  	  6	   	  	  	  	  	  	  	  	  	  	  7	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successful	  in	  purifying	  3	  mg	  of	  pure,	  seleno-­‐met	  BPSL1204-­‐MA	  in	  100	  µl	  from	  3.5	  g	  of	  cell-­‐paste.	  	  4.5.2	  Analysis	  of	  SeMet	  Incorporation	  	  3	  µl	  of	  30	  mg/ml	  seleno-­‐met	  BPSL1204-­‐MA	  was	  analysed	  by	  mass	  spectrometry	  (Domon	  &	  Aebersold,	  2006)	  by	  Simon	  Thorpe	  of	  the	  University	  of	  Sheffield	  Chemistry	  Department.	  As	  can	  be	  seen	  in	  Figure	  4.12,	  the	  mass	  spectra	  produced	  confirmed	  the	  100%	  incorporation	  of	  5	  selenomethionine	  into	  BPSL1204-­‐MA.	  This	  was	  something	  of	  a	  surprise	  because	  it	  implied	  that	  the	  N-­‐terminal	  methionine	  not	  present	  in	  the	  native	  BPSL1204-­‐MA	  was	  present	  in	  the	  seleno-­‐met	  derivative,	  presumably	  reflecting	  differences	  in	  the	  processing	  of	  expressed	  polypeptides	  in	  the	  presence	  of	  seleno-­‐methionine.	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   4	  Met	  BPSL1204-­MA	  
(Da)	  
5	  Met	  BPSL1204-­MA	  
(Da)	  
S-­Met	   17197	   17329	  
+1	  Se-­Met	   17244	   17376	  
+2	  Se-­Met	   17291	   17423	  
+3	  Se-­Met	   17338	   17470	  
+4	  Se-­Met	   17385	   17517	  
+5	  Se-­Met	   N/A	   17564	  
Figure 4.12: Mass spectra of Se-Met BPSL1204-MA (top) and table of possible Se-
Met incorporation masses (bottom). The mass spectra show a mass of 17566 Da 
recorded, which corresponds to the incorporation of 5 (100%) Se-Met residues into 
BPSL1204-MA 
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Chapter	  5:	  Crystallisation	  and	  Structure	  Determination	  of	  BPSL1204	  	  
5.1	  Protein	  Sample	  Preparation	  	  5.1.1	  Buffer-­‐exchanging	  the	  Final	  Sample	  	  After	  the	  combination	  of	  gel	  filtration	  fractions	  under	  the	  peak	  of	  the	  UV	  trace	  (6-­‐8	  ml),	  pure	  BPSL1204-­‐MA	  was	  reduced	  to	  a	  volume	  of	  approximately	  300	  µl	  using	  a	  6	  ml	  VivaSpin	  10	  kDa	  centrifugal	  filter-­‐column,	  available	  from	  Sartorius,	  by	  centrifuging	  in	  a	  Sigma	  3-­‐16K	  11133	  rotor	  for	  20-­‐30	  minutes	  at	  4500	  rpm	  at	  10°C.	  For	  crystallographic	  screening	  the	  lowest	  concentration	  buffer	  with	  no	  contaminating	  salt	  was	  required.	  In	  order	  to	  remove	  the	  0.5	  M	  NaCl	  from	  the	  gel	  filtration	  buffer	  and	  exchange	  the	  50	  mM	  Tris	  pH	  8.0	  buffer	  into	  10	  mM	  Tris	  pH	  8.0,	  the	  300	  µl	  was	  then	  re-­‐suspended	  to	  6	  ml	  by	  the	  addition	  of	  5.7	  ml	  of	  10	  mM	  Tris	  pH	  8.0.	  This	  was	  then	  reduced	  to	  300	  µl	  again,	  and	  then	  re-­‐suspended	  back	  to	  6	  ml	  with	  fresh	  10	  mM	  Tris	  pH	  8.0.	  This	  left	  approximately	  4.5	  mg	  of	  pure	  protein	  in	  6	  ml	  of	  10	  mM	  Tris	  pH	  8.0	  with	  less	  than	  1.5	  mM	  NaCl.	  	  5.1.2	  Concentration	  of	  Protein	  Sample	  for	  Crystallography	  	  In	  order	  to	  raise	  the	  concentration	  of	  the	  protein	  solution	  to	  a	  level	  that	  would	  allow	  super-­‐saturation	  of	  protein	  leading	  to	  crystallisation	  via	  vapour-­‐diffusion	  (Chayen	  &	  Saridakis,	  2008),	  the	  pure	  protein	  in	  low	  concentration	  buffer	  was	  ideally	  to	  be	  of	  a	  final	  sample	  concentration	  of	  greater	  than	  8-­‐10	  mg/ml.	  Using	  the	  same	  VivaSpin	  column	  as	  in	  the	  buffer-­‐exchange	  step,	  the	  6	  ml	  sample	  in	  10	  mM	  Tris	  pH	  8.0	  was	  centrifuged	  at	  4500	  rpm	  at	  10°C	  for	  50-­‐60	  minutes	  until	  the	  solution	  reached	  a	  suitable	  concentration.	  The	  sample	  was	  then	  removed	  by	  pipetting	  from	  the	  VivaSpin.	  The	  sample	  was	  pipetted	  up	  and	  down	  from	  the	  bottom	  of	  the	  filter	  several	  times	  before	  removal,	  to	  ensure	  maximum	  retrieval	  of	  protein	  from	  the	  filter-­‐base,	  where	  protein	  concentration	  was	  highest	  post-­‐centrifugation.	  From	  3.5	  g	  starting	  mass	  of	  cell-­‐paste	  it	  was	  typically	  possible	  to	  achieve	  4	  mgs	  of	  pure	  BPSL1204-­‐MA	  in	  a	  200	  µl	  solution	  at	  20	  mg/ml	  protein,	  buffered	  by	  10	  mM	  Tris	  pH	  8.0.	  The	  Bradford	  Assay	  was	  used	  to	  determine	  protein	  concentration.	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5.2	  Automated	  Screening	  of	  Crystallisation	  Conditions	  	  5.2.1	  Creation	  of	  Sitting-­‐drop	  Robot	  Trials	  	  The	  pure,	  concentrated	  sample	  of	  BPSL1204-­‐MA	  was	  used	  to	  carry	  out	  initial	  screening	  of	  potential	  crystallisation	  conditions	  using	  a	  Hydra	  II	  crystallisation	  robot	  manufactured	  by	  Matrix	  Technologies.	  Each	  of	  the	  following	  screens	  used,	  bought	  from	  Qiagen	  Nextal,	  consisted	  of	  96	  different	  conditions	  per	  screen:	  JCSG+,	  Classics,	  pHClear,	  PEG,	  PACT,	  Crystal	  Screen	  I,	  Ammonium	  Sulphate,	  MPD.	  The	  contents	  of	  each	  screen	  can	  be	  found	  via	  the	  Nextal	  website	  (www.qiagen.com).	  For	  each	  condition	  200	  µl	  were	  pipetted	  into	  the	  96	  reservoirs	  of	  a	  plastic	  MRC	  sitting-­‐drop	  plate	  (Molecular	  Dimensions),	  from	  which	  approximately	  200	  nl	  were	  transferred	  to	  the	  raised	  platform-­‐dimple	  of	  each	  plate.	  Onto	  the	  drop	  in	  each	  dimple	  the	  robot’s	  nano-­‐needle	  aspirated	  approximately	  200	  nl	  of	  the	  pure	  protein	  sample.	  Each	  96-­‐condition	  plate	  was	  then	  sealed	  using	  a	  sheet	  of	  airtight	  and	  adhesive	  ClearVue	  (Molecular	  Dimensions)	  to	  created	  96	  individually	  sealed	  vapour-­‐diffusion	  experiments.	  Trays	  were	  centrifuged	  at	  2000	  rpm	  in	  a	  Grant-­‐Bio	  LMC-­‐3000	  R-­‐2	  rotor	  for	  2	  minutes	  at	  19°C	  to	  ensure	  proper	  mixing	  of	  drops	  in	  the	  raised	  platforms.	  	  These	  screens	  were	  each	  repeated	  several	  times	  over	  an	  extended	  period	  of	  several	  months,	  in	  order	  to	  vary	  incubation	  temperature,	  protein	  concentration	  used	  and	  freshness	  of	  protein	  sample,	  dependant	  on	  the	  short-­‐term	  results	  of	  the	  previous	  repeat	  of	  the	  screen.	  	  5.2.2	  Incubation	  of	  Screens	  	  Screens	  were	  set	  up	  in	  duplicate,	  and	  left	  at	  2	  different	  temperatures.	  One	  was	  left	  to	  equilibrate	  in	  a	  temperature-­‐controlled	  room	  set	  to	  17°C	  whilst	  the	  other	  copy	  of	  the	  screen	  was	  left	  refrigerated	  at	  7°C.	  This	  was	  in	  case	  nucleation	  happened	  too	  quickly,	  too	  slowly	  or	  not	  at	  all	  at	  one	  temperature	  in	  differing	  conditions,	  but	  was	  appropriate	  at	  another	  temperature	  (Judge	  et	  al,	  1999).	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5.2.3	  Examination	  of	  Growth	  Conditions	  	  Screens	  were	  investigated	  immediately	  post-­‐sealing	  to	  note	  and	  establish	  those	  conditions	  that	  led	  to	  immediate	  precipitation.	  These	  were	  then	  discounted	  from	  the	  list	  of	  potential	  conditions	  straight	  away.	  In	  approximately	  one	  quarter	  of	  all	  conditions,	  BPSL1204-­‐MA	  precipitated	  immediately.	  Each	  screen	  was	  then	  gently	  removed	  from	  its	  incubator	  1-­‐day	  post-­‐trial,	  to	  again	  either	  establish	  further	  conditions	  that	  had	  precipitated	  over	  a	  short	  incubation	  period	  or	  to	  witness	  the	  fast	  over-­‐night	  growth	  of	  any	  crystals.	  In	  the	  case	  of	  BPSL1204-­‐MA,	  several	  more	  conditions	  per	  screen	  had	  precipitated,	  leaving	  behind	  roughly	  half	  the	  conditions	  still	  with	  clear	  drops	  and	  thus	  potentially	  still	  able	  to	  yield	  crystals.	  No	  crystals	  were	  witnessed	  growing	  overnight	  in	  any	  BPSL1204-­‐MA	  trial.	  From	  then	  on,	  screens	  were	  checked	  twice	  weekly	  for	  the	  first	  month,	  then	  weekly	  for	  the	  months	  after	  that.	  	  5.2.4	  Selection	  of	  Potential	  Hits	  	  Over	  a	  period	  of	  several	  months,	  screening	  was	  carried	  out	  and	  the	  resulting	  sitting-­‐drop	  trays	  monitored.	  Screens	  in	  sitting-­‐drop	  robot	  trays	  were	  labelled	  as	  rows	  A-­‐H	  with	  columns	  1-­‐12.	  Table	  5.1	  summarises	  the	  eight	  conditions	  that	  generated	  low-­‐quality	  crystals	  from	  all	  variations	  of	  all	  screens	  done	  for	  BPSL1204-­‐MA.	  	  
5.3	  Optimisation	  to	  Hanging-­drop	  Trays	  	  5.3.1	  Broad-­‐range	  Screening	  Around	  Potential	  Hits	  	  Broad-­‐range	  screens	  of	  hanging-­‐drop	  trials	  were	  created,	  centred	  on	  the	  initial	  hits	  described	  in	  5.2.4,	  following	  the	  method	  described	  in	  3.7.3.	  The	  first	  hanging-­‐drop	  screens	  consisted	  of	  ±6%	  precipitant	  (in	  2%	  steps),	  variation	  of	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JCSG+	   C3	   0.2M	  Ammonium	  nitrate	  pH6.3	  20%	  PEG3350	   13.5	   17	   60	  
JCSG+	   C4	   0.1M	  HEPES	  pH7.0	  10%	  PEG6000	   8	   17	   20	  
JCSG+	   C11	   2M	  AmSO4	  0.1M	  Sodium	  acetate	  pH4.6	   13.5	   17	   3	  
MPD	   E2	   0.1M	  Sodium	  acetate	  pH5.0	  10%	  MPD	   24.5	   17	   10	  
PEG	   A8	   0.1M	  MES	  pH6.5	  40%	  PEG300	  	   24.5	   17	   15	  
PEG	   B8	   0.1M	  Tris.HCl	  pH8.5	  30%	  PEG300	   24.5	   17	   15	  
PEG	   F2	   0.2M	  Potassium	  thiocyanate	  20%	  PEG3350	   24.5	   17	   15	  
PEG	   G5	   0.2M	  Potassium	  acetate	  20%	  PEG3350	   24.5	   17	   15	  	  
	  
	  	  	  
Table 5.1: The table shows the potential crystallisation conditions found after 
investigation of initial screening attempts. The images below show initial hits, from 
left to right, of JCSG+ C3, MPD E2 and JCSG+ C11. 
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buffers	  by	  ±0.5	  pH	  (as	  well	  as	  the	  original	  pH)	  and	  variations	  of	  additives	  by	  ±0.1	  M	  (as	  well	  as	  the	  original	  concentrations).	  Hanging-­‐drops	  were	  created	  as	  1	  µl	  protein:1	  µl	  reservoir	  solution,	  using	  20	  mg/ml	  BPSL1204-­‐MA.	  Of	  the	  initial	  hits	  described	  in	  5.2.4	  only	  JCSG+	  C3,	  C4,	  C11	  and	  MPD	  E2	  were	  reproducible	  from	  sitting-­‐drop	  to	  the	  first	  stage	  of	  hanging-­‐drop	  optimisation	  over	  a	  17°C	  incubation	  period	  of	  less	  than	  4	  weeks.	  Each	  formed	  thin,	  ball-­‐like	  needle	  clusters	  that	  seemed	  a	  little	  thicker	  than	  those	  discovered	  in	  the	  initial	  robot-­‐screens.	  Attempts	  to	  optimise	  PEG	  A8,	  B8,	  F2	  and	  G5	  were	  taken	  no	  further	  after	  the	  lack	  of	  success	  in	  this	  first	  stage	  of	  optimisation.	  	  	  5.3.2	  Focussing	  onto	  Optimal	  Growth	  Conditions	  	  After	  reproduction	  and	  slight	  improvement	  of	  the	  thin	  rods	  in	  the	  initial	  robot-­‐screens,	  the	  condition	  from	  each	  that	  gave	  the	  thickest	  looking	  clusters,	  or	  sometimes	  thin	  individual	  rods,	  were	  further	  optimised	  by	  ±3%	  precipitant	  (in	  0.5%	  steps),	  ±0.25	  pH	  (as	  well	  as	  the	  original	  optimised	  hit	  pH)	  and	  the	  same	  concentration	  of	  additive	  as	  in	  the	  original	  optimised	  hit.	  Fresh	  protein	  was	  purified	  for	  each	  round	  of	  optimisations.	  Each	  hanging-­‐drop	  condition	  of	  the	  second	  round	  of	  optimisations	  was	  done	  in	  triplicate	  in	  order	  to	  both	  increase	  the	  number	  of	  crystals	  produced	  should	  they	  form	  useful	  crystals,	  and	  also	  to	  screen	  for	  success	  even	  if	  one	  drop	  failed	  to	  equilibrate	  or	  nucleate	  properly	  for	  an	  unexpected	  reason.	  These	  were	  then	  incubated	  at	  17°C	  and	  checked	  twice	  weekly.	  	  	  Of	  the	  4	  screens	  taken	  forward	  to	  the	  second-­‐round	  of	  screening,	  only	  JCSG+	  C4	  and	  MPD	  E2	  showed	  any	  marked	  improvement	  in	  forming	  clusters	  of	  thicker	  needles	  and	  rods	  over	  a	  period	  of	  3	  weeks.	  These	  were	  then	  optimised	  further	  by	  ±2%	  of	  the	  best	  precipitant	  %	  (in	  0.25%	  steps)	  and	  ±0.25	  pH	  (as	  well	  as	  the	  current	  best	  pH).	  Each	  condition	  was	  repeated	  in	  triplicate,	  and	  for	  each	  member	  of	  a	  triplicate	  4	  drops	  were	  set	  up	  of	  µl	  protein:	  µl	  reservoir	  ratios	  of	  1:1,	  1:2,	  2:1	  and	  2:2	  to	  investigate	  the	  effects	  of	  these	  ratios	  on	  nucleation	  speed,	  crystal	  quality	  and	  the	  number	  of	  crystals	  produced	  per	  drop.	  These	  were	  then	  incubated	  at	  17°C	  and	  checked	  twice	  weekly.	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5.3.3	  Production	  of	  High	  Quality	  BPSL1204-­‐MA	  Crystals	  	  Investigation	  after	  2	  weeks	  of	  the	  third	  round	  of	  optimisations	  showed	  no	  improvement	  on	  the	  relatively	  low	  quality	  needle/rod-­‐cluster	  formed	  by	  optimisations	  of	  JCSG+	  C4,	  so	  this	  condition	  was	  pursued	  no	  further.	  However,	  MPD	  E2	  optimisations	  had	  generated	  large	  rod-­‐clusters	  with	  individual	  rods	  reaching	  approximately	  30-­‐40	  µm	  in	  width	  and	  300-­‐400	  µm	  in	  length.	  The	  clusters	  were	  all	  tightly	  packed	  with	  crystals	  growing	  in	  all	  directions,	  but	  each	  seemed	  to	  grow	  as	  a	  single	  rod	  that	  shared	  a	  nucleation	  point	  with	  the	  others	  (Figure	  5.1a).	  The	  best	  rod-­‐clusters	  were	  grown	  in	  1:1	  µl	  drops	  of	  9%	  MPD	  and	  0.1	  M	  sodium	  acetate	  pH	  5.0	  using	  a	  1	  ml	  reservoir,	  although	  the	  production	  of	  crystals	  with	  reasonable	  visual	  quality	  occurred	  in	  8.5-­‐10.5%	  MPD	  with	  0.1	  M	  sodium	  acetate	  of	  pH	  5.25-­‐5.75	  (Figure	  5.1b).	  Increasing	  the	  drop	  size	  ratio	  to	  2:2	  seemed	  to	  proportionately	  increase	  the	  number	  of	  nucleation	  points	  leading	  to	  more	  rod-­‐clusters	  like	  those	  in	  1:1,	  which	  in	  practical	  terms	  just	  led	  to	  ‘busier’	  drops,	  making	  the	  process	  of	  obtaining	  an	  individual	  rod	  more	  difficult.	  These	  crystals	  (1:1,	  9%	  MPD,	  0.1	  M	  sodium	  acetate	  pH	  5.0	  with	  17°C	  incubation	  for	  2	  weeks)	  were	  considered	  the	  best	  possible	  for	  this	  condition,	  and	  so	  samples	  were	  taken	  for	  X-­‐ray	  diffraction	  studies.	  	  
5.4	  In-­house	  Diffraction	  Studies	  	  5.4.1	  Establishing	  Cryo-­‐buffers	  	  In	  order	  to	  screen	  for	  an	  appropriate	  cryo-­‐protectant	  buffer	  that	  varied	  the	  mother-­‐liquor	  of	  the	  crystal	  under	  investigation	  the	  least,	  the	  9%	  MPD/0.1	  M	  sodium	  acetate	  pH	  5.0	  condition	  was	  supplemented	  with	  0-­‐25%	  glycerol	  or	  ethylene	  glycol	  in	  5%	  increases,	  to	  generate	  12	  cryo-­‐buffers	  for	  testing.	  As	  MPD	  itself	  could	  act	  as	  a	  cryo-­‐protectant,	  it	  was	  hoped	  that	  relatively	  little	  would	  need	  to	  be	  added	  to	  prevent	  the	  freezing	  of	  water	  within	  the	  condition	  selected.	  A	  300	  µm	  loop	  was	  filled	  with	  each	  cryo-­‐buffer	  in	  turn,	  mounted	  onto	  the	  goniometer	  so	  that	  the	  loop	  was	  in	  the	  100	  Kelvin	  nitrogen-­‐stream	  and	  in	  the	  path	  of	  X-­‐ray	  radiation,	  and	  then	  was	  exposed	  to	  X-­‐rays	  for	  2	  minutes.	  If	  the	  resulting	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1	  mm	  
500	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Figure 5.1a: Condensed rod-cluster grown in 1:1 6% MPD 
and 0.1 M sodium acetate pH 5.5 
Figure 5.1b: Cluster of thick rods grown in 1:1 9% MPD 
and 0.1 M sodium acetate pH 5.0. A single rod was taken 
from this cluster for native data collection 
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detector-­‐image	  showed	  ice-­‐rings	  (commonly	  most	  prevalent	  at	  ~3.5	  Å	  resolution)	  the	  buffer	  was	  discarded	  and	  the	  next	  5%	  increase	  tested.	  Detector-­‐images	  of	  cryo-­‐buffers	  with	  0-­‐5%	  glycerol	  and	  0-­‐10%	  ethylene	  glycol	  presented	  ice-­‐rings,	  so	  therefore	  mother-­‐liquor	  supplemented	  with	  10%	  glycerol	  was	  used	  as	  a	  cryo-­‐buffer.	  	  	  5.4.2	  Mounting	  Individual	  1204-­‐MA	  Crystals	  	  Under	  a	  microscope,	  large	  rod-­‐clusters	  were	  shattered	  at	  their	  core	  using	  a	  sterile	  acupuncture	  needle.	  Then	  by	  combining	  physical	  but	  gentle	  separation	  of	  crystals	  using	  the	  needle	  and	  manipulating	  the	  surface	  tension	  of	  the	  drop	  to	  align	  suitable	  candidates,	  several	  conjoined,	  thick	  rods	  were	  looped	  from	  the	  mother-­‐drop	  and	  quickly	  but	  carefully	  transferred	  to	  a	  3	  µl	  drop	  of	  fresh	  cryo-­‐buffer	  in	  place	  on	  a	  siliconized,	  polished	  coverslip.	  Usually	  the	  act	  of	  transferring	  the	  crystals	  led	  to	  further	  separation	  for	  easier	  mounting	  of	  an	  individual	  rod.	  Often	  attempting	  to	  loop	  an	  individual	  crystal	  directly	  from	  the	  mother-­‐drop	  led	  to	  the	  generation	  of	  lots	  of	  crystal-­‐debris	  and	  the	  loss	  of	  other	  potentially	  useful	  crystals.	  Crystals	  were	  left	  to	  soak	  in	  the	  cryo-­‐buffer	  for	  no	  more	  than	  120	  seconds	  before	  being	  looped	  onto	  the	  X-­‐ray	  machine,	  ensuring	  that	  the	  loop	  chosen	  supported	  the	  crystals	  in	  potential	  ‘shatter-­‐zones’	  whilst	  providing	  a	  suitable	  volume	  of	  cryo-­‐protectant.	  Rods	  were	  aligned	  so	  that	  the	  length	  of	  the	  crystal	  was	  parallel	  to	  the	  direction	  of	  the	  neck	  of	  the	  mounted	  loop.	  This	  way	  a	  long	  crystal	  could	  be	  rotated	  and	  shot	  along	  its	  length	  using	  the	  finer	  focus	  beams	  available	  at	  synchrotrons	  (Axford	  et	  al,	  2012).	  	  5.4.3	  Detection	  of	  Diffraction	  	  Crystals	  were	  only	  tested	  in-­‐house,	  with	  full	  data	  collection	  left	  for	  a	  synchrotron	  light	  source.	  Two	  test-­‐images	  of	  1°	  oscillation	  through	  φ,	  90°	  apart,	  were	  collected	  using	  an	  exposure	  of	  5	  minutes	  at	  8.014	  KeV/1.546	  Å	  CuKα,	  with	  the	  detector	  set	  to	  200mm	  distance.	  The	  best	  diffraction	  achieved	  in	  tests,	  later	  to	  become	  the	  high-­‐resolution	  native	  dataset,	  was	  to	  a	  maximum	  resolution	  of	  2.1	  Å	  in-­‐house.	  When	  crystals	  that	  when	  tested	  led	  to	  initial	  calculation	  of	  symmetry	  space-­‐group	  and	  cell-­‐dimensions	  were	  detected,	  they	  were	  saved	  in	  a	  vial	  of	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liquid	  nitrogen	  and	  stored	  in	  a	  nitrogen-­‐filled	  dewar	  for	  transportation	  to	  a	  synchrotron.	  	  	  5.4.4	  Space-­‐group,	  Cell-­‐refinement	  and	  Collection	  Strategy	  Calculation.	  	  In-­‐house	  test	  images	  were	  loaded	  into	  iMOSFLM	  (Battye	  et	  al,	  2011)	  and	  subjected	  to	  auto-­‐indexing	  of	  reflections	  once	  parameters	  such	  as	  beam-­‐centre	  and	  resolution	  limit	  had	  been	  selected.	  iMOSFLM	  then	  calculated	  the	  potential	  space-­‐groups	  from	  the	  two	  images	  supplied,	  and	  the	  most	  likely	  selected	  was	  the	  order	  of	  symmetry	  with	  the	  least	  number	  of	  penalties	  after	  discounting	  the	  zero-­‐penalty	  P1.	  In	  the	  case	  of	  BPSL1204-­‐MA,	  the	  most	  likely	  space-­‐group	  was	  C2	  (C121).	  These	  images	  were	  then	  processed	  further	  by	  iMOSFLM	  to	  refine	  cell-­‐parameters	  using	  the	  chosen	  space-­‐group,	  with	  BPSL1204-­‐MA	  in	  C2	  given	  dimensions	  of	  a=99.96	  Å,	  b=32.91	  Å,	  c=48.35	  Å,	  α	  =90.0°	  β=116.14°	  γ	  =	  90.0°	  (see	  Table	  5.2	  in	  Section	  5.10.4).	  Combined,	  this	  information	  allowed	  the	  generation	  of	  a	  data-­‐collection	  strategy	  using	  iMOSFLM,	  which	  suggested	  a	  full	  dataset	  minimising	  overlaps	  would	  require	  the	  collection	  of	  180°	  of	  data	  consisting	  of	  180	  images,	  each	  image	  having	  an	  oscillation	  of	  1°	  about	  φ.	  	  	  
5.5	  Collection	  and	  Analysis	  of	  Native	  Diffraction	  Data.	  
	  5.5.1	  Collection	  of	  Diffraction	  Images	  Using	  a	  Synchrotron	  Light	  Source	  	  All	  native	  data	  were	  collected	  at	  the	  Diamond	  Synchrotron	  Light	  Source	  (DSLS)	  in	  Oxford,	  UK.	  Using	  the	  beamline	  I02	  at	  the	  standard	  energy	  of	  12.658	  KeV	  (0.979	  Å),	  data	  were	  collected	  for	  each	  crystal	  under	  experiment	  using	  the	  strategy	  predicted	  by	  iMOSFLM,	  following	  the	  same	  process	  as	  in	  Section	  5.4.4.	  200°	  were	  collected	  for	  each	  data	  set	  to	  ensure	  completeness,	  using	  an	  exposure	  of	  0.5	  seconds	  per	  image	  at	  20-­‐25%	  beam-­‐transmission.	  The	  detector	  plate	  was	  set	  to	  allow	  for	  data-­‐collection	  to	  resolutions	  of	  1.2	  Å.	  Test-­‐images	  taken	  showed	  that	  from	  the	  best	  crystals	  diffraction	  occurred	  to	  a	  resolution	  limit	  of	  1.295	  Å	  (Figure	  5.2),	  compared	  to	  the	  2.1	  Å	  achievable	  in-­‐house.	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Figure 5.2: A diffraction image of native BPSL1204 crystals to 1.295 Å, collected 
on the I02 beamline at DSLS. The detector plate was set to a 1.2 Å resolution limit 
at the edges of the image above 
	   121	  
5.5.2	  Indexing,	  Integration	  and	  Reduction	  of	  Native	  Data	  	  Native	  data	  images	  had	  their	  reflections	  indexed	  by	  iMOSLFM	  using	  the	  default	  settings	  for	  I/σ(I)	  spot	  discrimination	  threshold,	  spot	  size	  and	  separation	  thresholds	  and	  the	  box-­‐size	  of	  the	  local	  background.	  The	  beam-­‐centre	  was	  set	  and	  the	  region	  of	  no	  diffraction	  caused	  by	  the	  beam-­‐stop	  was	  masked	  and	  applied	  to	  all	  images	  collected.	  The	  resolution	  limit	  of	  spots	  to	  be	  indexed	  was	  also	  set	  to	  cut	  off	  at	  1.2	  Å.	  Reflections	  not	  adhering	  to	  these	  parameters	  were	  rejected	  as	  part	  of	  data	  reduction.	  Indexed	  images,	  with	  mosaicity	  of	  0.58°	  were	  then	  integrated	  into	  an	  .mtz	  file	  once	  cell-­‐refinement	  had	  calculated	  a	  sensible	  unit-­‐cell.	  The	  output	  nat.mtz	  file	  was	  then	  taken	  forward	  to	  the	  CCP4	  Suite	  (Winn	  et	  al,	  2011)	  for	  further	  data	  processing.	  A	  table	  of	  cell	  parameters	  (Table	  5.2)	  is	  included	  later	  on	  in	  this	  chapter,	  for	  comparison	  with	  seleno-­‐met	  derivative	  crystals	  (Section	  5.8.2)	  	  5.5.3	  Scaling	  of	  Data,	  Resolution	  Limits	  and	  Data	  Quality	  	  The	  .mtz	  file	  containing	  the	  intensities	  of	  integrated	  reflections	  from	  the	  entire	  native	  dataset	  were	  then	  scaled	  and	  merged	  together	  using	  the	  Scala	  program	  (Evans,	  2006)	  in	  the	  CCP4i	  GUI	  (Potterton	  et	  al,	  2003).	  Upon	  investigation	  of	  the	  output	  log	  file	  (Figure	  5.3),	  it	  was	  decided	  that	  the	  resolution	  limit	  of	  data	  that	  gave	  the	  best	  signal-­‐to-­‐noise	  (I/σ(I)	  =	  2.2,	  accepted	  as	  >2.0),	  completeness	  (99.6%)	  and	  acceptable	  high	  resolution	  Rmerge	  (0.34,	  accepted	  as	  <0.35)	  was	  1.3	  Å.	  With	  the	  resolution	  limits	  now	  set,	  the	  data	  were	  scaled	  back	  to	  only	  merge	  intensities	  <1.3	  Å,	  with	  a	  re-­‐run	  of	  the	  Scala	  process	  formatting	  the	  output	  file	  into	  .sca	  (Scalepack)	  format,	  for	  further	  processing	  in	  HKL2MAP	  (Pape	  and	  Schneider,	  2004)	  running	  ShelXC/D/E	  (Sheldrick,	  2010)	  when	  datasets	  for	  phasing	  became	  available.	  	  With	  the	  known	  cell-­‐dimensions	  and	  known	  molecular	  weight	  of	  BPSL1204-­‐MA	  as	  17200	  Da,	  the	  Matthews	  Coefficient	  program	  Matthews_coef	  was	  also	  run	  in	  CCP4i	  to	  predict	  the	  number	  of	  molecules	  in	  the	  unit-­‐cell	  using	  the	  input	  scaled	  .mtz	  file	  (Kantardjieff	  &	  Rupp,	  2003).	  It	  was	  predicted	  that	  in	  the	  calculated	  cell-­‐	  
	   122	  
Figure	  5.3:	  SCALA	  output	  file	  after	  scaling	  and	  data	  reduction.	  Native	  data	  was	  scaled	  and	  cut	  to	  1.3	  Å	  resolution	  gave	  a	  I/σI	  of	  2.2	  and	  an	  Rmerge	  of	  0.34	  
	   123	  
volume	  of	  142910	  Å3	  one	  molecule	  of	  BPSL1204-­‐MA	  existed	  with	  a	  solvent	  content	  of	  40.8%.	  
	  
5.6	  Heavy-­atom	  Soaks	  and	  Initial	  Phasing	  Attempts	  	  5.6.1	  Heavy-­‐atom	  soaks	  	  While	  attempts	  were	  being	  made	  to	  prepare	  and	  crystallise	  selenomethionine-­‐incorporated	  protein,	  which	  proved	  difficult	  (see	  Section	  5.7),	  it	  was	  decided	  to	  attempt	  some	  heavy	  atom	  soaks.	  With	  a	  reliable	  source	  of	  high	  quality,	  diffracting	  crystals	  attempts	  to	  solve	  the	  phase	  problem	  began.	  Phasing	  required	  the	  anomalous	  signal	  created	  by	  the	  presence	  of	  regularly	  distributed,	  electron-­‐dense	  atoms	  incorporated	  into	  the	  crystal	  lattice	  sub-­‐structure	  (Schneider	  &	  Sheldrick,	  2002).	  A	  variety	  of	  water-­‐soluble	  heavy-­‐atom	  compounds	  were	  soaked	  into	  preformed	  native	  crystals	  in	  the	  hope	  that	  potential	  sites	  of	  occupation	  existed	  within	  the	  protein	  or	  within	  the	  protein-­‐lattice.	  KAu(CN)2,	  KAuCl4,	  K2PtCl4,	  K2PtBr4,	  K2Pt(CN)4,	  HgCl2,	  K3UO2F5,	  UO2(CH3CO2)2,	  Pb(NO3)2	  and	  Pb(CH3CO2)2	  were	  all	  soaked	  into	  preformed	  BPSL1204-­‐MA	  crystals	  in	  9%	  MPD	  and	  0.1M	  NaCH3CO2	  at	  pH5.0	  to	  a	  concentration	  of	  ~5	  mM.	  From	  these,	  attempts	  were	  made	  to	  collect	  anomalous	  data	  at	  DSLS	  over	  a	  period	  of	  several	  months.	  	  	  Due	  to	  the	  abundant	  supply	  of	  native	  crystals	  and	  the	  delicate	  nature	  of	  an	  individual	  rod,	  soaks	  were	  carried	  out	  by	  addition	  to	  the	  mother-­‐drop	  to	  reduce	  the	  amount	  of	  physical	  disturbance	  that	  could	  destroy	  a	  target-­‐crystal.	  10	  mM	  heavy-­‐atom	  compound	  was	  incorporated	  into	  a	  fresh	  solution	  of	  reservoir	  solution,	  and	  a	  1	  µl	  drop	  was	  placed	  on	  a	  cover-­‐slip	  about	  1	  mm	  away	  from	  an	  approximately	  1	  µl	  mother-­‐drop	  containing	  preformed	  crystals.	  The	  two	  drops	  were	  then	  gently	  bridged	  using	  an	  acupuncture	  needle	  to	  allow	  the	  gentle	  diffusion	  of	  the	  heavy-­‐atom	  compound	  into	  the	  crystal	  to	  a	  final	  concentration	  of	  5	  mM.	  The	  heavy-­‐atom-­‐containing	  drop	  was	  placed	  on	  the	  opposite	  side	  of	  the	  mother–drop	  from	  the	  best	  crystals	  whenever	  possible,	  to	  reduce	  the	  ‘shock’	  of	  breaking	  surface	  tension	  when	  the	  drops	  were	  gently	  bridged	  together.	  The	  cover-­‐slip	  was	  then	  resealed	  over	  its	  reservoir	  and	  left	  for	  30-­‐40	  minutes	  to	  soak	  in.	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Crystals	  were	  then	  looped	  from	  the	  mother-­‐drop	  into	  a	  pre-­‐determined	  cryo-­‐buffer	  containing	  5	  mM	  heavy-­‐atom	  for	  two	  minutes,	  to	  cryo-­‐protect	  and	  prevent	  back	  soaking-­‐out	  of	  non-­‐covalent	  incorporated	  compounds,	  before	  mounting	  on	  a	  goniometer	  head	  held	  in	  a	  cryo-­‐stream,	  for	  initial	  diffraction	  tests	  and	  saving	  into	  liquid	  nitrogen	  for	  transportation	  to	  a	  synchrotron.	  	  	  5.6.2	  Overview	  of	  Collection	  of	  MAD	  data	  and	  Anomalous	  Signal	  Detection	  	  The	  detailed	  collection	  and	  processing	  of	  MAD	  data	  will	  be	  discussed	  for	  the	  collection	  of	  data	  at	  the	  selenium	  edge	  in	  Section	  5.8.	  In	  general,	  a	  200°	  dataset	  with	  an	  oscillation	  angle	  of	  1°	  was	  collected	  at	  the	  peak	  and	  inflection	  energy	  of	  the	  L-­‐3	  edge	  of	  each	  potential	  heavy-­‐atom	  in	  the	  derivative,	  with	  a	  high-­‐energy	  remote	  collected	  at	  +150	  eV	  of	  the	  peak	  energy.	  The	  edges	  of	  each	  heavy-­‐atom	  were	  determined	  using	  a	  Vortex	  fluorescence	  detector	  at	  DSLS.	  Datasets	  were	  then	  processed	  through	  iMOSFLM	  and	  Scala	  programs	  to	  be	  assessed	  by	  the	  ShelXC/D/E	  programs	  for	  the	  presence	  of	  anomalous	  signal.	  	  	  Of	  all	  the	  10	  heavy-­‐atom	  soaks	  performed,	  only	  Pb(NO3)2	  gave	  a	  very	  weak	  anomalous	  signal	  at	  its	  peak	  energy,	  assessed	  by	  a	  ShelXD	  d´´	  of	  0.94	  at	  a	  resolution	  of	  4.5	  Å.	  However	  when	  the	  resulting	  calculated,	  ‘phased’	  density	  .mtz	  files	  of	  both	  possible	  enantiomorphs	  were	  loaded	  into	  Coot	  (Emsley	  &	  Cowtan,	  2004),	  there	  was	  no	  properly	  phased	  density	  as	  judged	  by	  the	  lack	  of	  obvious	  solvent-­‐boundaries	  and	  lack	  of	  distinguishable	  secondary-­‐structural	  features	  such	  as	  α–helices.	  It	  was	  decided	  to	  solve	  the	  phase	  problem	  by	  the	  incorporation	  of	  selenomethione	  directly	  into	  the	  polypeptide	  of	  BPSL1204-­‐MA.	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5.7	  Crystallisation	  of	  a	  Selenomethionine	  Derivative	  	  5.7.1	  Preparation	  of	  Protein	  Samples	  	  Incorporation	  of	  seleno-­‐met	  into	  BPSL1204-­‐MA	  was	  carried	  out	  using	  the	  media	  and	  growth	  protocol	  described	  in	  sections	  3.5.2	  and	  3.5.3	  respectively.	  Seleno-­‐met	  BPSL1204-­‐MA	  was	  purified	  using	  the	  same	  methodology	  as	  that	  used	  for	  native	  BPSL1204-­‐MA,	  as	  described	  in	  4.5.1.	  After	  the	  Viva-­‐spin	  concentration	  step	  as	  described	  in	  section	  5.1.2,	  it	  was	  possible	  to	  achieve	  30	  mg/ml	  in	  100	  µl	  of	  10	  mM	  Tris	  pH	  8.0	  as	  determined	  by	  Bradford	  Assay.	  100%	  incorporation	  of	  seleno-­‐met	  was	  confirmed	  by	  mass	  spectrometry,	  as	  previously	  shown	  in	  Figure	  4.11.	  This	  revealed	  that	  an	  extra	  N-­‐terminal	  seleno-­‐met	  was	  present	  in	  the	  protein;	  presumably	  due	  to	  the	  presence	  of	  seleno-­‐methionine	  rather	  than	  methionine	  preventing	  the	  action	  of	  an	  E.	  coli	  aminopeptidase	  that	  post-­‐translationally	  removed	  the	  native	  sulphur-­‐methionine	  (Ben-­‐Bassat	  et	  al,	  1987).	  	  	  5.7.2	  Attempts	  to	  Repeat	  Native	  Conditions	  	  A	  hanging-­‐drop	  screen	  of	  8-­‐13%	  MPD	  and	  0.1	  M	  sodium	  acetate	  pH	  5.0	  was	  set	  up	  using	  1:1	  µl	  drops	  over	  a	  1	  ml	  reservoir	  using	  30,	  20	  and	  10	  mg/ml	  seleno-­‐met	  BPSL1204-­‐MA	  protein	  samples.	  After	  2	  weeks	  of	  incubation	  at	  17°C	  with	  bi-­‐weekly	  investigation	  it	  was	  seen	  that	  no	  nucleation	  had	  occurred,	  the	  drops	  remaining	  clear.	  This	  created	  a	  problem	  because	  seleno-­‐methionine	  BPSL1204-­‐MA	  crystals	  were	  required	  for	  structure	  solution,	  and	  preferably	  they	  would	  be	  isomorphous	  to	  the	  native	  crystals	  that	  had	  already	  been	  processed	  to	  high-­‐resolution.	  It	  was	  proposed	  that	  this	  inability	  to	  grow	  in	  the	  native	  conditions	  might	  be	  due	  to	  the	  extra	  N-­‐terminal	  methionine	  present	  in	  the	  seleno-­‐met	  derivative.	  	  5.7.3	  Original	  Streak-­‐Seeding	  Experiments	  	  In	  an	  attempt	  to	  avoid	  the	  potentially	  lengthy	  process	  of	  re-­‐screening	  for	  crystallisation	  conditions,	  seeding	  experiments	  were	  attempted	  using	  native	  crystals	  in	  the	  native	  growth	  conditions.	  A	  24-­‐well	  hanging-­‐drop	  plate	  was	  set	  up	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with	  8	  multiplicates	  of	  9,	  10	  and	  11%	  MPD	  in	  0.1	  M	  sodium	  acetate	  pH	  5.0,	  with	  each	  2	  µl	  drop	  consisting	  of	  1:1	  20	  mg/ml	  seleno-­‐met	  protein:reservoir	  over	  a	  1	  ml	  reservoir.	  An	  autoclaved	  cats-­‐whisker	  was	  stroked	  across	  the	  surface	  of	  a	  preformed	  native	  crystal	  from	  the	  relevant	  native	  condition,	  and	  then	  streaked	  through	  the	  each	  of	  the	  8	  corresponding	  drops	  containing	  selenomethionine-­‐incorporated	  protein	  in	  succession	  without	  returning	  to	  the	  original	  ‘donor’	  drop	  so	  that	  each	  would	  receive	  less	  nucleation	  than	  the	  last.	  Each	  dilution	  was	  then	  sealed	  and	  incubated	  at	  17°C.	  Due	  to	  the	  supplement	  of	  preformed	  nucleation	  points	  transferred	  by	  the	  serrations	  of	  the	  cats-­‐whisker	  (Guerin	  et	  al,	  2003),	  the	  screen	  was	  checked	  daily	  due	  to	  the	  expectation	  of	  faster	  crystallisation.	  After	  2	  days	  numerous,	  condensed	  groups	  of	  rods,	  like	  hay-­‐bales,	  appeared	  in	  all	  drops,	  but	  all	  were	  useless	  for	  data	  collection	  purposes	  in	  terms	  of	  size	  and	  number,	  as	  shown	  in	  Figure	  5.4.	  It	  was	  considered	  that	  too	  high	  a	  concentration	  of	  nucleation	  points	  was	  being	  used,	  and	  that	  dilution	  by	  streak-­‐seeding	  was	  not	  robust	  enough	  a	  method.	  	  5.7.4	  Serial	  Dilution	  of	  Seeding	  	  A	  process	  of	  serial	  dilution	  of	  nucleation	  points	  achieved	  crystals	  of	  seleno-­‐met	  BPSL1204-­‐MA	  in	  the	  same	  form	  as	  the	  native	  protein.	  An	  entire	  native-­‐drop	  of	  9%	  MPD/0.1	  M	  sodium	  acetate	  pH	  5.0	  mother-­‐liqour	  containing	  several	  rod	  clusters	  of	  native	  BPSL1204-­‐MA	  was	  repeatedly	  pipetted	  up	  and	  down	  to	  shatter	  the	  crystals	  into	  fragments.	  Then	  the	  entire	  drop	  (~1	  µl	  after	  water-­‐vapour	  equilibration)	  was	  transferred	  to	  a	  sterile	  Eppendorf	  containing	  999	  µl	  of	  fresh	  mother-­‐liquor	  and	  was	  vortexed	  to	  further	  shatter	  the	  transferred	  crystal	  fragments.	  	  	  From	  this	  x1000-­‐diluted	  solution	  of	  native	  BPSL1204-­‐MA	  fragments	  (nucleation	  ‘seeds’),	  1	  µl	  was	  transferred	  to	  999	  µl	  of	  fresh	  mother-­‐liquor	  and	  vortexed	  again.	  This	  process	  was	  repeated	  eight	  times	  to	  leave	  a	  range	  of	  nucleation-­‐point	  dilutions	  from	  1x10-­‐3	  to	  1x10-­‐24	  in	  decreases	  of	  1x10-­‐3.	  A	  screen	  was	  then	  set	  up	  using	  fresh,	  1	  ml	  9%	  MPD/0.1	  M	  sodium	  acetate	  pH	  5.0	  mother-­‐liquor	  reservoirs	  but	  instead	  of	  mixing	  1:1	  µl	  protein:reservoir,	  1	  µl	  20	  mg/ml	  seleno-­‐met	  protein	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Figure 5.4: Streak-seeded seleno-met crystals. Top: numerous small crystals 
generated even after streaking through 24 2 µl drops. Bottom: Closer inspection 
of crystals revealed them to be clusters of very small rods. 
20	  µm	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was	  mixed	  with	  1	  µl	  of	  a	  dilution	  of	  native	  BPSL1204-­‐MA	  fragments	  in	  mother-­‐liquor.	  Each	  drop	  was	  performed	  in	  triplicate,	  sealed	  and	  left	  to	  incubate	  at	  17°C.	  After	  2	  days,	  crystals	  of	  the	  same	  morphology	  as	  the	  native	  ones	  grew	  in	  the	  dilution	  range	  of	  1x10-­‐9-­‐1x10-­‐15	  (Figure	  5.5).	  1x10-­‐3	  and	  1x10-­‐6	  gave	  similar	  results	  to	  streak-­‐seeding	  experiments;	  whilst	  dilution	  of	  native	  fragments	  beyond	  1x10-­‐18	  must	  have	  been	  diluted	  too	  far	  as	  to	  practically	  say	  there	  were	  no	  nucleation	  points	  transferred.	  	  5.7.5	  Confirmation	  of	  Crystallised	  Seleno-­‐met	  Protein	  	  Before	  collection	  of	  MAD	  data	  using	  a	  synchrotron	  beam-­‐line,	  confirmation	  hat	  what	  had	  crystallised	  was	  seleno-­‐met	  BPSL1204-­‐MA	  was	  carried	  out	  to	  prevent	  the	  wasting	  of	  synchrotron	  beamtime.	  	  A	  seleno-­‐met	  crystal	  similar	  in	  size	  and	  shape	  to	  that	  from	  which	  the	  native	  dataset	  was	  collected	  was	  carefully	  looped	  from	  its	  mother-­‐drop	  and	  transferred	  delicately	  to	  a	  5	  µl	  drop	  of	  fresh	  mother-­‐liquor	  to	  ‘wash’	  it.	  This	  was	  repeated	  3	  times,	  using	  a	  clean	  loop	  each	  time,	  to	  ensure	  that	  the	  final	  crystal	  was	  separated	  from	  any	  non-­‐crystallised	  material	  or	  native	  fragments	  that	  might	  have	  been	  left	  in	  the	  original	  drop.	  The	  final,	  ‘clean’	  crystal	  was	  then	  looped	  and	  dissolved	  into	  5	  µl	  of	  sterile,	  autoclaved,	  deionised	  water	  and	  was	  sent	  for	  analysis	  by	  mass	  spectrometry.	  The	  resulting	  spectra	  was	  identical	  to	  that	  of	  pure	  seleno-­‐met	  BPSL1204-­‐MA	  in	  section	  4.5.2,	  suggesting	  that	  with	  the	  exception	  of	  the	  native	  nucleation-­‐point	  (which	  likely	  formed	  the	  core	  of	  the	  rod-­‐clusters)	  seleno-­‐met	  BPSL1204-­‐MA	  crystals	  of	  100%	  selenium-­‐incorporation	  had	  been	  successfully	  grown	  in	  the	  same	  crystal	  form	  as	  native,	  in	  spite	  of	  the	  extra	  N-­‐terminal	  seleno-­‐met.	  	  
5.8	  Collection	  of	  MAD	  Data	  Using	  Synchrotron	  Light	  	  5.8.1	  Detection	  of	  Selenium	  Fluorescence	  and	  Determination	  of	  X-­‐ray	  Wavelengths	  for	  MAD	  Data	  Collection	  	  At	  DSLS,	  the	  robot	  within	  the	  beam-­‐line	  experimental	  hutch	  carried	  out	  automated-­‐mounting	  of	  crystals	  from	  the	  transport	  ‘puck’	  in	  a	  nitrogen	  bath	  onto	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Figure 5.5: Crystals of seleno-met BPSL1204-MA similar to those 
of native protein. Top: 1 x 10-9 dilution-seeding. Bottom: 1 x 10-15 
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the	  goniometer	  and	  cryo-­‐stream.	  A	  Vortex	  fluorescence	  detector	  was	  used	  for	  the	  determination	  of	  the	  emitting	  energy-­‐edges,	  thus	  confirming	  again	  the	  presence	  of	  selenium	  within	  the	  lattice	  sub-­‐structure	  and	  allowing	  for	  the	  determination	  of	  experimental	  wavelength	  energies	  around	  the	  L-­‐3	  edge	  (Figure	  5.6).	  	  The	  peak	  was	  determined	  to	  be	  of	  12646.43	  eV,	  therefore	  Peak	  data	  were	  collected	  just	  up	  of	  this	  value	  at	  12648.0	  eV	  to	  ensure	  peak	  anomalous	  signal	  was	  not	  missed.	  Inflection	  data	  were	  collected	  at	  12644.0	  eV,	  and	  High-­‐Energy	  Remote	  data	  were	  collected	  well	  up	  of	  the	  Peak	  at	  12796.4	  eV	  in	  accordance	  with	  the	  theory	  presented	  in	  Section	  2.6.2.	  	  5.8.2	  Data	  Collection	  of	  Peak,	  Inflection	  and	  High-­‐Energy	  Remote	  Data	  	  To	  check	  the	  isomorphous	  nature	  of	  the	  MAD	  data	  collected	  in	  comparison	  to	  the	  high-­‐resolution	  native	  data	  already	  collected	  and	  processed,	  two	  test	  images	  of	  Δφ=	  1°	  and	  90°	  apart	  on	  φ	  were	  taken	  to	  estimate	  the	  resolution	  limit	  of	  the	  crystals	  and	  to	  calculate	  cell-­‐parameters.	  With	  a=99.71	  Å,	  b=32.89	  Å,	  c=48.34	  Å,	  α=90°,	  β=115.89°	  and	  γ=90°	  it	  was	  seen	  that	  a	  very	  similar	  unit-­‐cell	  in	  C2	  was	  present	  as	  discovered	  in	  the	  native	  data	  presented	  in	  section	  5.4.4	  (Table	  5.2	  in	  Section	  5.10.4),	  leading	  to	  an	  assumption	  of	  isomorphism.	  Resolution	  using	  a	  transmission	  of	  20%	  and	  0.5	  second	  exposure	  reached	  approximately	  1.8	  Å	  in	  the	  test	  images.	  	  	  Due	  to	  the	  radiation-­‐damage	  that	  could	  potentially	  ensue	  from	  exposing	  the	  crystals	  to	  synchrotron	  radiation,	  combined	  with	  the	  need	  to	  collect	  three	  full	  datasets	  from	  the	  same	  crystal	  with	  the	  added	  radiation-­‐damage	  of	  anomalous,	  heavy-­‐atom	  scattering	  (Garman	  &	  Nave,	  2002)	  it	  was	  decided	  not	  to	  push	  transmission	  or	  exposure	  time	  further	  to	  increase	  resolution.	  Instead,	  upon	  the	  survival	  of	  the	  crystal	  post-­‐MAD	  data	  collection,	  a	  higher	  resolution	  Remote	  data	  set	  was	  collected,	  to	  complement	  the	  extension	  of	  resolution	  by	  phase-­‐extending	  MAD	  data	  with	  the	  1.3	  Å	  native	  dataset	  during	  processing	  data.	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Figure 5.6: Determination of the seleno-met BPSL1204-MA peak (f˝) and inflection 
(f´) points. The image shows the CHOOCH output from selenium fluorescence at the 
L-3 edge, detected by a Vortex detector at Diamond Synchrotron Light Source. 
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A	  200-­‐image	  dataset	  with	  an	  oscillation	  angle	  of	  Δφ=	  1°	  per	  image	  was	  collected	  using	  30%	  beam	  transmission	  at	  the	  chosen	  Peak	  energy	  first	  with	  the	  detector	  distance	  set	  to	  a	  1.5	  Å	  limit,	  followed	  by	  re-­‐attenuation	  of	  the	  beam	  to	  Inflection	  energy	  data	  collection.	  Then	  the	  beam	  was	  attenuated	  to	  the	  High-­‐Energy	  Remote	  energy	  for	  a	  dataset	  to	  be	  collected	  with	  the	  same	  experimental	  parameters	  as	  the	  Peak	  and	  Inflection,	  followed	  by	  a	  repeated	  dataset	  collected	  with	  a	  1.2	  Å	  resolution	  detector	  limit	  at	  60%	  transmission	  for	  0.5-­‐second	  exposure.	  This	  2nd	  high-­‐energy	  remote	  gave	  indexable	  diffraction	  with	  no	  visible	  radiation-­‐damage	  to	  1.4	  Å.	  	  	  
5.9	  Processing	  of	  MAD	  Data	  for	  Phasing	  	  5.9.1	  Indexing,	  Integrating	  and	  Scaling	  Measured	  Reflections	  	  Each	  dataset	  was	  processed	  to	  the	  point	  of	  obtaining	  a	  scaled	  and	  merged	  .sca	  file	  of	  intensities	  as	  described	  for	  the	  native	  data	  in	  Section	  5.5.2	  and	  5.5.3.	  Very	  little	  change	  was	  made	  to	  the	  original	  resolution	  limits,	  as	  estimated	  by	  eye	  and	  post-­‐integration,	  as	  all	  data	  gave	  acceptable	  I/(σI),	  %completeness	  and	  high-­‐resolution	  Rmerge	  (Table	  5.2	  in	  Section	  5.10.4)	  meaning	  there	  was	  now	  Peak	  and	  Inflection	  data	  cut	  to	  1.8	  Å,	  and	  High-­‐Energy	  Remote	  data	  to	  cut	  to	  1.4	  Å.	  These	  could	  be	  used	  for	  the	  detection	  of	  anomalous	  scattering	  signal	  and	  the	  calculation	  of	  the	  solution	  to	  the	  phase-­‐problem.	  The	  1.3	  Å	  native	  data	  were	  saved	  for	  phase-­‐extension	  later	  on	  as	  part	  of	  structural	  refinement.	  	  5.9.2	  Detection	  of	  Anomalous	  Signal	  and	  Phasing	  	  The	  scaled	  .sca	  files	  for	  each	  of	  the	  MAD	  datasets	  were	  loaded	  into	  ShelXC	  (Sheldrick,	  2008);	  part	  of	  the	  ShelxC/D/E	  suite	  of	  phasing	  programs	  ran	  through	  the	  HKL2MAP	  platform.	  ShelxC	  then	  performed	  the	  necessary	  preparations	  for	  phase	  calculations,	  such	  as	  creation	  of	  ΔF	  and	  Fa	  statistics.	  A	  .hkl	  file	  of	  ‘native’	  ΔFs	  and	  a	  _fa.hkl	  file	  of	  anomalous	  Fa’s	  were	  output.	  The	  d´´	  statistic	  that	  gives	  an	  indication	  of	  anomalous	  signal	  if	  >0.8	  gave	  signals	  of:	  Peak=1.3,	  Inflection=0.9	  and	  High-­‐Energy	  Remote=0.98	  for	  data	  to	  2.4	  Å	  resolution	  (Figure	  5.7a),	  thus	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Figure 5.7a: Output from ShelxC. Top: ShelxC statistics for peak data. Bottom: 
ShelxC plot of signal Vs resolution. Anomalous signal was calculated to be of 
significance in the peak MAD dataset to a resolution of 2.4 Å with a d´´ of 1.13 
Figure 5.7b: Output from ShelxD. Plot of calculated heavy-atom site occupancies 
Vs heavy atom peaks. It was decided that 3 heavy atom sites were significantly 
occupied, described by the peaks found prior to a significant drop in occupancy. 
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giving	  confidence	  to	  the	  successful	  next	  step	  of	  calculating	  phases	  for	  the	  modification	  of	  electron	  density.	  	  The	  _fa.hkl	  file	  was	  then	  input	  to	  ShelXD	  (Schneider	  &	  Sheldrick,	  2002)	  for	  the	  location	  of	  heavy	  atom	  sites	  for	  phasing	  using	  maximum	  resolution	  of	  2.4	  Å,	  limiting	  the	  search	  to	  500	  tries.	  Three	  potential	  sites	  were	  found	  (Figure	  5.7b),	  which	  combined	  with	  the	  Matthews	  estimation	  of	  one	  molecule	  in	  the	  unit	  cell	  with	  40.7%	  solvent	  (which	  matched	  the	  native	  Matthews	  in	  Section	  5.5.3)	  seemed	  acceptable	  if	  for	  3/5	  seleno-­‐methionines	  were	  scattering	  and	  the	  N-­‐terminal	  methionine	  and	  one	  internal	  methionine	  were	  in	  a	  state	  of	  disorder.	  The	  heavy-­‐atom	  sites	  were	  then	  output	  as	  a	  _fa.pdb.	  	  	  The	  .hkl	  and	  _fa.hkl	  files	  were	  then	  input	  to	  ShelXE	  (Sheldrick,	  2008)	  for	  phasing	  using	  the	  identified	  anomalous	  signal	  and	  then	  the	  refinement	  of	  electron	  density	  using	  the	  new	  phase	  information.	  The	  density	  was	  phased	  and	  refined	  for	  20	  cycles,	  using	  a	  ShelX-­‐calculated	  solvent	  content	  that	  matched	  that	  of	  the	  independently	  carried	  out	  Matthews	  analysis.	  Phasing	  was	  carried	  out	  for	  the	  substructures	  of	  both	  potential	  enantiomorphs	  of	  the	  heavy	  atom	  substructure.	  Both	  output	  .phs	  files	  were	  then	  assessed	  for	  the	  most	  likely	  enantiomorphic	  solution	  by	  identifying	  which	  file	  contained	  the	  largest	  pseudo-­‐free	  Correlation	  Coefficient	  (pseudo-­‐freeCC),	  with	  a	  value	  above	  70%	  usually	  indicating	  an	  interpretable	  map	  (Figure	  5.8).	  The	  pseudo-­‐freeCC	  is	  a	  figure	  of	  merit	  calculated	  by	  the	  removal	  of	  a	  subset	  of	  10%	  of	  random	  reflections,	  which	  are	  then	  independently	  density	  modified	  for	  one	  cycle	  and	  back-­‐Fourier	  transformed	  for	  comparison	  to	  every	  Nth	  cycle	  of	  density	  modification,	  as	  an	  evaluation	  of	  phase	  improvement	  (Pal	  et	  al,	  2009;	  Sheldrick,	  2010).	  Ultimately	  the	  output	  .pdb	  coordinate	  file	  was	  loaded	  into	  the	  Coot	  electron-­‐density	  modification	  program	  (Emsley	  &	  Cowtan,	  2004)	  along	  with	  each	  enantiomorphs	  .phs	  or	  _I.phs	  (original	  and	  inverted	  hand	  respectively,	  converted	  to	  .mtz	  files	  using	  Convert_to_MTZ	  in	  CCP4i)	  file	  to	  investigate	  whether	  solvent-­‐boundaries	  and	  secondary-­‐	  or	  tertiary-­‐structures	  were	  clearly	  visible	  in	  the	  calculated	  electron-­‐density.	  The	  inverted	  enantiomorph	  gave	  the	  best	  statistics	  and	  the	  best-­‐defined	  density	  into	  which	  model	  building	  could	  begin	  (Figure	  5.9).	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Figure 5.8: ShelXE heavy-atom site density calculations and pseudo-freeCCs 
of calculated electron density map enantiomorphs. Top: Original 
enantiomorph. Bottom: Inverted enantiomorph.  
 
Assessment of phased density modification statistics prior to the examination 
of calculated electron density maps suggested that the high pseudo-freeCC 
(>70%) and greater density for refined heavy atom sites that were calculated 
for the Inverted enantiomorph made it the most likely candidate for correctly 
phased density. 
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Figure 5.9: Investigation of the the .phs outputs from ShelxE in Coot (at a map sigma 
of 1.0). Top: Original enantiomorph density. Bottom: Inverted enantiomorph density.  
 
The original density shows limited connectivity, with little evidence of tertiary 
structure. The inverted enantiomorph shows clear connectivity, and tertiary-elements 
such as the β–sheet shown are prominent. As suggested by the statistical outputs, the 
inverted density was the best-phased map. 
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5.9.3	  Automatic	  Model	  Building	  	  The	  phased	  electron	  density	  output	  from	  ShelX	  proved	  to	  be	  very	  clear	  and	  well	  defined,	  to	  2.4	  Å	  resolution.	  Without	  any	  model	  building	  yet	  undertaken,	  it	  was	  easy	  to	  recognise	  features	  of	  primary-­‐,	  secondary-­‐	  and	  tertiary	  protein	  structure,	  for	  example	  at	  a	  σ-­‐level	  of	  0.98	  the	  individual	  atoms	  of	  a	  tyrosine	  ring	  were	  clearly	  visible	  (Figure	  5.10).	  Therefore	  the	  data	  seemed	  a	  perfect	  candidate	  for	  automated	  model	  building.	  Using	  the	  CCP4i	  ARP/wARP	  7.0.1	  program	  (Langer	  et	  al,	  2008),	  supplied	  with	  the	  expected	  amino-­‐acid	  sequence	  for	  BPSL1204-­‐MA	  in	  .pir	  format,	  automated	  model-­‐building	  using	  the	  Maximum	  Likelihood	  target	  function	  for	  50	  cycles	  of	  build-­‐and-­‐refine	  were	  run	  to	  look	  for	  one	  molecule	  of	  147	  amino-­‐acids	  per	  asymmetric	  unit.	  	  	  ARP/wARP	  successfully	  modelled	  100	  residues	  of	  the	  expected	  147	  residues	  into	  the	  density.	  Initial	  investigation	  showed	  generally	  very	  good	  fitting,	  and	  the	  presence	  of	  disorder	  in	  the	  first	  and	  last	  5	  residues,	  accounting	  for	  ~7%	  of	  the	  atoms	  in	  the	  polypeptide.	  Disregarding	  the	  disordered	  residues	  meant	  an	  overall	  fitting	  of	  ~73%	  of	  the	  possible	  sequence,	  which	  was	  considered	  a	  very	  good	  start	  success.	  Phases	  were	  extended	  to	  1.3	  Å	  resolution	  native	  data	  using	  the	  CCP4i	  program	  Convert	  to/Modify/Extend	  MTZ	  program,	  applying	  the	  FreeR	  dataset	  used	  for	  the	  2.4	  Å	  resolution	  seleno-­‐met	  data-­‐processing,	  with	  refinement	  carried	  out	  using	  Refmac5	  (Murshudov	  et	  al,	  1997).	  	  
5.10	  Refinement	  of	  the	  BPSL1204	  Structure	  	  5.10.1	  Fitting	  of	  the	  Complete	  Model	  	  	  Even	  though	  ARP/wARP	  generated	  a	  fairly	  complete	  model,	  it	  was	  still	  required	  to	  be	  manually	  investigated	  to	  find	  the	  missing	  37	  residues	  and	  later	  for	  correction	  of	  inconsistencies	  such	  as	  impossible	  stereochemical	  angles,	  unrealistic	  chemical	  bonds	  and	  the	  placing	  of	  true	  but	  unlikely	  residue	  conformations	  that	  may	  have	  been	  incorrectly	  orientated.	  A	  typical	  example	  was	  the	  rotation	  of	  the	  Cγ	  of	  Asn85	  in	  order	  to	  align	  the	  nitrogen	  to	  ensure	  chemically	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Figure 5.10: Electron density prior to automated model building at a map sigma 
level of 0.98. All the atoms of a tyrosine residue are easily seen without fitting of 
a model, providing a good candidate electron density map for automated model 
building by ARP/wARP.  
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viable	  hydrogen	  bonding	  was	  taking	  place	  with	  the	  main-­‐chain	  oxygen	  of	  Asp81	  and	  the	  oxygen	  of	  MPD1	  (Figure	  5.11).	  This	  was	  in	  addition	  to	  the	  manual	  fitting	  of	  the	  remaining	  37	  residues	  unaccounted	  for	  by	  the	  automated	  modelling	  and	  the	  correct	  alignment	  of	  all	  residues	  centrally	  within	  the	  lumen	  of	  connected	  electron	  density.	  Manipulation	  of	  the	  model	  built	  into	  the	  calculated	  electron	  density	  was	  carried	  out	  using	  the	  graphics	  program	  Coot	  0.5.2	  (Emsley	  &	  Cowtan,	  2004)	  and	  refined	  using	  Refmac5.	  	  5.10.2	  Preventing	  Bias	  in	  the	  Model	  	  ARP/wARP	  built	  a	  model	  on	  the	  basis	  of	  placing	  ‘dummy’	  atoms	  into	  regions	  of	  density	  and	  then	  attempted	  to	  match	  them	  up	  into	  side-­‐chains	  and	  polypeptide-­‐backbones.	  Therefore	  certain	  errors	  were	  found	  upon	  manual	  inspection,	  commonly	  concerning	  aromatic	  side-­‐chains,	  where	  density	  from	  the	  automated,	  refined	  density	  did	  not	  match	  the	  obvious	  aromatic-­‐ring	  density	  that	  had	  been	  seen	  in	  the	  experimentally	  observed	  electron	  density	  prior	  to	  automated	  modelling	  and	  refinement,	  such	  as	  Trp77	  and	  Arg34	  shown	  in	  Figure	  5.12.	  Therefore	  as	  part	  of	  the	  refinement	  of	  the	  model,	  these	  regions	  of	  imposed	  data-­‐bias	  were	  manually	  corrected	  in	  Coot.	  	  	  5.10.3	  Fitting	  of	  Ligands	  and	  Water	  Molecules	  	  After	  the	  process	  of	  correcting	  and	  refining	  regions	  of	  ambiguity	  in	  the	  ARP/wARP	  model	  and	  the	  manual	  modelling	  of	  regions	  of	  unmodelled,	  connected	  electron	  density,	  the	  modelling	  of	  other	  regions	  of	  unexplained	  density	  was	  carried	  out.	  Using	  the	  difference	  map	  after	  refining	  with	  the	  experimental	  model,	  Coot	  identified	  ‘blobs’	  of	  true	  electron	  density.	  These	  were	  then	  modelled	  as	  either	  water,	  or	  networks	  of	  water,	  if	  blobs	  were	  present	  as	  single	  spheres	  with	  sensible	  hydrogen-­‐bonding	  distances	  of	  1.9-­‐2.5Å,	  or	  as	  potential	  ligands.	  Ligands	  expected	  were	  the	  contents	  of	  the	  mother-­‐liqour	  (MPD	  or	  sodium	  acetate)	  and	  the	  glycerol	  soaked	  in	  during	  cryo-­‐protection.	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Figure 5.11: Correction of ARP/wARP model building. Top: original fitting. Bottom: 
Corrected for chemical viability. Residues with high rotational ability (such as Asn85) 
pictured were manually investigated to correct hydrogen bonding. 
 
 In this example, a 180° rotation around Cγ was required to align the nitrogen (pink) 
of Asn85 with the oxygen (yellow) of MPD1 to fulfil correct hydrogen bond potential. 
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Figure 5.12: Model bias induced by automated ARP/wARP building. 
Top: Trp77. Bottom: Arg34. The density altered by refinement against the 
automated model (purple) occasionally induced incorrect orientations of 
side-chains when compared to the experimentally observed density 
(blue). These were corrected before further refinement. The yellow ‘star’ 
represents an unconnected ‘dummy’ atom placed into density by 
ARP/wARP. 
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During	  this	  process,	  unmodelled	  density	  was	  also	  investigated	  in	  case	  it	  revealed	  possible	  biological	  ligands	  that	  might	  help	  with	  the	  elucidation	  of	  BPSL1204	  function.	  This	  however	  was	  not	  the	  case.	  Alongside	  the	  auto-­‐fitting	  of	  100	  now	  corrected	  residues	  and	  the	  37	  residues	  modelled	  in	  manually,	  1	  molecule	  of	  MPD	  per	  protein	  molecule	  was	  modelled	  into	  ‘blobs’	  alongside	  179	  water	  molecules.	  This	  was	  quite	  a	  low	  number	  of	  solvent	  molecules	  for	  high	  resolution	  data,	  with	  a	  residue:water	  ratio	  of	  1:1.3.	  On	  average,	  a	  ratio	  of	  1:1	  is	  common	  for	  data	  to	  2	  Å	  resolution,	  however	  when	  using	  data	  to	  approximately	  1	  Å	  resolution,	  a	  1:1.6	  ratio	  is	  more	  common	  (Carugo	  &	  Bordo,	  1999).	  	  5.10.4	  Phase	  Extension	  to	  1.05	  Å	  Resolution	  	  At	  a	  later	  date	  from	  the	  collection	  of	  MAD	  data,	  native	  crystals	  were	  re-­‐grown	  and	  data	  to	  1.05	  Å	  resolution	  were	  collected	  at	  80%	  synchrotron	  beam-­‐transmission	  at	  12,658	  keV	  on	  the	  Diamond	  I02	  beamline.	  Cell	  dimensions	  of	  a=	  99.76	  Å,	  b=	  32.82	  Å,	  c=	  48.28	  Å,	  α=90°,	  β=116.11°	  and	  γ=90°	  were	  calculated,	  which	  were	  very	  similar	  to	  those	  of	  the	  MAD	  and	  original	  native	  data.	  Using	  Convert/Modify/ExtendMTZ	  in	  CCP4i,	  phases	  from	  the	  1.3	  Å	  resolution	  data	  were	  extended	  to	  1.05	  Å	  resolution	  after	  data	  indexing	  and	  scaling,	  with	  the	  FreeR	  dataset	  from	  the	  original	  2.4	  Å	  resolution	  MAD	  data	  applied.	  	  	  5.10.5	  Refinement	  and	  R-­‐factors	  	  Refinement	  of	  the	  built	  model	  was	  carried	  out	  in	  Refmac5	  (Murshudov	  et	  al,	  1997).	  Each	  round	  of	  refinement	  carried	  out	  10	  cycles	  of	  maximum-­‐likelihood-­‐restrained	  refinement	  whilst	  allowing	  for	  unweighted,	  individual	  anisotropic	  B-­‐factors.	  Isotropic	  B-­‐factors	  assume	  that	  vibrational	  or	  thermal	  motion	  of	  an	  atom	  in	  a	  molecule	  can	  occur	  in	  every	  direction	  about	  a	  mean	  position	  (Tronrud,	  2004).	  Anisotropic	  B-­‐factors	  are	  a	  more	  realistic	  interpretation	  of	  the	  vibrational	  movement	  of	  a	  molecule	  at	  an	  atomic	  scale,	  when	  covalent	  bonds	  and	  torsion	  angles	  restrict	  movement	  to	  only	  a	  few	  directions.	  Anisotropic	  Displacement	  Parameters	  (ADPs)	  are	  only	  enforceable	  when	  the	  data	  used	  are	  of	  a	  sufficiently	  high	  resolution	  (commonly	  >1.2	  Å)	  (Eyal	  et	  al,	  2007),	  as	  was	  the	  case	  with	  the	  1.05	  Å	  resolution	  BPSL1204	  data.	  B-­‐factors	  were	  unweighted	  to	  reduce	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restraints	  on	  movement	  and	  B-­‐factor	  occupancy	  of	  individual	  atoms.	  This	  allowed	  for	  refinement	  of	  B-­‐factors	  to	  a	  level	  best	  approximating	  reality,	  as	  the	  model	  was	  fitted	  to	  well	  defined,	  near-­‐atomic-­‐resolution	  experimental	  density.	  	  A	  B-­‐factor	  cut-­‐off	  monitoring	  limit	  of	  10.00σ	  was	  imposed,	  in	  order	  to	  identify	  in	  the	  output	  log-­‐file	  any	  parts	  of	  the	  model	  exhibiting	  potentially	  excessive	  deviation	  in	  thermal	  motion	  between	  consecutive	  atoms,	  which	  could	  then	  be	  corrected	  in	  the	  model	  if	  considered	  invalid	  before	  further	  refinement.	  	  In	  addition,	  refinement	  of	  the	  model	  was	  carried	  out	  with	  5%	  of	  the	  experimental	  data	  (free	  R-­‐factor)	  not	  used	  in	  refinement	  as	  a	  control	  against	  model-­‐bias	  (Brunger,	  1993),	  which	  can	  lead	  to	  misleading	  density	  features.	  This	  would	  have	  biased	  the	  model	  away	  from	  the	  true	  structure.	  	  An	  assessment	  of	  increasing,	  unbiased	  refinement	  was	  the	  reduction	  of	  Rwork	  and	  Rfree	  (Brunger,	  1993).	  Rwork	  is	  a	  value	  that	  describes	  how	  well	  the	  built	  model	  predicts	  the	  actual	  experimental	  data,	  by	  comparing	  the	  structure	  factors	  calculated	  from	  the	  model	  (Fcalc)	  with	  those	  from	  the	  original	  measured	  diffraction	  intensities	  (Fobs).	  Rfree	  consists	  of	  a	  subset	  (5%	  for	  the	  BPSL1204-­‐MA	  structure	  described	  here)	  of	  data	  excluded	  from	  the	  refinement.	  Therefore	  the	  refinement	  of	  the	  model	  was	  judged	  to	  be	  effective	  as	  long	  as	  after	  each	  round	  of	  refinement	  both	  of	  the	  R-­‐factors	  decreased	  in	  value	  as	  the	  model	  approached	  the	  best	  fit	  to	  the	  experimental	  density.	  	  Over	  ten	  rounds	  of	  refinement,	  Rfree	  and	  Rwork	  decreased	  from	  0.3496	  and	  0.3458	  to	  0.1617	  and	  0.1390	  respectively.	  Table	  5.2	  summarises	  all	  the	  crystal	  and	  refinement	  parameters	  calculated	  for	  the	  datasets	  used	  in	  the	  solution	  of	  the	  BPSL1204-­‐MA	  crystal	  structure.	  	  
5.11	  Structure	  Validation	  	  5.11.1	  Molprobity	  	  As	  part	  of	  refinement	  and	  validation,	  a	  late-­‐stage	  Rfree=0.1908	  and	  Rwork	  0.1667	  .pdb	  file	  was	  input	  to	  the	  Molprobity	  server	  (Duke	  University)	  (Davis	  et	  al,	  2007)	  for	  analysis	  of	  atomic	  contacts	  and	  clash-­‐scores,	  with	  analysis	  of	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Dataset	   Native	  (1)	   Native	  (2)	   Seleno-­Met	  
(peak)	  Space	  Group	   C2	   C2	   C2	  
Cell	  Dimensions	   	   	   	  A	  (Å)	   99.96	   99.76	   99.71	  B	  (Å)	   32.91	   32.82	   32.89	  C	  (Å)	   48.35	   48.28	   48.34	  α	  (°)	   90.00	   90.00	   90.00	  β	  (°)	   116.04	   116.11	   115.89	  γ	  (°)	   90.00	   90.00	   90.00	  Resolution	  (Å)	   20.8-­‐1.29	   30.8-­‐1.05	   45-­‐2.4	  Beamline	   Diamond	  I02	   Diamond	  I02	   Diamond	  I04	  Wavelength	  (Å)	   0.932	   0.979	   0.98	  Observed/unique	  refls	   125464/35052	   195595/65407	   35268/9842	  Rmerge	  (outer	  shell)	   3.5	  (34.1)	   4.7	  (46.1)	   3.3	  (9.7)	  Completeness	  (%)	  (outer	  shell)	   90.4	  (99.9)	   99.6	  (99.5)	   99.8	  (100.0)	  Redundancy	  (outer	  shell)	   3.6	  (3.5)	   3.0	  (2.9)	   3.6	  (3.6)	  I/σI	  (outer	  shell)	   22.3	  (3.5)	   22	  (1.6)	   18.3	  (6)	  Heavy	  atom	   -­‐	   -­‐	   Se	  No.	  of	  sites	   -­‐	   -­‐	   3	  Solvent	  content	  (%)	   -­‐	   40.82	   -­‐	  Matthews	  coefficient	  (Å3/Da)	   -­‐	   2.08	   -­‐	  
Final	  Refinement	  Statistics	   	   	   	  No.	  of	  reflections	  (working/free)	   -­‐	   62118/3106	   -­‐	  No.	  of	  atoms	  (protein/water/MPD)	   -­‐	   2168/179/8	   -­‐	  Rwork/Rfree	   -­‐	   0.1390/0.1617	   -­‐	  
RMS	  deviations	  from	  ideality:	   	   	   	  Bond	  length	  (Å)	   -­‐	   0.0330	   -­‐	  Bond	  angles	  (°)	   -­‐	   2.2163	   -­‐	  
Average	  B-­factors:	   	   	   	  Overall	  (Å2)	   -­‐	   12.9	  	   -­‐	  Main	  chain	  (Å2)	   -­‐	   10.9	   -­‐	  Side	  chain	  (Å2)	   -­‐	   13.6	   	  Water	  (Å2)	   -­‐	   22.2	   -­‐	  
Ramachandran	  plot	  proportions:	   	   	   	  Favoured/Allowed/Disallowed(%)	   -­‐	   98.5/1.5/0.0	   -­‐	  
Table 5.2: Data collection, phasing and refinement statistics. 
Hydrogens are not included in these statistics. 
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geometry	  on	  a	  residue-­‐to-­‐residue	  basis	  highlighting	  bad	  rotamers,	  Ramachandran	  outliers	  and	  anomalous	  bond-­‐lengths.	  This	  allowed	  further	  refinement	  of	  the	  structure	  to	  ensure	  accurate	  stereochemical	  representation	  of	  the	  experimental	  density	  in	  the	  model,	  including	  incorporation	  of	  ‘riding’	  hydrogen	  atoms	  into	  the	  structure	  refinement.	  	  	  Hydrogen	  positions	  were	  not	  directly	  refined	  into	  the	  model	  due	  to	  little	  observed	  density	  in	  the	  expected	  regions	  for	  hydrogens	  in	  protein,	  even	  at	  high	  resolution	  when	  electron	  density	  maps	  were	  contoured	  as	  low	  as	  0.5σ.	  However,	  their	  relative	  riding	  positions	  were	  used	  in	  order	  to	  assess	  and	  refine	  bond	  lengths	  and	  angles.	  As	  in	  reality	  proteins	  do	  have	  hydrogens,	  the	  use	  of	  riding	  hydrogens	  during	  refinement	  brought	  the	  model	  closer	  to	  reality,	  measured	  as	  a	  decrease	  in	  R-­‐factors.	  The	  Reduce	  program,	  run	  using	  Molprobity,	  added	  1069	  hydrogens	  to	  the	  model	  for	  validation	  (Chen	  et	  al,	  2010).	  This	  was	  for	  stereochemical	  analysis	  of	  the	  structure	  using	  the	  logic	  that	  only	  a	  structure	  that	  leaves	  room	  for	  hydrogens	  can	  be	  accurate.	  Any	  collisions	  that	  occurred	  between	  hydrogens	  were	  incorporated	  into	  the	  clash-­‐score.	  	  Several	  further	  rounds	  of	  refinement	  were	  carried	  out	  to	  achieve	  the	  final	  structure.	  Clash-­‐scores	  were	  reduced	  from	  16.21	  to	  1.86	  clashes	  with	  >0.4Å	  overlaps	  per	  1000	  atoms;	  poor	  rotamers	  were	  reduced	  from	  5.08%	  to	  0.87%;	  bad	  angles	  and	  bad	  bond-­‐lengths	  were	  reduced	  from	  1.46%	  and	  3.65%	  respectively	  to	  0%	  and	  the	  Molprobity	  score,	  where	  lower	  is	  better,	  was	  reduced	  from	  2.30	  to	  0.95.	  This	  improved	  the	  structure	  enough	  to	  raise	  it	  from	  the	  25th	  percentile	  to	  the	  97th	  percentile	  of	  all	  structures	  assessed	  by	  Clash-­‐score	  and	  the	  99th	  percentile	  of	  Molprobity	  scores	  from	  structures	  of	  similar	  resolution	  (Figure	  5.13).	  A	  multi-­‐criterion	  chart	  was	  created	  for	  Coot,	  to	  facilitate	  the	  inspection	  of	  each	  residue	  that	  may	  have	  contributed	  to	  penalties.	  Study	  of	  those	  residues	  that	  added	  to	  scores	  such	  as	  poor	  rotamers	  and	  Cβ	  deviations	  revealed	  that	  the	  model	  fit	  the	  density	  very	  well,	  indicative	  of	  true	  but	  chemically	  uncommon	  angles	  within	  the	  protein	  structure.	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Figure 5.13: Output from the Molprobity analysis (Davis et al, 
2007) of the final BPSL1204 structure 
	   147	  
5.11.2	  PROCHECK	  	  The	  structure	  was	  further	  validated	  by	  the	  PROCHECK	  program	  (Laskowski	  et	  al,	  1993)	  run	  through	  CCP4i.	  This	  program	  also	  analysed	  bond-­‐angles	  and	  bond-­‐lengths	  of	  chi-­‐angles,	  main-­‐chain	  bonds,	  planar-­‐groups	  and	  overall	  side-­‐chain	  stereochemistry	  presented	  in	  the	  form	  of	  graphs	  and	  plots	  against	  standard,	  accepted	  values	  (Figure	  5.14).	  A	  comprehensive	  Ramachandran	  plot	  to	  illustrate	  the	  validity	  of	  the	  overall	  structure	  was	  also	  created	  (Figure	  5.15).	  	  	  	  The	  Ramachandran	  plot	  (Ramachandran	  et	  al,	  1963)	  generated	  revealed,	  as	  with	  the	  Ramchandran	  anaylsis	  of	  Molprobity,	  that	  98.5%	  of	  residues	  occupied	  favoured	  steric	  angles,	  with	  only	  1.5%	  occupying	  φ	  and	  ψ	  angles	  that	  were	  allowed	  but	  not	  ideal.	  There	  were	  assessed	  to	  be	  no	  residues	  occupying	  disallowed	  angles	  (Figure	  5.15).	  Investigation	  of	  individual	  residue	  plots	  of	  χ-­‐angles,	  main-­‐chain	  and	  side-­‐chain	  angles	  showed	  that	  the	  model	  fit	  to	  the	  density	  conformed	  to	  established	  stereochemistry.	  The	  bar	  chart	  output	  analysing	  deviation	  of	  χ-­‐angles	  from	  the	  mean	  was	  used	  to	  locate	  possible	  problem	  residues	  and	  further	  refine	  them	  to	  improve	  the	  geometrical	  statistics.	  	  	  The	  program	  SFCheck	  (Vaguine	  et	  al,	  1999)	  was	  also	  run	  as	  part	  of	  the	  PROCHECK	  program,	  which	  analysed	  the	  relationship	  between	  the	  created	  atomic	  model	  and	  the	  original	  experimental	  data.	  In	  addition,	  an	  overall	  B-­‐factor	  was	  calculated	  of	  18	  Å2,	  suggesting	  that	  the	  model	  built	  represents	  a	  protein	  of	  reasonably	  high	  overall	  order,	  with	  low	  levels	  of	  disorder.	  
	   148	  
Figure 5.14: Procheck analyses (Laskowski et al, 1993). Left: Plots of 
main-chain features. Right: Plots of side-chain features. For the main-
chain, all aspects (including peptide-bond planarity and hydrogen bond 
energies) fall within the accepted purple boundaries, which represent 
well-fit structures of similar resolution.  
 
Side chain features such as chi-1 angles fall within the accepted purple 
boundaries. The measurement of chi-2 angle outliers are due to the 
uncommon but experimentally true rotamers 
1ang_ChainAandC_FH_04.ps
PROCHECK Main-chain parameters
1ang_ChainAandC_FH - Chain A
1.0 1.5 2.0 2.5 3.0 3.5 4.0
   20
   40
   60
   80


















1.0 1.5 2.0 2.5 3.0 3.5 4.0
    5
   10
   15
   20












1.0 1.5 2.0 2.5 3.0 3.5 4.0
   10
   20
   30
   40
   50
   60



































































Comparison values No. of
                                No. of   Parameter  Typical   Band    band widths       
Stereochemical parameter       data pts    value     value    width    from mean        
a. %-tage residues in A, B, L    115        93.9      89.7    10.0        0.4    Inside 
b. Omega angle st dev            133         6.0       6.0     3.0        0.0    Inside 
c. Bad contacts / 100 residues      0         0.0       0.9    10.0       -0.1    Inside 
d. Zeta angle st dev             127         2.0       3.1     1.6       -0.7    Inside 
e. H-bond energy st dev           88         0.8       0.6     0.2        0.9    Inside 
f. Overall G-factor              135        -0.2       0.0     0.3       -0.8    Inside 
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Plot statistics
Comparison values No. of
                                No. of   Parameter  Typical   Band    band widths       
Stereochemical parameter       data pts    value     value    width    from mean        
a. Chi-1 gauche minus st dev      16         6.3       9.4     6.5       -0.5    Inside 
b. Chi-1 trans st dev             24        12.3      12.0     5.3        0.1    Inside 
c. Chi-1 gauche plus st dev       68         7.9      10.4     4.9       -0.5    Inside 
d. Chi-1 pooled st dev           108         9.2      10.9     4.8       -0.4    Inside 
e. Chi-2 trans st dev             31        10.1      15.3     5.0       -1.0    BETTER 
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Figure 5.15: PROCHECK Ramachandran analysis (Laskowski et al, 1993). 
98.5% of residues were shown to occupy favoured regions, with 1.5% in 







General/Pre-Pro/Proline Favoured General/Pre-Pro/Proline Allowed
Glycine Favoured Glycine Allowed
Number of residues in favoured region (~98.0% expected) :  131  (98.5%)
Number of residues in allowed region (~2.0% expected) :  2  (1.5%)
Number of residues in outlier region :  0  (0.0%)
RAMPAGE by Paul de Bakker and Simon Lovell available at http://www-cryst.bioc.cam.ac.uk/rampage/ 
Please cite: S.C. Lovell, I.W. Davis, W.B. Arendall III, P.I.W. de Bakker, J.M. Word, M.G. Prisant, J.S. Richardson & D.C. Richardson (2002)
Structure validation by C? geometry: ?!? and C? deviation. Proteins: Structure, Function & Genetics. 50: 437-450
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Chapter	  6:	  Structural	  Investigation	  of	  BPSL1204	  Function	  	  
6.1	  Structural	  Features	  of	  BPSL1204	  	  The	  BPSL1204-­‐MA	  crystal	  structure	  revealed	  a	  protein	  that	  consists	  of	  two	  domains	  connected	  by	  a	  short	  loop,	  an	  N-­‐terminal	  domain	  consisting	  of	  one	  α–helix	  and	  a	  4-­‐stranded	  β–sheet	  and	  a	  C-­‐terminal	  domain	  comprising	  two	  α-­‐helices	  and	  a	  4-­‐stranded	  β–sheet	  (Figure	  6.1).	  These	  domains	  appear	  structurally	  very	  similar	  to	  each	  other	  and	  are	  arranged	  stacked	  together	  so	  that	  the	  N-­‐terminal	  domain’s	  β–sheet	  is	  backed	  onto	  by	  the	  C-­‐terminal	  domain’s	  α–helices.	  Figure	  6.2	  shows	  the	  secondary	  structure	  arrangement	  and	  topology	  of	  BPSL1204.	  An	  11-­‐residue	  N-­‐terminal	  ‘linker’	  region	  (of	  which	  only	  6	  residues	  are	  sufficiently	  ordered	  to	  be	  modelled	  and	  refined)	  connects	  the	  first	  α–helix	  in	  the	  N-­‐terminal	  domain	  to	  the	  point	  at	  which	  the	  lipid	  anchor	  was	  truncated	  (Ala20),	  immediately	  after	  the	  LLAGCA	  glycerylcysteine	  lipoprotein	  motif.	  	  	  During	  the	  building	  of	  the	  BPSL1204	  structure,	  Met42	  was	  seen	  to	  occupy	  multiple	  conformations	  when	  a	  model	  was	  built	  into	  the	  experimental	  electron	  density,	  in	  a	  roughly	  7:3	  ratio,	  as	  shown	  in	  Figure	  6.3a.	  This	  residue	  was	  found	  to	  be	  on	  the	  extreme	  reach	  of	  the	  β2-­‐β3	  loop.	  Though	  the	  loop	  itself	  appears	  well	  ordered	  with	  low	  B-­‐factors,	  the	  significant	  sulphur	  atom	  (or	  selenium	  in	  the	  original	  MAD	  data)	  was	  seen	  to	  have	  reasonably	  high	  B-­‐factors	  (Figure	  6.3b).	  This	  conformational	  flexibility	  without	  uniformity	  throughout	  the	  crystal	  is	  likely	  the	  reason	  for	  phase	  calculations	  being	  based	  upon	  only	  3/5	  of	  the	  possible	  methionines	  in	  the	  BPSL1204	  sequence.	  The	  other	  un-­‐phased	  methionine	  was	  the	  N-­‐terminal	  Met1,	  shown	  to	  be	  present	  via	  MS	  experiments	  (Section	  4.5.2),	  and	  was	  thus	  disordered	  in	  the	  crystal	  lattice.	  	  Investigation	  of	  the	  molecular	  interface	  between	  the	  two	  domains	  revealed	  several	  key	  interactions.	  Figure	  6.4	  shows	  these	  interaction	  networks	  in	  the	  graphical	  representation	  in	  Pymol.	  Several	  hydrogen	  bonds	  create	  the	  region	  of	  the	  interface	  furthest	  away	  from	  the	  connective	  loop	  L1,	  namely	  Tyr26OH-­‐Glu24OE1,	  Glu24OE1-­‐Arg88N	  and	  Arg34NH1-­‐Val84O.	  Several	  networks	  of	  water	  molecules	  also	  support	  these	  interactions.	  These	  types	  of	  interactions	  are	  typical	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Figure 6.1: The 1.05 Å resolution structure of BPSL1204. The cartoon model was 
created using PyMol (Schrödinger, LLC), with N- to C-terminus coloured as blue-
red, to represent the overall folding and structural arrangement of BPSL1204. 
 
Two domains of α1β4 and α2β4 are clearly seen, separated by a very short loop 
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Figure 6.2: Top: Secondary structure arrangement of α–helical, β-strand and β-
sheet elements of BPSL1204. Bottom: Topology schematic of BPSL domain 
arrangements, with α–helices represented by cylinders and β–strands represented 
as arrows. 
 
The above illustrations allow for the identification of the specific secondary 
structure a particular residue is involved in, in addition to aiding with the location 
of one secondary structure element in regards to the overall protein structure and 
sequence. The diagrams were created using the PDBsum application made 
available by the PDB (Laskowski, 2009). 	  	  
α1	  
β1	  β2	  	  β3	  β4	  
α2	   α3	  
β5	  β6	  β7	  β8	  
L1	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Figure 6.3a: Met42 was seen to occupy two conformations. From left-to-right in the 
above image a roughly 3:7 ratio was modelled into the electron density in Coot. 
β2	   β3	  
Figure 6.3b: Location and flexibility of Met42 in BPSL1204. Met42 is found at the ‘tip’ of 
the β–turn between β2 and β3. The inset image shows the B-factors of the atoms in the side-
chain of Met42. There appears to be a reasonably high degree of positional movement 
around the Cγ and Sδ of the residue, the root of the two different conformations seen. 
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Figure 6.4: Investigation of the domain interface in Pymol of the BPSL1204 
crystal structure.  
 
Hydrogen bonds are coordinated between residues Tyr26OH-Glu24OE1, Glu24OE1-
Arg88N and Arg34NH1-Val84O. In addition an ion-pair is seen to bridge over the 
interdomain loop L1 between Arg61 and Glu68. 
L1	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of	  those	  expected	  at	  a	  protein	  interface,	  biologically	  or	  in	  a	  crystal.	  However,	  the	  presence	  of	  hydrophilic	  residues	  such	  as	  glutamate	  and	  arginine	  that	  create	  the	  hydrogen	  bonds,	  within	  a	  reasonably	  buried	  interfacial	  region,	  raises	  doubt	  as	  to	  the	  biological	  relevance	  of	  such	  an	  interface.	  	  	  This	  is	  compounded	  when	  the	  interdomain	  region	  surrounding	  the	  small	  L1	  loop	  between	  the	  two	  domains	  is	  probed.	  As	  shown	  in	  both	  Figure	  6.4	  and	  Figure	  6.5,	  the	  loop	  is	  bridged	  by	  a	  potential	  ion-­‐pair	  of	  Arg61NH1	  and	  Glu68OE1.	  A	  water	  bridge	  crossing	  the	  domains	  between	  Arg61NH2-­‐H203-­‐Asn85OD1	  further	  supports	  this	  strong	  interaction.	  In	  addition,	  a	  potential	  ion-­‐pair	  is	  seen	  between	  Arg54NH2	  and	  Asp50OD2.	  Although	  these	  residues	  both	  belong	  to	  the	  N-­‐terminal	  domain,	  their	  strong	  interaction	  leads	  to	  an	  orientation	  of	  Arg34NH1	  that	  allows	  hydrogen	  bonding	  with	  Val84O	  in	  the	  C-­‐terminal	  domain.	  	  When	  the	  B-­‐factors	  of	  the	  residues	  of	  L1	  are	  examined	  as	  in	  Figure	  6.6,	  it	  can	  be	  seen	  that	  the	  loop	  has	  very	  little	  vibrational	  movement	  with	  low	  B-­‐factors,	  highly	  suggestive	  of	  a	  rigid	  structure.	  However	  when	  one	  considers	  that	  the	  loop	  is	  flanked	  by	  very	  strong	  ionic	  interdomain	  interactions,	  one	  may	  well	  expect	  to	  see	  very	  little	  movement	  in	  this	  small	  loop	  as	  it	  becomes	  almost	  clamped	  into	  place.	  It	  is	  also	  unusual	  to	  find	  such	  charged,	  hydrophillic	  interactions	  buried	  between	  two	  protein	  domains	  with	  hydrophobic	  interactions	  much	  more	  common	  (Barlow	  &	  Thornton,	  1983).	  Therefore	  it	  may	  be	  possible	  that	  the	  low	  B-­‐factors	  seen	  in	  L1	  are	  a	  non-­‐biological	  representation	  of	  the	  region’s	  flexibility	  with	  the	  interdomain	  interactions	  formed	  as	  a	  product	  of	  packing	  into	  a	  crystal	  lattice.	  The	  biological	  conformation	  of	  BPSL1204	  domains	  may	  be	  different	  to	  that	  witnessed	  in	  the	  crystal	  structure,	  perhaps	  with	  an	  increase	  in	  flexibility	  between	  domains.	  	  With	  the	  crystal	  structure	  now	  solved	  to	  a	  resolution	  of	  1.05	  Å,	  bioinformatic	  investigation	  was	  required	  to	  establish	  potential	  structural	  similiarities	  and	  to	  attempt	  to	  predict	  binding	  partners	  in	  order	  to	  obtain	  insights	  into	  the	  unknown	  function	  of	  BPSL1204	  in	  Burkholderia	  pseudomallei.	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Figure 6.5: Investigation using Coot of the major bonds formed in the interface 
between BPSL1204 domains. Electron density is contoured to 2σ at 1.05 Å 
resolution. 
 
The ionic interaction between Asp50 and Arg34 holds an interdomain hydrogen 
bond between Arg34 and the main chain of Val84. 
 
A further ion pair is seen to flank L1, between Arg61 and Glu68. This acts to 
strongly hold either end of the interdomain loop L1 in an inflexible conformation. 
In addition to determining the interface surrounding L1, Arg61 is also then held in 
coordination with H203, creating a cross-domain water-bridge to Asn85, further 
structuring the quaternary arrangement of the protein. 	  
L1	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Figure 6.6: B-factors within the short L1 interdomain loop. The figure shows each 
main-chain atom within the L1-loop for analysis of potential flexibility. B-factor values 
are shown as Å2. Val60 and Phe69 are shown as the next residues either side of L1. 
 
No main-chain atom from Arg61 to Glu68 breaches the >10.00 Å2 cut-off included in 
refinement, reflecting a very rigid structure with little flexibility. The Arg61 and Glu68 
side chains are shown to illustrate the ion-pair (shown by the yellow dotted line) that is 
potentially responsible for the low vibrational movement in L1. 
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6.2	  DALI	  analysis	  of	  BPSL1204-­MA	  	  6.2.1	  The	  DALI	  server	  	  The	  structural	  coordinates	  of	  BPSL1204-­‐MA	  in	  the	  format	  of	  a	  .pdb	  file	  were	  uploaded	  to	  the	  DALI	  server	  (http://ekhidna.biocenter.helsinki.fi/dali_server)	  (Holm	  &	  Rosenstrom,	  2010).	  DALI	  performed	  a	  comparison	  of	  the	  protein	  with	  all	  the	  protein	  structural	  coordinates	  present	  in	  the	  PDB	  (Protein	  Data	  Bank)	  (Berman	  et	  al,	  2000),	  to	  find	  those	  coordinates	  that	  shared	  most	  3D	  similarity	  to	  BPSL1204.	  Each	  potential	  hit	  was	  given	  a	  Z-­‐score	  (Holm	  et	  al,	  2008)	  to	  identify	  the	  level	  of	  3D	  similarity.	  The	  higher	  in	  value	  the	  Z-­‐score	  was	  the	  greater	  the	  structural	  similarity	  and	  Z-­‐scores	  of	  less	  than	  8	  were	  counted	  as	  probably	  not	  significant.	  Other	  information	  like	  the	  level	  of	  sequence	  identity,	  the	  number	  of	  residues	  involved	  and	  the	  RMSD	  values	  of	  the	  Cα	  atoms	  superimposed	  were	  also	  given	  by	  Dali.	  	  6.2.2	  Results	  of	  Dali	  Search	  	  The	  structure	  in	  the	  PDB	  with	  the	  strongest	  structural	  similarity	  to	  BPSL1204-­‐MA	  was	  that	  of	  the	  161-­‐residue	  β–lactamase	  Inhibitory	  Protein	  I	  (BLIP-­‐I)	  from	  
Streptococcus	  mutans.	  This	  model	  (PDB	  entry	  3d4e,	  Joint	  Center	  for	  Structural	  Genomics,	  http://www.jcsg.org)	  had	  a	  Z-­‐score	  of	  9.2	  in	  comparison	  to	  BPSL1204-­‐MA,	  an	  RMSD	  of	  1.7	  Å	  for	  Cα	  atoms	  but	  only	  9%	  sequence	  identity.	  BLIP-­‐I	  is	  also	  a	  two-­‐domain	  protein,	  with	  both	  domains	  consisting	  of	  α2β4,	  which	  appeared	  structurally	  similar	  to	  each	  other	  and	  to	  the	  two	  BPSL1204	  domains.	  	  	  Structural	  similarity	  to	  the	  87-­‐residue	  E.	  coli	  OsmE	  osmotically-­‐inducible	  lipoprotein	  of	  unknown	  function	  was	  also	  seen	  (PDB:	  4dm5,	  Mamelli	  et	  al),	  with	  a	  Z-­‐score	  of	  8.9	  and	  a	  Cα	  RMSD	  of	  1.8	  Å.	  This	  protein	  consists	  of	  a	  single	  α3β4α1	  domain,	  which	  when	  superimposed	  upon	  BPSL1204	  showed	  very	  high	  structural	  similarity	  with	  the	  BPSL1204	  C-­‐terminal	  α2β4	  domain	  (Figure	  6.7).	  However,	  due	  to	  the	  presence	  of	  extra	  helices	  in	  the	  single	  OsmE	  domain	  and	  the	  existence	  of	  two	  domains	  in	  BLIP-­‐I	  that	  both	  exhibited	  similarity	  to	  both	  of	  the	  two	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Figure 6.7: Superimposition of BPSL1204 (blue) with OsmE (green) in PyMol. 
Top: Side view of the α3β4α1 OsmE on the α1β4/α2β4 BPSL1204. Bottom: 
Above view of the OsmE:BPSL1204 superimposition. 
 
The side view (top) clearly shows OsmE matching well to the α2β4 C-terminal 
domain of BPSL1204, however a small extra α–helix (bottom front) and an 
extra C-terminal α–helix in OsmE do not agree with the BPSL1204 structure. 
 
The above view (bottom) shows how the superimposition contains α–helices 
that overlay well in both structures and maintains the curvature of the β–sheet. 
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domains	  of	  BPSL1204,	  coupled	  with	  the	  lack	  of	  assigned	  OsmE	  function,	  it	  was	  decided	  that	  BLIP-­‐I	  provided	  the	  best	  candidate	  for	  further	  structural	  comparisons.	  	  Aside	  from	  BLIP-­‐I	  and	  OsmE,	  among	  the	  top-­‐scoring	  structures	  found	  by	  the	  Dali	  search	  were	  complexes	  of	  BLIP-­‐I	  bound	  to	  a	  β–lactamase	  (PDBs:	  2g2w,	  1jtg,	  3c7u,	  1s0w	  and	  2b5r),	  with	  homology	  found	  with	  the	  BLIP-­‐I	  component	  of	  each	  complex.	  The	  results	  of	  the	  Dali	  search	  are	  summarised	  below:	  	  	  
	   PDB	  code	   Z-­‐score	   Cα	  RMSD	   No	  of	  Res	   Description	  3d4e	   9.0	   1.7	   162	   Putative	  BLIP-­‐I	  	  4dm5	   8.9	   1.8	   87	   OsmE	  	  2g2w	   7.8	   3.4	   164	   β-­‐lactamse	  SHV-­‐1	  with	  BLIP-­‐I	  1jtg	   7.0	   3.3	   165	   β-­‐lactamse	  TEM-­‐1	  with	  BLIP-­‐I	  3c7u	   6.9	   3.4	   165	   β-­‐lactamse	  TEM-­‐1	  with	  BLIP-­‐I	  1s0w	   6.9	   3.3	   165	   β-­‐lactamse	  TEM-­‐1	  with	  BLIP-­‐I	  2b5r	   6.9	   3.3	   165	   β-­‐lactamse	  TEM-­‐1	  with	  BLIP-­‐I	  	  	  	  The	  BPSL1204	  Dali	  search	  summary	  above	  (Holm	  et	  al,	  2008)	  shows	  the	  top	  7	  results	  from	  a	  list	  of	  1000,	  which	  rapidly	  decreased	  in	  Z-­‐score	  and	  increased	  in	  RMSD	  after	  BLIP-­‐I	  and	  OsmE	  results.	  As	  can	  be	  seen,	  BLIP-­‐I	  and	  OsmE	  gave	  the	  lowest	  RMSD	  suggestive	  of	  the	  best	  matching	  coordinates,	  with	  Z-­‐scores	  >8.0	  significance	  level.	  All	  of	  the	  structures	  identified	  as	  being	  potentially	  structurally	  similar	  to	  BPSL1204	  held	  low	  sequence	  identity.	  Therefore	  preliminary	  structural	  analysis	  of	  BPSL1204	  suggested	  structural	  similarities	  to	  BLIP-­‐I,	  and	  therefore	  offered	  a	  potential	  biological	  function.	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6.3	  Comparisons	  of	  BPSL1204-­MA	  and	  BLIP-­I	  	  6.3.1	  Sequence	  Homology	  	  When	  the	  sequence	  of	  BPSL1204	  and	  BLIP-­‐I	  from	  Streptococcus	  mutans	  are	  aligned	  using	  the	  ClustalW	  server	  (www.ebi.ac.uk/Tools/msa/clustalw2)	  (Larkin	  et	  al,	  2007),	  only	  16	  of	  BLIP-­‐I’s	  179	  residues	  are	  identical	  to	  the	  entire	  166-­‐residue	  sequence	  of	  BPSL1204	  (Figure	  6.8).	  As	  a	  20-­‐residue	  truncated	  BPSL1204-­‐MA	  was	  actually	  used	  for	  the	  structural	  analysis	  in	  DALI,	  this	  removed	  a	  single	  aligned	  residue	  from	  BPSL1204	  and	  left	  only	  8.4	  %	  identity	  for	  BLIP-­‐I	  (15/179)	  or	  10.3%	  identity	  (15/146)	  for	  BPSL1204-­‐MA	  between	  the	  two	  protein	  sequences.	  30	  non-­‐conserved	  residues	  in	  the	  truncated	  alignment	  also	  possessed	  similar	  chemical	  properties	  (16.8%	  of	  BLIP-­‐I	  and	  20.5%	  BPSL1204-­‐MA),	  but	  in	  general	  it	  is	  clear	  that	  the	  sequences	  shared	  very	  little	  significant	  homology	  to	  each	  other.	  	  	  In	  addition	  if	  the	  Burkholderia	  family	  of	  bacteria,	  which	  reports	  only	  homologs	  of	  unknown	  function	  BPSL1204	  lipoprotein,	  are	  excluded	  from	  a	  search	  of	  the	  NCBI	  BLAST	  database	  then	  even	  with	  the	  database	  search	  loosened	  to	  report	  the	  top	  1000	  matches	  from	  all	  other	  recorded	  species	  there	  is	  no	  homology	  found	  with	  a	  BLIP	  or	  BLIP-­‐related	  protein.	  Indeed,	  even	  a	  simple	  BLASTp	  (Altschul	  et	  al,	  1990)	  against	  all	  the	  translated	  sequences	  of	  just	  S.	  mutans	  strains	  did	  not	  find	  a	  sequence	  homolog	  of	  BPSL1204,	  with	  proteins	  such	  as	  a	  replicative	  DNA	  helicase	  with	  Evalue	  =	  1.2	  being	  found	  before	  BLIP-­‐I.	  Therefore	  with	  no	  detectable	  sequence	  homology	  found	  between	  BPSL1204	  and	  BLIP-­‐I,	  the	  structural	  arrangements	  of	  each	  macromolecule	  were	  investigated	  and	  compared.	  	  6.3.2	  Similarities	  of	  Individual	  Domains	  	  When	  the	  superimposed	  BLIP-­‐I	  coordinates	  (PDB:	  3d4e)	  from	  the	  DALI	  server	  (Holm	  et	  al,	  2008)	  are	  overlaid	  with	  the	  BPSL1204-­‐MA	  structure	  (Figure	  6.9),	  it	  is	  clear	  that	  there	  is	  a	  high	  degree	  of	  3D	  similarity	  between	  the	  N-­‐terminal	  α2β4	  domain	  of	  BLIP-­‐I	  and	  the	  C-­‐terminal	  α2β4	  domain	  of	  BPSL1204-­‐MA.	  In	  addition	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Figure 6.8: ClustalW-alignment of full-length BPSL1204 (top row) 
with full-length BLIP-I (bottom row). Colours indicate residues with 
similar chemical properties (Larkin et al, 2007). 
 
When aligned, only 16 residues out of 166 BPSL1204 residues match 
those in BLIP-I (*). When truncated only 15 align, leaving a low % 
sequence identity. Some residues exist as conservative substitutions (:), 
but in general no significant sequence homology exists. 
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Figure 6.9: Dali superimposition of BLIP-I (blue) on BPSL1204 (red), 
made in PyMol. Both proteins consist of two domains, α2β4/α2β4 and 
α1β4/α2β4 respectively, but the best structural superimposition places the 
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to	  this,	  as	  illustrated	  by	  Figure	  6.10,	  each	  of	  the	  two	  domains	  from	  each	  protein	  can	  be	  superimposed	  upon	  each	  other	  in	  all	  possible	  combinations	  (1204-­‐N:BLIP-­‐C,	  1204-­‐C:BLIP-­‐C,	  1204-­‐N:BLIP-­‐N	  and	  1204-­‐C:BLIP-­‐N).	  These	  domains,	  which	  exhibit	  no	  significant	  sequence	  homology	  to	  each	  other,	  all	  possess	  strikingly	  similar	  tertiary	  structure.	  It	  is	  therefore	  clear	  that	  the	  N-­‐terminal	  and	  C-­‐terminal	  domains	  of	  both	  proteins	  all	  have	  essentially	  the	  same	  fold	  (Figure	  6.11).	  	  Both	  the	  BLIP-­‐I	  N-­‐terminal	  and	  the	  BPSL1204-­‐MA	  C-­‐terminal	  domain	  share	  the	  same	  α2β4	  arrangement,	  whereas	  the	  BPSL1204-­‐MA	  N-­‐terminal	  domain	  exists	  as	  α1β4,	  perhaps	  due	  to	  the	  solubilising	  truncation.	  Figure	  6.12	  shows	  the	  predicted	  secondary	  sequence	  of	  full-­‐length	  BPSL1204,	  which	  holds	  the	  potential	  for	  another	  N-­‐terminal	  α–helix.	  	  However,	  there	  does	  not	  appear	  to	  be	  enough	  N-­‐terminal	  polypeptide	  upstream	  of	  α1	  when	  BPSL1204	  is	  truncated	  after	  the	  LLXGCX	  motif	  to	  allow	  the	  formation	  of	  an	  α1-­‐loop-­‐α2,	  as	  seen	  at	  the	  BLIP-­‐I	  N-­‐terminus.	  Sequence	  analysis	  by	  RADAR	  (Rapid	  Automatic	  Detection	  and	  Alignment	  of	  Repeats)	  (Heger	  &	  Holm,	  2000)	  detected	  no	  significant	  repeated	  sequences	  within	  either	  protein.	  Therefore	  the	  observed	  structural	  similarities	  in	  both	  the	  inter-­‐	  and	  intramolecular	  superimpositions	  may	  be	  due	  to	  chance,	  although	  there	  is	  also	  the	  possibility	  that	  they	  have	  related	  functions	  but	  diverged	  evolutionarily	  a	  long	  time	  ago,	  perhaps	  through	  some	  gene	  doubling	  event.	  	  6.3.3	  Differential	  Arrangement	  of	  Tertiary	  Structure	  	  Upon	  further	  investigation	  of	  the	  BLIP-­‐I:BPSL1204	  superimposition,	  it	  was	  clear	  that,	  although	  the	  domains	  individually	  share	  very	  similar	  3D	  structures	  between	  each	  protein,	  the	  spatial	  arrangement	  of	  domains	  in	  each	  crystal	  structure	  differ	  considerably.	  The	  two	  domains	  of	  BLIP-­‐I	  lie	  reasonably	  flat	  side-­‐by	  side	  connected	  by	  a	  looped	  region	  that	  crosses	  behind	  the	  second	  2α4β	  to	  begin	  the	  C-­‐terminal	  domain,	  whereas	  the	  domains	  of	  BPSL1204-­‐MA	  stack	  on	  top	  of	  one	  another	  connected	  by	  a	  considerably	  shorter	  looped	  region	  that	  directly	  joins	  domains	  and	  gives	  a	  slight	  twist	  between	  them	  (Figure	  6.13).	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Figure 6.10: Superimpositions of individual BLIP-I (blue) and BPSL1204 (red) 
domains in PyMol. Top left: C-dom BPSL1204, N-dom BLIP. Top right: C-dom 
BPSL1204, C-dom BLIP. Bottom left: N-dom BPSL1204, C-dom BLIP. Bottom right: 
N-dom BPSL1204, N-dom BLIP. 
 
Superimposition of the individual domains of each protein overlay with a high degree 
of structural similarity, suggestive of both proteins fulfilling a structurally similar 
function. 
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Figure 6.11: Self-superimpositions of BPSL1204 and BLIP N- and C-
domains (red/orange and blue/cyan respectively). 
 
Both domains of both proteins superimpose very well upon themselves 
(above) and each other (Figure 6.10). All domains have essentially the 
same fold. 
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Figure 6.12: The predicted secondary structure for BPSL1204. As can be seen, the 
full-length protein sequence carries the potential for a α2β4 N-terminal domain as 
seen in BLIP-I. However, the presence of the well-established glycerylcysteine-
anchoring motif, as indicated by the red line, makes it unlikely that this helix truly 
could exist as part of a soluble protein. 
 
In comparison to the actual secondary structure created post-de novo structure 
solution, the location in terms of sequence for the N-terminal domain secondary 
structures and the C-terminal β–sheet was well predicted. However, in the prediction 
a C-terminal α–helix is absent, although admittedly low in confidence of a coil at the 
expected region, highlighting the unreliability of predicting structure from sequence 
using current methods. 
 
The figure was prepared using the PsiPred server from UCL (Jones, 1999b). 
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Figure 6.13: Comparison of BPSL1204 and BLIP-I domain arrangements. Left top: 
BPSL1204 above view. Right top: BLIP-I above view. Left bottom: Schematic 
diagram of BPLS1204 domain arrangement. Right bottom: Schematic diagram of 
BLIP-I domain arrangement. Schematic diagrams represent α–helices as circles and 
β–strands as triangles. All images are coloured blue to red, N- to C-terminus. 
 
As can be seen, BPSL1204 domains stacked on top of each other, whilst BLIP-I 
domains exist in a side-by-side conformation. 
N 
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This	  was	  clearly	  demonstrated	  by	  the	  DALI	  superimposition	  of	  BPSL1204	  upon	  the	  TEM-­‐1:BLIP-­‐I	  inhibition	  complex,	  which	  placed	  the	  best	  two	  complementing	  domains	  over	  one	  another,	  whilst	  the	  remaining	  domain	  for	  BPSL1204	  extended	  into	  3D	  space	  in	  a	  totally	  different	  orientation	  from	  the	  key	  inhibiting	  BLIP-­‐I	  domain	  (Figure	  6.14).	  	  	  Further	  investigation	  of	  the	  looped	  regions	  between	  domains	  showed	  that	  B-­‐factors	  of	  residues	  in	  the	  BLIP-­‐I	  loop	  appeared	  to	  create	  a	  region	  of	  slight	  flexibility	  (higher	  B-­‐factors),	  whereas	  the	  connecting	  loop	  in	  the	  BPSL1204	  structure	  showed	  residues	  occupying	  space	  with	  relatively	  low	  B-­‐factors,	  indicative	  of	  a	  more	  rigid	  3D	  structure	  that	  may	  not	  have	  led	  to	  a	  similar	  structural	  flexibility	  between	  domains.	  	  6.3.4	  Crystal	  Packing	  Versus	  Biological	  Conformation.	  	  With	  the	  high	  structural	  similarity	  between	  BLIP-­‐I	  and	  BPSL1204	  domains,	  but	  with	  significant	  difference	  in	  domain	  arrangements,	  it	  was	  possible	  that	  the	  process	  of	  crystallising	  BPSL1204	  might	  have	  caused	  the	  packing	  of	  monomers	  into	  the	  crystal	  lattice	  in	  a	  non-­‐biological	  conformation.	  This	  is	  clearly	  not	  the	  case	  for	  BLIP-­‐I	  because,	  as	  seen	  in	  Section	  6.3.4,	  a	  number	  of	  independent	  structures	  of	  BLIP-­‐I	  as	  a	  monomer	  and	  in	  complex	  with	  its	  inhibition	  target	  β-­‐lactamase	  show	  a	  consistent	  side-­‐by-­‐side	  domain	  orientation.	  However	  with	  only	  one	  BPSL1204	  structure	  it	  was	  possible	  that	  in	  a	  different	  crystal	  lattice,	  BPL1204	  might	  have	  the	  same	  domain	  arrangement	  as	  BLIP-­‐I.	  	  Extensive	  initial	  crystallisation	  trials	  of	  BPSL1204	  (see	  Section	  5.2)	  had	  suggested	  that	  the	  9%	  MPD/0.1M	  sodium	  acetate	  pH5.5	  condition	  from	  which	  the	  crystals	  that	  led	  to	  the	  1.05	  Å	  resolution	  structure	  was	  the	  only	  condition	  to	  generate	  crystals	  of	  useful	  diffraction	  (see	  Section	  5.3.3).	  Therefore	  it	  was	  proposed	  a	  structure	  solution	  of	  a	  high	  sequence	  homologue	  from	  a	  closely	  related	  species	  to	  B.	  pseudomallei	  should	  be	  carried	  out	  to	  see	  if	  that	  had	  a	  different	  domain	  arrangement	  from	  BPSL1204	  and	  resembled	  that	  of	  BLIP-­‐I.	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Figure 6.14: Superimposition of BPSL1204 (red) on a complex of BLIP-I 
(blue) with its TEM-1 β–lactamase target protein (green).  
 
The best alignment placed the C-terminal domain of BPSL1204 over the 
C-terminal domain of BLIP-I, but due to differential domain arrangements 
the N-terminal BPSL1204 domain extended out into non-interacting space. 
 
In the BLIP-I inhibition of TEM-1, the N-terminal domain of BLIP-I is 
responsible for forming the inhibition complex, via the protruding loop 
designated by         . If the domain arrangement seen in BPSL1204 was 
biologically accurate, then it seemed unlikely that BLIP-I-like activity was 
possible due to a different quaternary arrangement of domains. 
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If	  so,	  then	  it	  would	  allow	  the	  inference	  that	  BPSL1204	  and	  its	  homologue	  are	  both	  functional	  homologs	  of	  BLIP-­‐I.	  	  To	  this	  end	  the	  92%	  amino-­‐acid	  sequence	  identical	  protein	  BCAL2351	  from	  B.	  
cenocepacia	  was	  identified	  by	  a	  BLAST	  search	  using	  BPSL1204	  (see	  Section	  7.1.2).	  BCAL2351	  was	  restriction-­‐cloned	  into	  pET14b	  and	  pBAD/hisB	  (genome	  of	  B.	  cenocepacia	  H111	  supplied	  by	  the	  lab	  of	  Dr	  Mark	  Thomas,	  University	  of	  Sheffield	  Medical	  School)	  to	  include	  an	  identical	  truncation	  to	  that	  of	  BPSL1204-­‐MA	  (following	  the	  general	  protocol	  described	  in	  Section	  3.4.2).	  Unfortunately,	  even	  after	  extensive	  over-­‐expression	  trials	  in	  BL21	  and	  Tuner	  (DE3)	  and	  Top10	  cells	  it	  was	  not	  possible	  to	  achieve	  soluble	  protein	  (Figure	  6.15),	  even	  though	  the	  two	  protein	  sequences	  differed	  by	  only	  11	  residues,	  most	  of	  which	  were	  conservative	  substitutions	  (Figure	  6.16).	  	  	  However	  due	  to	  the	  lack	  of	  flexibility	  in	  loop	  L1,	  as	  judged	  by	  low	  B-­‐factors	  and	  the	  presence	  of	  a	  strong	  ionic	  interaction	  in	  the	  interdomain	  looped	  region	  of	  BPSL1204,	  it	  was	  considered	  unlikely	  that	  BPSL1204	  and	  all	  near	  identical	  sequence	  homologues	  would	  occupy	  the	  exact	  same	  domain	  arrangement	  as	  BLIP-­‐I.	  Nevertheless	  the	  high	  structural	  similarity	  between	  domains	  made	  it	  possible	  that	  BPSL1204	  performs	  a	  similar	  biological	  function	  to	  BLIP-­‐I.	  	  6.3.5	  Potential	  Interactions	  With	  TEM-­‐1	  Target	  	  The	  best	  Dali	  structural	  match	  was	  with	  the	  N-­‐terminal	  of	  BLIP-­‐I	  over	  the	  C-­‐terminal	  of	  BPSL1204.	  If	  the	  α1β4	  N-­‐terminal	  domain	  of	  BPSL1204-­‐MA	  alone	  is	  superposed	  on	  the	  α2β4	  N-­‐terminal	  domain	  of	  BLIP-­‐I	  (from	  Streptomyces	  
exfoliatus)	  in	  complex	  with	  its	  inhibition	  target	  TEM1	  (from	  Escherichia	  coli)	  using	  the	  DALI	  alignment,	  then	  it	  is	  clearly	  seen	  that	  both	  N-­‐terminal	  domains	  present	  a	  short,	  protruding	  loop	  that	  forms	  a	  concave	  surface	  that	  occupies	  the	  convex	  lip	  of	  the	  TEM1	  active	  site	  (PDB	  3gmw)(Gretes	  et	  al,	  2009).	  This	  is	  the	  accepted	  mode	  of	  inhibition	  of	  TEM1	  β-­‐lactamase	  activity	  by	  BLIP-­‐I	  (Figure	  6.17).	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Figure 6.15: Example of SDS-PAGE analysis of BCAL2351-MA from 
BL21:pET14b over-expression for 3 hours in 1 mM IPTG. Lane 1= Mark12. 
Lane 2-5: No induction, 25, 30 and 37°C soluble fractions. Lane 6-9: No 
induction, 25, 30 and 37°C insoluble fractions. 
 
Heavy insoluble over-expression of BCAL2351-MA is seen, with no soluble 
protein observed. Variations in [IPTG], expression temperature from 4-37°C 
and expression time from 3-28 hours were investigated, but no BCAL2351-MA 
was produced.  
 
The same experiments were performed in TOP10 cells transformed with 
pBAD/hisB:BCAL2351-MA, using arabinose (0.1-1x10-5 %) as the inducing 
agent, but again no soluble protein was produced resulting in SDS-PAGE gels 
like the one shown above. 	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Figure 6.16: Sequence alignment of BPSL1204 (Query) with BCAL2351 (Subject). 
Both sequences contain the LLAGCA glycery-cysteine lipid-anchoring motif. As can 
be seen, the two proteins are sequence homologs of each other. 
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Figure 6.17: Inhibition-complex of TEM-1 (yellow) with the N-terminal 
domain of BLIP-I (blue) (Strynadka et al, 1996), superimposed with the N-
terminal domain of BPSL1204 (red) in PyMol. 
 
The concave surface offered by the BLIP-I loop is approximately replicated in 
structure by BPSL1204 (indicated by the black arrow) and rests over the 
small loop-helix-loop in the active site entrance, though the loop does not rest 
in the opening of the active site in BPSL1204 in the same conformation as 
BLIP-I. 
 
This could be due to the unbound BPSL1204, with a loop not in the 
conformation held when in complex, being superimposed to the best possible 
fit upon a rigidly bound BLIP-I held in conformation by the specific contacts 
that allow inhibition-complex formation. 
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This	  potential	  ‘inhibitory’	  loop	  from	  BPSL1204	  did	  not	  superimpose	  perfectly	  upon	  that	  of	  BLIP-­‐I	  (Figure	  6.17)	  but	  it	  was	  concluded	  that	  the	  slight	  variation	  could	  potentially	  be	  a	  difference	  between	  possible	  complexed	  and	  uncomplexed	  conformations	  of	  the	  loop,	  with	  more	  rigidity	  expected	  in	  the	  inhibition-­‐complex	  structure.	  Figure	  6.18	  shows	  the	  structural	  alignment	  of	  uncomplexed	  BLIP-­‐I	  from	  S.	  exfoliatus	  with	  the	  same	  BLIP-­‐I	  complexed	  with	  its	  TEM-­‐1	  target.	  The	  structural	  alignment	  had	  great	  confidence	  with	  a	  Z-­‐score	  of	  27.8,	  in	  addition	  to	  a	  very	  low	  Cα	  RMSD	  of	  0.5.	  It	  can	  be	  seen	  that	  there	  is	  a	  slight	  conformational	  change	  in	  the	  inhibitory	  loop	  upon	  binding	  to	  TEM-­‐1,	  supporting	  a	  potential	  BPSL1204	  binding-­‐event.	  Furthermore	  the	  loop	  regions	  from	  complexed	  BLIP-­‐I,	  uncomplexed	  BLIP-­‐I	  and	  BPSL1204	  were	  isolated	  from	  their	  independent	  .pdb	  files	  and	  aligned	  for	  comparison	  using	  Dali-­‐lite	  (Holm	  et	  al,	  2008).	  The	  results	  are	  summarised	  in	  Figure	  6.19.	  As	  expected,	  the	  uncomplexed	  and	  complexed	  BLIP-­‐I	  loops	  aligned	  in	  3-­‐D	  very	  well,	  whilst	  the	  BPSL1204	  loop	  appeared	  to	  align	  with	  uncomplexed	  BLIP-­‐I	  slightly	  better	  than	  complexed	  BLIP-­‐I.	  	  However,	  upon	  comparison	  of	  the	  amino-­‐acid	  sequences	  of	  the	  short	  inhibition	  loops	  there	  is	  very	  little	  homology.	  When	  the	  loop	  sequences	  of	  BLIP-­‐I	  from	  S.	  
mutans,	  S.	  clavigulus	  and	  S.	  exfoliatus	  are	  all	  compared	  against	  the	  loop	  in	  	  BPSL1204,	  a	  single	  glycine	  residue	  was	  the	  only	  residue	  to	  align	  between	  the	  4	  proteins	  (Figure	  6.20).	  It	  had	  been	  previously	  discovered	  within	  several	  TEM1:BLIP-­‐I	  complexes,	  for	  example	  PDB	  3gmw	  and	  2g2w	  (containing	  the	  TEM1	  homolog	  SHV1	  from	  Klebsiella	  pneumoniae	  and	  the	  Streptomyces	  clavuligerus	  BLIP-­‐I),	  that	  residues	  Gly48	  and	  Asp49	  played	  an	  integral	  part	  of	  the	  inhibition	  mechanism	  (Reynolds	  et	  al,	  2006).	  Gly48	  offers	  increased	  Ramachandran	  rotation	  angles	  to	  facilitate	  the	  sharp	  bend	  in	  the	  loop	  and	  a	  hydrogen	  bond	  with	  the	  TEM1	  Tyr105,	  which	  in	  turn	  offered	  multiple	  hydrogen	  bonds	  between	  Asp49	  and	  several	  TEM1	  active	  site	  residues	  (Ser130,	  Lys234and	  Arg244),	  essential	  for	  BLIP-­‐I	  binding	  (Figure	  6.21)	  (Strynadka	  et	  al,	  1996).	  	  	  Investigation	  of	  the	  equivalent	  loop	  in	  BPSL1204	  with	  the	  knowledge	  that	  the	  conserved	  glycine	  functions	  to	  provide	  increased	  rotational	  flexibility	  means	  it	  is	  possible	  that	  the	  BPSL1204	  loop	  could	  twist	  to	  align	  the	  adjacent	  glutamate	  with	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Figure 6.18: Superimposition of uncomplexed BLIP-I upon BLIP-I in complex with TEM1. 
 
The N-terminal inhibitory loop of BLIP-I occupies similar coordinates in both the apo- and 
halo-structures, however there is a slight change in conformation upon binding to TEM-1. 
Figure 6.19: Dali-lite structural alignment of the inhibitory loop region of uncomplexed 
BLIP-I, complexed BLIP-I and the relative looped region in BPSL1204. The 15 residues 
either side of a conserved and essential glycine (see Figure 6.20) are shown, as the Dali 
server requires a minimum of 30 residues for 3-D alignment. 
 
The uncomplexed BPSL1204 appears to resemble the loop of an uncomplexed BLIP-I 
slightly more than a complexed BLIP-I, with slightly lower Cα RMSD and slightly 
higher (but still poor) Z-score. 
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Figure 6.20: Alignment of inhibiting loops from multi-species BLIP-Is with 
crystal structures (essential Asp ±10 residues) with the corresponding region in 
BPSL1204. Alignment was performed using ClustalW, with colour reflecting 
residues with similar properties. 
 
All species lack homology throughout the 21 residues in the loop, but several 
conservative substitutions are seen (:), with a totally conserved (*) Gly/G 
residue -1 from the essential Asp/D (:). 
 
A Glu/E in BPSL1204 replaces the essential, conserved Asp in the BLIPs. This 
conveys similar chemical properties but presents an extra δC, which may induce 
steric hindrance preventing BPSL1204 binding a β–lactamase. 
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Figure 6.21: Investigation of TEM-1 (yellow) active site binding by BLIP-I (blue), 
and corresponding BPSL1204 (red) binding potential, in PyMol.  
 
In BLIP-I binding, Gly48 rotation twists the loop to align Asp49 to occupy the active 
site mouth, where electrostatic interaction with TEM-1 Arg244 and Lys234 facilitates 
binding. The loop is further stabilised by TEM-1 Tyr105 and Ser130 hydrogen-
bonding to the twisted loop backbone. 
 
By superimposing unbound BPSL1204 superimposed on TEM-1:BLIP-I, it is 
possible to visualise a rotation around Gly43 (bottom of the picture) that might 
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the	  essential	  aspartate	  of	  BLIP-­‐I	  (Figure	  6.21).	  This	  would	  offer	  the	  same	  potential	  for	  hydrogen	  bonding,	  although	  the	  side	  chain	  would	  extend	  further	  into	  the	  binding	  site	  in	  the	  opening	  of	  the	  TEM1	  active	  site.	  Slight	  differences	  elsewhere	  in	  the	  BPSL1204	  loop	  might	  ‘lift’	  the	  glutamate	  away	  from	  the	  binding	  site	  enough	  to	  account	  for	  the	  extra	  atom.	  Alternatively	  BPSL1204	  could	  bind	  to	  a	  protein	  similar	  to	  TEM1	  but	  with	  a	  deeper	  active	  site	  entrance.	  	  6.3.6	  Potential	  Explanations	  for	  Structural	  Similarity	  of	  BPSL1204	  to	  BLIP-­‐I	  	  Given	  the	  striking	  structural	  similarity	  between	  the	  individual	  domains	  of	  BPSL1204	  and	  BLIP-­‐I,	  and	  the	  discovery	  of	  the	  structural	  if	  not	  sequential	  potential	  for	  the	  N-­‐terminal	  domain	  of	  BPSL1204	  to	  provide	  a	  BLIP-­‐I	  like	  inhibition-­‐loop,	  it	  was	  proposed	  that	  BPSL1204	  might	  act	  upon	  a	  protein	  with	  a	  function	  similar	  to	  that	  of	  a	  β–lactamase.	  This	  theory	  was	  supported	  by	  the	  fact	  that	  proteins	  such	  as	  cell-­‐wall	  transpeptidases	  and	  other	  penicillin-­‐binding	  proteins	  have	  very	  similar	  structures	  to	  those	  of	  β–lactamases	  (Knox	  et	  al,	  1996)(Figure	  6.22).	  On	  the	  basis	  of	  structural	  similarites	  in	  fold	  and	  in	  active	  site	  residues	  and	  the	  fact	  that	  they	  all	  bind	  β–lactam	  antibiotics,	  it	  has	  been	  proposed	  that	  β-­‐lactam	  hydrolysing	  enzymes	  such	  as	  β–lactamases	  evolved	  from	  proteins	  that	  manipulated	  cell-­‐wall	  peptidoglycan	  structure	  (Samraoui	  et	  al,	  1986).	  	  	  Such	  an	  explanation	  could	  explain	  the	  different	  arrangement	  of	  domains	  with	  high	  structural	  similarity,	  as	  they	  may	  be	  involved	  in	  an	  analogous	  function	  to	  that	  of	  a	  BLIP	  that	  requires	  an	  alteration	  in	  binding	  orientation.	  In	  addition,	  it	  was	  considered	  that	  the	  BPSL1204	  structure	  used	  in	  comparisons	  was	  that	  of	  an	  N-­‐terminal	  20-­‐residue	  truncate,	  with	  the	  truncation	  in	  aid	  of	  releasing	  solvent-­‐interacting	  domains	  from	  a	  membrane-­‐associating	  glycerylcysteine	  lipoprotein	  anchor.	  β–lactamases	  are	  traditionally	  thought	  of	  as	  secreted	  proteins	  (Koshland	  &	  Botstein,	  1980),	  therefore	  questions	  were	  raised	  as	  to	  the	  biological	  purpose	  of	  covalently	  anchoring	  an	  effector	  of	  a	  secreted	  process.	  Therefore	  BPSL1204	  might	  have	  the	  potential	  to	  function	  in	  a	  membrane-­‐associated	  process	  with	  some	  analogy	  to	  β–lactamase	  activity	  or	  cell	  wall	  biosynthesis.	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Figure 6.22: Structural comparison of a β–lactamase with a transpeptidase in Pymol. 
Top left: E. coli TEM1 β–lactamase (PDB: 1BTL)(Jelsch et al, 1993). Top right:  
S. pneumoniae PBPx2 transpeptidase (PDB: 1PYY)(Chesnel et al, 2003). Bottom 
center: Dali-lite pairwise super-imposition of 1PYY and 1BTL (Holm et al, 2008). 
 
The two proteins share high structural similarity, with most α–helices and β–sheets 
superimposing to a high degree. Both also present the same-shaped opening to the 
active site, designated by      .  	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However	  it	  is	  also	  possible	  a	  structural	  similarity	  in	  the	  absence	  of	  sequence	  similarity	  may	  be	  purely	  due	  to	  chance.	  It	  is	  believed	  that	  there	  may	  only	  be	  a	  limited	  number	  of	  protein	  folds	  (Govindarajan	  et	  al,	  1999)	  and	  therefore	  there	  may	  be	  structural	  resemblances	  that	  do	  not	  have	  any	  relationship	  to	  a	  common	  function.	  Nevertheless	  in	  the	  case	  of	  BPSL1204,	  particularly	  because	  like	  BLIP-­‐I	  the	  domains	  are	  duplicated,	  the	  resemblance	  seemed	  worth	  investigating	  further.	  	  
6.4	  E.	  coli	  TEM-­1	  Inhibition	  Assay	  	  6.4.1	  Assay	  Design	  and	  Data	  Collection	  	  Given	  the	  inter-­‐species	  TEM1:BLIP-­‐I	  complexes	  that	  had	  been	  previously	  solved	  (PDB	  3gmw	  and	  2g2w)	  and	  shown	  to	  exhibit	  inhibition,	  it	  was	  proposed	  that	  an	  assay	  to	  analyse	  possible	  inhibition	  of	  the	  E.	  coli	  TEM1	  β–lactamase	  by	  BPSL1204-­‐MA	  would	  be	  carried	  out,	  in	  order	  to	  see	  if	  it	  is	  a	  general	  β–lactamase	  inhibitory	  protein	  like	  BLIP-­‐I.	  Following	  the	  procedure	  described	  in	  Section	  3.8.1,	  data	  were	  collected	  across	  a	  range	  of	  BPSL1204-­‐MA:TEM1	  concentrations	  up	  to	  4000:1,	  using	  a	  control	  assay	  of	  TEM1	  and	  substrate	  without	  BPSL1204	  and	  a	  control	  assay	  of	  substrate	  alone.	  Any	  increase	  in	  absorbance	  at	  a	  wavelength	  of	  486	  nm	  resulting	  from	  the	  hydrolysis	  of	  the	  β–lactam	  ring	  of	  the	  chromogenic	  β–lactamase	  substrate	  Nitrocefin	  (Figure	  6.23)	  would	  be	  measured.	  	  	  6.4.2	  Inhibition	  Assay	  Results	  and	  Observations	  	  The	  graph	  in	  Figure	  6.24	  represents	  the	  data	  collected	  during	  the	  inhibition	  assays.	  No	  absorbance	  was	  detected	  at	  λ	  486nm	  in	  the	  absence	  of	  TEM1,	  whereas	  absorbance	  increased	  over	  time	  in	  the	  presence	  of	  only	  TEM1.	  The	  addition	  of	  BPSL1204-­‐MA	  even	  to	  ratios	  as	  high	  as	  4000:1	  BPSL1204-­‐MA:TEM1	  resulted	  in	  no	  inhibition	  of	  TEM1,	  represented	  by	  a	  line	  that	  actually	  increased	  at	  a	  greater	  rate	  than	  that	  of	  the	  TEM1	  only	  control.	  This	  slight	  increase	  is	  probably	  due	  to	  minute	  differences	  between	  experimentally	  applied	  substrate:enzyme	  ratios,	  perhaps	  due	  to	  pipette	  inaccuracies	  and	  the	  high	  sensitivity	  of	  the	  assay.	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Figure 6.23: The chemical structure of Nitrocefin (picture from Calbiochem). 
Cleavage of the square β–lactam ring results in a change in absorbance from 380 nm 
to 486 nm. 
Figure 6.24: Line graph of Nitrocefin hydrolysis plotted over time in Microsoft Excel. 
 
The graph showed that there was no hydrolysis of Nitrocefin in the absence of TEM1 (green and 
purple). Control time courses were only carried out for 30 minutes and repeated only once, due 
to a constant plateau being measured.  
 
Upon introduction of TEM1 (red) hydrolysis was measured as an increase in absorbance at 486 
nm, with a reading taken every 30 seconds for 60 minutes. However upon the addition of 
BPSL1204 in saturating concentrations (blue) no decrease in absorbance was seen when a 
reading was taken every 30 seconds for 60 minutes, indicative of lack of inhibition of TEM1. 
The error bars represent the standard deviation from 3 repeats of each experiment. Standard 
deviations regularly overlap in the above plot, and therefore the results of the experiment were 
considered as not being significantly different between experiments. 
 
No further enzymatic measurements or calculations of TEM1 inhibition were carried out as it 
was considered apparent that BPSL1204 did not act in a BLIP-I-like fashion upon E. coli TEM1.	  	  	  	  
Time	  (minutes)	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The	  conclusion	  that	  can	  be	  made	  is	  that	  BPSL1204-­‐MA	  shows	  no	  sign	  of	  inhibiting	  the	  activity	  of	  the	  E.	  coli	  general	  β–lactamase	  TEM1.	  	  	  6.4.3	  Conclusions	  of	  the	  TEM1	  Inhibition	  Assay	  	  Regretfully,	  the	  assay	  was	  limited	  by	  the	  fact	  that	  the	  only	  conclusive	  result	  would	  be	  if	  inhibition	  did	  occur,	  otherwise	  the	  lack	  of	  inhibition	  allowed	  only	  further	  speculation.	  As	  it	  was	  seen	  that	  BPSL1204-­‐MA	  does	  not	  inhibit	  E.	  coli	  TEM1,	  this	  led	  to	  several	  possible	  conclusions.	  Lack	  of	  inhibition	  suggested	  that	  BPSL1204-­‐MA	  did	  not	  interact	  with	  this	  E.	  coli	  β–lactamase,	  but	  still	  may	  have	  the	  potential	  to	  act	  as	  an	  inhibitor	  of	  B.	  pseudomallei-­‐specific	  β–lactamases.	  Additionally,	  the	  truncated	  BPSL1204-­‐MA	  was	  used	  in	  the	  assay.	  Perhaps	  a	  full	  length	  BPL1204	  may	  confer	  inhibition	  onto	  a	  β–lactamase	  target,	  but	  with	  the	  conserved	  glycerylcysteine	  lipoprotein	  LLAGCA	  motif	  immediately	  upstream	  of	  the	  truncation	  site,	  this	  seemed	  unlikely.	  Moreover,	  we	  had	  not	  successfully	  over-­‐expressed	  the	  full-­‐length	  BPSL1204	  in	  a	  soluble	  form.	  Thirdly,	  BPSL1204	  may	  interact	  with	  other	  penicillin-­‐binding	  proteins	  such	  as	  cell-­‐wall	  transpeptidases.	  Finally,	  it	  could	  be	  the	  case	  that	  BPSL1204	  functions	  with	  a	  totally	  different,	  potentially	  novel	  biological	  function.	  	  
6.5	  Implications	  of	  Structural	  Bioinformatics	  	  Investigation	  of	  the	  crystallographic	  model	  of	  BPSL1204	  revealed	  new	  information	  about	  this	  putative	  lipoprotein	  from	  B.	  pseudomallei.	  It	  was	  confirmed	  that	  BPSL1204	  has	  two	  structurally	  similar	  domains	  that	  stack	  on	  top	  of	  one	  another	  and	  are	  connected	  by	  a	  seemingly	  rigid,	  short	  loop.	  A	  reasonably	  long	  11-­‐residue	  linker	  region	  exists	  between	  the	  first	  domain	  and	  the	  point	  of	  covalent	  linkage	  to	  a	  cell	  membrane,	  presumably	  conferring	  relatively	  flexible	  orientations	  whilst	  protruding	  from	  the	  membrane.	  However,	  although	  structural	  comparisons	  generated	  many	  observations	  that	  allow	  some	  speculation	  about	  the	  function	  of	  this	  previously	  unknown	  structure,	  no	  solid	  evidence	  for	  a	  function	  has	  been	  obtained.	  It	  was	  therefore	  decided	  that	  further	  biological	  experiments	  were	  required	  in	  order	  to	  establish	  the	  cellular	  function	  of	  BPSL1204.	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Chapter	  7:	  Biological	  Investigation	  of	  BPSL1204	  Function	  
	  
7.1	  Design	  of	  a	  Pull	  Down	  Assay	  	  7.1.1	  Burkholderia	  cenocepacia	  	  Due	  to	  the	  dangerous	  nature	  of	  B.	  pseudomallei	  (see	  Section	  1.1)	  as	  a	  pathogenic	  Class	  III	  biohazard	  organism,	  it	  was	  not	  possible	  to	  perform	  experiments	  involving	  live	  cultures	  in	  any	  of	  the	  Class	  I	  and	  II	  laboratories	  available	  in	  Sheffield.	  Therefore	  experiments	  involving	  the	  elucidation	  of	  BPSL1204’s	  biological	  function	  were	  carried	  out	  using	  the	  Class	  II	  paraphyletic	  species	  
Burkholderia	  cenocepacia	  (strains	  HIII	  and	  J2315,	  provided	  by	  Dr	  Mark	  Thomas	  of	  the	  Sheffield	  Medical	  School).	  This	  close	  relative	  of	  B.	  pseudomallei	  is	  a	  plant	  pathogen	  (Mahenthiralingam	  et	  al,	  2008),	  although	  it	  does	  also	  infect	  humans	  with	  cystic	  fibrosis	  (CF)	  to	  a	  high	  mortality	  rate	  (Jones	  et	  al,	  2004).	  Of	  the	  seven	  Gram-­‐negative	  B.	  cepacia	  complex	  species	  over	  90%	  of	  the	  fatalities	  in	  B.	  cepacia-­‐infected	  CF	  patients	  are	  caused	  by	  B.	  cenocepacia	  and	  B.	  multivorans	  (Mahenthiralingam	  et	  al,	  2008).	  As	  a	  very	  close	  genetic	  relative	  of	  B.	  
pseudomallei,	  B.	  cenocepacia	  also	  possesses	  a	  proteome	  in	  which	  many	  polypeptide	  amino	  acid	  sequences	  are	  identical	  or	  very	  similar.	  Therefore	  it	  was	  proposed	  that	  any	  interactions	  observed	  in	  B.	  cenocepacia	  homologs	  of	  B.	  
pseudomallei	  proteins	  could	  allow	  for	  the	  inference	  of	  those	  proteins’	  biological	  functions	  within	  B.	  pseudomallei.	  	  7.1.2	  BPSL1204	  and	  BCAL2351	  	  By	  performing	  a	  BLAST	  search	  using	  the	  full-­‐length	  amino	  acid	  sequence	  of	  BPSL1204	  against	  the	  entire	  proteome	  of	  non-­‐redundant	  sequences	  from	  B.	  
cenocepacia	  (Strain	  J2315,	  isolated	  from	  a	  CF	  patient	  in	  Edinburgh),	  it	  was	  discovered	  that	  one	  protein,	  BCAL2351,	  had	  an	  Evalue	  of	  3e-­‐109	  and	  88%	  identity	  with	  BPSL1204.	  In	  addition	  to	  this,	  the	  lipoprotein	  glycerylcysteine	  membrane-­‐anchoring	  motif	  LLAGCA	  was	  also	  present	  further	  showing	  that	  BCAL2351	  was	  confidently	  a	  homolog	  of	  BPSL1204.	  An	  alignment	  of	  BPSL1204-­‐MA	  was	  then	  carried	  out	  using	  BLAST	  against	  a	  similarly	  N-­‐terminal	  truncated	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BCAL2351	  sequence	  in	  order	  to	  compare	  the	  soluble	  domains	  to	  be	  used	  in	  the	  experiment.	  This	  required	  the	  removal	  of	  23	  residues	  from	  the	  BCAL2351	  N-­‐terminus	  compared	  to	  the	  20	  residues	  removed	  from	  BPSL1204	  (Figure	  7.1).	  This	  resulted	  in	  a	  sequence	  with	  92%	  identity	  to	  BPSL1204-­‐MA.	  This	  meant	  that	  BCAL2351	  is	  a	  clear	  protein	  homolog	  of	  BPSL1204,	  and	  is	  therefore	  extremely	  likely	  to	  have	  a	  soluble	  region	  with	  domains	  of	  identical	  structure	  to	  BPSL1204-­‐MA.	  	  7.1.3	  Aims	  of	  the	  Assay	  	  With	  the	  results	  of	  structural	  comparisons	  being	  inconclusive	  as	  to	  the	  function	  of	  BPSL1204,	  it	  was	  proposed	  that	  performing	  a	  pull-­‐down	  assay	  using	  a	  purified	  and	  immobilised	  B.	  cenocepacia	  homolog	  of	  BPSL1204	  washed	  with	  whole-­‐cell	  B.	  
cenocepacia	  lysate	  would	  lead	  to	  the	  isolation	  of	  proteins	  that	  biologically	  interact	  with	  the	  BCAL2351	  homolog.	  The	  cellular	  processes	  that	  isolated	  binding-­‐partners	  were	  involved	  with	  could	  then	  also	  allow	  for	  the	  discovery	  of	  the	  BPSL1204	  function	  in	  B.	  pseudomallei	  through	  inference.	  	  	  In	  addition	  to	  the	  discovery	  of	  biological	  binding	  partners,	  it	  was	  proposed	  that	  the	  results	  of	  a	  pull-­‐down	  assay	  might	  aid	  in	  the	  confirmation	  or	  rejection	  of	  structural	  conclusions	  regarding	  BLIP-­‐I.	  The	  use	  of	  whole-­‐cell	  lysate	  would	  provide	  soluble	  target	  proteins	  from	  the	  cytoplasm	  and	  periplasm	  of	  the	  bacterial	  cell.	  In	  Gram-­‐negative	  bacteria,	  β-­‐lactamases	  are	  commonly	  found	  in	  the	  periplasm,	  therefore	  the	  assay	  would	  allow	  for	  the	  possibility	  of	  BCAL2351	  binding	  to	  enzymes	  that	  are	  related	  to	  β-­‐lactamases.	  	  	  
7.2	  N-­terminal	  His-­tagged	  BCAL2351	  	  7.2.1	  pET28a	  Cloning	  and	  Transformation	  	  To	  facilitate	  immobilisation	  of	  BCAL2351-­‐MA,	  it	  was	  originally	  decided	  to	  clone	  a	  6xHis-­‐tag	  to	  the	  N-­‐terminus	  of	  the	  truncated	  protein	  for	  ionic	  attachment	  to	  a	  Ni-­‐NTA	  column.	  Primers	  were	  designed	  to	  introduce	  a	  5´	  6xHis-­‐tag	  nucleotide	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Figure 7.1: Sequence alignment of BPSL1204 and BCAL2351 in ClustalW. 
Colours represent residues with similar chemical properties. 
 
Most residues are identical (*), with most differences existing as conservative 
substitutions (:). Both proteins share the LLAGCA motif. 
Point	  of	  truncation	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sequence	  with	  a	  10-­‐residue	  linker	  region	  when	  cloned	  into	  pET28a,	  generating	  a	  construct	  with	  a	  51	  bp	  addition	  to	  the	  444	  bp	  BCAL2351-­‐MA.	  PCR	  was	  carried	  out	  following	  the	  protocol	  described	  in	  Section	  3.2.1,	  using	  an	  annealing	  temperature	  of	  55°C	  and	  0.5	  µl	  of	  a	  single	  B.	  cenocepacia	  colony	  boiled	  in	  30	  µl	  sterile	  water	  (Figure	  7.2).	  The	  PCR	  product	  was	  then	  restriction	  cloned	  into	  pET28a	  using	  NdeI	  and	  BamHI,	  using	  the	  protocol	  described	  in	  Section	  3.4.2.	  A	  ligation	  was	  carried	  out	  and	  then	  sub-­‐cloned	  into	  DH5α,	  with	  successful	  clones	  isolated	  using	  colony	  PCR,	  confirmed	  by	  plasmid	  DNA	  sequencing	  and	  transformed	  into	  the	  BL21(DE3)	  over-­‐expression	  strain,	  following	  the	  methods	  described	  in	  Sections	  3.4.2	  and	  3.4.3	  respectively.	  	  7.2.2	  Insolubility	  in	  BL21	  (DE3)	  Cells	  	  A	  BL21(DE3)	  pET28a:bcal2351-­‐MA	  colony	  was	  cultured	  overnight	  and	  subjected	  to	  5-­‐50	  ml	  over-­‐expression	  trials,	  optimised	  around	  the	  standard	  method	  described	  in	  Section	  3.5.3.	  Extensive	  variations	  of	  conditions	  such	  as	  inducing	  temperature	  (4-­‐37°C),	  length	  of	  over-­‐expression	  time	  (2-­‐24	  hours),	  concentration	  of	  inducing	  agent	  (0.1-­‐2	  mM	  IPTG	  in	  0.5	  mM	  steps)	  and	  method	  of	  cell	  lysis	  (sonication	  and	  BugBuster	  fractionation)	  were	  employed,	  but	  all	  analysis	  by	  SDS-­‐PAGE	  (Figure	  7.3)	  showed	  that	  any	  protein	  that	  was	  being	  produced	  existed	  entirely	  in	  an	  insoluble	  state.	  This	  suggested	  that	  as	  BCAL2351-­‐MA	  and	  BPSL1204-­‐MA	  were	  92%	  identical	  in	  sequence,	  then	  the	  resulting	  insolubility	  might	  have	  been	  due	  to	  the	  modified	  N-­‐terminal	  His-­‐tag	  contributing	  an	  extra	  16	  residues	  (an	  additional	  11%)	  of	  ‘alien’	  polypeptide.	  It	  was	  decided	  to	  attempt	  to	  refold	  the	  protein.	  	  7.2.3	  Inclusion	  Body	  Preparation	  and	  Refolding	  Assays.	  	  Cell-­‐paste	  containing	  insoluble	  His-­‐tagged	  BCAL2351-­‐MA	  was	  produced	  using	  the	  media	  and	  method	  described	  in	  Section	  3.5.	  Protein	  over-­‐expression	  was	  induced	  for	  4	  hours	  at	  37°C	  using	  1	  mM	  IPTG.	  5	  g	  of	  cells	  were	  resuspended	  in	  50	  ml	  of	  50	  mM	  Tris	  pH	  8.0,	  sonicated	  on	  ice	  for	  3x20	  seconds	  at	  16	  microns,	  and	  the	  insoluble	  fraction	  isolated	  into	  a	  pellet	  by	  centrifugation	  in	  a	  JA25.50	  rotor	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Figure 7.2: 1% agarose gel electrophoresis of N-his BCAL2351-MA PCR product.  
Lane 1 = PCR product. Lane 2 = Hyperladder I (bp).  
A pure band is seen at the expected molecular weight of 495 bp (444 + 51 bp). 
Figure 7.3: SDS-PAGE analysis of N-hisBCAL2351-MA over-expression, at 1mM 
IPTG for 4 hours. Lane 1 = Mark12 (kDa), Lane 2-4 = No induction, 15 and 37°C 
soluble Bugbuster fractionation. Lane 5-7 = No induction, 15 and 37°C insoluble 
Bugbuster fractionation. Lane 8+9 = 25°C, fractionation by sonication, soluble and 
insoluble respectively. 
 
Lane 7 represents the typical amount of insoluble N-hisBCAL2351-MA produced 
from many variations of time, [IPTG], temperature and fractionation method. No 
soluble protein was ever produced. 
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for	  15	  minutes	  at	  24500	  rpm	  at	  4°C.	  The	  pellet	  was	  resuspended	  with	  sonication	  in	  50	  mM	  Tris	  pH	  8.0,	  0.1	  M	  NaCl	  and	  0.5%	  Triton	  X-­‐100,	  and	  then	  re-­‐pelleted	  at	  10000	  rpm	  for	  20	  minutes	  in	  a	  JA25.50	  rotor	  to	  collect	  the	  inclusion	  bodies.	  This	  step	  was	  repeated	  2	  further	  times,	  in	  the	  absence	  of	  Triton	  X-­‐100,	  to	  wash	  away	  all	  cell-­‐debris	  and	  purify	  inclusion	  bodies	  into	  a	  pellet.	  The	  final	  inclusion	  body	  pellet	  was	  resuspended	  in	  2	  ml	  of	  8	  M	  urea,	  with	  the	  protein	  concentration	  then	  established	  by	  a	  Bradford	  Assay	  to	  allow	  for	  the	  addition	  of	  8	  M	  urea	  to	  give	  a	  final	  protein	  concentration	  of	  1	  mg/ml.	  	  This	  sample	  was	  then	  applied	  to	  the	  QuickFold	  kit,	  available	  from	  Athenaes	  Enzyme	  Systems,	  and	  the	  screening	  protocol	  in	  Application	  Manual	  V.2	  supplied	  with	  the	  kit	  was	  followed	  exactly	  for	  all	  of	  the	  15	  conditions	  provided.	  Analysis	  of	  the	  refolding	  screen	  was	  carried	  out	  by	  SDS-­‐PAGE	  of	  samples	  of	  the	  soluble	  supernatants	  after	  the	  last	  microcentrifugation	  step	  of	  the	  manufacturers	  protocol.	  As	  can	  be	  seen	  in	  Figure	  7.4,	  results	  of	  the	  screen	  suggest	  refolding	  Condition	  11	  (50	  mM	  Tris.HCl	  pH	  8.5,	  9.6	  mM	  NaCl,	  0.4	  mM	  KCl,	  1	  mM	  EDTA,	  0.5%	  Triton	  X-­‐100,	  1	  mM	  DTT)	  resulted	  in	  at	  least	  some	  soluble,	  refolded	  protein.	  However,	  upon	  optimisation	  to	  remove	  EDTA	  (to	  improve	  binding	  to	  a	  Ni-­‐NTA	  column	  by	  reducing	  the	  Ni2+-­‐chelating	  effect	  of	  EDTA	  presence)	  and	  Triton	  X-­‐100	  (a	  strong	  detergent	  that	  may	  have	  been	  difficult	  to	  remove	  in	  wash	  steps	  and	  may	  have	  perturbed	  biological	  interactions),	  it	  was	  not	  possible	  to	  obtain	  soluble	  protein	  as	  protein	  visibly	  precipitated,	  and	  the	  supernatant	  post-­‐microcentrifuge	  contained	  no	  protein	  as	  assessed	  by	  SDS-­‐PAGE.	  	  The	  remaining	  majority	  of	  the	  8	  M	  urea-­‐denatured	  N-­‐His	  BCAL2351-­‐MA	  was	  scaled	  up	  and	  treated	  to	  a	  1:20	  dilution	  using	  Condition	  11,	  as	  applied	  in	  the	  QuickFold	  protocol.	  This	  was	  then	  spun	  down	  at	  20000	  rpm	  at	  4°C	  for	  20	  minutes	  in	  a	  JA25.50	  rotor	  to	  remove	  permanently	  insoluble	  material,	  and	  then	  the	  soluble,	  N-­‐His	  BCAL351-­‐MA-­‐containing	  supernatant	  was	  concentrated	  to	  a	  final	  volume	  of	  2	  ml	  of	  2	  mg/ml	  protein.	  This	  was	  then	  run	  on	  a	  gel-­‐filtration	  column,	  following	  the	  method	  described	  in	  Section	  3.6.4,	  to	  assess	  stoichiometric	  state	  and	  to	  confirm	  BPSL1204-­‐MA-­‐like	  soluble	  behaviour	  in	  the	  absence	  of	  an	  activity	  assay.	  As	  can	  be	  seen	  in	  Figure	  7.5,	  the	  gel	  filtration	  profile	  generated	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Figure 7.4: SDS-PAGE analysis of QuickFold refolding experiment.  
Lane 1 = Mark12 (kDa). Lane 2-8 = Condition 9-15 soluble fraction.  
Lane 9 = Soluble N-hisBCAL2351 in 8 M urea. 
 
The gel analysis suggested that N-hisBCAL2351 could be refolded using 
QuickFold Condition 11 (Lane 4), compared to the 8 M solubilised protein 
in Lane 9. Conditions 1-8 gave no soluble protein on SDS-PAGE. 
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Figure 7.5: Gel-filtration trace of N-hisBCAL2351 post-refolding optimisation. 
The peak runs off the column after 110ml in Fraction 34 (BPSL1204 ran off 
after 100ml) indicating a folded monomer of N-hisBCAL2351, however the 
sample did not bind a HisTrap column.  
110	  ml	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was	  very	  similar	  to	  that	  of	  pure,	  monomeric	  BPSL1204-­‐MA	  as	  documented	  in	  Section	  4.4.4	  (Figure	  4.8).	  However,	  when	  the	  6	  ml	  fractions	  under	  the	  gel-­‐filtration	  peak,	  now	  buffer-­‐exchanged	  into	  50	  mM	  Tris	  pH	  8.0	  and	  0.5	  M	  NaCl	  via	  the	  gel-­‐filtration	  process,	  were	  applied	  to	  a	  fully	  charged	  1	  ml	  His-­‐Trap	  Ni-­‐NTA	  column	  there	  was	  no	  binding	  of	  N-­‐His	  BCAL2351-­‐MA	  to	  the	  His-­‐Trap	  column.	  It	  was	  therefore	  concluded	  that	  although	  N-­‐His	  BCAL2351-­‐MA	  seemed	  to	  have	  refolded	  post-­‐urea	  denaturing,	  it	  had	  mis-­‐folded	  to	  adopt	  a	  soluble,	  monomeric	  conformation	  that	  buried	  the	  6xHis-­‐tag	  and	  therefore	  could	  not	  be	  a	  biological	  conformation	  similar	  to	  that	  of	  BPSL1204,	  negating	  the	  use	  of	  N-­‐His	  BCAL2351-­‐MA	  in	  any	  possible	  pull-­‐down	  assay.	  	  
7.3	  Affi-­Gel15	  Pull	  Down	  Assay	  	  7.3.1	  Design	  of	  a	  Second	  Pull-­‐down	  Method	  	  Giving	  the	  insolubility	  of	  BCAL2351-­‐MA	  (N-­‐His	  construct	  described	  in	  Section	  7.2.2	  and	  without	  a	  tag	  described	  in	  Section	  6.3.3),	  a	  different	  approach	  was	  decided	  upon.	  With	  the	  aim	  of	  the	  pull-­‐down	  to	  model	  BPSL1204	  interactions	  using	  B.	  cenocepacia	  homologs,	  it	  was	  proposed	  that	  BPSL1204	  would	  interact	  with	  the	  same	  proteins	  as	  BCAL2351	  from	  B.	  cenocepacia	  cell-­‐free	  extract.	  Therefore	  with	  soluble,	  untagged	  BPSL1204-­‐MA	  already	  obtainable,	  a	  method	  for	  immobilisation	  was	  required.	  It	  was	  decided	  that	  immobilisation	  of	  the	  acidic	  BPSL1204-­‐MA,	  with	  a	  theoretical	  pI	  of	  5.32	  as	  calculated	  by	  the	  online	  ExPASy	  ProtParam	  tool,	  to	  Affi-­‐Gel	  15	  cross-­‐linked	  agarose	  beads	  available	  from	  Bio-­‐Rad	  would	  allow	  the	  purification	  of	  binding	  partner(s)	  from	  cell-­‐free	  B.	  cenocepacia	  extract	  via	  bead	  affinity	  chromatography.	  	  	  7.3.2	  Culturing	  B.	  cenocepacia	  and	  Safe	  Practice	  	  The	  Class	  II	  Thomas	  laboratory	  routinely	  used	  B.	  cenocepacia	  to	  microbiologically	  and	  biochemically	  investigate	  aspects	  of	  infection	  of	  CF	  patients.	  Therefore	  all	  cultures	  were	  carried	  out	  under	  their	  supervision	  using	  that	  lab’s	  equipment.	  Following	  the	  LB	  media	  preparation	  and	  culturing	  methods	  described	  in	  Section	  3.5,	  the	  protocol	  applied	  to	  E.	  coli	  cultures	  was	  used	  for	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growing	  B.	  cenocepacia	  with	  the	  exception	  of	  using	  a	  lower	  shaking	  speed	  of	  150	  rpm	  to	  reduce	  aerosol	  production.	  LB	  media	  was	  supplemented	  with	  100	  mg/ml	  ampicillin,	  to	  which	  B.	  cenocepacia	  is	  highly	  resistant.	  All	  work	  with	  whole	  cells,	  in	  culture	  or	  in	  a	  pellet,	  was	  carried	  out	  in	  a	  BioMat2	  Class	  II	  Microbiology	  Safety	  Cabinet	  with	  laminar	  airflow,	  sealable	  protective	  screen	  and	  UV	  sterilisation	  capabilities,	  with	  all	  waste	  media	  and	  equipment	  used	  autoclave-­‐sterilised	  before	  leaving	  the	  Class	  II	  lab	  environment.	  For	  the	  initial	  assays,	  B.	  cenocepacia	  was	  cultured	  overnight	  (16-­‐18	  hours)	  at	  37°C.	  	  7.3.3	  First	  Pull-­‐Down	  Assay	  	  Pure	  BPSL1204-­‐MA	  was	  immobilised	  to	  the	  Affi-­‐Gel	  15	  cross-­‐linked	  agarose	  beads	  via	  N-­‐hydroxysuccinimide	  esterification	  of	  free	  primary	  amines,	  such	  as	  lysine	  side-­‐chains,	  upon	  combination	  in	  an	  aqueous	  environment.	  50	  mM	  HEPES	  pH	  7.5	  was	  used	  rather	  than	  Tris,	  to	  prevent	  swamping	  of	  the	  beads	  with	  primary	  amines.	  After	  bait-­‐protein	  immobilisation,	  excess	  hydroxysuccinimide	  moieties	  were	  blocked	  by	  the	  addition	  of	  ethanolamine.	  Cell-­‐free	  extract	  was	  prepared	  by	  sonication	  of	  B.	  cenocepacia	  cell-­‐paste	  in	  50	  mM	  HEPES	  pH	  7.5,	  followed	  by	  centrifugation	  to	  remove	  insoluble	  proteins	  and	  cell-­‐debris.	  Cell-­‐free	  extract	  was	  then	  used	  to	  wash	  the	  Affi-­‐Gel	  15:BPSL1204-­‐MA	  beads,	  which	  were	  then	  washed	  in	  low	  salt	  concentration	  to	  remove	  non-­‐binding	  proteins	  before	  elution	  of	  binding	  partners	  was	  achieved	  by	  high	  salt	  concentration	  elution	  or	  boiling	  in	  LDS.	  All	  steps	  were	  applied	  to	  a	  non-­‐Burkholderia	  control	  protein,	  the	  34	  kDa	  YloQ	  from	  Bacillus	  subtilis,	  (Cladiere	  et	  al,	  2006;	  Ruzheinikov	  et	  al,	  2004)	  to	  account	  for	  random	  Affi-­‐Gel	  15:immobilised	  protein	  background.	  The	  full	  details	  of	  the	  protocol	  used	  can	  be	  found	  in	  Section	  3.8.2.	  	  7.3.4	  Analysis	  of	  Isolated	  Fractions	  By	  SDS-­‐PAGE	  	  Samples	  of	  bait	  proteins,	  cell-­‐free	  extract	  before	  the	  assay	  and	  all	  fractions	  taken	  during	  the	  assay	  were	  run	  on	  a	  4-­‐12%	  NuPAGE	  gradient	  SDS-­‐PAGE	  gel,	  available	  from	  Invitrogen,	  to	  identify	  the	  molecular	  weights	  of	  proteins	  present	  in	  each	  step	  of	  the	  experiment.	  This	  was	  stained	  in	  colloidal	  Coomassie	  G-­‐250	  InstantBlue	  protein	  stain/destain,	  to	  allow	  for	  ‘from-­‐gel’	  mass	  spectrometry	  at	  a	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later	  stage,	  as	  standard	  non-­‐colloidal	  Coomassie	  R-­‐250	  is	  not	  compatible	  with	  mass	  spectrometric	  methods.	  As	  can	  be	  seen	  in	  Figure	  7.6,	  in	  both	  LDS-­‐boiled	  beads	  and	  both	  NaCl	  elutions	  there	  was	  a	  band	  present	  at	  ~80	  kDa	  that	  was	  not	  present	  in	  the	  YloQ	  control	  lanes.	  This	  band	  represented	  a	  potential	  protein	  binding-­‐partner	  for	  BPSL1204-­‐MA.	  A	  massive	  background	  of	  contamination	  in	  all	  samples	  was	  witnessed	  in	  Figure	  7.6,	  perhaps	  due	  to	  non-­‐specfic	  interactions	  with	  the	  agarose	  beads	  regardless	  of	  the	  ethanolamine	  blocking	  reaction.	  However,	  this	  contamination	  was	  present	  in	  all	  control	  lanes	  too,	  thus	  still	  allowing	  comparisons	  for	  potential	  binding-­‐partners	  of	  BPSL1204.	  	  	  Inspection	  of	  YloQ	  control	  lanes	  shows	  that	  YloQ	  was	  also	  present	  in	  the	  elutions	  (due	  to	  in	  vitro	  dimeric	  nature	  leading	  to	  salt-­‐induced	  dissociation	  of	  subunits)	  that	  may	  mask	  other	  potential	  binding	  partners	  that	  have	  mass	  of	  ~34	  kDa.	  It	  was	  decided	  in	  future	  assays	  to	  use	  the	  monomeric	  BPSL1549	  (Cruz-­‐Migoni	  et	  al,	  2011)	  as	  a	  control	  protein.	  	  7.3.5	  Second	  Pull-­‐Down	  Assay	  	  In	  order	  to	  corroborate	  the	  results	  of	  the	  original	  assay,	  the	  pull-­‐down	  was	  repeated	  again	  using	  the	  B.	  pseudomallei	  BPSL1549	  protein	  as	  a	  control,	  chosen	  as	  it	  was	  monomeric	  and	  also	  of	  interest	  to	  see	  if	  BPSL1549	  would	  pull-­‐down	  B.	  
cenocepacia	  proteins	  different	  to	  those	  of	  BPSL1204.	  Empty	  beads	  blocked	  only	  with	  ethanolamine	  were	  used	  as	  a	  second	  control,	  to	  account	  for	  the	  background	  attributable	  to	  non-­‐specific	  interactions	  with	  the	  beads.	  The	  method	  described	  in	  Section	  3.8.2	  was	  employed	  and	  boiling	  in	  LDS	  or	  ionic	  perturbation	  by	  2	  M	  NaCl	  was	  used	  to	  elute	  final	  fractions.	  	  NuPAGE	  4-­‐12%	  SDS-­‐PAGE	  analysis	  of	  the	  resulting	  fractions	  and	  controls	  (Figure	  7.7)	  revealed	  that	  the	  ~80	  kDa	  band	  discovered	  in	  the	  original	  Affi-­‐Gel	  15:BPSL1204-­‐MA	  pull-­‐down	  (Section	  7.3.4)	  was	  once	  again	  isolated	  from	  the	  cell-­‐free	  extract,	  along	  with	  the	  large	  quantity	  of	  background	  non-­‐specific/bead-­‐	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Figure 7.6: SDS-PAGE analysis of first pull-down. 
 
Lane 1 = Mark12 (kDa).  
Lane 2 = Purified BPSL1204.  
Lane 3 = Purified YloQ 
Lane 4 = B. cenocepacia cell-free extract 
Lane 6 = BPSL1204 LDS-boiled eluate  
Lane 7 = YloQ LDS-boiled eluate 
Lane 9= YloQ 1.5 M NaCl eluate 
Lane 10 = BPSL1204 1.5 M NaCl eluate 
Lane 11 = YloQ 2 M NaCl eluate 
Lane 12 = BPSL1204 2 M NaCl eluate 
Lane 5 + 8 = Empty 
 
Many contaminating proteins were pulled out in all experiments. A single band 
was pulled out of the cell-extract in the BPSL1204 pull-down only, at ~80 
kDa, using either LDS or NaCl elution ( ). The presence of YloQ in 
control lanes is due to the dimeric nature of the control protein.  
!
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Figure 7.7: SDS-PAGE analysis of second pull-down. 
 
Lane 1 = Mark12 (kDa) 
Lane 3 = Purified BPSL1204 
Lane 4 = Purified BPSL1549 
Lane 6 = B. cenocepacia cell-free extract 
Lane 8 = BPSL1204 LDS eluate 
Lane 9 = BPSL1549 LDS eluate 
Lane 10 = Empty beads LDS eluate 
Lane 12 = BPSL1204 2 M NaCl eluate 
Lane 13 = Empty beads 2 M NaCl eluate 
Lane 14 = BPSL1549 2 M NaCl eluate 
Lanes 2, 5, 7 and 11 = empty lanes 
 
The ~80 kDa band seen in the first pull down assay using BPSL1204 was 
replicated in the second pull-down assay (lane 8 and 12,    ). In addition, 
a further band was isolated at around ~45 kDa in the BPSL1204 pull-down 
only (         ).  
 
The BPSL1549 control beads did not pull down any bands that did not 
appear in the empty beads control. 
!
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interacting	  contaminants	  present	  in	  the	  control	  samples.	  However,	  in	  these	  experiments	  an	  additional	  band	  of	  ~45	  kDa	  was	  seen	  to	  be	  present	  only	  in	  the	  BPSL1204	  lanes.	  This	  secondary	  band	  however	  appeared	  to	  contribute	  to	  significantly	  less	  of	  the	  mass	  of	  isolated	  proteins	  in	  the	  BPSL1204	  pull-­‐down	  samples	  than	  the	  twice	  isolated	  ~80	  kDa	  band,	  and	  was	  not	  witnessed	  in	  the	  first	  pull-­‐down	  assay	  that	  had	  used	  exactly	  the	  same	  cell-­‐free	  extract	  sample	  and	  same	  elution	  methods	  as	  the	  second	  assay.	  	  7.3.6	  Identification	  of	  Proteins	  ‘Pulled-­‐Out’	  of	  Cell	  Extract	  	  The	  colloidal-­‐Coomassie-­‐stained	  gels	  were	  subjected	  to	  band	  excision,	  reduction	  via	  DTT	  and	  alkylation	  via	  iodoacetamide	  of	  the	  protein-­‐gel	  slice	  followed	  by	  overnight	  tryptic	  digestion.	  Separation	  of	  protein	  from	  the	  gel	  was	  achieved	  by	  systematic	  addition	  of	  ammonium	  bicarbonate	  with	  increasing	  concentrations	  of	  acetonitrile,	  followed	  by	  treatment	  with	  formic	  acid	  (Shevchenko	  et	  al,	  2006).	  Finally	  MALDI-­‐TOF	  mass	  spectrometry	  of	  the	  resulting	  trypsin-­‐digested	  peptide	  fragments	  was	  performed	  (Bonk	  &	  Humeny,	  2001).	  These	  procedures	  were	  performed	  by	  Dr	  Mark	  Dickman	  of	  the	  University	  of	  Sheffield	  ChELSI	  (Chemical	  Engineering	  at	  the	  Life	  Science	  Interface)	  Department	  of	  Chemical	  and	  Biological	  Engineering.	  Both	  of	  the	  isolated	  bands	  unique	  to	  the	  Affi-­‐Gel	  15:BPSL1204	  lanes	  from	  the	  second	  pull-­‐down	  assay	  were	  investigated,	  alongside	  the	  corresponding	  region	  in	  the	  adjacent	  control	  lanes	  to	  account	  for	  non-­‐specific	  background	  components.	  The	  masses	  of	  the	  ionised	  trypsin-­‐fragments	  from	  each	  of	  the	  2	  identified	  bands	  were	  independently	  input	  into	  the	  MASCOT	  server	  (Cottrell,	  2012)	  (www.matrixscience.com/server.html),	  which	  calculated	  which	  translated	  protein	  sequences	  from	  the	  B.	  cenocepacia	  J2315	  genome	  were	  most	  likely	  to	  generate	  the	  observed	  trypsin-­‐fragment	  masses.	  	  	  The	  mass	  spectrometry	  analysis	  revealed	  that	  the	  ~80	  kDa	  band	  in	  only	  BPSL1204	  pull-­‐downs	  was	  a	  Methionyl	  tRNA	  Synthetase	  with	  97	  matching	  fragments	  and	  a	  score	  of	  2159	  (Figure	  7.8).	  However	  the	  experiment	  performed	  on	  the	  ~45	  kDa	  band	  gave	  a	  less	  confident	  result,	  with	  three	  putative	  protein	  hits	  of	  Glutamate-­‐1-­‐semialdehyde	  2,1-­‐aminomutase	  with	  12	  fragments	  scoring	  293,	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Figure 7.8: Results of MASCOT server analysis of mass spectroscopic trypsin-
digested pull-down targets. Top: List of proteins detected in the ~80 kDa band. 
Bottom: List of proteins in the ~45 kDa band. 
 
The most convincing hit of all detected was the 79.1 kDa Met-tRNA Synthetase. 
Gel slices taken from the corresponding regions of the control lanes revealed only 
contaminating human proteins 
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TolB	  with	  7	  fragments	  scoring	  158	  and	  Enolase	  with	  3	  fragments	  scoring	  76.	  Various	  keratins	  discovered	  in	  most	  experiments	  were	  presumably	  a	  product	  of	  human	  skin	  or	  hair	  contamination	  either	  during	  the	  gel	  staining/destaining	  process	  or	  the	  gel-­‐excision	  procedure.	  	  	  7.3.7	  Choice	  of	  Target	  Protein	  	  Given	  the	  large	  number	  of	  fragments	  generated,	  increasing	  the	  likelihood	  of	  locating	  the	  correct	  protein	  sequence,	  and	  that	  any	  score	  under	  75	  is	  considered	  insignificant,	  the	  79.1	  kDa	  methionyl-­‐tRNA	  synthetase	  was	  the	  most	  confident	  result	  from	  all	  the	  mass	  spectrometry	  outputs.	  In	  addition	  to	  this,	  this	  protein	  was	  the	  only	  one	  present	  in	  both	  pull-­‐down	  assays	  and	  in	  the	  greatest	  abundance	  in	  the	  samples	  that	  were	  loaded	  onto	  the	  original	  SDS-­‐PAGE	  gels.	  Enolase	  was	  discounted	  immediately	  due	  to	  its	  very	  low	  score	  and	  fragment	  count.	  The	  glutamate	  aminomutase	  was	  also	  discounted	  as	  an	  artifact	  of	  random	  interaction	  due	  to	  its	  low	  score	  and	  low	  fragment	  count.	  	  TolB	  scored	  low	  also,	  but	  is	  a	  periplasmic	  protein	  involved	  in	  uptake	  of	  colicin	  A	  by	  the	  Tol/Pal	  system	  (in	  E.	  coli)	  (Walburger	  et	  al,	  2002).	  As	  β–lactamases	  and	  cell-­‐wall	  transpeptidases	  are	  thought	  to	  exist	  in	  the	  periplasm,	  this	  may	  be	  more	  relevant	  both	  in	  relation	  to	  the	  BLIP	  similarity	  and	  also	  in	  relation	  to	  the	  subcellular	  location	  expected	  of	  BPSL1204.	  However,	  the	  apparently	  low	  binding	  capability	  to	  BPSL1204,	  as	  seen	  by	  only	  appearing	  in	  1	  out	  of	  2	  pull-­‐down	  assays	  in	  lower	  abundance	  than	  the	  methionyl-­‐tRNA	  synthetase,	  combined	  with	  a	  low	  MASCOT	  score	  and	  fragment	  count	  made	  the	  odds	  of	  a	  stable	  biological	  interaction	  improbable.	  In	  addition	  to	  experimental	  results,	  the	  Tol/Pal	  system	  is	  well	  established	  (Vianney	  et	  al,	  1996)	  with	  no	  reported	  relation	  to	  proteins	  with	  domain-­‐folds	  similar	  to	  BLIP-­‐I.	  	  	  It	  was	  decided	  to	  investigate	  the	  seemingly	  strong	  interaction	  between	  methionyl-­‐tRNA	  synthetase	  and	  BPSL1204.	  It	  was	  considered	  whether	  BPSL1204	  might	  act	  as	  a	  regulatory	  protein	  of	  methionyl-­‐tRNA	  synthetase	  function,	  or	  aid	  in	  the	  delivery	  of	  one	  or	  both	  of	  the	  enzymes’	  tRNA	  and	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methionine	  substrates.	  This	  did	  however	  seem	  unlikely	  as	  tRNA	  synthetases	  are	  cytoplasmic	  but	  BPSL1204	  is	  likely	  to	  be	  covalently	  anchored	  to	  a	  membrane.	  Alternatively	  BPSL1204	  may	  not	  be	  a	  true	  lipoprotein,	  or	  that	  the	  interactions	  discovered	  by	  the	  Affi-­‐Gel	  15	  pull-­‐down	  assays	  may	  have	  been	  strong	  but	  non-­‐specific	  and	  non-­‐biological.	  It	  was	  decided	  that	  experiments	  investigating	  the	  ability	  of	  pure	  BPSL1204-­‐MA	  and	  pure	  methionyl-­‐tRNA	  synthetase	  to	  form	  a	  stable,	  soluble	  complex	  were	  required,	  in	  tandem	  with	  assays	  for	  tRNA	  synthetase	  activity.	  This	  would	  also	  allow	  for	  crystallographic	  investigation	  of	  any	  potential	  biological	  interactions.	  	  
7.4	  BPSL0998	  	  7.4.1	  Novel	  Features	  of	  BPSL0998	  	  Investigation	  of	  the	  genetic	  origin	  of	  the	  methionyl-­‐tRNA	  synthetase	  using	  the	  BLAST	  databases	  revealed	  it	  to	  be	  the	  gene	  product	  of	  BCAL2646	  in	  B.	  
cenocepacia.	  As	  the	  source	  of	  the	  BPSL1204	  bait-­‐protein	  under	  investigation	  was	  from	  B.	  pseudomallei,	  the	  genome	  of	  B.	  pseudomallei	  was	  searched	  for	  BCAL2646	  homologs,	  uncovering	  the	  88%	  identical	  BPSL0998	  with	  a	  match	  of	  Evalue	  =	  0.0.	  Figure	  7.9	  shows	  the	  sequence	  of	  BCAL2646	  aligned	  with	  BPSL0998.	  Upon	  BLAST	  investigation	  of	  the	  BPSL0998	  sequence	  compared	  to	  the	  E.	  coli	  equivalent	  in	  the	  PDB	  (PDB:	  3H9C,	  used	  as	  a	  potential	  homology-­‐model	  for	  Molecular	  Replacement)	  it	  was	  discovered	  that	  the	  N-­‐terminal	  and	  central	  region	  (residues	  1-­‐514)	  of	  BPSL0998	  has	  55%	  identity	  with	  E.	  coli	  Met-­‐tRNA	  synthetase,	  however	  the	  C-­‐terminal	  region	  of	  the	  BPSL0998	  sequence	  (residues	  540-­‐637)	  lacked	  any	  homology	  to	  the	  E.	  coli	  protein	  (Figure	  7.10).	  	  	  After	  a	  26-­‐residue	  ‘linker’	  region,	  the	  sequence	  of	  this	  region	  has	  48%	  identity	  to	  the	  Trbp111	  structure-­‐specific	  tRNA-­‐binding	  protein	  from	  Aquifex	  aeolicus	  (Swairjo	  et	  al,	  2000)(Figure	  7.10).	  Individual	  Trbp111	  protein	  is	  proposed	  to	  dimerise,	  bind	  and	  stabilise	  the	  right-­‐angled	  T-­‐loop	  common	  to	  all	  tRNA	  macromolecules	  (Li	  et	  al,	  1996).	  Apart	  from	  any	  BPSL1204	  interest,	  this	  meant	  that	  BPSL0998	  was	  interesting,	  as	  the	  presence	  of	  a	  single	  structure-­‐specific	  tRNA-­‐binding	  domain	  added	  to	  a	  protein	  such	  as	  a	  met-­‐tRNA	  synthetase	  that	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Figure 7.9: Sequence alignment of BCAL2646 with BPSL0998, made in ClustalW. 
* signifies conserved residues, whilst : signifies conservative substitutions. 
 
BPSL0998 is the B. pseudomallei homologue of B. cenocepacia BCAL2646 
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Figure 7.10: Alignment of BPSL0998 with the 3H9C E. coli MetRS and Trbp111 in 
ClustalW. The brackets ([]) enclose the linker region in BPSL0998 that connects the 3H9C- 
and Trbp111-like domains. Trbp111 and 3H9C do not share any sequence homology.  
	   202	  
already	  binds	  tRNA	  as	  a	  catalytic	  substrate	  was	  an	  interesting	  situation,	  which	  might	  be	  investigated	  by	  X-­‐ray	  crystallographic	  studies.	  	  7.4.2	  pBAD/hisB	  Cloning	  of	  BPSL0998	  	  In	  order	  to	  produce	  and	  purify	  BPSL0998,	  the	  gene	  was	  PCR	  amplified	  using	  the	  primers	  described	  in	  Section	  3.4.1	  and	  a	  self-­‐designed	  touchdown	  method	  based	  upon	  the	  general	  protocol	  in	  Section	  3.2.1,	  due	  to	  difficulties	  in	  purity	  and	  amount	  of	  amplification.	  This	  required	  a	  10-­‐fold	  dilution	  of	  B.	  pseudomallei	  genome,	  twice	  the	  concentration	  of	  primers	  described	  in	  the	  standard	  method	  and	  a	  final	  10%	  DMSO	  concentration.	  Then	  20	  cycles	  of	  5x	  standard	  PCR	  loops	  were	  employed,	  with	  each	  cycle	  dropping	  the	  annealing	  temperature	  by	  1°C	  from	  70-­‐50°C.	  This	  allowed	  for	  swamping	  of	  the	  genomic	  template	  with	  primers,	  and	  by	  starting	  the	  reaction	  above	  the	  annealing	  temperature	  and	  touching	  down	  the	  annealing	  it	  allowed	  the	  very	  specific	  primers	  to	  bind	  either	  side	  of	  the	  large	  2178	  bp	  gene	  instead	  of	  the	  partially	  specific,	  smaller-­‐fragment	  binding	  sites	  that	  were	  leading	  to	  unfavourable	  contaminants	  in	  the	  original	  PCR	  reaction	  (Figure	  7.11).	  	  	  Amplified	  genes	  were	  then	  purified	  by	  gel-­‐extraction	  and	  subjected	  to	  restriction	  cloning	  into	  the	  pBAD/hisB	  vector	  (available	  from	  Invitrogen)	  using	  NcoI	  and	  BamHI	  following	  the	  method	  described	  in	  Section	  3.4.2.	  After	  selection	  of	  a	  successful	  DH5α	  sub-­‐clone	  by	  colony	  PCR	  (Figure	  7.11),	  the	  pBAD/hisB:BPSL0998	  construct	  was	  transformed	  into	  the	  arabinose-­‐inducible	  Top10	  E.	  coli	  cell-­‐line.	  	  	  7.4.3	  Insolubility	  in	  Top10	  Cells	  	  Extensive	  over-­‐expression	  tests	  were	  performed	  upon	  the	  Top10:pBAD/hisB:BPSL0998	  cell-­‐line	  in	  LB	  media	  and	  100	  µg/ml	  carbenicillin,	  including	  variations	  in	  temperature	  (4-­‐37°C),	  length	  of	  over-­‐expression	  (3-­‐30	  hours),	  method	  of	  cell-­‐lysis	  (sonication	  and	  BugBuster	  fractionation)	  and	  concentration	  of	  arabinose	  inducing-­‐agent	  (1x10-­‐5	  –	  0.1	  %).	  All	  tests	  were	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Figure 7.11: 1% gel electrophoresis of BPSL0998 cloning stages.  
 
Lane 1-3 = Standard PCR method, 50, 55 and 58°C annealing.  
Lane 4 = Hyperladder I (bp).  
Lane 5 = 1Kb ladder (bp).  
Lane 6 = Pure BPSL0998 (2178 bp) PCR product using touchdown.  
Lane 7-10 = Colony PCR products. 
 
High contamination by non-specific low MW fragments was seen using 
standard PCR methods, so more intricate techniques were applied to 
achieve the purity seen in Lane 6. Of only four colonies isolated after 
pBAD/hisB:BPSL0998 transformation into DH5, three generated positive 
BPSL0998 fragments. 
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analysed	  by	  SDS-­‐PAGE,	  and	  as	  can	  be	  seen	  in	  Figure	  7.12	  BPSL0998	  was	  heavily	  over-­‐expressed,	  but	  was	  only	  ever	  produced	  into	  the	  insoluble	  fraction	  of	  E.	  coli	  Top10	  cells	  regardless	  of	  over-­‐expression	  optimisation	  attempts.	  	  
7.5	  Attempts	  to	  Purify	  BCAL2646	  by	  Bulk	  Pull	  Down	  	  7.5.1	  BCAL2646	  and	  BPSL0998	  are	  Homologs	  	  Following	  the	  discovery	  that	  over-­‐expressed	  BPSL0998	  was	  insoluble	  in	  E.	  coli	  Top10,	  it	  was	  decided	  that	  as	  B.	  pseudomallei	  BPSL0998	  and	  B.	  cenocepacia	  BCAL2646	  are	  homologs	  (Section	  7.4.1)	  and	  BCAL2646	  had	  already	  been	  isolated	  as	  a	  soluble	  protein	  from	  B.	  cenocepacia	  cell-­‐extract	  in	  small-­‐scale	  pull-­‐down	  assays,	  then	  it	  might	  be	  possible	  to	  purify	  BCAL2646	  via	  a	  large-­‐scale	  pull-­‐down	  assay.	  Therefore	  interactions	  between	  a	  cross-­‐species	  complex	  were	  investigated.	  	  7.5.2	  Log	  Phase	  and	  Overnight	  Culturing	  of	  B.	  cenocepacia	  	  Given	  the	  biological	  role	  of	  BPSL0998	  and	  BCAL2646	  as	  methionyl-­‐tRNA	  synthetases,	  it	  was	  proposed	  that	  BCAL2646	  would	  be	  more	  abundant	  in	  B.	  
cenocepacia	  cultures	  that	  were	  currently	  in	  a	  log-­‐phase	  of	  growth.	  As	  at	  this	  stage	  of	  rapid	  cell	  proliferation	  protein	  synthesis	  in	  each	  individual	  cell	  would	  be	  at	  the	  highest	  rate	  in	  the	  cell	  cycle,	  it	  was	  anticipated	  that	  this	  would	  allow	  for	  a	  greater	  BCAL2646	  concentration	  per	  cell	  lysed.	  However,	  in	  order	  to	  replicate	  the	  results	  already	  witnessed	  in	  the	  original	  assays,	  overnight	  cultures	  were	  also	  prepared	  as	  in	  Section	  7.3.2.	  	  7.5.3	  Scaling	  up	  of	  the	  Assay	  	  	  Based	  upon	  the	  protocol	  described	  in	  Section	  3.8.2,	  the	  50	  µl	  assays	  were	  scaled	  up	  20-­‐fold	  in	  all	  respects	  to	  a	  final	  Affi-­‐Gel15	  bead	  slurry	  volume	  of	  1	  ml.	  The	  large-­‐scale	  pull-­‐down	  assay	  was	  carried	  out	  twice,	  using	  either	  log-­‐phase	  B.	  
cenocepacia	  or	  cells	  from	  an	  overnight	  culture.	  The	  only	  alteration	  to	  the	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Figure 7.12: SDS-PAGE analysis of BPSL0998 over-expression in the pBAD system.  
 
Lane 1 + 12 = Mark12 (kDa) 
Lane 2-6 = 0, 0.00001, 0.0001, 0.001. 0.01 % arabinose soluble, 3 hrs at 37°C 
Lane 7-11 = 0, 0.00001, 0.0001, 0.001. 0.01 % arabinose insoluble, 3 hrs at 37°C 
Lane 13-15 = 4, 25, 37°C, 6 hrs at 0.1 % arabinose, soluble 
Lane 16-18 = 4, 25, 37°C, 6 hrs at 0.1 % arabinose, insoluble 
 
All variations in over-expression attempts resulted in heavy over-expression of the 79.1 
kDa BPSL0998, but only in the insoluble fraction. No soluble protein was ever obtained. 
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previously	  used	  procedure	  was	  that	  20	  mg	  of	  pure	  BPSL1204	  in	  50	  mM	  HEPES	  pH	  8.0	  were	  left	  to	  bind	  at	  4°C	  on	  a	  slowly	  rotating	  wheel	  for	  3	  days.	  Of	  this,	  only	  approximately	  8.5	  mg	  of	  BPSL1204	  bound,	  judged	  by	  the	  post-­‐binding	  supernatant	  containing	  7.8	  mg	  protein,	  and	  each	  of	  the	  two	  wash-­‐step	  supernatants	  containing	  3.1	  and	  0.5	  mg	  of	  protein	  respectively.	  This	  left	  a	  protein	  concentration	  of	  approximately	  20	  mg/ml	  of	  AffiGel15:BPSL1204	  beads.	  	  	  Variation	  of	  the	  protocol	  in	  Section	  3.8.2	  was	  carried	  out	  to	  optimise	  the	  bulk	  collection	  of	  BCAL2646.	  6.5	  g	  of	  B.	  cenocepacia	  cell-­‐paste	  from	  the	  log-­‐phase	  culture	  was	  resuspended	  in	  13	  ml	  of	  0.1	  M	  NaCl	  and	  50	  mM	  HEPES	  pH	  7.5,	  sonicated	  and	  the	  insoluble	  fraction	  pelleted	  by	  centrifugation,	  leaving	  approximately	  360	  mg	  of	  soluble,	  B.	  cenocepacia	  cell-­‐free	  protein	  extract.	  The	  13	  ml	  was	  used	  to	  resuspend	  Affi-­‐Gel15:BPSL1204	  1	  ml	  of	  beads	  in	  a	  15	  ml	  Falcon	  tube,	  and	  was	  allowed	  to	  bind	  to	  the	  beads	  for	  three	  hours	  on	  a	  rotating	  wheel	  at	  4°C.	  After	  washing	  of	  unbound	  material	  by	  2	  x	  15ml	  of	  50	  mM	  HEPES	  pH	  7.5	  in	  0.2	  M	  NaCl,	  100	  µl	  of	  2	  M	  NaCl	  in	  50	  mM	  HEPES	  pH	  7.5	  was	  used	  to	  elute	  bound	  protein	  following	  a	  1	  minute	  incubation	  and	  a	  gentle	  centrifugation	  step	  to	  leave	  BCAL2646-­‐containing	  supernatant.	  This	  elution	  step	  was	  performed	  three	  times	  to	  totally	  elute	  bound	  protein,	  and	  the	  entire	  process	  was	  then	  repeated	  using	  the	  overnight-­‐cultured	  B.	  cenocepacia	  cells.	  However	  very	  little	  protein	  was	  actually	  obtained	  (Table	  7.1),	  with	  little	  difference	  witnessed	  between	  log-­‐phase	  and	  overnight	  cultures,	  although	  SDS-­‐PAGE	  analysis	  of	  25	  µl	  of	  each	  eluate	  (Figure	  7.13)	  showed	  that	  BCAL2646	  constituted	  the	  major	  component	  of	  each	  wash	  step.	  	  7.5.4	  Limitations	  of	  Purifying	  by	  Bulk	  Assay	  	  Even	  though	  the	  component	  of	  each	  eluted	  fraction	  contained	  BCAL2646	  (Figure	  7.13),	  there	  was	  very	  little	  mass	  of	  protein	  actually	  eluted.	  With	  8.5	  mg	  of	  BPSL1204	  bait-­‐protein	  originally	  bound,	  the	  greatest	  mass	  of	  protein	  eluted	  was	  in	  the	  1st	  eluate	  with	  a	  total	  mass	  of	  0.12	  mg	  protein,	  of	  which	  an	  estimated	  40%	  was	  BCL2646.	  Therefore	  there	  was	  an	  elution	  ratio	  of	  approximately	  1:0.0056	  mg	  BPSL1204:BCAL2646	  [(0.12/100	  x	  40)/8.5].	  It	  was	  concluded	  that	  either	  	  










total)	  Log-­‐phase	  culture	  	   1st	  105	  µl	  2	  M	  NaCl	   120	   48	  	  	   2nd	  90	  µl	  2	  M	  NaCl	   70	   28	  	  	   3rd	  85	  µl	  2	  M	  NaCl	   30	   12	  Overnight	  culture	  	   1st	  85	  µl	  2	  M	  NaCl	   120	   48	  	  	   2nd	  60	  µl	  2	  M	  NaCl	   55	   22	  	  	   3rd	  65	  µl	  2	  M	  NaCl	   20	   8	  1st	  Test	  Pull-­‐down	  	   1st	  	  25µl	  1.5	  M	  NaCl	   25	   10	  	  	   2nd	  25	  µl	  2	  M	  NaCl	   10	   4	  
Table 7.1: Retrieval of BCAL2646 from bulk pull-downs using AffiGel15:BPSL1204 
and B. cenocepacia cell-extract. 
 
Combination of all the above elutions gave a final sample of 450 mg in 500 µl (0.9 
mg/ml), of which approximately 40% was BCAL2646, therefore a very low yield of 
~180 mg target protein from ~20 g of combined starting cell-mass. There was very little 
difference observed between using log-phase or overnight cultures for BCAL2646 
isolation. 
	   208	  
Figure 7.13: SDS-PAGE analysis of bulk pull-down assays. 
 
Lane 1 = Mark12 (kDa) 
Lane 2 = Cell-free extract 
Lane 3-5 = Eluates 1-3 in 2 M NaCl from log-phase culture 
Lane 6-8 = Eluates 1-3 in 2 M NaCl from overnight culture 
 
Each eluate (25 µl loaded) shows that the 79.1 kDa BCAL2646 
is the major component of each elution, but only to a maximum 
of approximately 40%.  
	  	  1	  	  	  	  	  	  	  	  	  	  2	   	  	  	  	  	  	  	  3	   	  4	  	  	  	  	  	  	  	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  	  6	   	  	  7	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97.4	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only	  0.013%	  [100/(360	  mg	  cfe/8.5	  BPSL1204	  available)	  x	  0.0056	  mg	  BCAL2646	  eluted]	  of	  the	  soluble	  protein	  from	  B.	  cenocepacia	  was	  BCAL2646	  in	  the	  first	  place	  or	  that	  the	  interaction,	  though	  always	  occurring,	  was	  very	  transient.	  	  	  As	  B.	  cenocepacia	  is	  predicted	  to	  contain	  approximately	  5700	  proteins	  (including	  membrane	  and	  secreted	  proteins,	  which	  were	  very	  unlikely	  to	  be	  in	  the	  cell-­‐free	  extract),	  even	  if	  only	  1/5700	  of	  proteins	  per-­‐cell	  were	  BCAL2646	  at	  any	  given	  point	  in	  time,	  there	  should	  still	  have	  been	  at	  least	  approximately	  0.065	  mg	  of	  BCAL2646	  in	  the	  360	  mg	  cell-­‐free	  extract	  applied	  in	  the	  assay,	  therefore	  only	  74%	  of	  the	  theoretically	  minimum	  mass	  of	  BCAL2646	  possible	  was	  extracted.	  This	  was	  considered	  an	  unlikely	  situation,	  with	  at	  least	  hundreds	  of	  copies	  per	  cell	  of	  the	  methionyl-­‐tRNA	  synthetase	  BCAL2646	  likely	  to	  be	  present	  in	  a	  population	  of	  growing	  cells,	  therefore	  reflecting	  a	  very	  small	  yield	  from	  the	  bulk	  assay.	  It	  was	  therefore	  concluded	  that	  although	  at	  any	  point	  in	  time	  some	  BCAL2646	  macromolecules	  were	  interacting	  with	  BPSL1204,	  as	  seen	  constantly	  in	  gels	  such	  as	  Figure	  7.13,	  the	  vast	  majority	  of	  BCAL2646	  remained	  in	  an	  unbound	  state,	  either	  reflecting	  an	  above-­‐average	  occurrence	  of	  non-­‐specific,	  non-­‐biological	  interactions	  or	  a	  transient	  and	  unstable	  complex.	  	  7.5.5	  Heparin	  Column	  Purification	  of	  BPSL2646	  	  To	  investigate	  the	  potential	  formation	  of	  a	  BPSL1204:BCAL2646	  complex,	  all	  the	  6	  eluates	  from	  the	  bulk	  pull-­‐down	  assay	  (3	  x	  log-­‐phase	  culture	  and	  3	  x	  overnight	  culture)	  and	  the	  2	  M	  NaCl	  eluates	  from	  the	  original	  pull-­‐down	  assays	  (Figure	  7.13	  Lane	  3-­‐8	  and	  Figure	  7.6	  Lanes	  10	  and	  12)	  were	  pooled	  together	  to	  give	  approximately	  0.45	  mg	  in	  500	  µl	  of	  0.9	  mg/ml	  protein	  (Table	  7.1)	  in	  2	  M	  NaCl	  and	  50	  mM	  HEPES	  pH	  7.5,	  which	  was	  washed	  and	  Viva-­‐spin	  buffer-­‐transferred	  into	  50	  mM	  Tris	  pH	  7.5	  with	  minimal	  residual	  NaCl	  as	  in	  Section	  3.6.5.	  This	  was	  then	  applied	  to	  a	  1	  ml	  Heparin	  HiTrap	  column,	  available	  from	  GE	  Healthcare,	  on	  the	  prediction	  that	  due	  to	  the	  RNA-­‐binding	  capabilities	  of	  a	  methionyl-­‐tRNA	  synthetase,	  such	  as	  BCAL2646,	  the	  pooled	  fractions	  could	  be	  purified	  further	  using	  affinity	  chromatography.	  A	  gradient	  of	  0-­‐1.5	  M	  NaCl	  was	  used	  to	  elute	  protein	  from	  the	  heparin	  column	  in	  0.5	  ml	  fractions,	  with	  the	  UV	  trace	  set	  to	  high	  
	   210	  
sensitivity	  (Figure	  7.14),	  before	  the	  fractions	  under	  the	  peak	  were	  analysed	  by	  running	  50	  µl	  of	  each	  fraction	  on	  SDS-­‐PAGE	  (Figure	  7.15).	  Fractions	  14-­‐16	  contained	  the	  purest	  BCAL2646,	  and	  were	  combined	  to	  give	  a	  resulting	  1.4	  ml	  of	  0.05	  mg/ml,	  or	  70	  µg	  of	  approximately	  85%	  pure	  BCAL2646.	  	  7.5.6	  Analysis	  of	  BPSL1204:	  BCAL2646	  Complex	  Formation	  
	  Although	  70	  µg	  was	  a	  very	  small	  yield	  of	  BCAL2646,	  it	  was	  considered	  detectable	  as	  seen	  by	  the	  trace	  in	  Figure	  7.14.	  The	  1.4	  ml	  heparin	  column	  fractions	  were	  Viva-­‐spin	  buffer-­‐exchanged	  and	  concentrated	  into	  90	  µl	  of	  50mM	  Tris	  pH	  7.5	  and	  0.15	  M	  NaCl	  at	  approximately	  6.3	  µg/ml	  protein.	  This	  was	  combined	  with	  10	  µl	  of	  1	  mg/ml	  BPSL1204	  in	  the	  same	  buffer,	  to	  give	  a	  final	  complex	  ratio	  of	  ~1:0.7	  BPSL1204:BCAL2646.	  90	  µl	  of	  the	  complex	  mix	  was	  allowed	  to	  properly	  combine	  for	  15	  minutes	  at	  room	  temperature,	  before	  being	  loaded	  onto	  a	  Superdex200	  GL	  11	  gel-­‐filtration	  column,	  available	  from	  GE	  Healthcare,	  pre-­‐equilibrated	  with	  the	  complex	  buffer.	  The	  column	  was	  run	  at	  0.7	  ml/min	  and	  0.5	  ml	  fractions	  were	  collected,	  with	  the	  UV	  trace	  (Figure	  7.16)	  set	  to	  the	  highest	  sensitivity.	  No	  high	  molecular	  weight	  peaks	  were	  seen,	  corresponding	  to	  no	  BCAL2646:BPSL1204	  complex	  or	  monomeric	  BCAL2646,	  with	  a	  peak	  witnessed	  at	  Fraction	  23	  that	  corresponded	  with	  the	  classic	  monomeric	  BPSL1204-­‐MA	  peak	  seen	  in	  purification	  processes	  (Section	  4.4.4).	  The	  peak	  seen	  at	  the	  buffer	  front	  however	  was	  an	  anomaly.	  Fractions	  under	  the	  peaks	  and	  samples	  of	  the	  pre-­‐gel-­‐filtration	  samples	  were	  analysed	  by	  SDS-­‐PAGE	  (Figure	  7.17).	  Assessment	  of	  Fractions	  31	  and	  32	  revealed	  very	  low	  levels	  of	  BCAL2646,	  but	  at	  the	  running	  front	  of	  the	  buffer.	  Therefore	  it	  was	  proposed	  that	  BCAL2646	  perhaps	  interacted	  with	  the	  dextran-­‐agarose	  beads	  and	  definitely	  not	  BPSL1204.	  	  
7.6	  Conclusions	  	  The	  initially	  apparently	  reproducible	  interaction	  between	  BPSL0998/BCAL2646	  and	  AffiGel15:BPSL1204	  seemed	  to	  contradict	  the	  structural	  analysis	  of	  BPSL1204	  consisting	  of	  a	  BLIP-­‐like	  fold.	  However,	  upon	  attempts	  to	  purify	  BCAL2646	  by	  affinity	  to	  BPSL1204	  in	  bulk	  pull-­‐down,	  it	  was	  seen	  that	  the	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Figure 7.14: Heparin column trace of BCAL2646 purification. The 0-1.5 M NaCl 
gradient is seen as the red conductivity line. The blue line represents the high-sensitivity 
UV trace detecting protein presence. A peak is eluted between Fractions 12 and 16. 
Figure 7.15: SDS-PAGE analysis of BCAL2646 heparin column purification. 
 
Lane 1 = Mark12 (kDa) Lane 3 = Fraction 2 (non-binding wash) 
Lane 2 = Sample loaded  Lanes 4-17 = Fractions 10-23 
 
Combining Fractions 14-16 created a BCAL2646 sample of 1.4 ml of 50 
µg/ml. This was estimated to be 85% pure. 
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Figure 7.16: Gel filtration trace assessing BPSL1204:BCAL2646 complex formation.  
 
The ‘classic’ low molecular weight BPSL1204 monomeric peak is seen in Fraction 24, 
with no high molecular weight peak seen for BCAL2646 or BPSL1204:BCAL2646 
complex formation (excluded volume or Fraction 1-19 of included volume). An 
unexpected peak in Fraction 33, at the buffer running front, is seen. 
Figure 7.17: SDS-PAGE analysis of gel-filtration peaks from attempts to 
complex BPSL1204 with BCAL2646. 
 
Lane 1 = Mark12 (kDa)   Lane 4 = Fraction 22 
Lane 2 = Heparin-purified BCAL2646 Lane 5 = Fraction 31 
Lane 3 = Sample loaded on GF column Lane 6 = Fraction 32 
 
Fraction 22 contains monomeric BPSL1204. Some BCAL2646 appears to 
be anomalously present in Fraction 31, at the buffer running front 	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interaction	  between	  BCAL2646	  and	  BPSL1204	  was	  a	  very	  weak	  and	  transient	  one	  and	  as	  such	  was	  unlikely	  to	  be	  of	  biological	  significance.	  This	  was	  supported	  by	  the	  total	  lack	  of	  evidence	  for	  complex	  formation	  by	  gel-­‐filtration	  analysis.	  This	  therefore	  implied	  that	  BPSL1204	  did	  not	  interact	  with	  BCAL2646/BPSL0998	  or	  if	  it	  did,	  it	  required	  further	  complex	  stabilisation	  by	  co-­‐factors	  unknown.	  Therefore	  it	  seemed	  that	  the	  pull-­‐down	  result	  was	  a	  product	  of	  strong	  non-­‐specific	  interactions.	  	  Since	  BPSL1204	  carries	  a	  conserved	  glyceryl-­‐cysteine	  lipid-­‐anchoring	  motif,	  it	  was	  proposed	  that	  BPSL1204	  may	  interact	  with	  proteins	  associated	  with	  a	  cell	  membrane	  or	  may	  exist	  as	  a	  secreted	  protein.	  Therefore	  further	  experimentation	  yet	  was	  required	  to	  try	  to	  ascertain	  the	  cellular	  function	  and	  location	  of	  BPSL1204.	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Chapter	  8:	  Cellular	  Localisation	  of	  BPSL1204	  and	  the	  Discovery	  of	  Potential	  
Immunogenic	  Targets	  	  
8.1	  Preparation	  For	  Localisation	  Study	  	  8.1.1	  Supposition	  Behind	  Study	  	  To	  avoid	  safety	  issues	  associated	  with	  culturing	  B.	  pseudomallei,	  B.	  cenocepacia	  and	  BCAL2351	  were	  again	  used	  as	  a	  model	  for	  BPSL1204	  biochemical	  investigation.	  It	  was	  proposed	  that	  polyclonal	  antibodies	  raised	  in	  rats	  against	  epitopes	  present	  on	  BPSL1204	  would	  elicit	  a	  binding	  event	  when	  extracted	  in	  sera	  and	  used	  to	  challenge	  BCAL2351.	  This	  was	  due	  to	  the	  likelihood	  that	  one	  or	  more	  BPSL1204	  epitopes	  against	  which	  antibodies	  were	  raised	  by	  a	  host	  would	  be	  present	  on	  the	  92%	  identical	  soluble	  domain	  of	  BCAL2351.	  	  	  Therefore	  it	  was	  hypothesised	  that	  upon	  the	  fractionation	  of	  B.	  cenocepacia	  into	  cytoplasmic,	  periplasmic,	  secreted,	  inner	  membrane	  and	  outer	  membrane	  fractions,	  the	  said	  cellular	  compartments	  could	  be	  Western-­‐blotted	  to	  nitrocellulose	  (Burnette,	  1981)	  and	  subjected	  to	  binding	  by	  a	  primary	  rat	  IgG-­‐antibody	  against	  BPSL1204.	  Primary	  antibodies	  bound	  to	  BCAL2351	  could	  then	  be	  bound	  by	  a	  secondary	  anti-­‐rat-­‐IgG	  antibody	  conjugated	  to	  a	  horseradish	  peroxidase	  (HRP)	  reporter-­‐enzyme	  for	  detection	  by	  X-­‐ray	  film	  chemiluminesence	  (Kricka,	  1991).	  Analysis	  of	  the	  developed	  X-­‐ray	  film	  would	  then	  allow	  for	  the	  identification	  of	  the	  cellular	  fraction	  of	  the	  bacterium	  in	  which	  BCAL2351,	  and	  therefore	  by	  implication	  BPSL1204,	  could	  be	  found	  biologically.	  This	  might	  then	  add	  extra	  information	  to	  the	  structural	  and/or	  pull-­‐down	  results.	  	  8.1.2	  Generation	  of	  Polyclonal	  Antibodies	  and	  Rat	  Hyper-­‐immune	  Response	  to	  BPSL1204	  	  To	  facilitate	  the	  generation	  of	  anti-­‐BCAL2351/BPSL1204	  primary	  antibodies,	  BPSL1204	  was	  purified	  as	  in	  Section	  3.6	  into	  10	  mM	  Tris	  pH	  8.0	  to	  a	  concentration	  of	  1	  mg/ml.	  2	  x	  1	  ml	  of	  this	  fresh,	  pure	  BPSL1204	  solution	  was	  used	  to	  inoculate	  two	  rats,	  after	  the	  removal	  of	  a	  sample	  of	  pre-­‐immune	  blood.	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The	  Sheffield	  University-­‐based	  company	  BioServUK	  carried	  out	  all	  antibody	  production	  work	  under	  a	  Home	  Office	  licence.	  Both	  rats	  were	  allowed	  to	  mount	  an	  immune	  response	  to	  the	  BPSL1204	  antigen	  for	  7	  weeks,	  before	  test	  sera	  were	  removed	  and	  subjected	  to	  an	  in-­‐plate	  Enzyme-­‐Linked	  Immunosorbant	  Assay	  (ELISA)	  using	  an	  anti-­‐rat	  IgG-­‐Fc	  HRP-­‐linked	  antibody	  as	  a	  secondary	  reporter	  (King	  &	  Kochoumian,	  1979)	  against	  a	  plate-­‐immobilised	  BPSL1204	  with	  anti-­‐BPSL1204-­‐containing	  sera.	  Against	  a	  pre-­‐immune	  control,	  antibody	  titre	  (defined	  as	  the	  approximate	  dilution	  ratio	  that	  gave	  half	  of	  the	  maxiumum	  measurable	  signal,	  i.e.	  <1.0	  OD450nm)	  was	  determined	  by	  the	  fluorescence	  change	  generated	  upon	  conversion	  of	  3,3’,5,5’-­‐Tetramethylbenzidine	  Enhanced	  Chemiluminescence	  (TMB-­‐ECL)	  reagent	  by	  HRP	  (Frey	  et	  al,	  2000).	  Rat	  1	  gave	  a	  test-­‐titre	  of	  1:102400	  and	  Rat	  2	  gave	  a	  test-­‐titre	  of	  1:51200	  (Figure	  8.1).	  	  The	  immune	  response	  was	  boosted	  by	  the	  injection	  of	  a	  small	  volume	  of	  1	  mg/ml	  BPSL1204,	  and	  the	  rats	  were	  anaesthetically	  exsanguinated	  1	  week	  later.	  Final	  titres	  of	  1:409600	  for	  Rat	  1	  and	  1:102400	  for	  Rat	  2	  were	  achieved	  from	  ELISA’s	  of	  the	  final	  anti-­‐BPSL1204	  sera	  (Figure	  8.2).	  A	  titre	  greater	  than	  1:4000	  is	  considered	  a	  strong	  immune	  response	  in	  the	  strain	  of	  rats	  used	  (Dr	  Andrew	  Wright,	  BioServeUK,	  personal	  communication),	  and	  therefore	  Rat	  1	  gave	  a	  response	  100	  times	  greater	  than	  expected,	  whilst	  Rat	  2	  gave	  a	  response	  26	  times	  greater	  than	  expected.	  It	  was	  therefore	  proposed	  that	  the	  BPSL1204	  sequence	  and	  structure	  might	  present	  epitopes	  that	  elicit	  a	  particularly	  antigenic	  response	  in	  rats,	  perhaps	  reflecting	  a	  biological	  role	  in	  regards	  to	  cellular	  location	  and	  function.	  	  	  8.1.3	  Isolation	  of	  B.	  cenocepacia	  Cellular	  Fractions	  	  
B.	  cenocepacia	  was	  grown	  overnight	  and	  centrifuged	  into	  a	  pellet.	  A	  sample	  of	  the	  supernatant	  media	  was	  taken	  as	  representative	  of	  the	  secreted	  fraction.	  Pelleted	  cells	  were	  then	  resuspended	  in	  20%	  sucrose,	  30	  mM	  Tris	  pH	  8.0,	  1	  mM	  EDTA	  (STE)	  buffer	  for	  the	  osmotic	  permeabilisation	  of	  the	  outer	  membrane,	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 Test-Sera 
 Rat 1 Rat 2 Pre-Immune 
1:100 1.137 1.470 0.090 
1:200 1.258 1.440 0.062 
1:400 1.249 1.467 0.059 
1:800 1.214 1.686 0.054 
1:1600 1.216 1.717 0.048 
1:3200 1.147 1.880 0.052 
1:6400 1.196 2.018 0.053 
1:12800 1.307 1.847 0.052 
1:25600 1.788 1.188 0.047 
1:51200 1.506 0.690 0.048 
1:102400 0.941 0.378 0.059 
1:204800 0.565 0.237 0.054 
1:409600 0.319 0.172 0.043 
1:819200 0.191 0.128 0.049 
1:1638400 0.122 0.092 0.049 
1:3276800 0.098 0.079 0.050 
Figure 8.1: Results of test ELISA titre analysis of anti-BPSL1204 immune response in 
rats. Top: Table of ELISA dilution ratios and TMB-cleavage OD at 450nm. Bottom: 
Line graph of OD against serum dilution, plotted in Excel. 
 
In the table, the titre dilution ratios are highlighted in red. A titre of 1:4000 was 
considered to show a significant immune response. In these test sera of Rat 1 and Rat 2, 
titres of 1:102400 and 1:51200 respectively were achieved, indicative of a highly 
immunogenic response to BPSL1204. Both rats were allowed to proceed in generating 
anti-BPSL1204 polyclonal antibodies. No response was seen in the pre-immune sera, 
indicating that the titres seen were due to BPSL1204 inoculation. 
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 Final-Sera 
 Rat 1 Rat 2 Pre-Immune 
1:100 9.999 9.999 0.312 
1:200 9.999 9.999 0.179 
1:400 9.999 9.999 0.128 
1:800 9.999 6.317 0.108 
1:1600 9.999 9.999 0.081 
1:3200 9.999 9.999 0.077 
1:6400 9.999 9.999 0.076 
1:12800 9.999 2.841 0.086 
1:25600 9.999 2.171 0.163 
1:51200 2.761 1.418 0.111 
1:102400 2.009 0.827 0.095 
1:204800 1.281 0.508 0.096 
1:409600 0.793 0.289 0.086 
1:819200 0.494 0.191 0.085 
1:1638400 0.284 0.144 0.078 
Figure 8.2: Results of final ELISA titre analysis of anti-BPSL1204 immune response 
in rats. Top: Table of ELISA dilution ratios and TMB-cleavage OD at 450nm.  
Bottom: Line graph of OD against serum dilution, plotted in Excel. 
 
As can be seen in the graph, the immune response mounted by both rats is very large, 
with most serum dilutions off the scale. The final titres measured are highlighted red. 
No response seen in the pre-immune sera suggests that the large immune response is 
due solely to inoculation with pure BPSL1204. These sera were harvested by 
anaesthetic exsanguination to be used as the probes in BPSL1204 localisation studies. 
	   218	  
from	  which	  the	  supernatant	  after	  centrifugation	  was	  taken	  as	  the	  soluble	  periplasmic	  fraction.	  A	  sonication	  step	  to	  shatter	  membranes	  was	  employed,	  from	  which	  an	  ultracentrifuged	  supernatant	  was	  then	  taken	  as	  the	  cytoplasmic	  fraction.	  The	  inner	  membrane	  was	  selectively	  solubilised	  using	  the	  detergent	  sarkosyl	  (sodium	  lauroyl	  sarcosinate),	  from	  which	  the	  outer	  membrane	  was	  pelleted	  via	  centrifugation.	  The	  pellet	  was	  resuspended	  in	  10	  mM	  HEPES	  pH	  7.4	  to	  create	  the	  outer	  membrane	  fraction.	  A	  full	  account	  of	  this	  method	  is	  given	  in	  Section	  3.9.1.	  	  	  Analysis	  of	  fractions	  was	  carried	  out	  by	  SDS-­‐PAGE	  to	  discover	  the	  presence	  of	  differing	  protein	  profiles	  to	  assess	  success	  of	  fractionation	  (Figure	  8.3).	  It	  was	  seen	  that	  each	  fraction	  did	  appear	  to	  differ	  in	  protein	  profile,	  except	  that	  many	  cytoplamsic	  and	  periplasmic	  proteins	  were	  present	  in	  both	  samples.	  This	  was	  taken	  as	  an	  indication	  that	  the	  fractionation	  had	  been	  reasonably	  precise	  in	  terms	  of	  membrane	  preparation,	  but	  that	  the	  periplasmic	  fraction	  was	  contaminated	  with	  partial	  cytoplasmic	  leakage.	  This	  was	  provisionally	  considered	  as	  acceptable,	  unless	  a	  situation	  in	  which	  antibodies	  bound	  to	  non-­‐membrane	  fractions	  arose.	  	  	  
8.2	  Immunochemiluminesence	  Assays	  for	  Cellular	  Location	  of	  BPSL1204	  	  8.2.1	  Experimental	  Procedure	  	  13	  µl	  of	  each	  fraction	  was	  run	  on	  a	  13.5%	  SDS-­‐PAGE	  gel	  alongside	  a	  pure	  0.5	  µg	  BPSL1204	  control	  and	  a	  pre-­‐stained	  marker	  lane,	  which	  were	  then	  Western-­‐blotted	  onto	  a	  nitrocellulose	  membrane	  following	  the	  protocol	  described	  in	  Section	  3.9.3.	  The	  post-­‐Western	  blot	  SDS-­‐PAGE	  gel	  was	  stained	  and	  then	  destained	  for	  comparison	  to	  a	  co-­‐run	  pre-­‐Western	  blot	  gel,	  to	  assess	  transfer	  efficiency.	  After	  blocking	  of	  non-­‐sample-­‐bound	  nitrocellulose	  regions	  overnight	  in	  5%	  milk,	  0.1%	  Tween-­‐20	  and	  phosphate-­‐buffered	  saline	  (M-­‐T-­‐PBS)	  at	  4°C,	  the	  membrane	  was	  incubated	  for	  60	  minutes	  at	  room	  temperature	  with	  a	  1:2500	  dilution	  of	  primary	  rat	  anti-­‐BPSL1204	  sera	  from	  Rat	  2,	  washed	  and	  then	  incubated	  for	  45	  minutes	  at	  room	  temperature	  with	  a	  1:5000	  dilution	  of	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Figure 8.3: SDS-PAGE analysis of B. cenocepacia fractionation. 
 
Lane 1 = Mark12 (kDa)  Lane 5 = 13 µl secreted 
Lane 2 = 15 µg BPSL1204  Lane 6 = 13 µl inner membrane 
Lane 3 = 13 µl cytoplasm  Lane 7 = 13 µl outer membrane 
Lane 4 = 13 µl periplasm 
 
15 µg of pure BPSL1204 was run against the cytoplasmic fractions to allow 
for a rough estimation of concentration of fraction contents. As can be seen, 
the cytoplasmic fraction contains the most proteins, with some very faint 
bands seen in the periplasmic and secreted fractions. However cross 
contamination between the cytoplasm and periplasm is likely.  
 
The periplasmic and secreted proteins were at very low concentrations, but 
due to the extremely high titre of anti-BPSL1204 antibodies (Section 8.1.2) it 
was hoped that the high sensitivity of the probe used would compensate for 
this. 
 
The inner membrane and outer membrane fractions (Lane 6 and 7) exhibited 
significantly different protein profiles, suggestive of efficient separation.  
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secondary	  anti-­‐rat	  rabbit	  IgG	  HRP-­‐conjugate.	  Full	  details	  of	  this	  protocol	  can	  be	  found	  in	  Section	  3.9.4.	  After	  being	  washed	  to	  remove	  all	  secondary	  reporter	  antibodies,	  the	  side	  of	  the	  membrane	  onto	  which	  proteins	  were	  blotted	  was	  then	  coated	  in	  a	  solution	  of	  HRP-­‐substrate	  ECL	  reagent	  and	  the	  membrane	  was	  sealed	  in	  clean	  air-­‐bubble-­‐free	  plastic	  wrap.	  In	  a	  dark	  room,	  the	  fluorescent	  signal	  generated	  by	  the	  catalysis	  of	  ECL	  reagent	  by	  BPSL1204/BCAL2351-­‐bound	  HRP	  was	  visualised	  by	  exposure	  to	  X-­‐ray	  film.	  Exposure	  time	  was	  varied	  to	  achieve	  the	  best	  signal:noise	  image,	  and	  then	  the	  film	  was	  developed.	  This	  experimental	  procedure	  was	  carried	  out	  in	  triplicate,	  alongside	  controls	  of	  secondary	  antibody	  alone	  or	  use	  of	  rat	  pre-­‐immune	  sera	  as	  the	  primary	  antibody	  source.	  For	  a	  detailed	  description	  of	  this	  protocol,	  see	  Section	  3.9.5.	  	  	  8.2.2	  Results	  of	  the	  Experiment	  	  Confirmation	  of	  successful	  Western	  blotting	  of	  cellular	  fractions	  was	  achieved	  by	  resolution	  of	  pre-­‐	  and	  post-­‐Western	  SDS-­‐PAGEs	  (Figure	  8.4).	  It	  was	  seen	  that	  nearly	  complete	  transfer	  of	  low	  molecular	  weight	  proteins	  was	  achieved	  (such	  as	  BPSL1204	  in	  Lane	  2),	  but	  in	  general	  all	  lanes	  post-­‐transfer	  to	  nitrocellulose	  appeared	  much	  weaker.	  It	  had	  been	  well	  documented	  that	  the	  rate	  of	  lower	  weight	  protein	  transfer	  was	  far	  more	  efficient	  than	  that	  of	  higher	  weights.	  In	  addition	  to	  this,	  both	  low	  and	  high	  molecular	  weight	  pre-­‐stained	  proteins	  in	  the	  marker	  lane	  were	  seen	  to	  have	  transferred	  to	  the	  nitrocellulose	  membrane	  (Figure	  8.5,	  Lane	  1).	  	  As	  seen	  in	  Figure	  8.5,	  the	  anti-­‐BPSL1204	  antibodies	  bound	  BPSL1204	  with	  high	  affinity,	  with	  no	  signal	  generated	  from	  a	  control	  using	  secondary	  anti-­‐rat	  HRP-­‐conjugate	  alone	  (Figure	  8.6).	  The	  lack	  of	  signal	  from	  replacing	  post-­‐immune	  anti-­‐BPSL1204	  sera	  with	  pre-­‐immune	  sera,	  seen	  in	  Figure	  8.7,	  showed	  that	  binding	  events	  were	  solely	  a	  result	  of	  an	  anti-­‐BPSL1204:BPSL1204	  complex	  generated	  as	  a	  result	  of	  inducing	  a	  rat	  immune	  response.	  Analysis	  of	  Figure	  8.5	  showed	  that	  rat	  anti-­‐BPSL1204	  bound	  BCAL2351	  exclusively	  in	  the	  outer	  membrane	  fraction	  of	  B.	  cenocepacia.	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Figure 8.4: SDS-PAGE analysis of Western blot transfer of BPSL1204 and  
B. cenocepacia fractions. Left: Pre-Western. Right: Post-Western. 
 
Lane 1 = Mark12 (kDa)  Lane 5 = 13 µl secreted 
Lane 2 = 15 µg BPSL1204  Lane 6 = 13 µl inner membrane 
Lane 3 = 13 µl cytoplasm  Lane 7 = 13 µl outer membrane 
Lane 4 = 13 µl periplasm 
 
As can be seen, there was total transfer (as judged by eye) of BPSL1204 and 
most proteins < 20 kDa in all fractions. However, proteins with higher 
molecular weights seem less efficient at transferring during Western blotting.  
 
Nevertheless, as the aim of the experiment was to detect the BCAL2351 
homologue of BPSL1204, then as long as proteins of similar mass to 
BPSL1204 transferred then BCAL2351 localisation was still possible. 
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Figure 8.5: BPSL1204 and B. cenocepacia fractions immuno-blotted with anti-
BPSL1204. X-ray film was exposed for 30 seconds. 
 
Lane 1 = BroadRange pre-stained marker  Lane 9 = Secreted 
Lane 3 = Pure BPSL1204    Lane 11 = Inner membrane 
Lane 5 = Cytoplasm     Lane 13 = Outer membrane 
Lane 7 = Periplasm     Even lanes = Empty 
 
Even against a small amount of protein (0.5 µg) a considerable binding event 
was seen against pure BPSL1204 (Lane 3). The only other binding seen was in 
the outer membrane fraction. This band (Lane 13) ran slightly slower than pure 
BPSL1204, indicative of the detection of a native BCAL2351 processed-
lipoprotein covalently associated to the additional mass of a lipid-anchor. 
BCAL2351 was not detected in any other fraction 	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Figure 8.6: Secondary antibody control of BPSL1204 localisation immunoblots. 
Lane 1 = BroadRange pre-stained marker. Lane 2 = BPSL1204. Lane 3 = Outer 
membrane. X-ray film was exposed for 5 minutes. 
 
This immunoblot was probed with in the anti-rat HRP-conjugated secondary 
antibody. No binding is witnessed, indicating that the bands seen in Figure 8.5 
are due to the primary binding of an antibody in the rat anti-BPSL1204 sera 
Figure 8.7: Pre-immune sera control of BPSL1204 localisation immunoblots. 
Lane 1 = BPSL1204. Lane 2 = BroadRange pre-stained marker. Lane 3 = Outer 
membrane. X-ray film was exposed for 5 minutes. 
 
When probed with rat pre-immune sera as a source of primary antibody, no 
secondary antibody anti-rat HRP-conjugate binding was seen. This indicated 
that the primary binding seen in Figure 8.5 was due to antibodies raised against 
BPSL1204 post-inoculation, and not elements within native rat sera. 
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8.2.3	  Conclusions	  Drawn	  From	  the	  Experiment	  	  From	  the	  single	  band	  discovered	  in	  Figure	  8.5	  it	  was	  concluded	  that	  BPSL1204/BCAL2351	  is	  an	  outer-­‐membrane	  protein,	  anchored	  to	  the	  membrane	  via	  a	  probable	  glycyerlcystiene	  moiety.	  Although	  the	  band	  observed	  appeared	  to	  be	  of	  slightly	  larger	  MW	  than	  that	  of	  pure	  BPSL1204-­‐MA,	  this	  was	  probably	  because	  native	  BCAL2351	  identified	  in	  the	  outer	  membrane	  of	  B.	  cenocepacia	  had	  the	  addition	  of	  covalently	  associated	  lipids.	  The	  outer	  membrane	  fluorescent	  signal	  was	  not	  seen	  in	  the	  control	  using	  only	  secondary	  HRP	  reporter	  antibody	  (Figure	  8.6),	  therefore	  indicative	  of	  true	  localisation	  of	  BCAL2351/BPSL1204	  and	  not	  an	  interaction	  between	  a	  non-­‐specific	  protein	  and	  the	  secondary	  reporter.	  However,	  no	  information	  could	  be	  gleaned	  from	  the	  experiment	  in	  terms	  of	  orientation	  of	  BPSL1204	  on	  the	  outer	  membrane,	  and	  therefore	  further	  investigation	  was	  required	  to	  determine	  if	  BPSL1204/BCAL2351	  was	  located	  to	  the	  extracellular	  or	  periplasmic	  face	  of	  the	  outer	  membrane.	  	  
8.3	  Immunofluorescence	  Microscopy	  of	  the	  B.	  cenocepacia	  Outer	  
Membrane	  Protein	  BCAL2351	  (BPSL1204)	  
	  8.3.1	  Reasoning	  for	  the	  Fluorescence	  Microscopy	  Experiment	  	  Although	  the	  cellular	  localisation	  of	  BCAL2351	  to	  the	  outer	  membrane	  had	  been	  confirmed	  by	  immunoblot	  analysis	  of	  cellular	  fractions	  (Section	  8.2.2),	  it	  was	  still	  unclear	  as	  to	  the	  orientation	  of	  the	  protein	  in	  the	  outer	  membrane.	  It	  was	  hypothesised	  that	  due	  to	  the	  lack	  of	  disulphide-­‐bridge	  potential	  in	  the	  primary	  amino	  acid	  sequence	  that	  BPSL1204/BCAL2351	  was	  unlikely	  to	  exist	  as	  an	  extracellular	  protein	  without	  the	  structural	  strength	  endowed	  by	  disulphide	  covalent	  bonds	  (Raina	  &	  Missiakas,	  1997).	  Therefore	  it	  was	  proposed	  that	  immunofluorescence	  confocal	  microscopy	  of	  whole,	  fixed	  B.	  cenocepacia	  cells	  challenged	  with	  a	  rat	  anti-­‐BPSL1204	  primary	  antibody	  and	  a	  secondary	  anti-­‐rat	  FITC	  fluorophore	  conjugate	  (Riggs	  et	  al,	  1958)	  would	  allow	  the	  discovery	  of	  the	  orientation	  of	  BCAL2351	  on	  the	  outer	  membrane	  of	  B.	  cenocepacia	  and	  therefore	  of	  BPSL1204	  in	  B.	  pseudomallei.	  If	  BPSL1204	  were	  an	  internal	  lipoprotein,	  then	  there	  would	  be	  no	  green	  fluorescence	  from	  whole	  cells,	  with	  a	  green	  fluorescent	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signal	  only	  recorded	  if	  BPSL1204	  was	  externally	  anchored	  to	  the	  outer	  membrane	  and	  thus	  exposed	  to	  the	  extracellular,	  antibody-­‐containing	  environment.	  	  	  8.3.2	  Experimental	  Procedure	  	  Following	  the	  protocol	  described	  in	  greater	  detail	  in	  Section	  3.9.6,	  whole	  cells	  from	  a	  log-­‐phase	  B.	  cenocepacia	  culture	  were	  fixed	  with	  a	  formaldehyde	  and	  glutaraldehyde	  solution	  and	  then	  dried	  to	  a	  poly-­‐L-­‐lysine-­‐coated	  glass	  microscope	  slide	  and	  bound	  with	  rat	  anti-­‐BPSL1204	  primary	  and	  goat	  anti-­‐rat	  IgG-­‐FITC	  antibodies.	  Slides	  were	  then	  viewed	  and	  focussed	  for	  confocal	  Z-­‐stack	  image	  collection	  using	  a	  DeltaVision	  deconvolution	  microscope	  and	  SoftWoRx	  3.5.0	  software.	  Fluorescence	  of	  FITC	  was	  achieved	  by	  setting	  a	  laser	  excitation	  wavelength	  of	  490nm.	  Slide-­‐preparation	  and	  image-­‐collection	  was	  carried	  out	  with	  the	  aid	  and	  supervision	  of	  Victoria	  Kent	  from	  the	  lab	  of	  Professor	  Simon	  Foster	  of	  the	  University	  of	  Sheffield	  Department	  of	  MBB.	  	  Several	  control	  slides	  were	  also	  prepared,	  the	  first	  of	  which	  was	  a	  secondary	  antibody	  only	  slide	  to	  account	  for	  background	  fluorescence	  generated	  by	  non-­‐specific	  binding	  of	  the	  secondary	  FITC	  reporter.	  In	  addition,	  a	  slide	  was	  prepared	  using	  a	  sample	  of	  the	  pure,	  shattered	  outer	  membrane	  sample	  used	  in	  Section	  8.2.1.	  This	  slide,	  containing	  outer	  membrane	  with	  no	  regulated	  orientation,	  was	  designed	  to	  play	  a	  dual	  purpose.	  Firstly	  it	  was	  used	  as	  a	  control	  to	  show	  whether	  primary	  antibody	  from	  the	  sera	  would	  still	  bind	  BCAL2351,	  as	  seen	  in	  Section	  8.2.2,	  under	  microscopy	  conditions.	  Upon	  confirmation	  that	  anti-­‐BPSL1204	  bound	  to	  allow	  secondary	  FITC	  fluorophore	  signalling,	  this	  could	  be	  used	  to	  infer	  the	  results	  of	  the	  whole-­‐cell	  slide.	  If	  whole	  cells	  did	  not	  fluoresce	  but	  the	  shattered	  outer	  membrane	  sample	  did,	  then	  it	  may	  have	  indicated	  that	  BPSL1204	  was	  internalised,	  and	  not	  available	  for	  external	  binding	  in	  whole	  cells.	  This	  slide	  also	  had	  a	  counterpart	  secondary	  FITC	  antibody-­‐only	  control	  slide	  prepared,	  to	  account	  for	  any	  non-­‐specific	  signal	  generated	  by	  exposure	  of	  both	  sides	  of	  the	  outer	  membrane.	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8.3.3	  Preliminary	  Results	  of	  Fluorescence	  Microscopy	  	  Due	  to	  the	  low	  level	  of	  detail	  required	  from	  the	  microscopy	  experiments,	  with	  the	  external	  fluorescence	  under	  investigation	  either	  present	  or	  absent,	  Z-­‐stack	  images	  were	  processed	  using	  a	  Quick	  Projection	  function	  in	  which	  all	  images	  were	  layered	  on	  top	  of	  one	  another	  to	  generate	  one	  image.	  Investigation	  of	  the	  control	  slides	  treated	  with	  secondary-­‐reporter-­‐antibody	  only	  for	  both	  the	  whole	  cells	  and	  shattered	  OM-­‐fraction	  showed	  no	  generation	  of	  fluorescent	  signal.	  Images	  are	  not	  shown,	  as	  they	  were	  completely	  blank.	  	  This	  indicated	  that	  any	  green	  fluorescence	  seen	  was	  due	  to	  specific	  binding	  of	  the	  reporter	  to	  primary	  antibodies	  associated	  with	  BCAL2351/BPSL1204,	  and	  not	  random	  association	  of	  the	  reporter	  with	  incompletely	  blocked	  slides.	  	  	  The	  slides	  presenting	  random	  orientations	  of	  shattered	  outer	  membrane	  exhibited	  speckles	  of	  green	  (Figure	  8.8),	  witnessed	  in	  several	  repeats	  of	  the	  slides.	  Due	  to	  the	  fragmented	  nature	  of	  the	  outer	  membrane	  sample,	  this	  was	  the	  result	  predicted	  if	  BPSL1204	  and	  BCAL2351	  were	  presented	  on	  one	  of	  the	  two	  sides	  of	  the	  outer	  membrane,	  with	  both	  sides	  exposed	  to	  binding	  by	  the	  primary	  anti-­‐BPSL1204	  antibody.	  	  	  However,	  analysis	  of	  fixed,	  whole	  cells	  showed	  mixed	  results,	  with	  localised	  regions	  of	  green-­‐fluorescence	  on	  the	  surface	  of	  bacterial	  cells	  in	  some	  samples	  (5	  out	  of	  12	  slides)	  and	  no	  fluorescence	  in	  other	  slides	  of	  whole	  cells	  (7	  out	  of	  12	  slides).	  Examples	  of	  these	  results	  are	  shown	  in	  Figure	  8.9.	  This	  implies	  a	  lack	  of	  binding	  of	  the	  primary	  antibody	  to	  BCAL2351	  in	  the	  slides	  with	  no	  fluorescence,	  but	  potentially	  external	  binding	  to	  BCAL2351	  in	  the	  other	  slides,	  with	  some	  indication	  of	  specific	  localisation	  and	  clustering	  of	  the	  protein	  where	  fluorescence	  was	  seen.	  No	  fluorescence	  is	  seen	  in	  the	  areas	  of	  these	  slides	  where	  there	  are	  no	  cells.	  The	  normal,	  light	  microscope	  slides	  in	  Figure	  8.9	  show	  that	  whole	  cells	  were	  indeed	  fixed	  and	  present	  on	  the	  slides.	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Figure 8.8: DeltaVision fluorescence microscopy of FITC-taged BCAL2351 in 
the shattered outer membrane.  
 
The slide above is an example of multiple slides coated in sonicated and purified 
B. cenocepacia outer membrane. The membrane sample applied was assumed to 
be immobilised on the slide in small fragments of random orientation. The slide 
was bound first by rat anti-BPSL1204 and then goat anti-rat FITC conjugate. 
 
When excited by a laser, the secondary FITC-antibody fluoresced when bound to 
BCAL2351 via the primary binding. BCAL2351 is present, represented by the 
green ‘speckling’, reaffirming that BCAL2351 and BPSL1204 are outer-
membrane-associated. This does not allow the conclusion of the orientation of 
BCAL2351/BPSL1204 in the outer membrane. 
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Figure 8.9: Results of whole-cell DeltaVision fluorescence microscopy.  
B. cenocepacia cells were challenged with anti-BPSL1204 and a secondary FITC-
conjugate. Left, center and right columns:Bright-field, overlay (of left and right) and 
fluorescence images respectively. Top, middle, bottom rows: Positive, positive and 
negative examples for external binding respectively. 
 
The images in the Top and Middle row show (in the centre column) that a binding event 
occurs only within the boundaries of the bacterium, with no fluorescent noise seen from 
the surrounding slide. Top shows a cell potentially mid-division, with Middle a 
‘normal’ cell. Both exhibit patches of green-FITC binding, suggestive of specifically 
localised binding of anti-BPSL1204 to BCAL2351, however no pattern was seen. 
These images represent 42% of the samples investigated. 
 
The Bottom row images show whole-cell slides that do not show fluorescence within 
the boundaries of the bacterium or in the surrounding slide. The overlay and 
fluorescence images are independent from the bright-field image, due to availability of 
images, however all images in the Bottom row are representative of 58% of the samples 
investigated. This suggests that BCAL2351 is not accessible to be bound by anti-
BPSL1204, in contradiction with the Top and Middle images. 	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8.3.4	  Conclusions	  and	  Limitations	  of	  Microscopy	  Results	  
	  When	  compared	  to	  the	  total	  lack	  of	  signal	  in	  the	  secondary-­‐only	  control-­‐slides,	  the	  patches	  of	  green	  speckles	  in	  the	  fragmented	  outer	  membrane	  slides	  confirm	  that	  BPSL1204	  and	  BCAL2351	  are	  outer	  membrane	  proteins,	  and	  that	  under	  these	  experimental	  conditions	  the	  rat	  anti-­‐BPSL1204	  primary	  antibody	  can	  bind	  to	  BCAL2351	  when	  the	  protein	  is	  exposed	  and	  accessible	  on	  the	  outer	  membrane.	  However,	  the	  lack	  of	  any	  significant	  fluorescent	  signal	  in	  7/12	  slides	  when	  whole	  cells	  were	  treated	  with	  antibodies	  suggests	  that	  BCAL2351	  is	  not	  usually	  accessible	  to	  the	  primary	  antibody,	  and	  thus	  no	  secondary	  binding	  of	  the	  FITC-­‐conjugated	  goat	  anti-­‐rat	  antibody	  occurs.	  In	  contrast	  however,	  5/12	  whole-­‐cell	  slides	  suggest	  that	  BCAL2351	  is	  present	  on	  the	  outside	  of	  some	  of	  the	  cells	  where	  it	  can	  be	  bound	  by	  anti-­‐BPSL1204,	  and	  further	  suggests	  specifically	  localised	  binding	  on	  the	  bacterial	  cell	  surface.	  	  	  The	  cells	  used	  in	  the	  preparation	  of	  slides	  came	  from	  the	  same	  formaldehyde/glutaraldehyde-­‐fixed	  sample.	  The	  sample	  was	  taken	  from	  an	  overnight	  culture	  of	  B.	  cenocepacia	  and	  therefore	  had	  the	  potential	  to	  contain	  cells	  in	  various	  stages	  of	  the	  cell	  cycle.	  This	  led	  to	  the	  conclusion	  that	  from	  the	  preliminary	  experimental	  results	  in	  Section	  8.3.3	  BPSL1204/BCAL2351	  are	  external	  outer-­‐membrane	  proteins	  only	  expressed	  at	  certain	  stages	  of	  the	  B.	  
pseudomallei/B.	  cenocepacia	  cell-­‐cycle.	  However,	  an	  alternative	  explanation	  would	  be	  that	  the	  42%	  green	  signal	  witnessed	  in	  whole	  cells	  could	  be	  due	  to	  damage	  to	  the	  outer	  membrane	  in	  the	  fixing	  process,	  thus	  exposing	  the	  periplasmic	  face	  of	  the	  outer	  membrane	  to	  antibody-­‐binding,	  and	  that	  ordinarily	  BCAL2351/BPSL1204	  are	  internalised	  to	  the	  periplasmic	  face	  of	  the	  outer	  membrane	  and	  therefore	  give	  no	  green	  fluorescent	  signal,	  as	  seen	  58%	  of	  the	  time	  in	  these	  experiments.	  	  	  These	  experiments	  were	  carried	  out	  towards	  the	  end	  of	  the	  funding/writing-­‐up	  period	  for	  this	  project,	  and	  due	  to	  time	  constraints	  concerning	  the	  preparation	  of	  fresh	  whole	  cells	  and	  outer	  membrane	  fractions	  of	  B.	  cenocepacia,	  further	  repeats	  of	  this	  experiment	  were	  not	  possible.	  Although	  whole	  cells	  were	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immobilised	  on	  slides	  (Figure	  8.9)	  they	  were	  low	  in	  cell	  count	  per	  slide	  and	  did	  not	  appear	  to	  fully	  reflect	  various	  stages	  of	  the	  cell-­‐cycle	  as	  aimed	  for	  -­‐	  for	  example	  only	  a	  few	  cells	  were	  seen	  in	  mid-­‐division.	  This	  did	  leave	  the	  potential	  for	  BCAL2351	  to	  be	  expressed	  on	  the	  outside	  of	  the	  cell	  at	  only	  specific	  time-­‐points	  in	  the	  B.	  cenocepacia	  cell	  cycle	  not	  fully	  represented	  in	  the	  sample	  used.	  	  	  In	  addition	  to	  this,	  the	  conclusion	  that	  absence	  of	  exterior	  binding	  in	  the	  majority	  of	  whole	  cells	  reflects	  an	  internalised	  outer	  membrane	  protein	  was	  made	  on	  the	  visualisation	  of	  the	  outer	  membrane	  as	  a	  simple	  barrier.	  It	  may	  be	  more	  realistic	  to	  treat	  the	  external	  environment	  of	  the	  outer	  membrane	  as	  a	  dynamic	  system	  (Rajendran	  &	  Simons,	  2005),	  with	  constant	  processes	  such	  as	  protein	  secretion	  and	  exopolysaccharide	  production	  underway	  (Osborn	  &	  Wu,	  1980)	  which	  may	  block	  external	  antibody	  binding	  in	  whole	  cells	  at	  certain	  stages	  of	  the	  cell-­‐cycle,	  as	  illustrated	  in	  Figure	  8.10.	  Although	  treated	  with	  formaldehyde	  and	  glutaraldehyde	  to	  ‘kill-­‐and-­‐freeze’	  life-­‐processes,	  this	  may	  have	  also	  shielded	  external	  BPSL1204/BCAL2351	  from	  antibody	  binding	  behind	  other	  outer	  membrane	  processes	  immobilised	  by	  fixing.	  The	  shattered	  outer-­‐membrane	  fraction,	  purified	  away	  from	  an	  in	  vivo	  state,	  may	  have	  always	  allowed	  external	  antibody	  binding	  to	  the	  slides	  containing	  only	  outer	  membrane	  or	  in	  the	  immunoblots	  of	  Section	  8.2.2	  due	  to	  the	  stripping-­‐away	  of	  other	  biological	  factors	  during	  the	  membrane	  purification	  process.	  	  	  Therefore	  the	  conclusions	  made	  are	  that	  BPSL1204	  is	  clearly	  an	  outer-­‐membrane	  protein.	  At	  this	  point	  it	  is	  unclear	  whether	  it	  is	  located	  on	  the	  external	  face	  of	  the	  outer	  membrane	  at	  specific	  stages	  of	  the	  cell-­‐cycle	  or	  is	  located	  on	  the	  inner	  face	  of	  the	  outer	  membrane,	  with	  any	  antibody	  binding	  seen	  as	  an	  experimental	  by-­‐product	  due	  to	  ruptured	  outer	  membranes.	  Further	  experimentation	  is	  required	  to	  resolve	  these	  two	  possibilities.	  Optimisation	  of	  fluorescence	  microscopy	  slides	  to	  incorporate	  a	  greater	  cell-­‐count	  field	  per	  slide	  would	  allow	  for	  analysis	  of	  many	  cells	  across	  the	  exact	  same	  conditions,	  reducing	  variation	  due	  to	  disparity	  in	  slide-­‐preparation.	  Microbiological	  growth	  techniques	  could	  be	  improved	  so	  that	  cells	  could	  also	  be	  viewed	  at	  defined	  time-­‐	  







Figure 8.10: Illustration of the difference between pure and in vivo outer membrane. OM-E = 
Outer Membrane Exterior. OM-I = Outer Membrane Internal. 
 
The top image represents the scenario in which the outer membrane is considered as a simple 
barrier between the periplasm and the environment. The bottom image represents a more 
likely scenario where the outer membrane is a dynamic system within which BCAL2351 may 
function, and due to which in vivo binding of BCAL2351 by anti-BPSL1204 primary 
antibody may be prevented.  
 
The purple shapes denote other membrane-anchored proteins in the outer membrane, whilst 
the red shape is representative of exopolysaccharides secreted from and associated with 
membranes. The yellow and grey shapes represent peripheral and integral membrane proteins 
that can be found associated with membranes and the orange shape represents secreted 
proteins that can also be found in an external membrane environment. All these molecules 
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points	  of	  the	  B.	  cenocepacia	  cell	  cycle,	  which	  may	  present	  different	  external	  exposure	  or	  expression	  of	  BCAL2351/BPSL1204.	  	  	  In	  addition,	  the	  bioengineered	  conjugation	  of	  a	  fluorescent	  moiety	  such	  as	  green-­‐fluorescent	  protein	  (GFP)	  to	  BCAL2351	  may	  allow	  for	  direct	  visualisation	  via	  fixed	  and	  live-­‐cell	  microscopy	  of	  the	  orientation	  of	  BCAL2351	  and	  BPSL1204	  when	  associated	  with	  the	  outer	  membrane	  of	  B.	  cenocepacia.	  Application	  of	  a	  secondary	  fluorophore-­‐conjugate	  known	  to	  be	  periplasm-­‐specific	  may	  allow	  for	  the	  analysis	  of	  cell	  rupturing	  as	  the	  cause	  for	  variable	  signal	  in	  whole	  cells.	  
	  
8.4	  Investigation	  into	  Immunogenic	  Targets	  	  8.4.1	  Experimental	  Theory	  	  With	  the	  discovery	  of	  BPSL1204	  and	  BCAL2351	  as	  outer-­‐membrane	  proteins,	  and	  the	  large	  immune	  response	  observed	  against	  BPSL1204	  in	  rats	  (Section	  8.1.2),	  it	  was	  decided	  that	  an	  investigation	  into	  the	  potential	  immunogenic	  status	  of	  BPSL1204	  in	  melioidosis	  was	  needed.	  It	  was	  therefore	  proposed	  to	  employ	  a	  similar	  methodology	  to	  that	  used	  in	  Section	  8.2.1.	  Fractionated	  B.	  cenocepacia	  cells	  and	  BPSL1204	  would	  be	  run	  on	  SDS-­‐PAGE,	  Western-­‐blotted	  to	  nitrocellulose	  and	  challenged	  with	  Burkholderia–infected	  human	  sera	  as	  a	  source	  of	  primary	  antibodies.	  Proteins	  present	  that	  elicited	  an	  immune-­‐response	  during	  infection	  would	  be	  bound	  by	  the	  infected	  sera,	  to	  which	  an	  anti-­‐human	  HRP-­‐conjugate	  secondary	  reporter	  antibody	  would	  bind	  for	  detection	  by	  X-­‐ray	  film	  chemiluminesence.	  This	  would	  result	  in	  the	  identification	  of	  any	  major	  antigens	  shared	  by	  B.	  cenocepacia	  and	  the	  Burkholderia	  species	  against	  which	  antibodies	  were	  raised,	  and	  perhaps	  also	  would	  reveal	  BPSL1204	  as	  an	  immunogenic	  outer	  membrane	  protein.	  	  8.4.2	  Components	  of	  the	  Assay	  	  Access	  to	  B.	  pseudomallei-­‐infected	  human	  sera	  was	  impossible,	  due	  to	  low	  survival	  rates	  of	  patients	  and	  the	  dangers	  of	  handling	  blood	  contaminated	  with	  the	  bacterium.	  However,	  following	  the	  hypothesis	  of	  the	  original	  localisation	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immunoblot	  assays,	  the	  antigenic	  effect	  of	  B.	  pseudomallei	  infection	  was	  modelled	  in	  the	  infection	  of	  a	  human	  by	  B.	  mallei.	  Sera	  recovered	  from	  a	  human	  Glanders	  patient	  (sera	  of	  Dr	  David	  DeShazer,	  U.S.	  Army	  Medical	  Research	  Institute	  of	  Infectious	  Diseases,	  provided	  by	  Professor	  David	  Rice,	  University	  of	  Sheffield)	  was	  used	  as	  a	  source	  of	  anti-­‐Burkholderia	  mallei	  primary	  antibodies.	  However,	  growth	  of	  B.	  mallei	  is	  also	  prohibited	  in	  Sheffield,	  and	  therefore	  B.	  
pseudomallei	  infection	  was	  once	  again	  modelled	  in	  B.	  cenocepacia	  cell	  fractions	  (Section	  8.1.3)	  using	  a	  response	  against	  B.	  mallei.	  As	  very	  high	  sequence	  identity	  homologs	  of	  BPSL1204	  exist	  in	  all	  species	  used	  in	  the	  model,	  with	  the	  B.	  mallei	  homolog	  100%	  identical	  to	  BPSL1204,	  this	  was	  considered	  a	  viable	  test	  for	  BPSL1204	  immunogenicity.	  However	  any	  other	  proteins	  detected	  would	  require	  further	  bioinformatical	  and	  experimental	  investigation	  before	  being	  conclusively	  identified	  as	  true	  B.	  pseudomallei	  immunogenic	  proteins.	  	  	  8.4.3	  Experimental	  Procedure	  	  As	  with	  the	  localisation	  studies	  (Section	  8.1),	  13	  µl	  of	  each	  B.	  cenocepacia	  fraction	  was	  run	  on	  a	  13.5%	  SDS-­‐PAGE	  gel	  alongside	  10	  µg	  of	  pure	  BPSL1204.	  BPSL1204	  was	  relatively	  overloaded	  to	  supply	  plenty	  of	  antigen	  should	  binding	  have	  proven	  present	  but	  weak.	  Western	  blots	  were	  carried	  out	  as	  in	  Section	  3.9.3	  and	  the	  resulting	  nitrocellulose	  membrane	  was	  subjected	  to	  overnight	  blocking	  by	  M-­‐T-­‐PBS	  buffer,	  before	  being	  challenged	  with	  a	  1:5000	  dilution	  of	  primary	  antibody-­‐supplying	  human	  B.	  mallei-­‐infected	  sera	  in	  M-­‐T-­‐PBS.	  After	  washing,	  a	  1:2500	  dilution	  of	  goat	  anti-­‐human	  HRP-­‐conjugate	  secondary	  reporter	  antibody	  in	  M-­‐T-­‐PBS	  was	  incubated	  with	  the	  membrane.	  Alongside	  this	  experiment,	  a	  control	  that	  challenged	  the	  B.	  cenocepacia	  fractions	  and	  BPSL1204	  with	  secondary	  goat	  anti-­‐human	  HRP	  alone	  was	  carried	  out	  to	  ensure	  that	  any	  bands	  seen	  were	  not	  a	  product	  of	  non-­‐specific	  binding	  by	  the	  reporter.	  The	  membrane	  was	  then	  soaked	  in	  ECL	  reagent	  and	  fluorescence	  of	  bands	  from	  bound	  antibodies	  was	  recorded	  by	  the	  development	  of	  X-­‐ray	  film	  exposed	  to	  the	  resulting	  chemiluminescent	  reaction.	  Greater	  details	  of	  this	  process	  can	  be	  found	  in	  Section	  3.9.5.	  
	   234	  
8.4.4	  Results	  of	  the	  Experiment	  	  Comparison	  of	  pre-­‐	  and	  post-­‐Western	  blot	  SDS-­‐PAGEs	  gels	  (Figure	  8.11)	  suggested	  that	  lower	  MW	  proteins,	  including	  BPSL1204,	  had	  indeed	  transferred	  efficiently	  with	  their	  absences	  being	  obvious	  on	  the	  post-­‐Western	  gel.	  Higher	  MW	  bands,	  though	  still	  present	  on	  the	  post-­‐Western	  gel	  appeared	  weaker,	  suggesting	  at	  least	  partial	  transfer	  of	  every	  protein	  loaded	  onto	  the	  gel,	  supported	  by	  the	  total	  transfer	  of	  pre-­‐stained	  protein	  MW	  markers,	  seen	  as	  blue	  bands	  on	  the	  nitrocellulose	  post-­‐Western	  blot	  (Figure	  8.12).	  	  	  It	  was	  also	  noticed	  that	  in	  the	  outer	  membrane	  fraction	  of	  the	  pre-­‐Western	  SDS-­‐PAGE	  (Figure	  8.11)	  that	  a	  single	  band	  at	  around	  40	  kDa	  contributed	  to	  the	  majority	  of	  the	  protein	  present	  in	  the	  fraction.	  Consequently	  it	  was	  proposed	  that	  this	  protein	  might	  act	  as	  an	  antigen	  during	  infection	  or	  might	  represent	  a	  potential	  diagnostic	  marker,	  so	  therefore	  was	  identified	  by	  mass	  spectrometry	  (Section	  8.4.5).	  	  	  Analysis	  of	  the	  immunoblots	  generated	  revealed	  that	  any	  bands	  seen	  in	  the	  main	  assay	  (Figure	  8.12a)	  were	  a	  product	  of	  primary	  sera	  binding,	  as	  shown	  by	  a	  blank	  film	  in	  the	  secondary-­‐antibody	  only	  control	  (Figure	  8.12b).	  The	  anti-­‐B.	  
mallei	  human	  sera	  did	  not	  contain	  antibodies	  specific	  to	  BPSL1204,	  as	  seen	  by	  the	  lack	  of	  bands	  at	  ~17.2-­‐20	  kDa	  (variation	  due	  to	  potentially	  covalently	  associated	  lipids).	  However,	  many	  other	  bands	  were	  detected	  from	  several	  of	  the	  
B.	  cenocepacia	  fractions,	  amongst	  which	  a	  major	  band	  was	  seen	  in	  the	  secreted	  fraction	  (~60kDa)	  and	  three	  from	  the	  cytoplasmic	  fraction	  (~58,	  ~40	  and	  ~17	  kDa).	  Bands	  were	  seen	  at	  similar	  weights	  in	  multiple	  lanes,	  but	  this	  was	  considered	  a	  product	  of	  lane	  cross-­‐contamination.	  Regrettably	  assays	  could	  not	  be	  repeated	  in	  efforts	  to	  ‘clean-­‐up’	  due	  to	  the	  limited	  anti-­‐B.	  mallei	  sera	  available.	  The	  large	  ~40	  kDa	  protein,	  subjected	  to	  mass	  spectrometry	  (see	  Section	  8.4.5),	  seen	  in	  the	  SDS-­‐PAGE	  outer	  membrane	  fraction	  did	  not	  appear	  to	  elicit	  an	  immune	  response	  in	  this	  model.	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Figure 8.11: SDS-PAGE analysis of Western blot transfer of BPSL1204 and  
B. cenocepacia fractions for immunogenicity studies. 
 
Lane 1 = Mark12 (kDa)  Lane 5 = Inner membrane 
Lane 2 = Pure BPSL1549  Lane 6 = Cytoplasm 
Lane 3 = Pure BPSL1204  Lane 7 = Periplasm 
Lane 4 = Outer membrane  Lane 8 = Secreted 
 
The 23.3 kDa BPSL1549 sample used in Lane 2 was used to assess the limit between 
transfer efficiency and molecular weight. It was seen that BPSL1549 was totally 
electroblotted from the SDS-PAGE gel, though some proteins of similar mass in the 
cytoplasmic fraction (Lane 6) seemed to only partially transfer. The 17.2 BPSL1204 
appeared to completely transfer. 
 
A large proportion of the outer membrane fraction (Lane 4) appeared to be a single 
protein at ~40 kDa. 
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Figure 8.12: Immunoblot analysis of BPSL1204 and B. cenocepacia fraction 
immunogenicity. Left: a) immuno-blotted with primary and secondary-reporter 
antibodies, X-ray film exposed for 30 seconds. Right: b) immuno-blotted with 
secondary-reporter antibody only, X-ray film exposed for 5 minutes. 
 
Lane 1 = Secreted   Lane 5 = Outer membrane 
Lane 2 = Periplasm   Lane 6 = Pure BPSL1204 
Lane 3 = Cytoplasm   Lane 7 = Empty 
Lane 4 = Inner Membrane  Lane 8 = BroadRange prestained marker 
 
The secondary-only control was exposed to X-ray film for 10 times longer than 
the fully blotted nitrocellulose membrane, and detected no bands. Therefore any 
bands seen in the left membrane represent a binding event of B. mallei-infected 
sera against B. cenocepacia, and not non-specific secondary binding. 
 
BPSL1204 (Lane 5 and 6), and by inference its homologues, did not elicit a 
significant immune response in B. mallei infection of a human. Several B. 
cenocepacia bands did give strong immune responses in B. mallei infection, 
indicated by arrows. These represent potential future targets for the investigation 
of immunogenic targets in Burkholderia. 	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8.4.5	  Mass	  Spectrometry	  of	  a	  Potential	  Antigen	  or	  Diagnostic	  Marker	  	  A	  13.5%	  SDS-­‐PAGE	  gel	  of	  the	  outer	  membrane	  fraction	  of	  B.	  cenocepacia	  was	  run,	  and	  stained	  with	  InstantBlue	  colloidal	  Coomassie	  G-­‐250	  to	  be	  compatible	  with	  identification	  for	  gel-­‐excision,	  tryptic	  digestion	  and	  gel-­‐extraction	  for	  identification	  by	  trypsin-­‐fragment	  OrbiTrap	  mass	  spectrometry	  (Hu	  et	  al,	  2005).	  After	  the	  staining	  of	  the	  SDS-­‐PAGE,	  all	  procedures	  were	  carried	  out	  by	  Dr	  Richard	  Beniston	  of	  the	  University	  of	  Sheffield	  Department	  of	  Biomedical	  Science.	  Analysis	  of	  peptide	  fragments	  by	  the	  MASCOT	  server	  identified	  several	  potential	  proteins	  within	  the	  band,	  summarised	  as	  an	  Excel	  file	  in	  Figure	  8.13.	  Based	  upon	  the	  returned	  results,	  such	  as	  the	  high	  score,	  high	  %	  coverage	  and	  greatest	  number	  of	  peptides	  identified	  it	  was	  decided	  that	  the	  main	  constituent	  of	  the	  band	  was	  the	  putative	  porin	  with	  accession:206563776	  (BCAM1931	  in	  B.	  
cenocepacia	  and	  similar	  to	  BPSS0879	  in	  B.	  pseudomallei).	  	  8.4.6	  Conclusions	  of	  Immunogenic	  Studies	  	  Though	  modelled	  in	  a	  B.	  mallei	  infection,	  the	  100%	  identity	  shared	  with	  the	  B.	  
mallei	  protein	  and	  BPSL1204	  allowed	  for	  the	  inference	  that	  in	  vivo	  BPSL1204	  does	  not	  elicit	  an	  immune	  response	  during	  B.	  pseudomallei	  infection,	  regardless	  of	  the	  hyperimmune	  response	  witnessed	  in	  rats	  on	  exposure	  to	  pure	  protein	  (Section	  8.1.2).	  This	  supports	  the	  preliminary	  conclusions	  of	  Section	  8.2.3	  and	  supports	  one	  of	  the	  conclusions	  in	  8.3.4,	  that	  BPSL1204	  is	  an	  inward-­‐facing	  outer-­‐membrane	  protein	  that	  would	  not	  be	  presented	  to	  a	  host’s	  immune	  system	  during	  infection.	  However,	  the	  study	  did	  reveal	  several	  B.	  cenocepacia	  proteins	  that	  did	  elicit	  an	  immune	  response	  during	  a	  B.	  mallei	  infection	  that	  may	  represent	  potential	  targets	  for	  the	  identification	  of	  B.	  cenocepacia	  infection	  in	  CF-­‐patients,	  or	  Glanders	  in	  both	  humans	  and	  cattle.	  	  	  Although	  the	  putative	  porin	  protein	  discovered	  in	  B.	  cenocepacia	  appeared	  to	  be	  a	  major	  component	  of	  the	  outer	  membrane,	  it	  too	  did	  not	  elicit	  an	  immune	  response	  in	  B.	  mallei-­‐infection,	  though	  a	  78%	  homologue	  of	  the	  porin	  was	  discovered	  to	  exist	  in	  B.	  mallei.	  As	  porins	  are	  transmembrane	  proteins,	  and	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Accession # Unique 
Peptides 
# Peptides # PSMs Molecular Function # AAs MW [kDa] calc. pI 
325521856 3 3 3 transporter activity 219 23.8 8.76 
         
358076252 8 8 10 transporter activity 383 40.2 9.58 
         
206562870 9 10 14 transporter activity 386 39.6 8.18 
         
206561353 8 8 15 transporter activity 383 40.3 9.63 
         
206563776 22 23 252 transporter activity 359 37.5 9.45 
         
197295256 8 8 10 catalytic; metal binding 565 59.9 7.99 
         
206563581 5 5 6 transporter activity 367 39.7 7.27 
Accession Description Score Coverage # 
Proteins 
325521856 extracellular solute-binding protein [Burkholderia sp. TJI49] 138.90 15.98 15 
      
358076252 outer membrane protein (porin) [Burkholderia cenocepacia H111] 567.25 39.43 1 
      
206562870 putative porin [Burkholderia cenocepacia J2315] 712.90 40.41 1 
      
206561353 putative outer membrane porin protein [Burkholderia cenocepacia 
J2315] 
765.81 39.95 1 
      
206563776 putative porin [Burkholderia cenocepacia J2315] 11468.82 81.34 1 
      
197295256 zinc metalloprotease ZmpA [Burkholderia cenocepacia J2315] 502.77 21.24 3 
      
206563581 putative porin [Burkholderia cenocepacia J2315] 229.67 17.17 2 
Figure 8.13: Mass spectroscopic investigation of the ~40 kDa major OM protein.  
 
The MASCOT output summarised in Microsoft Excel suggests that the most likely identity 
of the ~40 kDa band (based upon factors such as the number of peptides analysed, highest 
MASCOT score and sequence coverage) is the putative porin with accession: 206563776. 
 
Although the 78% B. mallei homologue of this protein did not generate an immune response 
in B. mallei-infected human sera, it was still considered a potential diagnostic marker, due to 
its high occurrence in the outer membrane of B. cenocepacia. 
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therefore	  likely	  to	  be	  partially	  exposed	  on	  the	  cell	  surface,	  the	  lack	  of	  response	  was	  considered	  to	  be	  due	  to	  differing	  epitopes	  exposed	  on	  the	  cell-­‐surface.	  The	  porin	  was	  however	  still	  considered	  to	  hold	  the	  potential	  of	  a	  diagnostic	  marker	  due	  to	  its	  high	  occurrence	  in	  the	  outer	  membrane	  fraction.	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Chapter	  9:	  Conclusions	  and	  Suggestions	  for	  Future	  Work	  	  As	  described	  in	  Chapter	  4,	  from	  the	  examination	  of	  Kyte-­‐Doolittle	  hydropathy	  plots	  (Kyte	  &	  Doolittle,	  1982)	  of	  the	  entire	  proteome	  of	  B.	  pseudomallei,	  a	  short-­‐list	  of	  potentially	  membrane-­‐anchored	  proteins	  was	  created.	  Bioinformatical	  investigation	  shortened	  this	  list	  further	  to	  include	  only	  targets	  that	  exhibited	  no	  structural	  homologues	  in	  the	  PDB,	  with	  no	  folds	  predicted	  based	  upon	  sequence-­‐threading	  and	  that	  for	  safety	  reasons	  had	  homologues	  in	  the	  non-­‐virulent	  B.	  
thailandensis.	  In	  addition,	  targets	  were	  selected	  that	  were	  not	  already	  under	  investigation	  by	  other	  structural	  genomics	  consortia,	  exhibited	  low	  predicted	  tertiary	  disorder	  favourable	  for	  crystallisation	  (Yang	  et	  al,	  2005)	  and	  contained	  methionines	  for	  seleno-­‐met	  phasing.	  The	  final	  target	  selected	  was	  BPSL1204,	  a	  putative	  lipoprotein	  with	  an	  N-­‐terminal	  LLAGCA	  glyceryl-­‐cysteine	  covalent	  lipid-­‐anchoring	  motif.	  	  The	  bpsl1204	  gene	  was	  obtained	  by	  PCR	  from	  the	  B.	  pseudomallei	  genome	  and	  truncated	  to	  remove	  the	  first	  20	  largely	  hydrophobic	  residues	  up	  to	  and	  including	  the	  LLAGCA	  motif.	  This	  was	  to	  solubilise	  the	  functional	  domain(s)	  by	  removing	  its	  insoluble	  anchoring	  region.	  Upon	  cloning	  pure	  PCR	  product	  into	  the	  pETBlue	  system	  and	  over-­‐expressing	  in	  E.	  coli	  Tuner	  cells,	  BPSL1204-­‐MA	  (minus	  membrane	  anchor)	  was	  purified	  from	  cell-­‐free	  extract	  by	  DEAE	  ion-­‐exchange,	  ammonium	  sulphate	  precipitation	  and	  gel	  filtration.	  30	  mg/ml	  of	  monomeric	  BPSL1204-­‐MA	  was	  purified	  to	  >95%	  pure	  and	  used	  to	  carry	  out	  robotic,	  96	  well	  vapour	  diffusion	  crystallisation	  trials	  using	  the	  Hydra	  II	  microdispenser	  and	  screens	  from	  Nextal	  Qiagen.	  	  	  Initial	  crystal	  hits	  were	  optimised	  over	  a	  period	  of	  months	  until	  large	  rod-­‐clusters	  were	  obtained	  by	  2	  weeks	  growth	  in	  9%	  MPD	  and	  0.1	  M	  sodium	  acetate	  pH	  5.5.	  A	  1.3	  Å	  native	  dataset	  with	  cell	  dimensions	  a=99.96	  Å,	  b=32.91	  Å,	  c=48.35	  Å,	  α	  =90.0°	  β=116.14°	  and	  γ	  =	  90.0°	  in	  space	  group	  C2	  was	  collected	  at	  the	  Diamond	  Synchrotron	  Light	  Source	  in	  Oxford.	  Attempts	  to	  solve	  the	  phase	  problem	  by	  MAD/SAD	  data	  collected	  from	  heavy	  atom-­‐soaked	  derivatives	  of	  native	  BPSL1204-­‐MA	  generated	  no	  anomalous	  signal.	  Therefore	  over-­‐expression	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of	  BPSL1204-­‐MA	  in	  E.	  coli	  grown	  in	  minimal	  media,	  denied	  methionine	  and	  supplemented	  with	  seleno-­‐methionine	  allowed	  the	  incorporation	  of	  selenium	  into	  the	  primary	  sequence	  of	  BPSL1204-­‐MA.	  	  	  Once	  purified	  by	  similar	  methods	  to	  those	  used	  for	  native	  BPSL1204-­‐MA,	  seleno-­‐met	  BPSL1204-­‐MA	  was	  crystallised	  into	  the	  same	  morphology	  and	  under	  similar	  conditions	  to	  the	  native	  protein	  by	  a	  process	  of	  dilution-­‐seeding.	  MAD	  data	  isomorphous	  to	  native	  data	  was	  collected,	  processed	  in	  iMOSFLM	  (Battye	  et	  al,	  2011)	  and	  CCP4i	  (Potterton	  et	  al,	  2003),	  phases	  calculated	  and	  density	  modified	  in	  SHELX	  (Sheldrick,	  2008)	  and	  then	  phases	  were	  extended	  to	  1.3	  Å	  native	  resolution.	  Later	  a	  further	  native	  dataset	  was	  collected	  to	  1.05	  Å,	  into	  which	  phases	  were	  extended.	  A	  model	  was	  built	  into	  the	  calculated	  electron	  density,	  using	  Coot	  (Emsley	  &	  Cowtan,	  2004),	  and	  the	  structure	  was	  refined	  using	  the	  CCP4i	  program	  Refmac5	  (Murshudov	  et	  al,	  2011).	  The	  model	  was	  validated	  using	  MolProbity	  (Davis	  et	  al,	  2007)	  and	  PROCHECK	  (Laskowski	  et	  al,	  1998).	  	  The	  final	  1.05	  Å	  resolution	  BPSL1204	  structure	  was	  displayed	  in	  PyMol	  (Shrödinger,	  LLC),	  and	  revealed	  a	  protein	  consisting	  of	  an	  α1β4	  N-­‐terminal	  domain	  and	  an	  α2β4	  C-­‐terminal	  domain	  connected	  by	  a	  short	  loop.	  Structural	  comparison	  using	  the	  DALI	  server	  found	  the	  nearest	  structure	  with	  similarity	  to	  BPSL1204	  to	  be	  the	  β-­‐lactamase	  inhibitory	  protein	  I,	  BLIP-­‐I	  (Joint	  Center	  for	  Structural	  Genomics),	  which	  is	  comprised	  of	  two	  α2β4	  domains.	  However,	  the	  domains	  in	  BLIP-­‐I	  are	  orientated	  side-­‐by-­‐side,	  whilst	  the	  domains	  in	  BPSL1204	  are	  stacked	  on	  top	  of	  each	  other.	  The	  two	  proteins	  were	  seen	  to	  have	  no	  sequence	  similarity	  to	  each	  other.	  	  	  When	  the	  inhibitory	  N-­‐terminal	  domain	  of	  BLIP-­‐I	  in	  complex	  with	  the	  β–lactamase	  TEM1	  (Strynadka	  et	  al,	  1996)	  was	  superimposed	  with	  the	  N-­‐terminal	  domain	  of	  BPSL1204,	  it	  was	  seen	  that	  the	  inhibitory	  loop	  of	  BLIP-­‐I	  was	  matched	  by	  a	  loop	  with	  similar	  chemical	  properties	  in	  BPSL1204.	  However,	  assays	  designed	  to	  assess	  the	  inhibition	  of	  TEM1	  using	  the	  chromogenic	  penicillin	  analogue	  Nitrocefin	  (CalbioChem)	  showed	  that	  BPSL1204	  did	  not	  inhibit	  the	  E.	  
coli	  TEM1.	  It	  was	  proposed	  that	  BPSL1204-­‐MA	  possessed	  a	  biological	  function	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that	  was	  either	  a	  BLIP-­‐like	  role	  specific	  to	  B.	  pseudomallei	  or	  functioned	  in	  a	  process	  analogous	  but	  evolutionarily	  divergent	  to	  BLIP.	  	  In	  order	  to	  obtain	  more	  biochemical	  data	  on	  the	  function	  of	  BPSL1204-­‐MA,	  a	  pull-­‐down	  assay	  was	  carried	  out	  with	  the	  aim	  of	  discovering	  potential	  binding	  partners	  of	  the	  protein.	  The	  process	  was	  modelled	  in	  the	  less	  dangerous	  B.	  
cenocepacia	  using	  the	  92%	  identical	  BPSL1204	  homologue	  BCAL2351.	  Although	  a	  potential	  binding	  partner	  was	  isolated	  and	  purified,	  the	  methionyl-­‐tRNA	  synthetase	  (metRS)	  BCAL2646,	  a	  complex	  was	  not	  seen	  to	  form	  between	  the	  two	  pure	  proteins	  upon	  gel	  filtration.	  Thus	  it	  was	  concluded	  that	  the	  pull-­‐down	  interaction	  seen	  was	  an	  artefact	  of	  the	  bead-­‐immobilised	  pull-­‐down	  method	  and	  not	  a	  true	  biological	  interaction.	  	  In	  order	  to	  determine	  the	  cellular	  location	  of	  BPSL1204/BCAL2351,	  and	  thus	  gain	  more	  information	  about	  BPSL1204,	  rat	  anti-­‐BPSL1204-­‐MA	  antibodies	  were	  produced.	  Antibody	  production	  in	  rats	  appeared	  to	  reflect	  a	  hyper-­‐immune	  response,	  with	  100	  times	  more	  antibody	  produced	  than	  in	  a	  standard	  inoculation.	  Whole	  B.	  cenocepacia	  cells	  were	  subjected	  to	  fractionation	  via	  sucrose-­‐gradient	  osmotic	  shock,	  sonication,	  ultra-­‐centrifugation	  and	  selective	  Sarkosyl	  solubilisation	  to	  generate	  pure	  secreted,	  periplasmic,	  cytoplasmic,	  inner	  membrane	  and	  outer	  membrane	  samples.	  Western	  blot	  transfer	  of	  these	  fractions	  to	  a	  nitrocellulose	  membrane	  allowed	  for	  the	  probing	  of	  each	  fraction	  for	  the	  location	  of	  native	  BCAL2351	  using	  rat	  anti-­‐BPSL1204	  as	  a	  primary	  antibody.	  A	  secondary	  rabbit	  anti-­‐rat	  HRP-­‐conjugate	  was	  used	  to	  identify	  sites	  of	  BCAL2351	  binding	  by	  chemiluminescence	  of	  the	  HRP	  ECL-­‐substrate	  visualised	  as	  bands	  on	  developed	  X-­‐ray	  film.	  BCAL2351,	  and	  thus	  BPSL1204,	  was	  bound	  only	  in	  the	  pure	  outer	  membrane	  fraction	  with	  the	  only	  other	  band	  seen	  that	  of	  a	  pure	  BPSL1204	  control	  lane.	  	  In	  order	  to	  determine	  the	  orientation	  of	  BPSL1204	  and	  BCAL2351	  in	  the	  outer	  membrane,	  fluorescence	  microscopy	  of	  whole	  cells	  and	  pure,	  fractured	  outer	  membrane	  samples	  was	  carried	  out.	  Slides	  of	  immobilised	  whole	  B.	  cenocepacia	  cells	  and	  slides	  covered	  in	  immobilised,	  randomly	  orientated	  outer	  membrane	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fragments	  were	  washed	  with	  rat	  anti-­‐BPSL1204	  primary	  antibody,	  to	  which	  a	  secondary	  goat	  anti-­‐rat	  FITC-­‐conjugate	  was	  bound.	  Upon	  laser	  excitation	  of	  the	  FITC,	  green	  fluorescent	  ‘speckling’	  was	  seen	  in	  the	  fragmented	  outer	  membrane,	  representative	  of	  BCAL2351	  binding.	  When	  applied	  to	  whole-­‐cells,	  a	  portion	  of	  samples	  used	  exhibited	  fluorescence	  within	  the	  boundaries	  of	  the	  bacterium	  alone,	  suggestive	  of	  antibodies	  binding	  to	  surface-­‐exposed	  BCAL2351/BPSL1204.	  Furthermore,	  binding	  appeared	  to	  specifically	  localise	  to	  patches	  of	  the	  cell	  surface	  rather	  than	  all	  over	  the	  bacterium,	  perhaps	  reflecting	  a	  specific	  biological	  function.	  No	  conclusive	  pattern	  was	  seen	  in	  localisation	  however.	  In	  contrast,	  no	  green	  fluorescence	  was	  seen	  in	  the	  remaining	  whole-­‐cell	  slides.	  This	  may	  indicate	  that	  BCAL2351	  and	  BPSL1204	  are	  inward-­‐facing,	  outer	  membrane	  proteins	  and	  thus	  not	  exposed	  to	  be	  bound	  by	  antibodies	  applied	  to	  whole	  cells.	  	  	  It	  was	  proposed	  that	  BPSL1204	  and	  BCAL2351	  could	  be	  external	  outer	  membrane	  proteins	  selectively	  expressed	  or	  conditionally	  exposed	  on	  the	  cell	  surface	  to	  fulfil	  a	  specific	  biological	  function,	  perhaps	  associated	  with	  the	  cell-­‐cycle.	  Conversely,	  it	  was	  hypothesised	  that	  BPSL1204	  and	  BCAL2351	  are	  both	  outer	  membrane	  proteins	  facing	  the	  periplasm,	  and	  that	  the	  inconsistent	  fluorescent	  signal	  seen	  in	  some	  slides	  was	  due	  to	  outer-­‐membrane	  rupture-­‐damage	  incurred	  during	  slide	  preparation,	  thus	  exposing	  the	  periplasm	  in	  patches.	  	  A	  sample	  of	  serum	  from	  a	  human	  infected	  with	  B.	  mallei	  was	  obtained,	  a	  species	  that	  contains	  a	  100%	  homologue	  of	  BPSL1204	  and	  thus	  a	  92%	  homolog	  of	  BCAL2351.	  After	  Western	  blot	  transfer	  to	  a	  nitrocellulose	  membrane,	  B.	  
cenocepacia	  fractions	  were	  challenged	  with	  the	  anti-­‐B.	  mallei	  human	  antibodies	  in	  the	  sera,	  which	  were	  then	  bound	  by	  a	  secondary	  goat	  anti-­‐human	  HRP-­‐conjugate.	  Proteins	  from	  all	  fractions	  that	  elicited	  an	  immune	  response	  during	  infection	  were	  located	  by	  the	  development	  of	  X-­‐ray	  film	  exposed	  to	  the	  secondary	  HRP	  chemiluminescent	  conversion	  of	  ECL	  reagent	  upon	  the	  nitrocellulose	  membrane.	  Several	  unknown	  proteins	  were	  found	  to	  give	  a	  large	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signal	  (compared	  to	  no	  signal	  in	  secondary	  antibody	  only	  controls),	  considered	  as	  potential	  targets	  for	  future	  research	  into	  diagnostic	  and	  therapeutic	  targets.	  	  	  However,	  pure	  BPSL1204	  and	  native	  BCAL2351	  did	  not	  exhibit	  an	  immune	  response	  in	  B.	  mallei	  infection	  of	  humans.	  This	  lent	  support	  to	  the	  conclusion	  that	  BPSL1204/BCAL2351	  is	  an	  internal	  outer	  membrane	  protein,	  as	  infection	  by	  whole	  B.	  cenocepacia,	  B.	  pseudomallei	  or	  B.	  mallei	  cells	  would	  not	  present	  BPSL1204	  and	  its	  homologues	  to	  a	  host’s	  immune	  system,	  and	  instead	  conceal	  it	  within	  the	  periplasmic	  space.	  	  A	  series	  of	  cross-­‐discipline	  experiments	  comprising	  structural	  X-­‐ray	  crystallography,	  biochemical	  pull-­‐down	  and	  enzyme	  assays	  combined	  with	  immunohistochemical	  and	  microbiological	  fluorescence	  experiments	  have	  been	  used	  to	  investigate	  BPSL1204.	  It	  was	  concluded	  that	  BPSL1204	  possesses	  a	  two-­‐domain	  BLIP-­‐I-­‐like	  fold,	  though	  it	  differs	  in	  domain	  orientation	  from	  BLIP-­‐I	  and	  does	  not	  posses	  the	  same	  general	  β–lactamase	  inhibitory	  properties	  of	  BLIP-­‐I.	  BPSL1204	  also	  appeared	  not	  to	  pull	  down	  any	  strong	  binding	  partners	  from	  cell-­‐extract.	  Localisation	  studies	  modelled	  using	  the	  B.	  cenocepacia	  BCAL2351	  revealed	  BPSL1204	  to	  be	  an	  outer	  membrane-­‐anchored	  protein	  of	  unknown	  function	  covalently	  associated	  via	  a	  glyceryl-­‐cysteine	  to	  the	  outer	  lipid	  membrane	  of	  B.	  pseudomallei.	  The	  orientation	  of	  BPSL1204	  about	  the	  outer	  membrane	  is	  suggested	  to	  be	  periplasmic,	  but	  possibly	  may	  be	  conditionally	  found	  exposed	  on	  the	  cell-­‐surface.	  When	  modelled	  in	  B.	  mallei	  infection	  of	  humans,	  BPSL1204	  was	  found	  to	  be	  non-­‐immunogenic.	  	  In	  the	  future,	  further	  fluorescence	  microscopy	  experiments	  should	  be	  undertaken	  in	  order	  to	  determine	  whether	  the	  conclusion	  that	  BPSL1204	  is	  facing	  the	  inside	  of	  the	  outer	  membrane	  is	  valid	  or	  not.	  All	  future	  experiments	  require	  that	  multiple	  repeats	  with	  a	  greater	  field	  of	  bacteria	  per	  slide	  be	  used	  in	  order	  to	  confirm	  that	  different	  results	  seen	  between	  different	  slides	  are	  due	  to	  experimentally	  altered	  factors	  and	  not	  variation	  in	  the	  quality	  of	  slide	  preparation.	  Further	  to	  this	  all	  microscopy	  experiments	  seen	  in	  this	  thesis,	  performed	  as	  preliminary	  investigations,	  used	  antibody	  dilutions	  of	  1:600.	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Optimisation	  of	  antibody	  dilutions	  used	  may	  allow	  for	  better	  analysis	  of	  binding	  events	  and	  maybe	  improve	  the	  resolution	  of	  specific	  sites	  of	  anti-­‐BPSL1204/BCAL2351	  binding.	  	  Obtaining	  samples	  of	  cells	  in	  various,	  defined	  cell-­‐cycle	  stages	  may	  allow	  the	  investigation	  of	  any	  stages	  at	  which	  BPSL1204	  may	  be	  exposed	  on	  the	  cell-­‐surface,	  perhaps	  due	  to	  a	  role	  in	  cell-­‐wall	  transpeptidase	  regulation,	  a	  process	  evolutionarily	  analogous	  to	  β–lactamases.	  The	  application	  of	  a	  secondary	  fluorophore-­‐reporter	  known	  to	  be	  periplasm-­‐specific	  could	  act	  as	  a	  control	  for	  fluorescence	  due	  to	  outer	  membrane	  rupturing.	  In	  addition,	  the	  exact	  location	  of	  BPSL1204	  and	  BCAL2351	  could	  be	  further	  defined	  by	  the	  creation	  of	  a	  GFP-­‐fusion	  BCAL2351	  mutant	  in	  B.	  cenocepacia,	  in	  order	  to	  directly	  monitor	  the	  location	  of	  BCAL2351	  in	  both	  fixed	  and	  live-­‐cell	  fluorescence	  microscopy.	  	  	  Furthermore,	  microscopic	  localisation	  studies	  could	  be	  supported	  by	  the	  development	  of	  a	  whole-­‐cell	  protease	  assay	  in	  order	  to	  determine	  if	  BPSL1204	  and	  BCAL2351	  are	  exposed	  on	  the	  bacterial	  cell-­‐surface	  and	  thus	  accessible	  to	  proteolysis	  by	  an	  enzyme	  specific	  to	  part	  of	  the	  target	  protein	  sequence.	  The	  protease	  proline-­‐endopeptidase	  would	  cleave	  BCAL2351	  after	  Pro113	  and	  in	  BPSL1204	  after	  Pro109,	  therefore	  releasing	  an	  extracellular	  53-­‐	  or	  57-­‐residue	  polypeptide	  respectively.	  These	  could	  then	  be	  isolated	  by	  SDS-­‐PAGE	  and	  subjected	  to	  MALDI-­‐TOF	  MS	  to	  identify,	  or	  perhaps	  even	  identified	  by	  use	  of	  rat	  anti-­‐BPSL1204	  in	  an	  immunoblot	  assay	  if	  the	  released	  cleavage-­‐product	  presented	  epitopes	  recognised	  by	  the	  antibody	  used.	  	  	  Continuing	  with	  a	  microbiological	  theme,	  a	  potential	  route	  for	  the	  discovery	  of	  a	  biological	  function	  for	  BPSL1204	  and	  BCAL2351	  may	  entail	  the	  creation	  of	  a	  knock-­‐out	  mutant	  for	  either	  B.	  pseudomallei	  or	  B.	  cenocepacia.	  Upon	  the	  removal	  of	  a	  functional	  in	  vivo	  protein,	  the	  phenotype	  of	  a	  knock-­‐out	  strain	  may	  reveal	  a	  process	  in	  which	  BPSL1204	  is	  involved,	  for	  example	  if	  involved	  in	  the	  regulation	  of	  cell-­‐wall	  transpeptidases	  (analogous	  to	  β–lactamase	  activity)	  then	  morphological	  differences	  in	  cell-­‐shape	  and	  cell-­‐wall	  construction	  might	  be	  seen.	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In	  addition,	  further	  crystallographic	  investigations	  of	  BPSL1204	  homologues	  from	  multiple	  Burkholderia	  species	  should	  be	  undertaken,	  in	  order	  to	  conclusively	  determine	  the	  biological	  domain	  conformation	  of	  BPSL1204	  and	  its	  homologues	  with	  regards	  to	  BLIP-­‐I.	  Furthermore,	  the	  identification	  and	  isolation	  of	  β–lactamases	  and	  cell-­‐wall	  transpeptidases	  from	  Burkholderia	  species	  (including	  pseudomallei)	  may	  allow	  for	  the	  investigation	  of	  complex	  formation,	  either	  by	  enzymatic	  assays	  or	  biophysical	  techniques	  such	  as	  isothermal	  titration	  calorimetry	  (ITC).	  Any	  complex	  formation	  seen	  could	  then	  be	  investigated	  crystallographically	  in	  order	  to	  discover	  structural	  aspects	  of	  the	  complexes.	  	  Although	  to	  this	  stage	  BPSL1204	  appeared	  to	  not	  elicit	  an	  immune	  response	  during	  human	  infection	  (when	  modelled	  in	  B.	  mallei	  infection),	  an	  extraordinarily	  high	  immune	  response	  against	  BPSL1204	  was	  seen	  to	  occur	  in	  rats,	  with	  detection	  of	  BPSL1204	  to	  the	  ng	  (and	  potentially	  pg)	  level	  comprehensively	  seen	  in	  immuno-­‐blots.	  Therefore	  BPSL1204	  was	  considered	  to	  hold	  the	  potential	  to	  act	  as	  a	  rapid	  diagnostic	  marker	  for	  B.	  pseudomallei	  infection,	  perhaps	  upon	  antibody	  probing	  of	  in	  vitro	  blood-­‐samples	  from	  patients	  suspected	  to	  be	  infected	  with	  the	  bacterium.	  If	  a	  reliable	  and	  rapid	  ELISA-­‐based	  diagnostic	  assay	  for	  BPSL1204	  could	  be	  developed,	  it	  may	  help	  speed	  the	  identification	  of	  B.	  pseudomallei	  infection,	  leading	  to	  quicker	  application	  of	  therapeutic	  treatments	  against	  the	  lethal	  and	  potentially	  fast-­‐acting	  disease	  melioidosis.	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